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ABSTRACT 
Survivors of childhood, teenage and young adult cancer are at increased risk of developing 
adverse health outcomes. This thesis aims to address the gaps in knowledge regarding the 
most severe adverse health outcomes. 
 
The Teenage and Young Adult Cancer Survivor Study (TYACSS) provides 200,945 survivors 
of cancer diagnosed aged 15-39 years. The PanCare Childhood and Adolescent Cancer 
Survivor Care and Follow-Up Studies (PanCareSurFup) provides 69,460 survivors of cancer 
diagnosed aged <20 years. 
 
Within the TYACSS cohort 1) cancer survivors had increased risk of developing subsequent 
primary neoplasms, particularly in previously irradiated sites; 2) cancer survivors who likely 
received cranial irradiation had increased risk of a cerebrovascular event; and 3) central 
nervous system tumour survivors experienced premature mortality due to neoplastic and non-
neoplastic causes. Within the PanCareSurFup cohort 1) the excess number of subsequent soft-
tissue sarcoma was low, except leiomyosarcoma after retinoblastoma; and 2) the excess 
number of subsequent breast cancers remained elevated beyond 40 years of age among 
survivors of Hodgkin lymphoma, Wilms tumour and sarcoma. 
 
This thesis focuses on the most severe adverse health outcomes among childhood, teenage 
and young adult cancer survivors and provides evidence for developing clinical follow-up 
guidelines aimed at reducing such adverse health outcomes.  
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Introduction
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The purpose of this chapter is to introduce and provide a background of the topics that will be 
investigated and discussed throughout this thesis. This chapter will provide a background of i) 
teenage and young adult cancers, ii) childhood cancers, and iii) long-term clinical follow-up 
guidelines for cancer survivors. In addition, a description of the cohorts used in each chapter 
will be provided and the rationale and structure of the thesis will be described.  
 
1.1 TEENAGE AND YOUNG ADULT CANCER 
Teenage and young adult (TYA) cancer patients have been acknowledged as an understudied 
population1-3 and have been described as a “lost tribe” between paediatric and adult 
oncology4. Inconsistent definitions with regards to the age range of TYA cancer patients have 
hampered the development of guidelines for the care and follow-up of TYA cancer patients. 
Thus far, the definitions of TYA have included one of the following age ranges: 13-24 years5, 
15-24 years6, 15-29 years7, 8 or 15-39 years1, 9-11. The National Cancer Institute (NCI) 
proposed the latest definition of TYA cancer to include patients diagnosed with a malignant 
neoplasm (including all intracranial neoplasms regardless of behaviour) when aged 15-39 
years1. The lower limit of age 15 years was chosen as the number of patients receiving 
specialist paediatric care declines around this age. The upper limit of age 39 years was chosen 
as these patients will have reached pubertal maturation, but will not have reached ages at 
which the risk of developing mature onset morbidities start to increase in the general 
population. In addition these patients often identify more with their younger counterparts as 
opposed to the older population of cancer patients1.    
 
As the spectrum of cancers diagnosed in the TYA population is different to that observed 
among children and mature adults Birch et al. proposed and developed a new classification 
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for grouping TYA cancers6 which is based on the International Classification for Disease 
Oncology (ICD-O)12 and which was later refined by Barr et al13. The proposed TYA 
classification grouped cancers into ten main categories representing the most commonly 
diagnosed neoplasms between 15 and 39 years of age comprising: 1) leukaemia, 2) 
lymphoma, 3) central nervous system (CNS) tumours, 4) bone tumours, 5) soft-tissue 
sarcomas, 6) germ cell neoplasms, 7) malignant melanoma, 8) carcinomas, 9) miscellaneous 
specified neoplasms and 10) unspecified malignant neoplasms. Seven of these categories—
excluding germ cell tumours, carcinomas and unspecified malignant neoplasms— were 
further divided into histological subtypes. Germ cell tumours and carcinomas were further 
categorised by tumour anatomical location6, 13. Carcinomas were grouped as one category 
within the TYA classification as it was originally developed for cancers diagnosed in 
individuals aged 15-24 years, for whom carcinomas are less common than other cancers (e.g. 
lymphomas, leukaemia, and germ cell tumours). However carcinomas are much more 
common in the individuals diagnosed within the older TYA age range (25-39 years), therefore 
the subcategories within carcinomas provides information on the distribution of carcinomas 
observed in this age range.  
 
Currently available United Kingdom (UK) incidence and survival figures are restricted to 
TYA cancer diagnosed age 15-24 years6, 14, thus to provide incidence and survival relating to 
the most recent definition of TYA cancer (15-39 years) paragraphs 1.1.1 and 1.1.2 below refer 
to incidence and survival of TYA cancer in Europe, for which the most inclusive figures are 
available. 
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1.1.1 Incidence 
Approximately 66,000 patients are diagnosed with TYA cancer (age 15-39) each year in 
Europe—constituting 2% of all cancer registrations10. The most frequently diagnosed TYA 
cancers are: carcinomas (47%), malignant melanoma (14%), germ cell tumours (13%) and 
lymphomas (12%)10 (Figure 1.1). However the distribution of tumour types varies as a 
function of age within the TYA age span (Figure 1.2). The most common tumours in 15-19 
year olds are: Hodgkin lymphoma (21%), germ cell tumours (14%) and leukaemia (12%)10. 
The most common tumours in 25-29 year olds are: germ cell tumours (20%), melanoma 
(16%), and genital tract neoplasms in women (10%)10. The most common tumours in 35-39 
year olds are: carcinomas, particularly breast carcinomas (27%), and genital tract carcinomas 
in women (13%)10. The incidence of TYA cancer increases with age (Figure 1.3) with 
approximately 45% and 35% of TYA cancers diagnosed aged 35-39 years for women and 
men, respectively10. 
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Figure 1.1: Distribution of TYA cancers diagnosed in individuals aged 15-39 years in 
Europe10
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Figure 1.2: Proportion of TYA cancer types by age group in Europe 10
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Figure 1.3: Incidence of TYA cancer by age group and gender in Europe10. 
 
1.1.2 Survival 
Survival from TYA cancer has improved with the current European 5-year relative survival at 
80%11. Five-year relative survival is consistently, albeit only slightly, higher among women 
than men (Table 1.1); this probably caused by a higher rate of cancer types with poorer 
outcomes in men than in women10. Survival varies considerably depending on the type of 
TYA cancer—thyroid carcinomas, gonadal germ cell tumours and Hodgkin lymphoma have 
an extremely high five-year relative survival (>90%); in contrast, liver carcinomas, lung 
carcinomas and rhabdomyosarcoma have an extremely poor relative survival (<40%)10, 11. 
Five-year relative survival is poorer in TYA patients than children for acute lymphoid 
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leukaemia, acute myeloid leukaemia, Hodgkin lymphoma, non-Hodgkin lymphoma, 
rhabdomyosarcoma, Ewing’s sarcoma of the bone and osteosarcoma. However in general, 
TYA patients have a higher five-year relative survival than adult patients except for breast, 
prostate and colorectal carcinomas11. 
 
Table 1.1: five-year relative survival (RS) of TYA cancer in Europe stratified by age group 
and gender10. 
 
 
1.1.3 Adverse health outcomes 
The high survival among TYA cancer survivors has led to a large population who are at 
increased risk of adverse health outcomes later in life. Many adverse health outcomes develop 
as a complication of treatment for cancer and can occur many decades after treatment has 
finished3, 15. TYA cancer survivors still have many decades of life to live; therefore it is 
particularly important that the risk of developing adverse health outcomes is investigated with 
the ultimate aim of reducing the number of survivors affected in the future.  
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A cross-sectional study of TYA cancer survivors diagnosed age 15-39 years in the United 
States reported that 30% of TYA cancer survivors in their 40s, 50s and 60s reported poor 
health compared to less than 20% of the general population of the same age16. In a similar 
study, TYA cancer survivors reported a higher prevalence of chronic conditions, disability, 
poor mental health and poor physical health than individuals without a history of cancer17. 
Several studies have reported that TYA cancer survivors experience a greater number of 
hospitalisations than the general population18-22, however only one study has focused on the 
whole spectrum of TYA cancer survivors aged 15-39 years18. Rugbjerg and Olsen18 reported 
that the standardised hospitalisation ratio (SHR) among Danish TYA cancer survivors was 
highest for diseases of the blood (SHR=2.0), infectious and parasitic diseases (SHR=1.7), and 
subsequent primary neoplasms (SPNs) (SHR=1.6); whilst the absolute excess risk (AER) was 
highest for SPNs (AER=50 per 10,000 person-years), diseases of the digestive organs 
(AER=42 per 10,000 person-years), and diseases of the circulatory system (39 per 10,000 
person-years). Within the Danish cohort, survivors of leukaemia, brain tumours and Hodgkin 
lymphoma had the highest risk of hospitalisation than in the general population with 2.2-fold, 
1.9-fold and 1.9-fold increased risk, respectively.  
 
Previous literature suggests that TYA cancer survivors are at an increased risk of premature 
mortality22-28, subsequent primary neoplasms (SPNs)7, 18, 24, 29-38, circulatory disease18, 20, 21, 39-
42, pulmonary disease18, 20, 21, 26, 43, 44, adverse obstetric and perinatal outcomes45-48, 
gastrointestinal disease18, 20, 21, and endocrine disease18, 20. However, the majority of these 
previous studies of adverse health outcomes have focused on either survivors of childhood 
and adolescent cancer only or on adult cancers irrespective of age at diagnosis; few have 
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focused on survivors of cancer diagnosed aged 15-39 years. The type, distribution and 
biology of TYA cancer is distinct from childhood and adults cancers49, therefore more 
evidence focusing on survivors of cancer when aged 15-39 years is required.  
 
The following three sections describe the available literature regarding the most severe and 
potentially life-threatening adverse health outcomes experienced by cancer survivors: 
premature mortality, SPNs and circulatory disease. These adverse health outcomes are the 
focus of this thesis. 
 
 1.1.3.1 Premature mortality 
A few studies have reported an increased risk of premature mortality among subsets of TYA 
cancer survivors22-28; however no study has focused on the whole spectrum of TYA cancer 
survivors diagnosed aged 15-39 years. A study using data from the Finnish Cancer Registry 
observed a 4.2-fold risk of all-cause mortality among cancer survivors diagnosed aged 20-34 
years23 when compared to the general population. Similar estimates were observed among 
cancer survivors aged 20-24 years in British Columbia (5.9-fold)24, aged 15-24 years in 
Scotland (4.7-fold)25 and aged 15-20 years in the North American Childhood Cancer Survivor 
Study (CCSS) (7.9-fold)27. Within the Finnish cohort the standardised mortality ratio (SMR) 
for all-cause mortality was highest among survivors of CNS tumours (12.3-fold) and acute 
lymphoblastic leukaemia (14.2-fold)23. The SMR for all-cause mortality was also highest 
among CNS tumour survivors (23.6-fold) in Scotland25. The most frequent causes of death in 
the Finnish TYA cohort were death due to neoplastic causes (recurrence/progression of the 
TYA tumour and SPNs), and cardiovascular diseases23. Variation in the distribution of causes 
of excess deaths beyond that expected from the general population with increasing years from 
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diagnosis from TYA cancer has not been investigated.  Among childhood cancer survivors the 
number of excess deaths is greatest due to progression or recurrence of the childhood cancer 
in the initial years after diagnosis, however as time progresses SPNs, cardiovascular disease 
and other non-neoplastic causes of death account for the vast majority of the number of excess 
deaths50. Knowledge regarding the variation in the distribution of causes of death as years 
from diagnosis increases is vital to guide preventative strategies concerning premature 
mortality; because it would provide information on what diseases/outcomes preventative 
measures need to be focussed on. 
 
 1.1.3.2 Subsequent primary neoplasms 
A SPN is defined as the development of a further neoplasm that is not a recurrence or 
progression of the first primary neoplasm and is histologically distinct from the first primary 
neoplasm. A study using data from the Surveillance Epidemiology and End Results (SEER) 
registries is the only study that has investigated the risk of developing a SPN in the whole 
spectrum of TYA cancers diagnosed age 15-39 years29. The standardised incidence ratio (SIR) 
of developing a SPN was 1.6-fold compared to the general population and the cumulative risk 
at 30 years from diagnosis of a TYA cancer was 13.9%29. Survivors of Hodgkin lymphoma, 
breast cancer, acute myeloid leukaemia, non-Hodgkin lymphoma, testicular cancer and 
sarcomas had an increased risk of developing a SPN than that expected from the general 
population. The risk of developing a SPN among individuals aged 20-24 in British Columbia 
was 3-fold that expected from the general population; and was highest for SPNs in the 
respiratory system, digestive system, breast and endocrine glands24. The risk of developing a 
SPN among survivors of cancer diagnosed aged 15-29 years in the Netherlands was 3.1-fold 
and 2.0-fold that expected for men and women, respectively7. Several studies have 
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investigated the risk of specific SPNs among survivors of cancers that are relatively common 
among TYAs, but also included those diagnosed at any age30-38. Among these studies there 
was useful information relating to TYA for survivors of Hodgkin lymphoma and testicular 
cancer and this will be discussed in more detail in the following two sections. 
   
1.1.3.2.1 SPNs after Hodgkin lymphoma 
There is a considerable amount of literature describing the increased risk of developing a SPN 
among Hodgkin lymphoma survivors31, 36-38, 51-54. A large Dutch study of Hodgkin lymphoma 
survivors diagnosed aged 15-49 years reported increased risks of cancer of the oral cavity, 
gastrointestinal tract, lower respiratory system, skin, soft-tissue, breast (women), genital tract 
(women), urinary tract, thyroid gland and haematopoietic system36. From several case-control 
studies there are reports of a linear dose-response relationship between cumulative dose of 
radiation from radiotherapy to the chest and the risk of breast cancer in women55-57. The vast 
amount of evidence regarding the association of chest radiotherapy and the development of 
breast cancer has led to the development of clinical follow-up guidelines which recommend 
women treated with high dose chest radiotherapy (≥20 Gy) before age 30 to undergo breast 
cancer surveillance from age 25 or 8 years after treatment, whichever occurs last58. From 
several case-control studies there are reports of a linear dose-response relationship between 
cumulative dose of radiation from radiotherapy and the risk of lung cancer among Hodgkin 
lymphoma survivors51-53. There are contrasting reports as to whether lung cancer risk is 
increased with increasing number of cycles and cumulative dose of chemotherapy; further 
investigations are needed51-53. 
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1.1.3.2.2 SPNs after testicular cancer 
Testicular cancer is the most frequent TYA cancer diagnosed among men and has an 
extremely high relative survival with five-year survival at 97.8% for patients diagnosed age 
15-39 years59. However, it has been well documented that testicular cancer survivors are at 
increased risk of developing an SPN33, 35, 41, 60. Testicular cancer survivors treated with 
adjuvant infradiaphragmatic irradiation for potential lower-abdomen metastasis have a 1.5-
2.7-fold increased risk of developing a SPN, particularly SPNs occurring within the 
radiotherapy field such as bladder, stomach, pancreas or kidney33, 41, 60. Infradiaphragmatic 
radiotherapy increases the risk of SPNs in a dose-dependent manner41. Testicular cancer 
survivors are also at an increased risk of subsequent primary leukaemia61, 62; this increased 
risk has been associated with the use of platinum-based chemotherapeutic agents such as 
Cisplatin62.  
 
1.1.3.3 Circulatory disease 
Rugbjerg et al observed a 30% increased SHR for cardiovascular disease among a cohort of 
Danish cancer survivors diagnosed aged 15-39 years39 and an excess persisted up to 50 years 
from TYA cancer diagnosis, leading to a large excess number of cardiovascular diseases 
being observed beyond that expected from the general population39. Cardiovascular diseases 
included hypertension, ischaemic heart disease, pulmonary heart disease, valvular heart 
disease, cardiomyopathy, arrhythmia, cerebrovascular disease, arterial disease, and venous & 
lymphatic disease. A smaller study of cancer survivors diagnosed age 15-29 years in 
Yorkshire did not report an increased risk of hospitalisation for cardiovascular disease overall, 
however did report increased number of hospitalisations for pericardial disease, 
cardiomyopathy and heart failure, pulmonary heart disease, conduction disorders, and 
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hypertension8. Among a cohort of Hodgkin lymphoma survivors diagnosed before age 41, 
Aleman et al40 reported almost 4-fold the expected number of myocardial infarctions and 5-
fold the expected number of congestive heart failures. Treatment with mediastinal 
radiotherapy and anthracyclines was associated with increased risk of cardiac disease among 
this population of Hodgkin lymphoma survivors. Furthermore, cohorts of adult and childhood 
cancer survivors have also reported increased risks of cardiac disease after treatment with 
mediastinal radiotherapy and anthracyclines40, 63-67.  Among another cohort of Hodgkin 
lymphoma survivors, who were diagnosed before age 51, De Bruin et al42 reported 2-fold and 
3-fold the expected number of strokes and transient ischaemic attacks, respectively. 
Radiotherapy to the neck and mediastinum was associated with an increased risk of stroke 
among this population of Hodgkin lymphoma survivors. Furthermore, radiation to the head 
and neck has been associated with increased risk of stroke among cohorts of adult head and 
neck tumour survivors68-71. Among survivors of childhood cancer, cranial radiotherapy has 
also been associated with increased risk of strokes72-74.  
 
 
1.2 CHILDHOOD CANCER 
Childhood cancer is predominantly defined as a diagnosis of cancer among patients aged 0-14 
years inclusive75. In addition to patients aged 0-14 years, many cohorts of childhood cancer 
survivors are also supplemented by patients diagnosed as adolescents up to age 20 years 
inclusive76-78. Childhood cancers are commonly grouped according to the hierarchical 
International Classification for Childhood Cancers (ICCC)79. Several histological types of 
childhood cancer can appear in numerous anatomical sites; therefore the ICCC classifies 
childhood cancer by tumour histology (International Classification for Disease Oncology 
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[ICDO]) rather than the anatomical site (International Classification of Diseases [ICD]) that is 
often used to group adult cancers. The 12 main diagnostic groups within the ICCC are: 1) 
leukaemia, 2) lymphomas and reticuloendothelial neoplasms, 3) CNS tumours, 4) 
neuroblastoma, 5) retinoblastoma, 6) renal tumours (including Wilms tumour), 7) hepatic 
tumours, 8) bone tumours, 9) soft-tissue sarcomas, 10) germ cell tumours, 11) other malignant 
epithelial neoplasms and malignant melanoma, 12) other and unspecified neoplasms. These 
main diagnostic groups are further divided according to important entities or by tumours that 
have similar characteristics79.  
 
Many childhood cancer survivor cohorts include adolescents (15-19 years or 15-20 years) in 
addition to children (0-14 years), however the incidence and survival for these individuals 
was included in the age range of TYA cancer and has been described in sections 1.1.1 and 
1.1.2. Therefore, sections 1.2.1 and 1.2.2 describe the incidence and survival of childhood 
cancer diagnosed before age 15 only.  
 
1.2.1 Incidence 
Childhood cancer is rare and constitutes less than 1% of all cancer registrations each year in 
the UK75. The most common cancers diagnosed in children are: leukaemia (31%), CNS 
tumours (26%) and lymphomas (10%) (see figure 1.4)80. Childhood cancer is commonly 
diagnosed under age five with 49% of all childhood cancers diagnosed in this age group. The 
distribution of tumour types varies as a function of age—acute lymphoblastic leukaemia 
(ALL), neuroblastoma, Wilms tumour, hepatic tumours and retinoblastoma peak in children 
under age five, whereas bone tumours and Hodgkin lymphomas peak in adolescents75, 80.   
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An increase in incidence of childhood cancer has been observed for all regions of Europe81. 
There is slight variation in the world age standardised incidence rate of childhood cancer 
within Europe. In the period 1988-1997, the incidence of childhood cancer was highest in 
northern Europe (incidence rate = 160 per million) and lowest in the British Isles (incidence 
rate = 131 per million). 
 
 
Figure 1.4: Main types of childhood cancer in the United Kingdom from 2001 to 2010 80 
 
1.2.2 Survival 
Survival from childhood cancer has improved dramatically since the late 1960s due to major 
advances in anti-cancer treatments.  In Great Britain, five-year relative survival for all 
childhood cancers combined increased from 28% for children diagnosed in 1966-1970 to 82% 
for children diagnosed in 2006-201075, 82. Survival has improved over recent decades for all of 
the 12 childhood cancer diagnostic groups in ICCC and five-year survival increased 
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substantially between 1966-1970 and 1971-1975 for leukaemia, lymphoma and Wilms 
tumour (renal tumours)75. The introduction of combination chemotherapy in the late 1960s 
and early 1970s in addition to inductions into clinical trials is largely responsible for this 
increase in survival83. Similar to estimates from Great Britain, survival from childhood cancer 
in Europe has improved over the past few decades. However, there are still disparities in 
survival between European countries especially for Eastern Europe who present the lowest 
five-year survival (60-77%)84. 
 
1.2.3 Adverse health outcomes 
The increase in survival of childhood cancer has resulted in a large population of survivors—
estimated to be between 300,000 and 500,000 in Europe—who are at increased risk of 
developing long-term adverse health outcomes as a result of the cancer or treatment85. As 
each childhood cancer survivor still has the whole of their adult life ahead of them; the 
development of one or multiple adverse health outcomes may have a severe impact on their 
quality of life; or worse, may even result in premature mortality. The development of adverse 
health outcomes depends on numerous factors such as the type of childhood cancer, age at 
diagnosis of the childhood cancer, gender, and the type and cumulative dose of treatment 
exposures received86, 87. Among the CCSS, 62% of childhood cancer survivors reported at 
least once chronic health condition and 28% reported at least one severe or life-threatening 
condition88. A higher proportion of Dutch childhood cancer survivors reported having at least 
one chronic health condition (40%) and at least one severe or life-threatening condition 
(40%)89. In addition, 55% of Dutch patients who received radiotherapy reported a high or 
severe burden of adverse health outcomes89. Survivors of bone tumours, CNS tumours and 
Hodgkin lymphoma reported the highest number of severe or life-threatening conditions88, 89. 
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Childhood cancer survivors have an increased risk of numerous severe adverse health 
outcomes including: premature mortality, SPNs, circulatory complications, endocrine 
complications, neurological dysfunction, pulmonary complications, urological complications, 
gonadal disorders, muscoskeletal disorders and gastrointestinal disorders86, 87, 90, 91.  
 
The following paragraphs provide a summary of those adverse health outcomes experienced 
by childhood cancer survivors that account for the greatest number of excess deaths among 
mature survivors including premature mortality overall, SPNs and cardiovascular disease50, 92.  
 
1.2.3.1 Premature mortality 
The most severe adverse health outcome among long-term survivors of childhood cancer is 
premature mortality. The risk of mortality among childhood cancer survivors is 8.3-10.7 times 
that expected from the general population27, 50, 92, 93. Among the Childhood Cancer Survivor 
Study (CCSS), a large cohort of childhood cancer survivors diagnosed before age 21 in 
America, 30% of five year survivors had died by 50 years of age when 6% would have been 
expected to have died92. The three largest studies worldwide—the CCSS, British Childhood 
Cancer Survivor Study (BCCSS), and a Nordic cohort—all reported a significant decline in 
all-cause mortality, mortality due to recurrence/progression of the childhood tumour, and non-
neoplastic causes of death with more recent diagnostic period (CCSS: 1970-1999, BCCSS: 
1940-2006, Nordic:1960-1999); however they report conflicting evidence as to whether this 
decrease is observed for death due to SPNs or not50, 94, 95. The progression/recurrence of 
childhood cancer accounts for most of the excess number of deaths observed up to age 30 
years50. However as childhood cancer survivors age, the causes of death accounting for the 
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greatest number of excess deaths are SPNs and circulatory disease accounting for  31% and 
37% of the total excess number of deaths beyond age 60 years50.  
 
1.2.3.2 Subsequent primary neoplasms  
Childhood cancer survivors have a 3.3 to 11.2 fold increased risk of developing a SPN than 
that expected from underlying general populations with a similar demographic structure 96-
104.The risk of developing a SPN depends on the primary cancer diagnosis, genetic 
predisposition to cancer, age at treatment, years from diagnosis and the type and dose of 
treatment received90. Furthermore, studies with long follow-up have reported that attained age 
is an important risk factor for the development of SPNs98, 100. Studies of childhood cancer 
survivors have reported an increased risk of solid SPNs after treatment with radiotherapy96, 102, 
104-106 and an increased risk of leukaemia after treatment with chemotherapy96, 97, 107. 
Associations between particular radiotherapy or chemotherapy treatments and the risk of 
specific SPNs have been established and will be discussed below. 
 
Childhood cancers treated with chemotherapy including alkylating agents and topoisomerase 
II inhibitors (including Etoposide) have an increased risk of developing acute myeloid 
leukaemia (AML) and myelodysplasia96, 97, 107-111. Among survivors of childhood cancer 
diagnosed aged under 18 years between 1973 and 2002 in the SEER registries, the risk of 
developing AML was 29-fold that expected among childhood cancer survivors treated with 
chemotherapy compared to 3-fold that expected among those not treated with 
chemotherapy96. Radiotherapy is a known risk factor for the development of subsequent 
primary bone and soft-tissue sarcomas112-115. Several studies have observed a dose-dependent 
relationship of radiation and the development of bone and soft-tissue sarcomas113-115. 
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Sarcomas are also associated with genetic predisposition syndromes such as constitutional 
mutations in the RB1 gene116, 117 and Li-Fraumeni (p53) syndrome118; these syndromes are 
associated with an increased sensitivity to radiation and the development of SPNs117, 119, 120. 
 
Chest radiotherapy is often used to treat childhood cancers such as Hodgkin lymphoma or 
cancers that have metastasised to the lungs (for example, Wilms tumour). Chest radiotherapy 
increases the risk of tumours developing in organs that are located within the radiation field 
such as the breast38, 55, 57, 121-126. The risk of breast cancer in female childhood Hodgkin 
lymphoma survivors, for which high-dose chest radiation is often used is extremely high and 
is comparable or higher than breast cancer risk among BRCA1 and BRCA2 carriers38, 123, 125. 
Moskowitz et al123 reported that cumulative risk of breast cancer by age 50 years was 35%, 
31% and 10% for childhood Hodgkin lymphoma survivors, BRCA1 carriers and BRCA2 
carriers, respectively (Figure 1.5). 
 
Children diagnosed with a CNS tumour are often treated with cranial radiotherapy and are at 
an increased risk of developing a subsequent primary CNS tumour105, 127, 128. In addition, 
children diagnosed with acute lymphoblastic leukaemia in the late 1960’s and early 1970’s 
were treated with cranial radiotherapy to prevent leukaemia  spread to the CNS129. Such 
survivors are also at an increased risk of developing a subsequent primary CNS tumour105, 127, 
130, 131. More recently treatment to prevent leukaemia spread to the CNS has moved towards 
the use of intrathecal methotrexate or cranial radiation in a small proportion of patients 
(<10%) who have a high risk of CNS relapse129. Studies from the CCSS and the BCCSS have 
reported a linear dose-response relationship between the cumulative amount of radiation 
exposure to the cranium and the risk of developing subsequent primary gliomas and 
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meningioma105, 127. Within CNS tumour survivors in the CCSS, the cumulative incidence of 
developing a subsequent primary CNS tumour at 25 years from diagnosis was 7.1% for 
patients who received cranial radiation of 50 Gray or more compared to 1.0% for patients who 
were not treated with any radiotherapy128. The Children’s Oncology Group (COG) guidelines 
recommend children treated with cranial radiotherapy to undergo surveillance including, 
annual physical examinations, annual history and MRI screening if symptoms are present132. 
The UK Children’s Cancer and Leukaemia Group (UKCCLG) guidelines133 recommend CNS 
tumour survivors to be educated on the risk of SPNs within the radiation field and undergo 
regular examination of skin lesions. 
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Figure 1.5: Cumulative risk of breast cancer after childhood cancer compared with carriers of 
BRCA1 and BRCA2 mutations.123 
 
1.2.3.3 Circulatory disease 
The risk of mortality in survivors of childhood cancer due to circulatory diseases is 4.0-10.8 
times that expected from the general population27, 92, 93, 134, 135. Childhood cancer survivors are 
at an increased risk of developing congestive heart failure, myocardial infarction, pericardial 
disease and valvular abnormalities136.  The largest population–based study to investigate 
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cardiovascular late effects, a Nordic cohort of childhood cancer survivors diagnosed before 
age 20137, reported that childhood cancer survivors had twice the risk of being hospitalised for 
a cardiovascular disease than expected from the general population. Compared to the general 
population, childhood cancer survivors had an increased number of hospitalisations for 
hypertension (2-fold), ischaemic heart disease (1.7-fold), pulmonary heart disease (3.5-fold), 
peri-, myo- and endocardial disease (2.9-fold), valvular disease (4.6-fold), heart failure (5.2-
fold), conduction disorder (1.6-fold), cerebrovascular disease (3.7-fold), arterial disease (2.7-
fold), and venous- and lymphatic disease (1.5-fold)137. There is strong evidence that long-term 
cardiac toxicity is associated with previous treatment with anthracyclines and mediastinal 
radiotherapy63, 136, 138, 139.  Survivors who received such treatments may benefit from receiving 
long-term follow up care and surveillance for circulatory disease risk factors (diabetes, 
hypertension, obesity). 
 
 
1.3 CLINICAL LONG-TERM FOLLOW-UP GUIDELINES 
Clinical guidelines for the long-term care and surveillance of childhood cancer survivors have 
been produced by the Children’s Oncology Group (COG)132 in the US, The Scottish 
Intercollegiate Guideline Network (SIGN) in Scotland140, The UK Childhood Cancer and 
Leukaemia Group (UKCCLG) in the UK133 and The Dutch Children’s Oncology Group 
(DCOG) in the Netherlands141. All of the guidelines provide recommendations for the level of 
follow-up, screening or surveillance that childhood cancer survivors require based on their 
risks of adverse health outcomes given their previous therapeutic exposures and cancer type. 
These guidelines are regularly updated to provide the most up-to-date recommendations based 
on all evidence available. However, some of the recommendations are not consistent between 
 
 
24 
 
guidelines. The International Guideline Harmonisation Group (IGHG) was established to 
provide consistent and parsimonious guidelines for international use142. The main aim of the 
IGHG is to establish, through international collaboration, a common strategy and 
recommendations for the surveillance to prevent, diagnose early, or treat optimally the 
adverse health outcomes experienced by childhood, adolescent, and young adult cancer 
survivors. Thus far, the IGHG has published guidelines on breast cancer58, cardiomyopathy143 
and premature ovarian insufficiency144. In contrast to childhood cancer survivors, long-term 
follow-up guidelines are currently lacking for TYA cancer survivors. 
 
 
1.4 CHILDHOOD, TEENAGE AND YOUNG ADULT CANCER SURVIVOR 
COHORTS 
For this thesis the risk of specific adverse health outcomes has been investigated among two 
cohorts of cancer survivors: 1) The Teenage and Young Adult Cancer Survivor Study; and 2) 
The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies. This 
section will provide an overview of the cohorts included in this thesis. 
 
1.4.1 Teenage and Young Adult Cancer Survivor Study 
The Department of Health, National Institute for Health and Clinical Excellence, and the 
National Cancer Research Institute have all identified a need and priority for accurate 
information regarding the risks of adverse health outcomes after treatment for TYA 
cancers145-147. In response to the call for information, the Teenage and Young Adult Cancer 
Survivor Study (TYACSS) was established with the purpose of investigating: 1) the observed 
and expected causes of deaths beyond five-year survival, 2) the observed and expected risks 
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of SPNs, 3) the observed and expected risks of non-cancer serious morbidity. The ultimate 
aims of these investigations are to identify specific subgroups of TYA cancer survivors who 
are at a substantially increased risk of developing one or more adverse health outcomes. This 
will aid in the development of clinical follow-up guidelines, help educate and counsel 
survivors, help educate health professionals and provide a basis for developing future 
treatment protocols from a risk as well as benefit perspective.  
 
The Office for National Statistics (ONS) and the Welsh Cancer Registry provided all cancer 
registrations for 15-39 year olds between 1971 and 2006 in England and Wales. The first 
cancer registration for a malignant neoplasm, any intracranial or any intraspinal neoplasm per 
individual was taken as the TYA cancer and included in the final cohort.  Any individual who 
had a cancer registration before age 15 was excluded from the cohort by linking with the 
BCCSS. All diagnostic tumour types were included with the exception of non-epithelial non-
melanoma skin cancer (NMSC), as they are known to be under-ascertained due to differences 
in policies regarding recording of NMSC  between local cancer registries148. The TYACSS 
cohort consists of 200,945 five-year survivors of cancer diagnosed aged 15-39 years in 
England and Wales between 1971 and 2006. Characteristics of the cohort can be found in 
Table 1.2. The most common diagnoses are breast (18%), testis (12%), cervix (12%) and 
malignant melanoma (11%). 62% of the cohort are women and 62% were diagnosed from 
1990 until 2006.  
 
The TYACSS cohort has been linked to the national death register, national cancer register 
and the Hospital Episode Statistics (HES) database by NHS-Digital. This linkage notifies 
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when a cohort participant has died (vital status, date and cause of death), developed another 
cancer, or has had a hospital admission.  
 
Ethical approval was provided by the National Research Ethics Service (ref: 16/LO/0895) and 
permission to process information without individual consent by the National Information 
Governance Board (NIGB) for Health and Social Care (ref: 3-03(c)2010). 
 
1.4.2 Process to create and quality assurance of the TYACSS cohort 
All cancer registrations for patients diagnosed aged 15-39 years between 1971 and 2006, and 
all subsequent cancer registrations for these patients, were obtained from the Office for 
National Statistics. All cancer registrations were checked for missing information such as 
dates, behaviour codes, site codes, and morphology codes. All duplicate registrations were 
dropped. To provide vigorous checks, all cancer registrations were converted from their 
original coding classification into the 3rd revision of the International Classification of 
Disease for Oncology using the IARC/IACR Cancer Registry Tools conversion software. This 
enabled the data to be checked for errors using the IARC/IACR Cancer Registry Tools 
IARC/IACR check program. This program checks for inconsistencies and errors in tumour 
site, morphology, behaviour and sex. To distinguish between, first primary neoplasm, 
recurrence and subsequent primary neoplasms, the cleaned data was processed using the 
IARC/IACR Cancer Registry Tools Multiple Primary program. This program utilises the 
IARC/IACR rules for defining multiple primary tumours. Those classified as first primary 
neoplasms formed the TYACSS cohort. Figure 1.6 shows a flow diagram of the process used 
to create the TYACSS cohort from cancer registration data.
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Table 1.2: Cohort characteristics of the Teenage and Young Adult Cancer Survivor Study. 
 
 5-year 
Survivors 
% 
Total 200,945 100 
Sex   
Men 76,666 38.2 
Women 124,279 61.9 
First Primary Neoplasm   
Breast 36,236 18.0 
Testicular 24,309 12.1 
Cervix 23,281 11.6 
Melanoma 22,446 11.2 
CNS 17,280 8.6 
Hodgkin Lymphoma 16,971 8.5 
Non-Hodgkin Lymphoma 9,467 4.7 
Thyroid 7,809 3.9 
Gastrointestinal 7,224 3.6 
Soft tissue sarcoma 6,130 3.1 
Leukaemia 5,073 2.5 
Ovary 4,885 2.4 
Bladder 4,685 2.3 
Other Genitourinary* 4,672 2.3 
Head & neck 3,961 2.0 
Bone tumour 2,241 1.1 
Lung 1,219 0.6 
Other 3,056 1.5 
Age at Diagnosis   
15-19 12,248 6.1 
20-24 21,258 10.6 
25-29 35,894 17.9 
30-34 54,541 27.1 
35-39 77,004 38.3 
Years since Diagnosis   
5-9 38,164 19.0 
10-19 77,993 38.8 
20-29 53,013 26.4 
30-39 28,324 14.1 
40+ 3,451 1.7 
Attained Age at Exit   
20-29 3,677 3.0 
30-39 21,391 17.2 
40-49 59,433 47.9 
50-59 36,607 29.5 
60+ 3,106 2.5 
Decade at Diagnosis   
1971-1979 25,158 12.5 
1980-1989 51,573 25.7 
1990-1999 67,167 33.4 
2000-2006 57,047 28.4 
*Include genitourinary tract and kidney (excluding bladder). 
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Figure 1.6: Process to create and quality assure TYACSS cohort from cancer registration data
Cancer registrations from 
ONS, N=308,622 
N= 293,266 
N= 268,153 
N=266,534 
N=232, 523 
Initial Checks: 
 Invalid morphology range (8000-9992), n=193 
 Missing date of cancer registration, n=2 
 Behaviour code 0, 1, 2 and not intracranial or 
bladder, n=13,568. 
 Not in ICDO histology classification, n=24 
 Behaviour code 6 or 9, n=1,369 
 Secondary tumours, n=200 
 
Duplicate cancer registrations, n=25,113 
  
Coding errors identified from converting original 
classification system of cancer registrations to ICDO3 
and IARC/IACR check program: 
 Invalid morphology code, n=1,234 
 Invalid site code, n=53 
 Invalid morphology/behaviour combination, n=320 
 Invalid sex/site combination, n=1 
 Invalid sex/morphology, n=11 
  
Exclude Epithelial Skin Cancers, n=34,011 
  
N=205,113 
IARC/IACR multiple primary cancer rules: 
 Recurrent/progression of first primary tumour, 
n=10,924 
 Subsequent primary neoplasm, n=16,486 
  
N=200,945 
Final exclusions based on patient characteristics: 
 Incorrect age range (not 15-39), n=3,336 
 Incorrect diagnosis year (1971-2006), n=85 
 Non 5-year survivor, n=456 
 Had previous childhood cancer, n=176 
 Mistraced/wrong person/died abroad, n=115 
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1.4.3 PanCareSurFup 
PanCare (http://www.pancare.eu/en/) is a collaborative network of healthcare professionals, 
epidemiologists, childhood cancer survivors and families of childhood cancer survivors across 
Europe85. This pan-European network aims to reduce the burden of adverse health outcomes 
from treatment among childhood and adolescent cancer survivors by providing further 
information and research, developing and disseminating guidelines for survivorship care and 
spreading awareness and knowledge regarding cancer survival85. 
 
The PanCare Childhood and Adolescent Cancer Survivors Care and Follow-up Studies 
(PanCareSurFup) (http://www.pancaresurfup.eu/) is one of the European Commission funded 
projects established by PanCare and aims to investigate and ultimately reduce the more 
serious and life-threatening adverse health outcomes observed among childhood and 
adolescent cancer survivors85.  PanCareSurFup has established a retrospective European 
cohort of cancer survivors and this cohort will be utilised in this thesis to estimate the excess 
risk of specific SPNs (soft-tissue sarcoma and breast) among cancer survivors compared to 
the general population. Furthermore, beyond the scope of this thesis, the impact of cumulative 
dose of radiotherapy, cumulative dose of individual chemotherapy agents on the risk of 
developing subsequent genitourinary carcinomas, subsequent gastrointestinal carcinomas, 
subsequent bone sarcomas, subsequent soft-tissue sarcomas will be investigated using nested 
case-control studies.  
 
The PanCareSurFup cohort comprises thirteen European cohorts from twelve countries to 
produce a pan-European cohort of 69,460 five-year survivors of childhood and adolescent 
cancers. The thirteen cohorts consisted of eleven population-based cohorts from Hungary, 
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Italy, The Netherlands, Denmark, Sweden, Norway, Finland, Iceland, Slovenia, Switzerland 
and the UK, and two treatment centre cohorts from France and Italy. Ethical approval for each 
cohort was obtained from the appropriate bodies within each of the countries. To be eligible 
for inclusion, participants had to have a cancer diagnosis before age 20 in one of the 
participating cohorts and have survived for at least five years. Characteristics of the cohort 
and the diagnostic periods of each country are shown in Table 1.3 and Table 1.4, respectively.  
 
The British Childhood Cancer Survivor Study (BCCSS) cohort provided the UK contribution 
to PanCareSurFup. The BCCSS is a cohort of cancer survivors diagnosed before the age of 
15, thus there was no overlap with the previously described TYACSS cohort of TYA cancer 
survivors.  
 
1.4.4 Process to create and quality assurance of the PanCareSurFup cohort 
Each country participating in PCSF sent relevant childhood cancer cohort data to the data-
coordinating centre in Mainz, Germany, which was the lead organisation for data collection 
and harmonisation for the PanCareSurFup study. The coordinating centre performed validity 
checks on the data and combined the data from each individual country into one overall 
cohort of childhood cancer survivors. The entire cohort dataset was then transferred to 
Birmingham and the Centre’s IT-manager, and myself carried out further checks. To provide 
rigorous checks, all cancer registrations were converted from their original coding 
classification into the 3rd revision of the International Classification of Disease for Oncology 
using the IARC/IACR Cancer Registry Tools conversion software. This enabled the data to be 
checked for errors using the IARC/IACR Cancer Registry Tools IARC/IACR check program. 
Any errors or inconsistencies were discussed with each individual data provider and corrected 
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where required. To enable comparison with other studies, childhood cancers were classified 
according to the 3rd revision of the International Classification of Childhood Cancers 
(ICCC3). Tumours that were not classifiable to ICCC3 were excluded from the cohort. The 
process used to finalise the PanCareSurFup cohort is shown in figure 1.7. 
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Table 1.3: Cohort characteristics of the PanCareSurFup cohort. 
  
Five-year 
Survivors 
% 
Overall 69,460 100.0 
Sex   
Male 37,738 54.3 
Female 31,722 45.7 
Age at Diagnosis   
<5 years 26,969 38.8 
5–9 years 15,587 22.4 
10–14 years 15,423 22.2 
15–19 years 11,482 16.5 
Decade of Diagnosis   
<1970 8,993 13.0 
1970–1979 13,479 19.4 
1980–1989 20,900 30.1 
1990–1999 19,260 27.7 
≥2000 6,828 9.8 
Attained Age   
0–19 years 16,397 23.6 
20-–29 years 22,329 32.2 
30–39 years 17,522 25.2 
≥40 years 13,212 19.0 
Years from Diagnosis   
5–14 years 23,833 34.3 
15–24 years 22,282 32.1 
25–34 years 14,087 20.3 
35–44 years 6,796 9.8 
45+ years 2,462 3.5 
Childhood Cancer 
Diagnosis 
  
Leukaemia 16,595 23.9 
Hodgkin Lymphoma 6,000 8.6 
Non-Hodgkin Lymphoma 3,350 4.8 
Central Nervous System 14,096 20.3 
Neuroblastoma 3,169 4.6 
Retinoblastoma 2,578 3.7 
Wilms Tumour 4,756 6.9 
Bone Sarcoma 3,147 4.5 
Soft-Tissue Sarcoma 4,502 6.5 
Other 10,905 15.7 
Not classifiable 363 0.5 
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Table 1.4: Period of childhood cancer diagnosis and follow-up for each country contributing 
to the PanCareSurFup cohort. 
Country Years of Diagnosis End of Follow-up 
France 1946–1986 Sep-14 
Hungary 1971–2008 Dec-14 
Italy Population-based 1965–2005 May-10 
Italy Hospital-based 1960–2007 Dec-12 
Netherlands 1963–2001 Dec-12 
Denmark 1943–1998 Dec-03 
Sweden 1958–1998 Dec-03 
Norway 1953–1997 Dec-02 
Finland 1953–2006 Dec-11 
Iceland 1955–1998 Dec-03 
Slovenia 1960–2002 Jul-14 
Switzerland 1964–2005 Dec-13 
UK 1940–1991 Dec-06 
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Figure 1.7: Process to create and quality assure PanCareSurFup cohort – performed in 
Birmingham. 
 
Cohort received from 
Mainz, N=105,015 
Tumours not ascertained by all cohorts, thus decision to 
exclude: 
 Myelodysplastic Syndromes (ICDO3 codes 9980 to 
9989), n=95 
 Langerhans Cell Histiocytosis (ICDO3 codes 9751 to 
9753), n=246 
 Chronic myeloproliferative and lymphoproliferative 
disorders (ICDO3 codes 9950 to 9975) , n=188 
 Immunoproliferative diseases (ICDO3 codes 9760 to 
9769), n=2 
 
 
 
N=102,548 
 
Age at childhood cancer diagnosis not between 0–19 
inclusive, n=6 
N=102,542 
 
N=69,460 
 
N=104,484 
 
Non 5-year survivor, n=33,082 
 
 Behaviour code of 6 or 9. Cannot be certain if primary 
cancer, n=278 
 Non-malignant behaviour code (excess cranial), 
n=873 
 Not included within ICCC classification, n=785 
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1.5 RATIONALE AND AIMS OF THESIS 
Clinical follow-up guidelines are imperative for the long-term survival and care of childhood, 
teenage and young adult cancer survivors. Although guidelines for the long-term follow-up of 
childhood cancers exist, there are still some gaps in knowledge and inconsistencies between 
published guidelines. Thus far there have not been any guidelines published specifically for 
the long-term care of TYA cancer survivors. Large-scale studies are needed to provide robust 
estimates of the risk of adverse health outcomes among these cancer populations in order to 
inform and provide the required evidence for the development and updating of long-term 
follow-up guidelines. The PanCareSurFup provides the largest cohort of childhood and 
adolescent cancer survivors in the world thus can be used to develop accurate estimates of the 
most severe and life-threatening outcomes that arise after treatment for cancer. The TYACSS 
cohort provides a large population-based cohort that has been linked to several national 
databases therefore can be used to address the gap in knowledge regarding adverse health 
outcomes that has been identified as a research priority by the Department of Health, the 
National Institute for Health and Clinical Excellence and the National Cancer Research 
Institute145-147. The research conducted in this thesis will aid in revising and developing 
follow-up guidelines, informing survivors and parents, and raising awareness adverse health 
outcomes faced by childhood, teenage and young adult cancer survivors.  
 
The principal aims of this thesis are five-fold: 
1) Investigate which groups of survivors in the TYACSS cohort are at increased risk of 
developing specific types of SPNs. 
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2) With the use of the Hospital Episode Statistics (HES) database, investigate which 
groups of survivors in the TYACSS cohort are at increased risk of being hospitalised 
for a cerebrovascular event in England. 
3) Investigate which subgroups of CNS tumour survivors in the TYACSS cohort are at 
increased risk of specific causes of death compared to the age- and gender-matched 
general population. 
4) Investigate which subgroups of childhood cancer survivors in the PanCareSurFup 
cohort are at an increased risk of developing a subsequent primary soft-tissue sarcoma. 
5) Investigate which subgroups of childhood cancer survivors in the PanCareSurFup 
cohort are at an increased risk of developing a subsequent primary breast cancer. 
 
Each of the aforementioned studies was chosen as they investigate the risk of the most serious 
and life-threatening adverse health outcomes after childhood and TYA cancer. Both 
subsequent primary neoplasms and cerebrovascular disease contribute substantially to 
premature mortality among long-term cancer survivors; furthermore these events, in the 
absence of mortality, can be severely life debilitating. Therefore morbidity rather than 
mortality was chosen as the focus for these two endpoints. Premature mortality among CNS 
tumour survivors was chosen as a focus of this thesis due to existing literature24, 26 and 
preliminary analyses highlighting that these survivors experience a high risk of premature 
mortality. The aims of the PanCareSurFup studies were to provide estimates of the risk of 
developing SPNs in long-term survivors of childhood cancer. This thesis focuses on 
subsequent breast cancers and soft-tissue sarcoma, as previous literature have shown 
childhood cancer survivors to have a large risk of these SPNs, however there are gaps in 
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literature regarding risk of breast cancer after 40 years of age and the risk of specific types of 
soft-tissue sarcoma. 
 
1.6 FRAMEWORK OF THESIS 
The thesis comprises five main chapters which are based on the five aims stated above. 
Chapters Two to Four are concerned with the adverse health outcomes experienced by 
survivors within the TYACSS cohort. Chapter Two focuses on the risk of SPNs among TYA 
cancer survivors in England and Wales. Chapter Three focusses on the risk of hospitalisation 
for a cerebrovascular event among TYA cancer survivors in England. Chapter Four focusses 
on the risk of premature mortality and specific causes of death among TYA cancer survivors 
in England and Wales. Chapters Five and Six are concerned with subsequent primary 
neoplasms developed among survivors within the PanCareSurFup cohort.  Chapter Five 
focusses on the risk of developing a subsequent primary soft-tissue sarcoma among childhood 
and adolescent cancer survivors in Europe. Chapter Six focusses on the risk of developing a 
subsequent primary breast cancer among childhood and adolescent cancer survivors in 
Europe. To conclude, Chapter seven provides a summary of the main findings and also 
considers the implications of these findings.  
 
1.7 LITERATURE SEARCH 
Pubmed was used as the main source of obtaining relevant scientific papers. Search terms 
included, but were not limited to, ‘TYA’, ‘teenage and young adult cancer’, ‘AYA’, 
‘adolescent and young adult cancer’, ‘childhood cancer’, ‘survivor’, ‘second cancer’, 
‘subsequent cancer’, ‘subsequent primary neoplasm’, ‘cardiovascular disease’, ‘strokes’, 
‘adverse health outcome’, ‘premature mortality’. Other sources of literature included 
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bibliographies of relevant papers, attending and gaining knowledge from conferences, 
websites of known childhood, teenage and young adult cancer survivor cohorts, word of 
mouth, and discussions with colleagues and peers. 
 
1.8 DECLARATION OF WORK UNDERTAKEN 
Dr Raoul Reulen, Professor Mike Hawkins, David Winter, and the PanCareSurFup partners 
collected the initial data used throughout this thesis. David Winter and myself, performed 
separate data cleaning exercises to ensure there were no inconsistencies or errors within the 
data. The cleaning exercises performed by myself are described in the previous sections. I 
performed all of the statistical analysis, production of results, and drafting of each chapter. 
My supervisors, Dr Raoul Reulen and Professor Mike Hawkins, provided expert knowledge 
and proof read all chapters.  
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Chapter 2 
Long-term risks of subsequent primary neoplasms among 200,945 5-year 
survivors of teenage and young adult cancer
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2.1 ABSTRACT 
Background: In contrast to survivors of childhood cancer there is very little information 
addressing the risks of subsequent primary neoplasms (SPNs) experienced after teenage and 
young adult (TYA) cancer and no previous study has addressed the risks of specific SPNs 
after specific TYA cancers.  
Methods: The Teenage and Young Adult Cancer Survivor Study is a population-based cohort 
of 200,945 5-year survivors of cancer diagnosed when aged 15-39 years between 1971-2006 
in England and Wales. We focus on the absolute excess risks (AER), which provide the 
excess number of SPNs observed per 10,000 survivors per year. 
Results: Overall, 12,321 SPNs were diagnosed in 11,565 survivors; most frequently among 
survivors of breast, cervical, testicular cancer, and Hodgkin lymphoma. For the first time we 
provide excess risks of specific types of SPNs after each of 17 types of TYA cancer.  The 
excess number of SPNs observed increased with increasing years from diagnosis after each 
TYA cancer investigated, both in relation to SPNs overall and each specific SPN site 
potentially directly irradiated. Those surviving beyond 30 years from diagnosis of breast, 
testicular, cervical cancer and Hodgkin lymphoma experienced the following excess number 
of SPNs. Breast cancer survivors experienced 29 excess cancers overall; lung accounted for 
45% of this. Cervical cancer survivors experienced 47 excess cancers overall; lung, colorectal, 
and bladder accounted for 82% of this. Testicular cancer survivors experienced 127 excess 
cancers overall; prostate, bladder, colorectal and lung accounted for 61% of this. Among 
Hodgkin lymphoma survivors, women experienced 169 excess cancers overall, breast and 
lung accounted for 58% of this; men experienced 123 excess cancers overall, lung accounted 
for 41% of this. 
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Conclusion: We provide long-term excess numbers of the more common specific SPNs 
developing after specific types of TYA cancer, which gives an evidence-base for planning 
surveillance for SPNs in long-term follow-up clinics.  
 
2.2 INTRODUCTION 
Survival from cancer diagnosed in teenagers and young adults (TYA) has improved, currently 
5-year relative survival in Europe is 82%11. Survivors are at risk of developing serious 
morbidities, including subsequent primary neoplasms (SPNs). The risk overall has been 
estimated to be between 1.5- and 3.1-fold that expected from the general population7, 29, but 
previous cohorts were small. 
 
Previous research regarding the development of SPNs among survivors of TYA cancers has 
concentrated on the risk after the most common cancers such as lymphomas, testicular cancer, 
and breast cancer33, 34, 36, 38, 54, 60, 149-151. Only one study has comprehensively investigated the 
risk of developing any SPN after each TYA cancer, but the risks of specific types of SPN 
were not investigated29. It is anticipated that principal factors determining the risks of SPNs 
will relate to types and doses of TYA cancer treatments. TYA cancer treatment varies greatly 
by cancer type and therefore in the absence of detailed treatment information it is essential to 
investigate the risk of specific SPNs after specific types of TYA cancer. Such risk 
stratification information is necessary for the development of evidence-based long-term 
clinical follow-up guidelines. In contrast to survivors of childhood cancer there is very little 
literature currently available which addresses SPN risks after the entire spectrum of specific 
TYA cancers. 
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The main aims of this large-scale population-based study were to: 1) provide risks of all and 
specific types of SPN after each type of TYA cancer; 2) explore variation in such risks with 
years from diagnosis, age at diagnosis, decade of diagnosis, and gender where sufficient 
numbers were available.  
 
2.3 METHODS 
2.3.1 Teenage and Young Adult Cancer Survivor Study (TYACSS) 
The TYACSS is a large population-based cohort consisting of 200,945 5-year survivors of 
cancer diagnosed aged 15-39 years between 1971-2006 in England and Wales. It was 
ascertained from the Office for National Statistics and the Welsh Cancer Registry. Ethical 
approval was provided by the National Research Ethics Service (ref: 16/LO/0895) and 
permission to process information without individual consent by the National Information 
Governance Board (NIGB) for Health and Social Care (ref: 3-03(c)2010). First primary 
neoplasms (FPNs) were grouped according to the internationally acknowledged classification 
scheme for tumours diagnosed in adolescence and young adulthood (see Table 2.1)13. 
Carcinomas and germ cell tumours were further subdivided by anatomical site because the 
implications of treatment for the risk of SPN will vary depending on site of treatment. We 
aimed to produce risk estimates after each specific FPN therefore survivors of the 3,118 
‘other’ cancers were not included, resulting in 197,827 5-year survivors (See Table 2.2 for 
types of `other` cancers). 
 
2.3.2 Ascertainment of subsequent primary neoplasms 
Individual patient record linkage with NHS-Digital provided notification of vital status, date 
of death, date of emigration and when an individual developed a SPN, the anatomical site and 
 
 
43 
 
date of this neoplasm. Cancer registrations were classified as a SPN according to the 
International Association of Cancer Registries (IACR) and International Agency for Research 
on Cancer (IARC) rules for defining multiple primary tumours using the IACR/IARCtools 
software152. To ensure that potential SPNs were not a recurrence of the original TYA cancer, 
SPNs occurring in the same or neighbouring anatomical sites as the FPN were excluded (see 
Table 2.3 for exclusions). 
 
Tumours of the central nervous system (CNS) including meningiomas and bladder neoplasms 
were included in all analyses irrespective of histological tumour classification (malignant, 
benign, or uncertain).  
 
2.3.3 Statistical analysis 
Individuals were followed from date of 5-year survival from diagnosis of their TYA cancer 
until the first occurrence of death, emigration, or study end date (31st December 2012). To 
avoid bias multiple SPNs per individual were allowed for all comparisons with expected 
numbers from the general population. For the cumulative incidence the first SPN only was 
considered.  
 
Standardised incidence ratios (SIRs) were calculated as the observed divided by the expected 
number of neoplasms.  Absolute excess risks (AERs) were calculated as the observed minus 
expected number of neoplasms, divided by the person-years at risk and multiplied by 10,000. 
We often report the excess number of cancers without specifying the underlying person-years 
at risk because this is always per 10,000 person-years. The expected number of neoplasms 
was derived from multiplying the number of person-years accrued, stratified by sex, attained 
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age (five-year bands) and calendar year (one-year bands), by the corresponding cancer rate in 
the general population of England and Wales and then summing appropriately. For those 
TYA cancers with 200 or more observed SPNs (Table 2.4), SIRs were provided by specific 
type of SPN (Table 2.5). In the Results and Discussion we restrict attention to FPN/SPN 
combinations with at least 100 SPNs and a statistically significant SIR (highlighted in red in 
Table 2.5).  
 
AERs were calculated stratified by years from diagnosis, age at diagnosis, decade of 
diagnosis, and sex where there were at least 100 SPNs. To explore the simultaneous effect of 
these explanatory factors, multivariable Poisson regression incorporating the expected number 
of events was used to derive relative excess risks (RER) 153, 154. RERs can be interpreted as the 
ratio of AERs adjusted for other potential explanatory factors included within the statistical 
model. AERs by an explanatory factor were reported in the Results and Discussion if the 
trend in both the AERs and RERs were each statistically significant and the difference in the 
AERs between the lowest and highest level of the risk factor was at least 9 excess SPNs per 
10,000 person-years.  A two-sided p-value <0.05 was considered statistically significant for 
all analyses. All analyses were conducted in Stata version 14.1.  
 
2.4 RESULTS 
2.4.1 Cohort characteristics 
Within the follow-up period, 12,321 SPNs were diagnosed in 11,565 of the 197,827 survivors 
in the cohort. SPNs were most frequently observed among survivors of breast cancer 
(n=1877), cervical cancer (n=1675), Hodgkin lymphoma (n=1606), and testicular cancer 
(n=1435) (Table 2.4). Investigation of all FPN/SPN combinations with at least 100 SPNs 
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revealed that neither age at diagnosis nor decade of diagnosis was systematically associated 
with both the AERs and RERs (as specified above for reporting) except for breast cancer after 
Hodgkin lymphoma in women (Table 2.6), and lung cancer after Hodgkin lymphoma in men 
(Table 2.7).  In the remainder of the Results we consider only variation of AERs and RERs 
with years from diagnosis, in addition to these two findings (Table 2.8). 
 
2.4.2 SPN after breast cancer in women 
Among breast cancer survivors, women had 1.8-times the expected risk of developing a SPN 
(SIR=1.8, 95% confidence interval [CI]=1.7-1.8) corresponding to 20 excess SPNs 
(AER=19.5, CI=17.4-21.5) (Table 2.4). Statistically significant SIRs related to ovarian, lung, 
corpus uteri, other genital, melanoma, and colorectal cancer and were 2.8 (CI=2.5-3.1), 2.3 
(CI=2.1-2.6), 2.1 (CI=1.8-2.4), 1.4 (CI=1.1-1.6), 1.2 (CI=1.004-1.5), and 1.2 (CI=1.023-1.4) 
respectively (Table 2.5). The total AER increased from 12 at 5-9 years from diagnosis to 29 
beyond 30 years from diagnosis (multivariable Ptrend<0.001); the AER for lung cancer also 
increased with years from diagnosis (multivariable Ptrend <0.001) (Table 2.8). Among patients 
who had survived at least 30 years since their diagnosis, lung cancer accounted for 13 (45%) 
of the total number of excess neoplasms. The cumulative incidence of lung at 35 years from 
diagnosis was 2.9% (CI=2.5-3.2), whereas 2.0% was expected (Figure 2.1). 
 
2.4.3 SPN after cervical cancer 
Cervical cancer survivors had 1.3-times the expected risk of developing a SPN (SIR=1.3, 
CI=1.2-1.3), corresponding to 10 excess SPNs (AER=10.2, CI=8.0-12.4) (Table 2.4). 
Significant excess SIRs related to bladder (SIR=4.3, CI=3.5-5.1), lung (SIR=2.9, CI=2.6-3.2) 
and colorectal cancer (SIR=2.1, CI=1.8-2.3) (Table 2.5). There was a significant deficit in the 
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SIR related to breast cancer (SIR=0.7, CI=0.7-0.8) were likely related to treatment-induced 
menopause. The total AER increased from 7 at 5-9 years from diagnosis to 47 subsequent to 
30 years from diagnosis (multivariable Ptrend <0.001) (Table 2.8). The AER for each of lung, 
colorectal, and bladder neoplasms increased with years from diagnosis (each multivariable 
Ptrend <0.001).  Among patients who had survived at least 30 years since their diagnosis, lung, 
colorectal, and bladder cancer accounted for 17 (37%), 11 (23%) and 10 (22%) of the total 
number of excess neoplasms, respectively. The cumulative incidence of subsequent lung, 
colorectal, and bladder neoplasms at 35 years from diagnosis were 3.6% (CI=3.2-4.2), 2.6% 
(CI=2.2-3.0), and 1.3% (CI=1.0-1.6); whereas 1.6%, 1.5%, and 0.4% were expected, 
respectively (Figure 2.1). 
 
2.4.4 SPN after testicular cancer 
Testicular cancer survivors had 1.8-times the expected risk of developing a SPN (SIR=1.8, 
CI=1.7-1.9), corresponding to 19 excess SPNs (AER=18.9, CI=16.6-21.1) (Table 2.4). 
Specific sites with significant SIRs related to bladder, colorectal, lung, and prostate SPNs 
were 2.7 (CI=2.3-3.2), 1.9 (CI=1.6-2.2), 1.5 (CI=1.3-1.7), and 1.4 (CI=1.2-1.6), respectively 
(Table 2.5). The total AER increased significantly from 4 at 5-9 years from diagnosis to 127 
subsequent to 30 years from diagnosis (multivariable Ptrend <0.001) (Table 2.8). The AER for 
each of bladder, colorectal, lung, and prostate increased with years from diagnosis (each 
multivariable Ptrend <0.001). Among patients who had survived at least 30 years since their 
diagnosis, prostate, bladder, colorectal and lung cancers accounted for 25 (20%), 23 (18%), 
20 (15%) and 10 (8%) of the total excess number of neoplasms, respectively. The cumulative 
incidence of bladder and colorectal neoplasms at 35 years from diagnosis were 2.9% (CI=2.4-
3.6) and 3.0% (CI=2.5-3.6); whereas 1.1% and 1.8% were expected, respectively (Figure 2.1). 
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2.4.5 SPN after Hodgkin lymphoma in women 
Among Hodgkin lymphoma survivors, women were at 3.1-times the expected risk of 
developing a SPN (SIR=3.1, CI=2.9-3.3), corresponding to 56 excess neoplasms (AER=55.7, 
CI=50.4-61.1) (Table 2.4). Significant SIRs related to breast (SIR=3.2, CI=2.9-3.5) and lung 
(SIR=5.3, CI=4.3-6.5) (Table 2.5). The total AER increased significantly from 8 at 5-9 years 
from diagnosis, to 169 beyond 30 years from diagnosis (multivariable Ptrend <0.001); the AER 
for breast and lung cancer also increased with years from diagnosis (each multivariable Ptrend 
<0.001) (Table 2.8). Among patients who had survived at least 30 years since their diagnosis, 
breast and lung cancers accounted for 72 (43%) and 26 (15%) of the total excess number of 
neoplasms, respectively. The number of excess breast cancers observed declined significantly 
with increasing age at diagnosis (multivariable Ptrend <0.001) (Table 2.6). Those diagnosed at 
ages 15-19 and 35-39 years experienced 54 and 9 excess breast cancers, respectively. The 
cumulative incidence of breast and lung neoplasms at 35 years from diagnosis were 14.4% 
(CI=12.9-15.9) and 3.8% (CI=3.0-4.8); whereas 4.9% and 0.9% were expected, respectively 
(Figure 2.1). 
 
2.4.6 SPN after Hodgkin lymphoma in men 
Among Hodgkin lymphoma survivors, men were at 2.6-times the expected risk of developing 
a SPN (SIR=2.6, CI=2.4-2.8) corresponding to 30 excess neoplasms (AER=29.9, CI=26.3-
33.6) (Table 2.4). The SIR for lung neoplasms was significantly increased (SIR=4.8, CI=4.1-
5.5) (Table 2.5). The total AER increased significantly from 6 at 5-9 years from diagnosis to 
122 beyond 30 years from diagnosis (multivariable Ptrend <0.001) (Table 2.8). The AER for 
lung cancer also significantly increased with years from diagnosis (multivariable Ptrend 
<0.001). Among men who had survived at least 30 years since their diagnosis, lung cancer 
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accounted for 50 (41%) of the total number of excess neoplasms. The excess number of lung 
cancers observed decreased significantly with more recent decade of diagnosis (1971-2006) 
(multivariable Ptrend <0.001) (Table 2.7). The AER for lung cancer for survivors of Hodgkin 
lymphoma diagnosed in 1971-1979 was 19 compared to 1 among those diagnosed 1990-2006. 
The cumulative incidence of lung neoplasms was 5.1% (CI=4.3-6.0) at 35 years from 
diagnosis, whereas 1.4% was expected (Figure 2.1). 
 
2.4.7 SPN after thyroid cancer in women 
Among thyroid cancer survivors, women were at 1.4-times the expected risk of developing a 
SPN (SIR=1.4, CI=1.2-1.5) corresponding to 13 excess neoplasms (AER=13.1, CI=8.4-17.8) 
(Table 2.4). The SIR of breast neoplasms was significantly increased (SIR=1.3, CI=1.1-1.5) 
(Table 2.5). The total AER increased significantly from 5 at 5-9 years from diagnosis to 22 
beyond 30 years from diagnosis (multivariable Ptrend =0.048) (Table 2.8). 
 
2.4.8 SPN after other specific FPNs 
A significant deficit in the SIR was found for breast cancer after ovarian cancer (SIR=0.8, 
CI=0.6-0.9) (Table 2.5). Oophorectomy reduces circulating oestrogens and progesterones; 
such hormones are important in the development of hormone dependent breast cancers155.  
 
FPN/SPN combinations with between 25 and 99 observed SPNs and a SIR of at least 5 which 
was statistically significant are also highlighted in blue in Table 2.5. 
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2.5 DISCUSSION 
For the first time we provide excess risks of specific types of SPNs after each of 17 types of 
TYA cancer. There has previously been only one study which addressed the risk of all SPNs 
combined after each TYA cancer but no study has previously considered specific SPNs. We 
have almost double the number of SPNs and an additional million person-years of follow-up 
compared to this previous study and thus we are in an unprecedented position to address the 
risks of specific types of SPN after each type of TYA cancer. Previous studies investigating 
the risk of SPNs with years from diagnosis have focused on the SIR, a measure of 
multiplicative risk which relates to an arbitrary baseline risk and is therefore difficult to 
interpret. We concentrated on the AER, which is the excess number of observed SPNs beyond 
those expected from the general population and so is directly interpretable in terms of adverse 
health impact on survivors. To our knowledge we are the first to provide AERs by years from 
diagnosis for specific TYA cancers other than for Hodgkin lymphoma.  
 
Younger age at radiation exposure is a risk factor for the development of breast cancer among 
many populations exposed to radiation, including atomic bomb survivors, tuberculosis 
patients monitored with X-rays, children with benign disorders treated with radiotherapy, and 
childhood cancer survivors treated with chest radiotherapy55-57, 156. Thus, the age at 
diagnosis/treatment effect of breast cancer after Hodgkin lymphoma in our cohort is not 
entirely surprising. Among childhood cancer survivors, age at diagnosis/treatment is an 
important risk factor—younger age at treatment is associated with an increased risk of 
developing an SPN, particularly radiation-induced SPNs 97, 102. This could be due to increased 
susceptibility of tissues to mutagenesis at younger ages or genetic susceptibility157. These 
potential causes, are less likely to affect TYA cancer survivors (exception of breast tissue), 
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and could explain the lack of age at diagnosis/treatment effect on the risk of SPNs. However, 
this is the first study to investigate how the risk of developing a SPN varies within the TYA 
age range, thus further studies are required to confirm this lack of effect. 
 
Knowledge of late effects of cancer treatment has resulted in lower radiation exposures for 
treatments of good prognosis cancers in recent years158, 159, however the multivariable 
regression revealed that the risk of developing a SPN did not vary with decade of diagnosis 
with the exception of lung cancer after Hodgkin lymphoma in men. So at present there is no 
evidence that attempts to reduce the risk of SPNs among more recently treated TYA cancer 
survivors is having a detectable impact so far. 
 
2.5.1 SPN after breast cancer in women 
The SIRs which we report were broadly consistent with previous literature restricted to 
younger age groups34, 149-151. The increased risk of ovarian cancer could relate to shared 
genetic and hormonal risk factors (e.g. BRCA1/2 mutations)160. The increased risk of uterine 
cancers may relate to tamoxifen used to treat the breast cancer—a previous large case-control 
study found that risk of uterine cancer increases with duration of tamoxifen treatment161. 
Among the 6 anatomical sites at which an excess of SPNs was observed, only the lungs would 
be directly exposed if external-beam radiotherapy was used to treat the breast cancer. A 
previous large case-control study observed a dose-response relationship between radiation 
therapy and lung cancer risk among breast cancer survivors diagnosed at any age (not TYA 
specific)32. Of the 6 sites with an excess of SPNs, it was only for lung cancer that the AER 
increased with increasing years from diagnosis. Among patients who had survived at least 30 
years since their diagnosis, lung cancer accounted for 13 (45%) of the total number of excess 
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neoplasms. Smoking is an important risk factor for lung cancer, and the risk of lung cancer 
following radiation for breast cancer has been reported to be increased among smokers32. 
Smoking could contribute to the increased risk of lung cancer observed among breast cancer 
survivors in this study. In terms of evidence for long-term clinical surveillance of survivors of 
TYA breast cancer clearly lung cancer should be of principal concern and late effects follow-
up clinics should concentrate on effective counselling and smoking cessation advice. 
 
2.5.2 SPN after cervical cancer 
Among survivors of TYA cervical cancer there were over twice the expected numbers of 
bladder, lung, and colorectal cancer. The bladder and bowel would be directly exposed if 
external-beam radiotherapy was used to treat the cervical cancer. A large case-control study 
observed a dose-response relationship with radiotherapy and the risk of both bladder and 
rectal cancers among cervical cancer survivors162. The increased risk of lung cancer may be 
associated with smoking as both cervical cancer and smoking are more prevalent in lower 
socioeconomic groups163, 164. Furthermore previous studies have observed that cervical cancer 
survivors are more likely to smoke than the general population of the same age165. The AER 
increased with increasing years from diagnosis for lung, colorectal and bladder cancers. 
Among patients who had survived at least 30 years since their diagnosis, lung, colorectal, and 
bladder cancers accounted for 17 (37%), 11 (23%), and 10 (22%) of the total number of 
excess neoplasms, respectively—in aggregate accounting for 82% of the total number of 
excess neoplasms. Long-term clinical surveillance of survivors of TYA cervical cancer should 
concentrate on potential cancers of lung, bowel, and bladder. In addition, late effect clinics 
should concentrate on interventions to reduce smoking among cervical cancer survivors.  
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2.5.3 SPN after testicular cancer 
Treatment for testicular cancer may involve irradiating the para-aortic lymph nodes166 which 
may explain the excess of SPNs observed in abdominal sites (prostate, bladder and 
colorectal). The excess of SPNs observed in the abdomen is consistent with international 
studies of testicular cancer survivors33, 35, 41, 60.  The excess of lung SPNs may be due to 
radiotherapy to the lungs, previous studies have observed an increased risk of lung cancer 
among survivors of testicular cancer who were given chest radiotherapy53, 60. The AERs 
increased with increasing years from diagnosis for prostate, bladder, colorectal and lung 
cancer. Among patients who had survived at least 30 years since their diagnosis, prostate, 
bladder, colorectal, and lung cancer accounted for 25 (20%), 23 (18%), 20 (15%) and 10 (8%) 
of the total number of excess neoplasms—in aggregate accounting 61% of the total excess 
number. Long-term clinical surveillance of survivors of TYA testicular cancer should 
concentrate on potential prostate, bladder, colorectal and lung cancers. 
 
2.5.4 SPN after Hodgkin lymphoma in women 
The high numbers of excess breast and lung neoplasms observed is consistent with previous 
literature and is most likely caused by direct chest radiotherapy to treat the Hodgkin 
lymphoma 51-53, 55-57.  An increased susceptibility of breast tissue to radiation at younger ages 
might be the cause of the increased number of excess breast SPNs among survivors diagnosed 
at younger ages54. Our findings are consistent with previous large-scale studies of Hodgkin 
lymphoma survivors; for which a substantial amount of literature already exists, and unlike 
for other TYA cancers considered we have very little to add31, 36, 38, 54.  
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2.5.5 SPN after Hodgkin lymphoma in men 
Men who had survived Hodgkin lymphoma experienced approximately 5-fold the number of 
lung cancers expected. The lungs would be directly exposed if external-beam radiotherapy 
was used to treat the Hodgkin lymphoma; previous studies of Hodgkin lymphoma survivors 
provided evidence of a dose-dependent increase in lung cancer risk with radiotherapy 
with/without chemotherapy51-53. This study confirms the decrease in lung cancer risk with 
more recent calendar-period of diagnosis observed in a recent Dutch study of Hodgkin 
lymphoma survivors (Current study: 1971-2006; Dutch study: 1965-2000)36. This may be due 
to a latency effect where more recently diagnosed survivors simply have not had enough time 
to develop a lung SPN or due to changes in treatment for Hodgkin lymphoma over recent 
decades including withholding radiotherapy or irradiating less tissue than in previous 
decades159. However a decrease in lung cancer risk was not observed after Hodgkin 
lymphoma in women, therefore it is more likely that the decrease in lung cancer among men 
is due to changes in smoking habits over recent decades.  The AER for lung cancer increased 
with increasing years from diagnosis. Previous studies have reported an increase in the 
number of excess lung cancers with increasing years from diagnosis36, 54; however to our 
knowledge, we are the first to provide the number of excess lung cancers in men and women 
separately. Men had twice the number of excess lung cancers (50) than women (26) beyond 
30 years from diagnosis. Among men who had survived at least 30 years since their diagnosis, 
lung cancer accounted for 50 (41%) of the total number of excess neoplasms. Evidence-based 
long-term clinical surveillance for SPNs after Hodgkin lymphoma in men should concentrate 
on potential lung cancers and long-term clinical follow-up should advise survivors not to 
smoke.  
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2.5.6 Strengths and limitations 
Strengths of our cohort study relate to its large-scale and population-based design with the 
inclusion of all 5-year survivors in England and Wales. A limitation of using cancer 
registrations is the lack of detailed treatment information; however we have provided risk 
estimates for specific TYA cancers. Although cancer treatments for specific cancer types have 
changed over decades during which members of the cohort were treated, the variation in 
treatments for any specific cancer over these decades is, in general, appreciably less than 
variation in treatments between specific cancers.  
 
There is a possibility that recurrence or metastases of the TYA cancer could have been 
mistaken for a SPN. However we used the IACR/IARC rules to define multiple primary 
cancers and further excluded any additional neoplasms at the TYA cancer site. By using these 
criteria we excluded any contralateral SPNs such as breast or testicular SPNs. Therefore we 
provide a conservative estimate of the risk of specific SPNs after specific TYA cancers, and 
although many of the estimates we report are substantial they are likely to be an underestimate 
of the true risk. Also we were mindful of the common sites of metastatic spread for specific 
FPNs when interpreting the SPNs observed and commented on this possibility where we 
considered it appropriate. 
 
Smoking is an important risk factor for lung cancer, however we did not have information on 
smoking status of survivors therefore were unable to determine how much of the excess lung 
cancers observed were caused by smoking.  
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2.6 CONCLUSIONS 
For the first time we provide the excess risks of specific SPNs after each of 17 types of TYA 
cancer. This study demonstrates for the first time that the excess number of SPNs observed 
increased with increased period of follow-up from diagnosis after each TYA cancer 
investigated. Furthermore for each specific SPN site which would have been directly 
irradiated if external-beam radiotherapy was used to treat the original TYA cancer 
comparable relationships were observed. Among patients who had survived at least 30 years 
since their diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in women, 
breast cancer, and Hodgkin lymphoma in men, we have identified just a small number of 
specific SPNs which account for 82%, 61%, 58%, 45% and 41% of the total excess number of 
neoplasms, respectively. This is a considerable advance on existing knowledge and provides 
an initial basis for developing evidence-based long-term clinical follow-up guidelines for this 
understudied group of survivors. 
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Table 2.1: Groupings of TYA cancer based on the adolescent and young adult cancer classification 
scheme. (Refinements are highlighted in red) 
Broader Groupings used 
in current study AYA classification AYA code 
Leukaemia Acute Lymphoid Leukaemia 1.1 
 
Acute Myeloid Leukaemia 1.2 
 
Chronic Myeloid Leukaemia 1.3 
 
Other and Unspecified Leukaemias 1.4 
   
Non-Hodgkin Lymphoma Non- Hodgkin Lymphoma, specified subtype 2.1.1 
 
Unspecified Non-Hodgkin Lymphoma 2.1.2 
 
Myeloma, mast cell tumours and miscellaneous lymphoreticular neoplasms NEC 9.2.3 
   
Hodgkin Lymphoma Hodgkin Lymphoma, specified subtype 2.2.1 
 
Hodgkin lymphoma NOS 2.2.2 
   Brain Pilocytic Astrocytoma 3.1.1 
Pituitary Gland Other specified low grade astrocytic tumours 3.1.2 
Meninges Glioblastoma and anaplastic astrocytoma 3.1.3 
Spinal Cord & other CNS Astrocytoma, NOS 3.1.4 
 Oligodendroglioma 3.2.1 
 Other specified glioma 3.2.2 
 
Glioma, NOS 3.2.3 
 
Ependymoma 3.3 
 
Medulloblastoma 3.4.1 
 
Supratentorial PNET 3.4.2 
 
Craniopharyngioma 3.5.1 
 
Other pituitary tumours 3.5.2 
 
Pineal tumours 3.5.3 
 
Choroid plexus tumours 3.5.4 
 
Meningioma 3.5.5 
 
Nerve sheath tumours of CNS 3.5.6 
 
Other specified intracranial and intraspinal neoplasms 3.5.7 
 
Unspecified malignant intracranial and intraspinal neoplasms 3.6.1 
 
Unspecified benign and borderline intracranial and intraspinal neoplasms 3.6.2 
 
Germ cell intracranial 6.2.1 
   
Bone Neoplasms Osteosarcoma 4.1 
 
Chondrosarcoma 4.2 
 
Ewing sarcoma of bone 4.3.1 
 
Ewing sarcoma of specified site other than bone 4.3.2 
 
Ewing sarcoma of unspecified site 4.3.3 
 
Other specified bone tumours 4.4.1 
 
Unspecified bone tumours 4.4.2 
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Soft Tissue Sarcoma Fibrosarcoma 5.1.1 
 
Malignant Fibrous Histiocytoma 5.1.2 
 
Dermatofibrosarcoma 5.1.3 
 
Rhabdomyosarcoma 5.2 
 
Liposarcoma 5.3.1 
 
Leiomyosarcoma 5.3.2 
 
Synovial sarcoma 5.3.3 
 
Clear cell sarcoma 5.3.4 
 
Blood vessel tumours 5.3.5 
 
Nerve sheath tumours 5.3.6 
 
Alveolar soft part sarcoma 5.3.7 
 
Other specified 5.3.8 
 
Unspecified soft tissue sarcoma 5.4 
   
Melanoma Melanoma 7.1 
   
Carcinomas – by site  8 
Thyroid Thyroid Carcinoma 8.1 
   
Head and Neck Nasopharyngeal carcinoma 8.2.1 
 
Other sites in lip, oral cavity and pharynx 8.2.2 
 
Nasal cavity, middle ear, sinuses, larynx and other and ill-defined head and neck 8.2.3 
   
Lung Trachea, bronchus and lung 8.3 
   
Breast Carcinoma of breast (women only) 8.4 
   
Bladder Carcinoma of bladder 8.5.2 
 
Unspecified malignant neoplasms, NEC (in bladder site) 10 
 
Unspecified benign and borderline neoplasms, NEC (in bladder site) Not in AYA 
 
Benign and borderline neoplasms of bladder (ICDO3 code 8010-8589, 8982) Not in AYA 
   
GU Tract (other) Carcinoma of kidney 8.5.1 
 
Carcinoma of other and ill-defined sites in GU tract 8.5.5 
 
Wilms tumour 9.1.1 
   
Ovary Carcinoma of ovary 8.5.3 
 
Germ cell and trophoblastic neoplasms of gonads (women only) 6.1 
 
Other specified gonadal tumours (women only) 9.2.2 
   
Cervix Carcinoma of cervix 8.5.4 
   
Gastrointestinal Tract Carcinoma of colon and rectum 8.6.1 
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Carcinoma of stomach 8.6.2 
 
Carcinoma of liver and intrahepatic bile ducts 8.6.3 
 
Carcinoma of pancreas 8.6.4 
 
Carcinoma of other and ill-defined sites in GI tract 8.6.5 
   
Testis Germ cell gonadal (men only) 6.1 
 
Other specified gonadal tumours (men only) 9.2.2 
   
Other Other non-gonadal sites 6.2.2 
 
Non melanoma skin cancer (non-epithelial tumours only) 7.2 
 
Carcinoma of breast (men only) 8.4 
 
Adrenocortical carcinoma 8.7.1 
 
Carcinoma of other and ill-defined sites, NEC 8.7.2 
 
Neuroblastoma 9.1.2 
 
Other paediatric and embryonal, NEC 9.1.3 
 
Paraganglioma and glomus 9.2.1 
 
Other specified neoplasms, NEC 9.2.4 
 
Unspecified malignant neoplasms, NEC 10 
Abbreviations: AYA= adolescents and young adults; NEC=not elsewhere classified; NOS= not otherwise specified; GI= gastrointestinal; 
GU=genitourinary; CNS= central nervous system; PNET= primitive neuroectodermal tumour.  
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Table 2.2: Description of ‘Other’ TYA cancers excluded from analysis. 
Description Number of SPNs 
CNS tumour (located outside of the CNS) 62 
Germ cell neoplasm (non-gonadal, extracranial) 607 
Non-epithelial Skin Cancer 192 
Breast neoplasm in men 103 
Adrenocortical carcinoma 82 
Carcinoma of other and  ill-defined sites, NEC 528 
Neuroblastoma 59 
Other paediatric and embryonal neoplasms, NEC 63 
Paraganglioma and glomus neoplasms 143 
Other specified neoplasms, NEC 664 
Unspecified malignant neoplasm, NEC 615 
Total 3,118 
Abbreviations: SPNs – subsequent primary neoplasms, CNS – central nervous system, NEC – not elsewhere classified
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Table 2.3: Exclusions of TYA cancer and subsequent primary neoplasms combinations 
Subsequent Primary 
Neoplasms 
First Primary Neoplasm 
Breast 
(women) 
Testis Cervix Melanoma Hodgkin 
lymphoma 
NHL Thyroid Brain Colorectal STS Ovary Leukaemia 
Breast (women) Excluded N/A           
Corpus Uteri   Excluded        Excluded  
Ovary  N/A Excluded        Excluded  
Other Genital (women)  N/A Excluded        Excluded  
Kidney             
Bladder             
Other Urinary             
Prostate N/A  N/A        N/A  
Other Genital (men) N/A Excluded N/A        N/A  
Colorectal         Excluded    
Oesophagus             
Stomach             
Pancreas             
Other Digestive1             
Lung & Bronchus             
Other Respiratory             
Melanoma    Excluded         
Brain        Excluded     
Meninges             
Spinal Cord & other CNS             
Pituitary Gland             
Thyroid       Excluded      
STS          Excluded   
Bone Sarcoma          Excluded   
NHL     Excluded Excluded      Excluded 
Leukaemia     Excluded Excluded      Excluded 
Oral             
Other             
--Hodgkin lymphoma     Excluded Excluded      Excluded 
--Other lymphoid     Excluded Excluded      Excluded 
--Eye    Excluded         
--Breast (Men only) N/A            
--Other Endocrine             
 
 
61 
 
Table 2.3: continued 
Subsequent Primary 
Neoplasms 
First Primary Neoplasms 
Bladder Pituitary 
gland 
Head & 
Neck 
Lung Other Genital 
(women) 
Spinal Cord and 
Other CNS 
Other 
Digestive 
Meninges Urinary 
(other) 
Bone 
Tumour 
Other Genital 
(men) 
Breast (women)           N/A 
Corpus Uteri     Excluded      N/A 
Ovary     Excluded      N/A 
Other Genital (women)     Excluded      N/A 
Kidney Excluded        Excluded   
Bladder Excluded        Excluded   
Other Urinary Excluded        Excluded   
Prostate     N/A      Excluded 
Other Genital (men)     N/A      Excluded 
Colorectal            
Oesophagus       Excluded     
Stomach       Excluded     
Pancreas       Excluded     
Other Digestive       Excluded     
Lung & Bronchus    Excluded        
Other Respiratory   Excluded2 Excluded        
Melanoma            
Brain            
Meninges        Excluded    
Spinal Cord & other CNS      Excluded      
Pituitary Gland  Excluded          
Thyroid            
STS          Excluded  
Bone Sarcoma          Excluded  
NHL            
Leukaemia            
Oral   Excluded         
Other            
--Hodgkin lymphoma            
--Other lymphoid            
--Eye            
--Breast (Men only)     N/A       
--Other Endocrine            
Abbreviations: NHL – non Hodgkin lymphoma, STS – soft tissue sarcoma, CNS – central nervous system. 
1 All liver subsequent primary neoplasms were excluded because of substantial likelihood of metastatic spread. 
2Nasal cavity, middle ear, accessory sinuses and larynx excluded only. Trachea, lung and bronchus not exclude
 
 
62 
 
Table 2.4: Risk of any subsequent primary neoplasm after specific types of TYA cancer 
First Primary Neoplasm 
Total number of 
SPNs 
Women Men 
O/E SIR (95% CI) AER (95% CI) O/E SIR (95% CI) AER (95% CI) 
Breast (women) 1877 1877/1069.6 1.8 (1.7,1.8) 19.5 (17.4,21.5) - - - 
Cervix 1675 1675/1307.0 1.3 (1.2,1.3) 10.2 (8.0,12.4) - - - 
Hodgkin Lymphoma 1606 903/288.2 3.1 (2.9,3.3) 55.7 (50.4,61.1) 703/271.9 2.6 (2.4,2.8) 29.9 (26.3,33.6) 
Testicular 1435 - - - 1435/807.6 1.8 (1.7,1.9) 18.9 (16.6,21.1) 
Melanoma 981 751/665.7 1.1 (1.0,1.2) 4.5 (1.6,7.3) 230/195.8 1.2 (1.0,1.3) 4.2 (0.6,7.9) 
Colorectal 537 302/170.6 1.8 (1.6,2.0) 32.1 (23.8,40.4) 235/125.0 1.9 (1.6,2.1) 28.9 (21.0,36.8) 
Non-Hodgkin Lymphoma 511 216/149.5 1.4 (1.3,1.7) 14.8 (8.4,21.2) 295/163.4 1.8 (1.6,2.0) 18.6 (13.8,23.4) 
Thyroid 473 397/288.8 1.4 (1.2,1.5) 13.1 (8.4,17.8) 76/55.0 1.4 (1.1,1.7) 10.2 (1.9,18.4) 
Soft Tissue Sarcoma 400 255/165.7 1.5 (1.4,1.7) 19.8 (12.9,26.8) 145/106.5 1.4 (1.1,1.6) 9.3 (3.6,15.0) 
Ovary 349 349/255.3 1.4 (1.2,1.5) 12.3 (7.5,17.1) - - - 
Brain 347 170/104.7 1.6 (1.4,1.9) 17.4 (10.6,24.2) 177/89.7 2.0 (1.7,2.3) 19.1 (13.4,24.7) 
Bladder 344 88/87.9 1.0 (0.8,1.2) 0.0 (-8.9,8.9) 256/209.2 1.2 (1.1,1.4) 8.0 (2.6,13.4) 
Other Genital (women)* 269 269/141.8 1.9 (1.7,2.1) 37.2 (27.8,46.7) - - - 
Leukaemia 234 120/63.3 1.9 (1.6,2.3) 22.9 (14.2,31.5) 114/44.4 2.6 (2.1,3.1) 22.7 (15.9,29.5) 
Head & Neck 253 117/87.9 1.3 (1.1,1.6) 12.4 (3.4,21.5) 136/100.3 1.4 (1.1,1.6) 11.6 (4.2,19.0) 
Pituitary Gland 220 146/130.2 1.1 (0.9,1.3) 3.9 (-1.9,9.7) 74/65.1 1.1 (0.9,1.4) 3.4 (-3.0,9.7) 
Spinal Cord & other CNS 191 95/62.5 1.5 (1.2,1.9) 19.1 (7.9,30.3) 96/44.0 2.2 (1.8,2.7) 30.6 (19.3,41.9) 
Meninges 172 116/87.4 1.3 (1.1,1.6) 14.0 (3.7,24.3) 56/29.6 1.9 (1.4,2.5) 25.8 (11.4,40.1) 
Urinary(Other)* 139 58/39.0 1.5 (1.1,1.9) 19.1 (4.1,34.1) 81/45.7 1.8 (1.4,2.2) 24.5 (12.2,36.7) 
Other Digestive 107 45/30.3 1.5 (1.1,2.0) 19.3 (2.0,36.6) 62/29.5 2.1 (1.6,2.7) 33.9 (17.8,50.1) 
Bone Tumour 100 52/32.7 1.6 (1.2,2.1) 14.7 (3.9,25.5) 48/33.1 1.4 (1.1,1.9) 8.1 (0.7,15.6) 
Lung 80 38/30.0 1.3 (0.9,1.7) 10.2 (-5.2,25.6) 42/37.4 1.1 (0.8,1.5) 4.4 (-7.8,16.7) 
Other Genital (Men)* 21 - - - 21/16.8 1.2 (0.8,1.9) 7.2 (-8.2,22.5) 
Abbreviations: SPNs-subsequent primary neoplasms, O- observed number of SPNs, E- expected number of SPNs, SIR- standardised incidence ratio, AER-absolute excess risk, CI- confidence interval, CNS-central 
nervous system 
*Other genital cancers in men excludes testis; other genital cancer in women excludes the cervix and ovary; urinary cancer excludes bladder
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Table 2.5: Risk of subsequent primary neoplasms after 17 types of TYA cancer * (Blue: between 25-99 observed events, SIR≥5 and statistically significant; 
Red: ≥100 observed events and SIR statistically significant) 
 
Subsequent Primary 
Neoplasms 
First Primary Neoplasm 
All1 
Breast  
(women only) Cervix Testicular 
Hodgkin lymphoma (women 
only) 
Hodgkin lymphoma  
(men only) 
O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) 
Breast (women only) 2260/2032.1 1.1 (1.1,1.2) - - 532/684.8 0.8 (0.7,0.8) - - 431/136.3 3.2 (2.9,3.5) - - 
Lung & Bronchus 1740/855.8 2.0 (1.9,2.1) 357/152.2 2.3 (2.1,2.6) 335/116.9 2.9 (2.6,3.2) 171/115.5 1.5 (1.3,1.7) 101/19.0 5.3 (4.3,6.5) 198/41.3 4.8 (4.1,5.5) 
Colorectal 1290/801.9 1.6 (1.5,1.7) 179/150.2 1.2 (1.0,1.4)3 237/115.1 2.1 (1.8,2.3) 206/109.2 1.9 (1.6,2.2) 50/20.2 2.5 (1.8,3.3) 86/39.2 2.2 (1.8,2.7) 
Other 793/405.1 2.0 (1.8,2.1) 97/56.7 1.7 (1.4,2.1) 61/46.6 1.3 (1,1.6) 104/52.4 2.0 (1.6,2.4) 37/6.4 5.8 (4.1,8.0) 54/27.7 1.9 (1.5,2.5) 
Bladder 606/296.6 2.0 (1.9,2.2) 50/38.6 1.3 (1.0,1.7) 126/29.6 4.3 (3.5,5.1) 167/61.3 2.7 (2.3,3.2) 11/4.9 2.2 (1.1,4.0) 30/22.0 1.4 (0.9,1.9) 
Prostate 545/433.5 1.3 (1.2,1.4) - - - - 185/133.5 1.4 (1.2,1.6) - - 48/45.8 1.0 (0.8,1.4) 
Melanoma 500/385.6 1.3 (1.2,1.4) 100/81.0 1.2 (1.0,1.5)4 61/68.3 0.9 (0.7,1.1) 68/44.4 1.5 (1.2,1.9) 29/17.1 1.7 (1.1,2.4) 20/16.8 1.2 (0.7,1.8) 
Ovary 447/244.6 1.8 (1.7,2.0) 291/104.9 2.8 (2.5,3.1) - - - - 16/16.4 1.0 (0.6,1.6) - - 
Oral 406/215.3 1.9 (1.7,2.1) 44/28.3 1.6 (1.1,2.1) 42/23.2 1.8 (1.3,2.4) 56/40.7 1.4 (1.0,1.8) 21/4.6 4.6 (2.8,7.0) 51/14.8 3.5 (2.6,4.5) 
Corpus Uteri 404/214.8 1.9 (1.7,2.1) 204/95.7 2.1 (1.8,2.4) - - - - 21/12.8 1.6 (1.0,2.5) - - 
Kidney 371/175.8 2.1 (1.9,2.3) 39/27.9 1.4 (1.0,1.9) 32/22.2 1.4 (1.0,2.0) 53/30.4 1.7 (1.3,2.3) 11/4.0 2.7 (1.4,4.9) 23/11.0 2.1 (1.3,3.1) 
Non-Hodgkin Lymphoma 358/290.4 1.2 (1.1,1.4) 79/57.2 1.4 (1.1,1.7) 51/46.0 1.1 (0.8,1.5) 63/46.2 1.4 (1.0,1.7) - - - - 
Brain 317/186.7 1.7 (1.5,1.9) 28/29.4 1.0 (0.6,1.4) 22/24.0 0.9 (0.6,1.4) 26/28.9 0.9 (0.6,1.3) 11/5.4 2.0 (1.0,3.6) 16/11.4 1.4 (0.8,2.3) 
Oesophagus 297/158.4 1.9 (1.7,2.1) 46/20.4 2.3 (1.6,3.0) 23/15.6 1.5 (0.9,2.2) 46/29.8 1.5 (1.1,2.1) 26/2.6 10.2 (6.6,14.9) 46/10.7 4.3 (3.2,5.8) 
Pancreas 283/162.8 1.7 (1.5,2.0) 34/30.3 1.1 (0.8,1.6) 26/23.0 1.1 (0.7,1.7) 76/20.9 3.6 (2.9,4.6) 13/3.8 3.4 (1.8,5.8) 22/7.5 2.9 (1.8,4.4) 
Other Genital (women only) 282/219.7 1.3 (1.1,1.4) 111/82.0 1.4 (1.1,1.6) - - - - 31/19.8 1.6 (1.1,2.2) - - 
Stomach 264/147.6 1.8 (1.6,2.0) 32/20.4 1.6 (1.1,2.2) 22/15.2 1.4 (0.9,2.2) 81/25.7 3.2 (2.5,3.9) 7/2.8 2.5 (1.0,5.2) 26/9.4 2.8 (1.8,4.1) 
Other Digestive2 254/89.7 2.8 (2.5,3.2) 47/18.3 2.6 (1.9,3.4) 31/14.3 2.2 (1.5,3.1) 39/9.6 4.1 (2.9,5.6) 9/2.5 3.5 (1.6,6.7) 12/3.5 3.4 (1.8,6.0) 
Thyroid 244/90.8 2.7 (2.4,3.0) 35/20.4 1.7 (1.2,2.4) 20/17.5 1.1 (0.7,1.8) 13/5.4 2.4 (1.3,4.1) 47/5.1 9.2 (6.7,12.2) 26/2.1 12.3 (8.0,18.0) 
Leukaemia 229/151.9 1.5 (1.3,1.7) 51/28.4 1.8 (1.3,2.4) 28/22.7 1.2 (0.8,1.8) 39/25.5 1.5 (1.1,2.1) - - - - 
Other Respiratory 217/92.8 2.3 (2.0,2.7) 30/10.4 2.9 (1.9,4.1) 18/8.2 2.2 (1.3,3.5) 31/19.4 1.6 (1.1,2.3) 20/1.5 13.1 (8.0,20.3) 42/7.2 5.9 (4.2,7.9) 
Meninges 214/70.8 3.0 (2.6,3.5) 23/16.9 1.4 (0.9,2.0) 8/13.8 0.6 (0.3,1.1) 11/4.2 2.6 (1.3,4.7) 11/3.0 3.7 (1.8,6.5) ** ** 
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Table 2.5: continued 
Subsequent Primary Neoplasms 
First Primary Neoplasm 
Melanoma Colorectal Non-Hodgkin Lymphoma  Thyroid Soft Tissue Sarcoma Ovary 
O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) 
Breast (women only) 359/313.2 1.1 (1.0,1.3) 74/79.3 0.9 (0.7,1.2) 89/70.9 1.3 (1.0,1.5) 170/130.2 1.3 (1.1,1.5)† 88/72.5 1.2 (1.0,1.5) 101/131.1 0.8 (0.6,0.9) 
Lung & Bronchus 82/78.1 1.1 (0.8,1.3) 48/38.1 1.3 (0.9,1.7) 83/37.0 2.2 (1.8,2.8) 34/28.4 1.2 (0.8,1.7) 32/27.7 1.2 (0.8,1.6) 54/23.2 2.3 (1.7,3.0) 
Colorectal 80/77.5 1.0 (0.8,1.3) - - 47/35.4 1.3 (1.0,1.8) 33/28.2 1.2 (0.8,1.6) 46/26.6 1.7 (1.3,2.3) 58/23.0 2.5 (1.9,3.3) 
Other 64/42.4 1.5 (1.1,1.9) 31/17.1 1.8 (1.2,2.5) 33/16.7 2 (1.3,2.7) 33/15.2 2.2 (1.4,2.9) 19/14.1 1.3 (0.7,2) 19/9.4 2 (1.1,2.9) 
Bladder 27/27.8 1.0 (0.6,1.4) 32/15.5 2.1 (1.4,2.9) 33/16.5 2.0 (1.4,2.8) 11/9.4 1.2 (0.6,2.1) 13/11.2 1.2 (0.6,2.0) 24/6.0 4.0 (2.6,6.0) 
Prostate 40/32.9 1.2 (0.9,1.7) 33/27.3 1.2 (0.8,1.7) 35/29.8 1.2 (0.8,1.6) 14/9.1 1.5 (0.8,2.6) 24/17.8 1.4 (0.9,2.0) - - 
Melanoma - - 20/13.7 1.5 (0.9,2.3) 27/17.2 1.6 (1.0,2.3) 25/17.4 1.4 (0.9,2.1) 24/13.2 1.8 (1.2,2.7) 19/13.6 1.4 (0.8,2.2) 
Ovary 32/37.7 0.8 (0.6,1.2) 19/10.2 1.9 (1.1,2.9) 11/8.6 1.3 (0.6,2.3) 16/15.8 1.0 (0.6,1.6) 18/9.1 2.0 (1.2,3.1) - - 
Oral 13/20.8 0.6 (0.3,1.1) 16/8.8 1.8 (1.0,2.9) 31/11.0 2.8 (1.9,4.0) 13/7.0 1.9 (1.0,3.2) 16/7.5 2.1 (1.2,3.5) 10/4.5 2.2 (1.1,4.1) 
Corpus Uteri 33/32.6 1.0 (0.7,1.4) 68/9.5 7.2 (5.6,9.1) 8/7.3 1.1 (0.5,2.2) 11/13.5 0.8 (0.4,1.5) 11/8.0 1.4 (0.7,2.5) - - 
Kidney 31/17.4 1.8 (1.2,2.5) 23/7.7 3.0 (1.9,4.5) 11/8.8 1.3 (0.6,2.2) 10/6.0 1.7 (0.8,3.0) 14/6.2 2.3 (1.2,3.8) 6/4.3 1.4 (0.5,3.0) 
Non-Hodgkin Lymphoma 41/32.1 1.3 (0.9,1.7) 19/12.7 1.5 (0.9,2.3) - - 13/11.6 1.1 (0.6,1.9) 13/10.8 1.2 (0.6,2.1) 8/9.1 0.9 (0.4,1.7) 
Brain 45/18.4 2.4 (1.8,3.3) 21/7.0 3.0 (1.8,4.6) 9/8.8 1.0 (0.5,1.9) 13/6.6 2.0 (1.0,3.4) 13/6.3 2.1 (1.1,3.5) ** ** 
Oesophagus 14/14.1 1.0 (0.5,1.7) 12/7.3 1.6 (0.8,2.9) 20/8.0 2.5 (1.5,3.9) 5/4.7 1.1 (0.3,2.5) 5/5.5 0.9 (0.3,2.1) ** ** 
Pancreas 19/15.1 1.3 (0.8,2.0) 9/6.9 1.3 (0.6,2.5) 8/6.8 1.2 (0.5,2.3) 6/5.5 1.1 (0.4,2.4) ** ** 9/4.6 1.9 (0.9,3.7) 
Other Genital (women only) 25/35.9 0.7 (0.5,1.0) 27/8.1 3.3 (2.2,4.8) 13/8.4 1.5 (0.8,2.6) 16/15.5 1.0 (0.6,1.7) 8/8.6 0.9 (0.4,1.8) - - 
Stomach 7/13.1 0.5 (0.2,1.1) 14/6.9 2.0 (1.1,3.4) 18/7.3 2.5 (1.5,3.9) 10/4.5 2.2 (1.1,4.1) 13/5.1 2.6 (1.4,4.4) ** ** 
Other Digestive2 12/8.7 1.4 (0.7,2.4) 48/3.4 13.9 (10.3,18.4) ** ** 9/3.2 2.8 (1.3,5.3) 11/2.8 4.0 (2.0,7.1) 8/2.8 2.8 (1.2,5.6) 
Thyroid 21/11.0 1.9 (1.2,2.9) ** ** 12/3.4 3.6 (1.8,6.3) - - 9/2.8 3.3 (1.5,6.2) 9/3.6 2.5 (1.1,4.8) 
Leukaemia 15/16.7 0.9 (0.5,1.5) 9/6.9 1.3 (0.6,2.5) - - 10/6.1 1.7 (0.8,3.0) 9/5.8 1.6 (0.7,3.0) 10/4.6 2.2 (1.1,4.0) 
Other Respiratory 12/8.4 1.4 (0.7,2.5) 8/4.4 1.8 (0.8,3.6) 12/5.1 2.4 (1.2,4.1) 9/2.8 3.2 (1.5,6.1) ** ** ** ** 
Meninges 9/7.6 1.2 (0.5,2.2) ** ** 7/2.4 2.9 (1.2,6.0) 12/3.0 4.0 (2.0,6.9) 6/2.0 3.0 (1.1,6.5) 6/2.7 2.2 (0.8,4.9) 
 
 
 
 
 
65 
 
Table 2.5: continued 
Subsequent Primary Neoplasms 
First Primary Neoplasm 
Brain Bladder Other genital (women only) Leukaemia Head & Neck Pituitary Gland 
O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) O/E SIR (95% CI) 
Breast (women only) 37/47.6 0.8 (0.5,1.1) 29/39.3 0.7 (0.5,1.1) 80/71.2 1.1 (0.9,1.4) 50/30.3 1.6 (1.2,2.2) 44/39.2 1.1 (0.8,1.5) 28/59.3 0.5 (0.3,0.7) 
Lung & Bronchus 17/18.9 0.9 (0.5,1.4) 73/45.2 1.6 (1.3,2.0) 29/14.2 2.0 (1.4,2.9) 14/9.9 1.4 (0.8,2.4) 41/23.0 1.8 (1.3,2.4) 9/17.3 0.5 (0.2,1.0) 
Colorectal 17/18.8 0.9 (0.5,1.4) 39/39.8 1.0 (0.7,1.3) 65/13.7 4.7 (3.6,6.0) 16/10.5 1.5 (0.9,2.5) 23/21.2 1.1 (0.7,1.6) 14/17.2 0.8 (0.4,1.4) 
Other 56/15.7 3.6 (2.6,4.5) 26/19.1 1.4 (0.8,1.9) 15/5.2 2.9 (1.4,4.3) 15/7.3 2.1 (1,3.1) 28/11.6 2.4 (1.5,3.3) 18/10.5 1.7 (0.9,2.5) 
Bladder 8/8.3 1.0 (0.4,1.9) - - 20/3.6 5.5 (3.4,8.5) 8/4.4 1.8 (0.8,3.6) 14/10.1 1.4 (0.8,2.3) 9/6.9 1.3 (0.6,2.5) 
Prostate 15/13.5 1.1 (0.6,1.8) 62/46.4 1.3 (1.0,1.7) - - 5/6.1 0.8 (0.3,1.9) 15/19.6 0.8 (0.4,1.3) 10/10.4 1.0 (0.5,1.8) 
Melanoma 16/11.1 1.4 (0.8,2.3) 14/13.1 1.1 (0.6,1.8) 6/6.6 0.9 (0.3,2.0) 12/7.3 1.6 (0.8,2.9) ** ** 13/10.4 1.2 (0.7,2.1) 
Ovary ** ** ** ** - - ** ** ** ** 8/7.0 1.1 (0.5,2.3) 
Oral 9/6.0 1.5 (0.7,2.8) 12/10.9 1.1 (0.6,1.9) 7/2.4 2.9 (1.2,5.9) 29/3.7 7.8 (5.2,11.1) - - 6/5.2 1.2 (0.4,2.5) 
Corpus Uteri 7/4.4 1.6 (0.6,3.3) ** ** - - ** ** 7/4.3 1.6 (0.7,3.4) 12/5.7 2.1 (1.1,3.7) 
Kidney 61/4.7 13.0 (9.9,16.6) - - 4/2.5 1.6 (0.4,4.1) 7/2.8 2.5 (1.0,5.2) 13/4.9 2.6 (1.4,4.5) 10/4.1 2.4 (1.2,4.5) 
Non-Hodgkin Lymphoma 11/8.4 1.3 (0.7,2.3) 11/14.0 0.8 (0.4,1.4) 6/5.1 1.2 (0.4,2.6) - - 9/8.0 1.1 (0.5,2.1) 7/7.4 0.9 (0.4,1.9) 
Brain - - 8/8.0 1.0 (0.4,2.0) 5/2.6 1.9 (0.6,4.5) 17/3.3 5.1 (3.0,8.2) 9/4.6 2.0 (0.9,3.7) 19/4.4 4.3 (2.6,6.7) 
Oesophagus ** ** 7/9.6 0.7 (0.3,1.5) 5/1.9 2.6 (0.9,6.1) 14/2.2 6.3 (3.4,10.6) 13/4.8 2.7 (1.5,4.7) ** ** 
Pancreas 10/3.6 2.8 (1.3,5.1) 11/7.8 1.4 (0.7,2.5) 5/2.8 1.8 (0.6,4.1) ** ** ** ** 7/3.3 2.1 (0.9,4.4) 
Other Genital (women only) 7/6.7 1.0 (0.4,2.1) 7/4.1 1.7 (0.7,3.5) - - 9/4.2 2.1 (1.0,4.0) 7/4.4 1.6 (0.6,3.3) 11/7.4 1.5 (0.7,2.6) 
Stomach ** ** 12/9.0 1.3 (0.7,2.3) ** ** ** ** ** ** ** ** 
Other Digestive2 ** ** ** ** 6/1.7 3.6 (1.3,7.9) ** ** ** ** ** ** 
Thyroid ** ** ** ** 5/1.6 3.1 (1.0,7.2) 10/1.7 6.0 (2.9,11.0) 7/1.7 4.2 (1.7,8.7) ** ** 
Leukaemia 12/4.6 2.6 (1.3,4.5) 11/8.0 1.4 (0.7,2.5) ** ** - - ** ** 8/4.0 2.0 (0.9,4.0) 
Other Respiratory 7/2.7 2.6 (1.1,5.4) 9/6.0 1.5 (0.7,2.9) ** ** ** ** ** ** ** ** 
Meninges 40/1.5 26.0 (18.6,35.5) ** ** ** ** 13/1.0 13.2 (7.0,22.6) ** ** 20/1.6 12.5 (7.6,19.3) 
Abbreviations: O – observed number of SPNs, E- Expected number of SPNs, SIR- standardised incidence ratio, CI-confidence interval, CNS- central nervous system 
*excludes potential subsequent primary neoplasms at the same anatomical site as the TYA cancer, represented by ‘-‘ 
**results not reliable due to small number of SPNS:  <5 observed SPNs 
¹Includes all FPNs listed and other genital cancers in men and bone tumours 
2Consists of 80 small intestine, 62 gallbladder, 77 retroperitoneum and peritoneum and 31 other or unspecified. 
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3Confidence interval to three decimal places was (1.023-1.380) 
4Confidence interval to three decimal places was (1.004-1.501) 
†Breast SPNs after thyroid cancer occurred only in women – expected breast cancers in men was zero
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Table 2.6: Absolute excess risks (AERs) and relative excess risks (RERs) of subsequent primary 
breast neoplasms after Hodgkin lymphoma in women by age at diagnosis 
 
  O/E AER (95% CI) RER (95% CI)1 
Overall 431/136.3 26.7 (23.0,30.4)   
Age at Diagnosis 
   15-19 132/12.2 54.4 (44.2,64.7) 1.0 (1.0,1.0) 
20-24 115/26.2 29.4 (22.4,36.3) 0.5 (0.4,0.7) 
25-29 76/31.2 18.1 (11.2,25.0) 0.4 (0.2,0.6) 
30-34 63/34.0 15.2 (7.1,23.4) 0.3 (0.2,0.6) 
35-39 45/32.6 8.7 (-0.5,17.9) 0.2 (0.1,0.5) 
Ptrend   <0.001 <0.001 
Abbreviations: O – observed number of SPNs, E- Expected number of SPNs, AER- absolute excess risk, CI-confidence interval 
1From an externally controlled Poisson regression model which contained the following factors: attained age, decade of diagnosis and age at 
diagnosis. 
 
 
 
 
 
 
Table 2.7: Absolute excess risks (AERs) and relative excess risks (RERs) of subsequent primary lung 
neoplasms after Hodgkin lymphoma in men by decade of diagnosis 
 
  O/E AER (95% CI) RER (95% CI)1 
Overall 198/41.3 10.9 (9.0,12.8)   
Decade of Diagnosis 
   1971-1979 110/23.4 18.9 (14.4,23.3) 1.0 (1.0,1.0) 
1980-1989 78/14.1 11.9 (8.7,15.1) 0.9 (0.6,1.3) 
1990-2006 10/3.9 1.4 (-0.0,2.8) 0.2 (0.1,0.5) 
Ptrend   <0.001 <0.001 
Abbreviations: O – observed number of SPNs, E- Expected number of SPNs, AER- absolute excess risk, CI-confidence interval 
1From an externally controlled Poisson regression model which contained the following factors: attained age, decade of diagnosis and age at 
diagnosis. 
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Table 2.8: Absolute excess risk (AER) of all and specific SPNs after particular FPNs by years from diagnosis, with percentage of total AER contributed by specific SPNs† 
First Primary Neoplasm 
Subsequent Primary 
Neoplasm 
Years from Diagnosis   
5-9 10-19 20-29 30+ Multivariable 
Ptrend
‡
 O/E AER % AER O/E AER % AER O/E AER % AER O/E AER % AER 
Breast (women) 
Total1 371/190.4 11.7 100 730/391.7 19.6 100 581/338.5 34.5 100 195/149.0 29 100 <0.001 
Corpus Uteri 46/9.9 2.3 19.7 100/36.0 3.7 18.9 51/36.8 2.0 5.8 7/12.9 * * 0.973 
Ovary 74/20.6 3.5 29.9 128/43.0 4.9 25.0 71/31.2 5.7 16.5 18/10.1 4.4 15.2 0.504 
Other Genital 38/30.9 0.5 4.3 50/33.1 1.0 5.1 18/13.7 0.6 1.7 5/4.3 0.4 1.4 0.251 
Colorectal 24/19.8 0.3 2.6 63/51.6 0.7 3.6 65/51.9 1.9 5.5 27/26.9 0.1 0.3 0.125 
Lung 37/14.6 1.5 12.8 112/48.5 3.7 18.9 154/58.6 13.6 39.4 54/30.5 13.1 45.2 <0.001 
Melanoma 30/23.1 0.4 3.4 45/34.0 0.6 3.1 17/18.1 -0.2 -0.6 8/5.8 1.2 4.1 0.566 
Other 122/71.5 3.3 28.2 232/145.5 5.0 25.5 205/128.2 10.9 31.6 76/58.4 9.8 33.8 <0.001 
Cervical 
Total2 241/179.6 7.1 100 618/509.3 9.7 100 609/465.2 27.3 100 207/152.9 46.5 100 <0.001 
Breast 89/104.4 * * 251/294.6 * * 157/227.0 * * 35/58.8 * * - 
Bladder 11/2.1 0.8 11.3 40/8.4 2 20.6 52/12.9 5 18.3 23/6.1 10.1 21.7 <0.001 
Colorectal 23/10.4 1.2 16.9 66/37.9 1.8 18.6 110/46.7 8.1 29.7 38/20.0 10.7 23.0 <0.001 
Lung 45/7.3 3.5 49.3 101/34.5 4.2 43.3 137/52.0 10.8 39.6 52/23.2 17.2 37.0 <0.001 
Other 73/55.3 1.6 22.5 160/133.9 1.7 17.5 153/126.6 3.4 12.5 59/44.8 8.5 18.3 0.243 
Testicular 
Total3 124/81.9 3.8 100 378/246.2 9.0 100 605/318.3 46.6 100 328/161.1 127.0 100 <0.001 
Prostate 1/1.4 0.0 0.0 26/20.0 0.4 4.4 79/66.3 2.1 4.5 79/45.7 25.3 19.9 <0.001 
Bladder 9/5.0 0.4 10.5 30/17.4 0.9 10.0 84/25.0 9.6 20.6 44/14.0 22.8 18.0 <0.001 
Colorectal 16/9.4 0.6 15.8 45/33.4 0.8 8.9 97/44.1 8.6 18.5 48/22.3 19.6 15.4 <0.001 
Lung 7/7.1 0.0 0.0 42/32.0 0.7 7.8 83/49.9 5.4 11.6 39/26.6 9.5 7.5 <0.001 
Other 91/59.1 2.8 73.7 235/143.4 6.3 70.0 262/133.0 21.0 45.1 118/52.6 49.7 39.1 <0.001 
Hodgkin Lymphoma 
(women) 
Total4 66/38.6 8 100 316/104.2 44.7 100 374/100.8 119.5 100 147/44.6 168.6 100 <0.001 
Breast 20/17.0 0.9 11.3 168/52.0 24.5 54.8 181/48.8 57.8 48.4 62/18.4 71.8 42.6 <0.001 
Lung  7/1.0 1.8 22.5 25/4.8 4.3 9.6 48/8.0 17.5 14.6 21/5.2 26 15.4 <0.001 
Other 39/20.6 5.4 67.5 123/47.4 16 35.8 145/44.0 44.2 37.0 64/21.0 70.8 42 <0.001 
Hodgkin Lymphoma (men) 
Total5 51/25.1 5.9 100 192/72.9 19.5 100 289/105.1 60.2 100 171/68.8 121.9 100 <0.001 
Lung  6/2.1 0.9 15.3 56/9.8 7.6 38.8 82/17.5 21.1 35.0 54/11.9 50.2 41.2 <0.001 
Other 45/23.0 5.0 84.7 136/63.1 11.9 61.3 207/87.7 39.1 65.0 117/56.9 71.7 58.8 <0.001 
Thyroid (women) 
Total6 61/47.0 5.0 100 155/107.8 13.6 100 133/95.1 23.9 100 48/38.9 21.9 100 0.048 
Breast 27/22.1 1.7 34.0 63/53.2 2.8 20.8 59/41.2 11.2 46.9 21/13.7 17.6 80.4 0.061 
Other 34/24.9 3.3 66.0 92/54.6 10.7 79.2 74/53.9 12.7 53.1 27/25.2 4.3 19.6 0.179 
Abbreviations: FPN - First primary neoplasm, SPN- subsequent primary neoplasm,  O – observed number of SPNs, E- Expected number of SPNs, AER- absolute excess risk, CI-confidence interval, %AER – percentage 
of total AER 
* Negative numbers for the AER 
† Where the estimated AER for a specific SPN was negative then this was ignored and the percentages were based on the positively value AERs – the excesses. 
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‡ From an externally controlled Poisson regression model which contained the following factors: attained age, decade of diagnosis and age at diagnosis. 
1All SPNs after cancer in women excluding SPNs of the breast 
2All SPNs after cancer in women excluding SPN of genital sites 
3All SPNs after cancer in men excluding SPN of Other genital sites (prostate sites allowed) 
4All solid SPNs after cancer in women (excluding non-solid tumours) 
5All solid SPNs after cancer in men (excluding non-solid tumours) 
6All SPNs after cancer in women excluding SPNs of the thyroid 
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Figure 2.1: Observed (solid) and expected (dashed) cumulative incidence of specific SPNs among 
survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma.  
Note – different scale for Hodgkin lymphoma in women.
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Chapter 3 
Risk of cerebrovascular events in 178,962 5-year survivors of cancer 
diagnosed aged 15-39 years 
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3.1 ABSTRACT 
Background: Survivors of teenage and young adult (TYA) cancer are at risk of 
cerebrovascular events, but the magnitude of and extent to which this risk varies by cancer 
type, decade of diagnosis, age at diagnosis and attained age remains uncertain.  This is the 
largest ever cohort study to evaluate the risks of hospitalisation for a cerebrovascular event 
among long-term survivors of TYA cancer.  
Methods: The population-based Teenage and Young Adult Cancer Survivor Study 
(N=178,962) was linked to Hospital Episode Statistics data for England to investigate the 
risks of hospitalisation for a cerebrovascular event among 5-year survivors of cancer 
diagnosed when aged 15-39 years. Observed numbers of first hospitalisations for 
cerebrovascular events were compared to that expected from the general population using 
standardised hospitalisation ratios (SHR) and absolute excess risks (AER) per 10,000 person-
years. Cumulative incidence was calculated with death considered a competing risk. 
Results: Overall, 2,782 cancer survivors were hospitalised for a cerebrovascular event—40% 
higher than expected (SHR=1.4, 95% confidence interval [CI]=1.3-1.4). Survivors of central 
nervous system (CNS) tumours (SHR=4.6, CI=4.3-5.0), head & neck tumours (SHR=2.6, 
CI=2.2-3.1) and leukaemia (SHR=2.5, CI=1.9-3.1) were at greatest risk. Men had a 
significantly higher AER than women (AER=7 versus 3), especially among head & neck 
tumour survivors (AER=30 versus 11). By age 60, 9%, 6% and 5% of CNS tumour, head & 
neck tumour, and leukaemia survivors, respectively, had been hospitalised for a 
cerebrovascular event. Beyond age 60, every year 0.4% of CNS tumour survivors were 
hospitalised for a cerebral infarction (versus 0.1% expected). Whereas at any age, every year 
0.2% of head & neck tumour survivors were hospitalised for a cerebral infarction 7 (versus 
0.06% expected). 
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Conclusions:   Survivors of a CNS tumour, head & neck tumour, and leukaemia are 
particularly at risk of hospitalisation for a cerebrovascular event. The excess risk of cerebral 
infarction among CNS tumour survivors increases with attained age. For head & neck tumour 
survivors this excess risk remains high across all ages. These groups of survivors, and in 
particular men, should be considered for surveillance of cerebrovascular risk factors and 
potential pharmacological interventions for cerebral infarction prevention. 
 
3.2 INTRODUCTION 
Improvements in survival of cancer in teenagers and young adults (TYA, age 15-39 years) 
over the last few decades has resulted in current 5-year relative survival of over 80% 11. This 
has resulted in a large population of cancer survivors, who may be at increased risk of 
treatment related long-term adverse health effects3, 9. Notwithstanding this, TYA cancer 
survivors are an understudied population and little is known about the risks of long-term 
adverse health outcomes in this group1, 167.  
 
Previous studies of cancer survivors have observed an increased risk of cerebrovascular 
events after irradiation of the head, neck and mediastinum42, 68, 70, 72-74, 168. In addition to 
treatment, local recurrence and brain metastases are also potential causes of cerebrovascular 
events in cancer populations 169. Development of a cerebrovascular event after treatment for 
cancer is a serious, and potentially life-threatening adverse event26, yet only one other large-
scale population-based study has explored the risk of hospitalisation for a cerebrovascular 
event in individuals diagnosed with cancer, between the ages of 15 and 39 years (n=43,154 1-
year survivors) 39.  In this Danish study, there was a 30% increased risk of hospitalisation for 
a cerebrovascular event for all survivors combined than in the general population, however, 
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the risk varied by type of cerebrovascular event and cancer type. The magnitude of the effect 
of attained age, age at cancer diagnosis and decade of cancer diagnosis on the risk of specific 
types of cerebrovascular events (e.g. cerebral infarction, cerebral haemorrhage) has not 
previously been investigated and has often been encompassed within studies of all types of 
cardiovascular events combined8, 39, 42.  
 
Within the UK, the risk of having a cerebrovascular event doubles every decade after the age 
of 55 170. Currently it is unknown what the risk of cerebrovascular events is in TYA cancer 
survivors and whether this effect doubles beyond the age of 55. If this holds true for survivors 
of TYA cancer this could lead to a large population of cancer survivors developing a 
cerebrovascular event in older age. 
 
To our knowledge, this is the largest study to investigate the risk of hospitalisation for specific 
cerebrovascular events in survivors of all and specific types of cancer diagnosed in 
individuals aged 15-39 years. In addition, this is the first study to investigate whether the risk 
of hospitalisation for a cerebrovascular event varies with attained age, age at diagnosis and 
decade of diagnosis. 
 
3.3 METHODS 
3.3.1 Teenage and Young Adult Cancer Survivor Study  
The Teenage and Young Adult Cancer Survivor Study (TYACSS) is a large population-based 
cohort consisting of 200,945 5-year survivors of cancer diagnosed aged 15-39 years between 
1971 and 2006 in England and Wales. The cohort was ascertained from cancer registrations 
recorded by the Office for National Statistics and the Welsh Cancer Registry. Cancer 
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registrations were coded according to the relevant revisions of the International Classification 
of Diseases (ICD) (topography) and International Classification of Diseases for Oncology 
(ICDO) (morphology). We mapped all ICD-topography and ICDO-morphology codes into 15 
main cancer types based on the classification of cancers for TYAs 6, 13. We refined the 
classification slightly to allow for inclusion of finer groupings of carcinomas (see Table 3.1). 
Ethical approval was provided by the National Research Ethics Service (ref: 16/LO/0895) and 
permission to process information without individual consent by the National Information 
Governance Board (NIGB) for Health and Social Care (ref: 3-03(c)2010). 
  
3.3.2 Ascertainment of cerebrovascular events from Hospital Episodes Statistics  
The inpatient Hospital Episode Statistics (HES) database is a national electronic database of 
routinely collected data on individual hospital admissions to National Health Service (NHS) 
and private (if care was commissioned by the NHS) hospitals in England. For this study HES 
inpatient data were available from April 1997 to December 2012. Prior to linking the survivor 
cohort by NHS number, date of birth, postcode and sex to the inpatient HES database, we 
excluded all Welsh survivors (N= 11,099 patients) due to HES being restricted to England 
only. Individuals were also excluded if they had died or emigrated before the start of the 
follow-up period (1st April 1997) (N=10,128 patients) (see Figure 3.1 for flow-diagram of 
exclusions). It was not possible to determine the actual linkage rate of the survivor cohort to 
the inpatient HES database as not all survivors would have been admitted to hospital within 
the HES years 1997-2012. For the vast majority of survivors the key linkage identifiers—
NHS number, date of birth, postcode and sex—were available and it is thus more likely that 
such survivors would not have been admitted to hospital rather than an actual failure to link 
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the survivor to the correct HES record(s). Of the 179,718 survivors eligible to be linked with 
HES, 84% (150,942) had at least one inpatient admission record in HES. 
 
 Each inpatient admission initiates a record in the HES database and contains information on 
the date of admission, methods of admission and discharge, patient demographics, and up to 
20 diagnosis variables containing information on the primary condition, conditions diagnosed 
during hospital admission, and any pre-existing co-morbidities. All diagnosis variables are 
coded using the International Classification of Disease version 10 (ICD-10) and are coded at 
the time of hospital discharge by trained clinical coders or clinicians using all available 
clinical notes171. Cerebrovascular events (ICD-10: I60-I68) were identified from all 20 
diagnosis variables recorded in HES and categorised into the following subgroups: 
subarachnoid haemorrhage (ICD-10: I60), cerebral haemorrhage (ICD-10: I61-I62), 
cerebral infarction/occlusion/stenosis (ICD-10: I63, I65-I66), and ‘other cerebrovascular 
event’ (ICD-10: I64, I67-I68—stroke not specified as haemorrhage or infarction (ICD-10: 
I64), other cerebrovascular events (ICD-10: I67), cerebrovascular disorders in diseases 
elsewhere classified (ICD-10:I68). If an individual developed the same type of 
cerebrovascular event more than once, only the first event was retained for the analysis to 
ensure that any cerebrovascular event was not counted more than once due to potential 
duplicate recordings. Individuals who developed a cerebrovascular event within the first 5 
years from cancer diagnosis were excluded as time at risk started at 5-year survival. 
Individuals with a first event recorded as sequelae of cerebrovascular disease (ICD-10: I69), 
but no prior recorded cerebrovascular event in HES were also excluded, as such survivors 
would most likely have had a prior cerebrovascular event before April 1997. After these 
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exclusions, a cohort of 178,962 5-year survivors remained (see Figure 3.1 for flow-diagram of 
exclusions).   
 
3.3.3 Statistical analysis 
Individuals were followed-up for cerebrovascular events from 5-year survival or 1st April 
1997, whichever date was most recent. Follow-up ended at the first occurrence of death, 
emigration, hospitalisation for a cerebrovascular event or study end date (31st December 
2012). Cerebrovascular related hospitalisation rates for the general population were derived 
from the entire (anonymised) HES dataset for England (N=13,476,762) by dividing the 
number of individuals with a hospitalisation by the mid-year general population estimates172  
for each age (1-year bands), sex and calendar-year (1-year bands). The accumulated person-
years within each corresponding age, sex and calendar year stratum in the survivor cohort 
were multiplied by the general population rates to obtain the expected number of 
cerebrovascular hospitalisations. 
 
Analyses were conducted to investigate the risk of a hospitalisation for all cerebrovascular 
events combined and for specific types of cerebrovascular events. The observed number of 
hospitalisations for a cerebrovascular event was divided by the number expected from the 
general population (referred to as a standardised hospitalisation ratio (SHR)8). The absolute 
excess risk (AER) is the additional number of hospitalisation for a cerebrovascular event 
compared to that expected based on general population hospitalisation rates; it is calculated as 
the observed minus the expected number of hospitalisation divided by the person-years at 
risk. The AER has been expressed per 10,000 person-years throughout the manuscript 153. For 
each cerebrovascular event subtype, SHRs and AERs were stratified by the following factors: 
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cancer diagnosis, sex, age at cancer diagnosis (15-19/20-24/25-29/30-34/35-39 years), decade 
of cancer diagnosis (1971-1979/1980-1989/1990-1999/2000-2006) and attained age (20-
44/45-49/50-54/55-59/≥60 years). To investigate the simultaneous effect of these variables on 
the risk of hospitalisation for a cerebrovascular event, multivariable Poisson regression was 
conducted to derive relative risks (RR) and excess hospitalisation ratios (EHR). RRs can be 
interpreted as the ratio of the SHRs adjusted for potential confounders. EHRs can be 
interpreted as the ratio of the AERs adjusted for potential confounders154. Negative binomial 
regression was preferred to Poisson when the data showed signs of over-dispersion (see Table 
3.2 for dispersion parameters and regression methods used). A likelihood ratio test was used 
to test for linear trend of a factor by comparing the log-likelihood of a model including the 
factor variable of interest (e.g. attained age (20-44/45-49/50-54/55-59/≥60 years)), which was 
coded such that it had the median value of the variable at each level, with the log-likelihood 
of a model without the factor variable of interest. Cumulative incidence with attained age as 
the time scale was calculated treating death as a competing risk. A p-value of <0.05 (2-sided 
test) was taken as statistically significant. All statistical analyses were conducted in Stata 
statistical software (version 14.1, Stata Corp., College Station, TX).  
 
From here on “hospitalisation for a cerebrovascular event” and “cerebral 
infarction/occlusion/stenosis” will be referred to as “cerebrovascular event” and “cerebral 
infarction”, respectively. 
 
3.4 RESULTS 
3.4.1 Cohort characteristics 
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A total of 178,962 5-year survivors of TYA cancer were included in the analysis, contributing 
1,837,996 person-years of follow-up. Characteristics of the cohort can be found in Table 3.3. 
The median follow-up was 11.3 years (range: 0-15.8 years) with 36% of individuals followed 
for at least 15 years. In total, 2,782 (1.6%) individuals were hospitalised for at least one 
cerebrovascular event. With respect to specific types of cerebrovascular events; 618 (0.35% 
(0.18% expected)) individuals were hospitalised for a cerebral haemorrhage, 1,296 (0.72% 
(0.48% expected)) for a cerebral infarction, 262 (0.15% (0.15% expected)) for a subarachnoid 
haemorrhage and 1,114 (0.62% (0.49% expected)) for ‘other cerebrovascular events’. 
 
3.4.2 Risk of any cerebrovascular event 
Survivors experienced a 40% significantly increased risk of developing any cerebrovascular 
event than that expected from the general population (SHR=1.4, 95% confidence interval 
[CI]=1.3-1.4); corresponding to four excess events per 10,000 person-years (PY) (Table 3.4). 
Women experienced significantly fewer excess cerebrovascular events than men (AER=3 and 
AER=7, respectively; Pheterogeneity<0.001). In terms of age at cancer diagnosis, SHRs for a 
cerebrovascular event were highest among individuals diagnosed with a cancer aged 15-19 
years (SHR=3.6, CI=3.0-4.2; AER=9) and there was a significant trend for the SHR to 
decrease with increasing age at diagnosis (Ptrend <0.001). The SHR declined significantly with 
attained age (Ptrend<0.001), although the p-value for trend for the RR just fell short of 
significance when evaluated in the multivariable model (Ptrend =0.086) (Table 3.5). The AERs 
remained elevated at all ages, however; the multivariable analysis showed a significant 
increasing trend in the number of excess cerebrovascular events with increasing attained 
age—survivors older than 60 years had 2-fold the number of excess cerebrovascular events 
than survivors aged 20-44 years (EHR=2.4, CI=1.5-4.1;Ptrend<0.001) (Table 3.5).  
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With regards to TYA cancer type, survivors at the highest risk of developing a 
cerebrovascular event were: central nervous system (CNS) tumour survivors (SHR=4.6, 
CI=4.3-5.0; AER=34); head & neck tumour survivors (SHR=2.6, CI=2.2-3.1; AER=22) and 
leukaemia survivors (SHR=2.5. CI=1.9-3.1; AER=10). The cumulative incidence of 
developing a cerebrovascular event by age 60 was 9.0%, 6.4% and 5.1% among CNS tumour, 
head & neck tumour and leukaemia survivors, respectively, whereas 2.3% was expected 
(Figure 3.2a). Due to having substantially increased risk, further analyses were conducted for 
CNS tumour, head & neck tumour and leukaemia survivors. 
 
3.4.2.1 CNS tumour survivors 
Survivors of all CNS tumour types were at increased risk of developing a cerebrovascular 
event, particularly, survivors of embryonal tumours (SHR=12.9, CI=8.0-19.7; AER=78) and 
glial tumours (SHR=10.8, CI=9.5-12.3; AER=72) (Table 3.6). The SHR was highest among 
survivors diagnosed when aged 15-19 years (SHR=12.7, CI=10.1-15.9); however survivors 
aged 35-39 years at diagnosis were still at 3.5-fold increased risk (SHR=3.5, CI=3.0-4.0). The 
SHR declined with increasing attained age, however remained elevated among all ages 
(Ptrend<0.001). In contrast, the AER increased with attained age (Ptrend<0.001) reaching 55 
additional hospitalisations per 10,000 PY within individuals aged ≥60 years (Figure 3.3, Table 
3.6). 
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3.4.2.2 Head & neck tumour survivors 
Among head & neck tumour survivors, men had a significantly greater AER for a 
cerebrovascular event than women (Ptrend=0.002), with an excess of 30 events compared to 11 
per 10,000 PY, respectively (Table 3.7).  The AER remained significantly increased for all 
ages; however the multivariable analysis showed that the AER did not increase significantly 
with attained age (Ptrend=0.071) (Figure 3.4, Table 3.8).  
 
3.4.2.3 Leukaemia survivors 
Survivors of all types of leukaemia were at an increased risk of developing a cerebrovascular 
event and risk did not depend on type of leukaemia (Pheterogeneity=0.130) (Table 3.9). 
Leukaemia survivors diagnosed aged 15-19 years had the greatest SHR (SHR=5.1, CI=2.8-
8.6) and the SHR decreased significantly with older age at diagnosis (Ptrend=0.007).  The AER 
increased significantly with attained age until age 55 years (Ptrend=0.014) reaching 20 
additional hospitalisations per 10,000 PY within individuals aged 50-54 years. 
 
3.4.3 Risk of a cerebral haemorrhage 
The SHR for a cerebral haemorrhage was twice that expected (SHR=2.0, CI=1.8-2.1). The 
risk of developing a cerebral haemorrhage among survivors diagnosed more recently (1990-
2006), was increased nearly 4-fold relative to that expected from the general population 
(SHR=3.7, CI=2.9-4.7); whereas it was only 20% increased among survivors diagnosed 
earlier (1971-1979) (SHR= 1.2, CI=1.0-1.4) (Table 3.4). This increase in risk for the recent 
treatment decade was further confirmed by the multivariable analysis (Ptrend=0.005) (Table 
3.10). In terms of attained age, the SHR was highest for survivors younger than 45 years 
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(SHR=3.6, CI=3.1-4.2) and declined with increasing attained age, however remained 
significantly elevated for all ages (SHR at age 60+years = 1.2, CI=1.0-1.4) (Table 3.5).  
 
With regards to TYA cancer type, the SHR was highest among survivors of a CNS tumour 
and leukaemia, with an 8-fold (SHR=8.3, CI=7.2-9.6) and 5-fold (SHR=5.2, CI=3.4-7.6) 
increased risk, respectively (Table 3.4). The cumulative incidence of developing a cerebral 
haemorrhage by age 60 was 3.4% and 2.0% among CNS tumour and leukaemia survivors, 
respectively, whereas 0.4% was expected (Figure 3.2b). Notably, survivors of melanoma were 
at increased risk of developing a cerebral haemorrhage (SHR=2.0 CI=1.5-2.6); but were not at 
significantly increased risk of any other cerebrovascular event. 
 
3.4.3.1 CNS tumour survivors 
The risk of developing a cerebral haemorrhage was significantly elevated among all CNS 
tumour survivors. Survivors of glial tumours were at greatest risk (SHR=26.2, CI=21.5-31.6) 
(Table 3.6). The SHR and AER of developing a cerebral haemorrhage among CNS survivors 
diagnosed more recently (1990-2006), was 27-fold increased relative to that expected from 
the general population (SHR=26.5, CI=18.6-36.7; AER=20); whereas it was only 4-fold 
increased among survivors diagnosed earlier (1971-1979) (SHR= 4.2 , CI=2.7-6.1; AER=10). 
This increase in the SHRs and AERs by more recent treatment decade was confirmed by the 
multivariable analysis (Ptrend<0.001 and 0.005, respectively) (Table 3.11).  
 
3.4.4 Risk of cerebral infarction 
Overall, survivors had a 50% significantly increased risk of a cerebral infarction than that 
expected (SHR=1.5; CI=1.4-1.6; AER=2). In terms of age at cancer diagnosis, the SHR and 
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AER for a cerebral infarction was highest among survivors diagnosed aged 15-19 years 
(SHR=4.3, CI=3.3-5.4; AER=4) (Table 3.4); who had twice the risk of a cerebral infarction 
than survivors diagnosed aged 35-39 years (RR=0.5, CI=0.4-0.7) (Table 3.10). The AER 
increased with increasing attained age (Ptrend<0.001) (Table 3.5); after adjusting for potential 
confounders, survivors aged over 60 years had 6-fold the number of excess cerebral infarction 
than survivors aged less than 45 years (EHR=5.6, CI=2.9-10.8).  
 
With regards to TYA cancer type, the SHR was highest among survivors of CNS tumours 
(SHR=4.4, CI=3.9-5.0), head & neck tumours (SHR=3.5, CI=2.8-4.4), leukaemia (SHR=2.3, 
CI=1.5-3.3), and Hodgkin lymphoma (SHR=2.1, CI=1.8-2.5) (Table 3.4). The cumulative 
incidence of developing a cerebral infarction before age 60 was 4.2%, 3.6%, 2.3% and 2.0% 
among head & neck tumour, CNS tumour, leukaemia and Hodgkin lymphoma survivors, 
respectively, whereas 0.9% was expected (Figure 3.2c). 
 
3.4.4.1 CNS tumour survivors 
The risk of developing a cerebral infarction was significantly elevated among all CNS tumour 
survivors, with the exception of ‘other specified’ CNS tumour group. Survivors of embryonal 
tumours (SHR=18.8, CI=10.0-32.1) and germ cell tumours (SHR=10.5, CI=3.4-24.6) were at 
greatest risk (Table 3.6). The AER was substantially elevated among survivors of embryonal 
tumours, with 49 excess cerebral infarctions per 10,000 PY (Table 3.6). AERs increased 
sharply with attained age reaching 26 excess cerebral infarctions per 10,000 PY in survivors 
aged 60 years or older (Ptrend<0.001) (Figure 2, Table 3.6). In terms of absolute risk, every 
year approximately 0.4% of CNS tumour survivors over age 60 years were hospitalised for a 
cerebral infarction compared to approximately 0.1% in the general population.  
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3.4.4.2 Head & neck tumour survivors 
Among head & neck tumour survivors, the AER for a cerebral infarction was higher among 
men than women (AER=22 and AER=7, respectively; Ptrend<0.001) (Table 3.7). The SHR 
decreased with attained age (Ptrend<0.001), however remained elevated for all ages. The AER 
was high for all ages (AER=10-23); however did not vary significantly with attained age 
(Ptrend=0.159) (Figure 3.4). In terms of absolute risk, every year approximately 0.2% of head 
& neck tumour survivors were hospitalised for a cerebral infarction compared to 
approximately 0.06% in the general population. 
 
3.4.5 Risk of subarachnoid haemorrhage  
The risk of being hospitalised for a subarachnoid haemorrhage among TYA cancer survivors 
did not differ significantly from that observed in the general population (SHR=1.0, CI=0.9-
1.1; AER=0) (Results not shown). 
 
3.4.6 Risk of ‘other cerebrovascular events’  
Survivors had a 40% significantly increased risk of any ‘other cerebrovascular events’ than 
that expected (SHR=1.4, CI=1.3-1.5; AER=2) (Table 3.4). The SHR and AER was highest 
among survivors diagnosed aged 15-19 years (SHR=4.1, CI=3.1-5.4; AER=3) (Table 3.4); 
survivors diagnosed aged 15-19 years had over twice the risk of developing ‘other 
cerebrovascular events’ than survivors aged 35-39 years at diagnosis (Table 3.10). The AER 
increased with increasing attained age reaching 2 per 10,000 person-years after age 60 years, 
which was confirmed by the multivariable analysis, where the EHR increased substantially 
with attained age (Ptrend<0.001) (Table 3.5).  
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With regards to TYA cancer type, the risk was highest among survivors of: a CNS tumour 
(SHR=5.1, CI=4.5-5.8; AER=15), head & neck tumours (SHR=2.7, CI=2.0-3.5; AER=9) and 
leukaemia (SHR=2.6, CI=1.7-3.8; AER=4) (Table 3.4). The cumulative incidence of 
developing an ‘other cerebrovascular event’ by age 60 was 3.3%, 2.2% and 1.9% among CNS 
tumour, leukaemia and head & neck tumour survivors, respectively, whereas 0.8% was 
expected (Figure 3.2d). 
 
3.4.6.1 CNS tumour survivors 
Among CNS tumour survivors, the SHR and AER for ‘other cerebrovascular events’ was 
highest among survivors of embryonal tumours (SHR=20.2, CI=10.4-35.3 AER=46) and 
germ cell intracranial tumours (SHR=12.6, CI=4.1-29.5; AER=23) (Table 3.6). AERs 
increased substantially with attained age reaching 36 excess ‘other cerebrovascular events’ 
per 10,000 PY in CNS tumour survivors aged 60 years or older (Ptrend<0.001) (Figure 3.3, 
Table 3.6).  
 
3.4.6.2 Head & neck tumour survivors 
Among head & neck tumour survivors, the AER increased significantly with attained age 
reaching 26 excess ‘other cerebrovascular events’ per 10,000PY in survivors aged 60 years or 
older (Ptrend=0.002) (Figure 3.4, Table 3.7).  
 
3.5 DISCUSSION 
3.5.1 Main findings 
In this largest ever study of TYA cancer survivors, we report a 40% increased risk of 
hospitalisation for a cerebrovascular event than that expected in the general population. TYA 
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cancer survivors are at 2-fold, 1.5-fold and 1.4-fold increased risk of a cerebral haemorrhage, 
cerebral infarction and `other cerebrovascular event`, respectively. By age 60, 9%, 6% and 
5% of CNS tumour, head & neck tumour, and leukaemia survivors, respectively, had been 
hospitalised for a cerebrovascular event. Among TYA cancer survivors, men had a 
significantly higher number of excess cerebrovascular events than women, especially cerebral 
infarction among head and neck tumour survivors. We found that the excess risk of 
developing a cerebral infarction among CNS tumour survivors increases significantly with 
attained age. Beyond age 60, every year approximately 0.4% of CNS tumour survivors can 
expect to be hospitalised for a cerebral infarction. The excess risk of developing a cerebral 
infarction among head & neck tumour survivors did not vary with attained age but was 
consistently high. Every year approximately 0.2% of head & neck tumour survivors can 
expect to be hospitalised for a cerebral infarction.  
 
3.5.2 Previous studies 
The only other large-scale cohort investigating hospitalisation for cerebrovascular disease—a 
Danish cohort study of 43,153 1-year survivors of TYA cancer (age 15-39 years)—found a 
significant 1.3-fold increased risk of hospitalisation for any cerebrovascular disease for all 
survivors combined, which is comparable to the 1.4-fold increased risk observed in our study 
of 178,964 5-year survivors of TYA cancer 39. In a smaller scale study; van Laar et al. did not 
observe a significantly increased risk of cerebrovascular disease among 1,880 5-year 
survivors of TYA cancer diagnosed between 15 and 29 years in Yorkshire, England; however 
the study included only 7 cerebrovascular events compared to 3,201 in the current study8.  
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The Danish study by Rugbjerg et al. demonstrated that CNS tumour survivors had a 
substantially increased risk of being hospitalised for a cerebrovascular event (SHR=3.9, CI: 
3.4-4.5), particularly for a cerebral haemorrhage (SHR=7.6, CI=5.7-10.2) and other undefined 
cerebrovascular disease (SHR=4.5, CI=3.6-5.5) 39; these findings are generally consistent with 
the risk estimates observed in our study.  In contrast, this study showed that CNS tumour 
survivors had a 4.4-fold (CI=3.9-5.0) increased risk of developing a cerebral infarction—
significantly higher than the 2.9-fold (CI=2.2-3.8) risk observed by Rugbjerg et al. One 
explanation for this difference could be the more recent diagnosis period of our cohort 
(individuals diagnosed 1971-2006) compared to the Danish cohort (individuals diagnosed 
1943-2009); hence the background risk of developing a cerebral infarction in our study was 
lower. To our knowledge, we provide for the first time, risk estimates for cerebrovascular 
disease by type of CNS tumour among TYA cancer survivors. Risk estimates for developing 
cerebrovascular disease for other tumour types, such as testicular, Hodgkin lymphoma, non-
Hodgkin lymphoma, ovary, cervical, melanoma, thyroid and leukaemia were remarkably 
similar to those found by Rugbjerg et al39.   
 
3.5.3 Potential radiation-induced cerebrovascular disease 
Although the mechanisms of radiation-induced cerebrovascular disease are unknown, cranial 
irradiation has been implicated in causing direct damage to endothelial cells of the cerebral 
arteries resulting in weakened vessels, accelerated atherosclerosis and vascular insufficiency 
secondary to stenosis or occlusion68, 70, 173.  Previous studies among childhood CNS tumour 
survivors have reported a strong linear dose-response relationship between the amount of 
cranial irradiation exposure and risk of developing stroke72-74, 168. Prophylactic cranial 
irradiation for childhood leukaemia has also been shown to increase the risk of stroke in a 
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dose-dependent manner72. Given these observations among childhood cancer survivors, the 
substantially increased risks of cerebrovascular disease observed here among TYA survivors 
of CNS tumour and leukaemia are probably, to at least some extent, related to cranial 
irradiation as well.  Nonetheless, some cerebrovascular events—particularly cerebral 
haemorrhage—may be caused by compression or damage of intracranial vessels from local 
recurrence of a CNS tumour or brain metastasis from other tumours (e.g. melanoma or head & 
neck cancer)169. This could explain the increase in cerebral haemorrhage among CNS tumour 
survivors treated most recently—a higher proportion of high-grade glial tumours (which are 
likely to recur) were observed in 1990-2006 than in previous decades (1971-1989). We cannot 
rule out the possibility that the increase in cerebral haemorrhage among CNS tumour 
survivors diagnosed more recently may be an artefact of greater frequency of CNS imaging or 
improved diagnosis of haemorrhage in more recent years. Melanoma survivors were at 
increased risk of a cerebral haemorrhage, but not any other type of cerebrovascular event. 
Melanoma metastases are commonly haemorrhagic 174 , therefore this increase could in fact 
be due to metastases to the brain from recurrent melanoma subsequent to 5-year survival. 
 
This study observed a substantially increased risk of cerebral infarction among head and neck 
tumour survivors.  Several previous studies—mainly among head and neck cancer patients 
diagnosed after age 40 years—have observed an increased risk of cerebral infarction after 
radiation to the head and neck 68-71; this is more than likely due to radiation-induced damage 
of the carotid artery 173. The exact mechanism underlying the radiation-induced damage of the 
carotid artery remains elusive; however it may be due to direct damage to endothelial cells 
which are very radiosensitive, injury to the microvasculature network or accelerated 
atherosclerosis 173, 175-178. Radiation-induced carotid artery disease can lead to higher risk of 
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cerebral infarction due to stenosis of the carotid artery itself or by embolism of a dislodged 
thrombus blocking a cerebral artery 173. However, there is the possibility that both head and 
neck cancer and cerebrovascular disease have a shared aetiology, thus smoking and alcohol 
may also be implicated in the increased risk of cerebrovascular disease. Nonetheless, all head 
and neck tumour survivors in the TYA cohort were diagnosed under age 40 years, and thus, 
exposure to smoking and alcohol is likely to play a lesser role in the aetiology of head and 
neck cancer compared to patients diagnosed after age 40 years179.  In addition to carotid artery 
irradiation, an increased risk of cerebral infarction after mediastinal irradiation has also been 
observed among a population of Hodgkin lymphoma survivors, likely due to cardioemboli42. 
This, in addition to carotid artery irradiation could explain the 2-fold increased risk of cerebral 
infarction observed among Hodgkin lymphoma survivors in our study. 
 
In this study, the risk of cerebral haemorrhage was greatest among CNS tumour survivors 
diagnosed most recently (2000-2006). The increasing trend observed within this diagnosis 
period was significant for glial tumour survivors only (results not shown). Among survivors, 
the proportion of gliomas considered high grade increased from 9.5% in 1971-1979 to 17.5% 
in 2000-2006. High grade tumours are more difficult to treat successfully and are likely to 
recur and it is thus not inconceivable that, although a greater proportion of these individuals 
are becoming 5-year survivors, more aggressive treatment and/or recurrence of the tumour 
could increase the risk of cerebral haemorrhage.  
 
3.5.4 Recommendations for prevention of cerebrovascular disease 
To our knowledge, there are no specific guidelines for stroke prevention among cancer 
survivors. The American Heart Association/American Stroke Association (AHA/ASA) and 
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Scottish Intercollegiate Guidelines Network (SIGN) guidelines recommend that individuals 
who are considered to be at high risk of stroke in the general population (e.g. history of 
coronary heart disease, previous stroke, high blood pressure, and diabetes mellitus) undergo 
regular blood pressure checks, implement lifestyle modifications (stop smoking and reduce 
alcohol consumption) and are considered for pharmacological intervention (e.g. 
antihypertensive medication and statins) to reduce the risk of stroke 180, 181. In this study, the 
absolute excess risk of cerebral infarction among CNS tumour survivors and ‘Other 
Cerebrovascular Event’ among head & neck tumour survivors increased with attained age, 
resulting in substantial numbers of excess cerebral infarctions and ‘Other Cerebrovascular 
Event’ among older survivors. There is evidence suggesting that stroke risk is increased in 
cancer survivors treated with cranial irradiation in the absence of atherosclerotic risk factors 
68, 74. As previously mentioned, cranial irradiation has been implicated in causing accelerated 
atherosclerosis, therefore it could be argued that cranial irradiation itself is an atherosclerotic 
risk factor and patients treated with cranial irradiation should be considered at high risk such 
as patients with hypertension and diabetes. It may therefore not be unreasonable to suggest 
that TYA CNS tumour and head & neck tumour survivors (likely treated with head & neck 
irradiation) should be considered for pharmacological interventions even in the absence of 
other risk factors.  A randomised intervention study may be required to ascertain if, and to the 
extent to which, these survivors would benefit from such treatments.  
 
3.5.5 Study strengths and limitations 
Most previous studies used questionnaires to ascertain cerebrovascular events which rely on 
self-report and may suffer from non-response or recall bias. A strength of the current study—
in addition to the large cohort size—was that the ascertainment of cerebrovascular events was 
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entirely population-based through linkage of the TYACSS cohort with the population-based 
HES dataset, thereby eliminating potential non-response or recall bias. A limitation of our 
study is the lack of detailed treatment information, particularly the lack of detailed 
information on treatment with cranial radiotherapy (e.g. availability of cumulative radiation 
dose to the cranium). However, it would not be practically feasible to collect detailed 
information on treatment for the entire cohort of 178,962 survivors due the destruction of 
older medical notes in addition to cost and time restrictions. Nested case-control studies 
would be required to investigate the risks of developing cerebrovascular disease in relation to 
elements of treatment.  
 
Modifiable lifestyle factors such as hypertension, diabetes, obesity and smoking may 
contribute to the elevated risk of cerebrovascular disease among cancer survivors treated with 
radiotherapy to the head, neck and mediastinum 42, 68, 69, however, we cannot confirm this as 
collecting information on lifestyle factors was beyond the scope of this study. 
 
We acknowledge that survivors in this cohort were treated between 1971 and 2006, thus the 
findings presented may not be translatable to individuals treated with newer therapies in 
recent years e.g. proton beam therapy. Future prospective studies would be needed to 
investigate risks of cerebrovascular events after newer treatment protocols.  
 
3.6 CONCLUSIONS 
In this large scale study investigating cerebrovascular events in teenage and young adult 
cancer survivors, we found that survivors of a CNS tumour, head & neck tumour, and 
leukaemia are particularly at risk of hospitalisation for a cerebrovascular event. The excess 
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risk of developing a cerebral infarction among CNS tumour survivors increases with attained 
age. For head & neck tumour survivors this excess risk remains high across all ages. These 
groups of survivors, and in particular men, should be considered for surveillance of 
cerebrovascular risk factors and potential pharmacological interventions for cerebral 
infarction prevention. 
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Table 3.1: Groupings of TYA cancer based on the adolescent and young adult cancer classification 
scheme. (Refinements are highlighted in red) 
Broader Groupings used 
in current study AYA classification AYA code 
Leukaemia Acute Lymphoid Leukaemia 1.1 
 
Acute Myeloid Leukaemia 1.2 
 
Chronic Myeloid Leukaemia 1.3 
 
Other and Unspecified Leukaemias 1.4 
   
Non-Hodgkin Lymphoma Non- Hodgkin Lymphoma, specified subtype 2.1.1 
 
Unspecified Non-Hodgkin Lymphoma 2.1.2 
 
Myeloma, mast cell tumours and miscellaneous lymphoreticular neoplasms NEC 9.2.3 
   
Hodgkin Lymphoma Hodgkin Lymphoma, specified subtype 2.2.1 
 
Hodgkin lymphoma NOS 2.2.2 
   Central Nervous System 
and Other Intracranial 
and Intraspinal 
Neoplasms 
Pilocytic Astrocytoma 3.1.1 
Other specified low grade astrocytic tumours 3.1.2 
 
Glioblastoma and anaplastic astrocytoma 3.1.3 
 
Astrocytoma, NOS 3.1.4 
 
Oligodendroglioma 3.2.1 
 
Other specified glioma 3.2.2 
 
Glioma, NOS 3.2.3 
 
Ependymoma 3.3 
 
Medulloblastoma 3.4.1 
 
Supratentorial PNET 3.4.2 
 
Craniopharyngioma 3.5.1 
 
Other pituitary tumours 3.5.2 
 
Pineal tumours 3.5.3 
 
Choroid plexus tumours 3.5.4 
 
Meningioma 3.5.5 
 
Nerve sheath tumours of CNS 3.5.6 
 
Other specified intracranial and intraspinal neoplasms 3.5.7 
 
Unspecified malignant intracranial and intraspinal neoplasms 3.6.1 
 
Unspecified benign and borderline intracranial and intraspinal neoplasms 3.6.2 
 
Germ cell intracranial 6.2.1 
   
Bone Neoplasms Osteosarcoma 4.1 
 
Chondrosarcoma 4.2 
 
Ewing sarcoma of bone 4.3.1 
 
Ewing sarcoma of specified site other than bone 4.3.2 
 
Ewing sarcoma of unspecified site 4.3.3 
 
Other specified bone tumours 4.4.1 
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Unspecified bone tumours 4.4.2 
   
Soft Tissue Sarcoma Fibrosarcoma 5.1.1 
 
Malignant Fibrous Histiocytoma 5.1.2 
 
Dermatofibrosarcoma 5.1.3 
 
Rhabdomyosarcoma 5.2 
 
Liposarcoma 5.3.1 
 
Leiomyosarcoma 5.3.2 
 
Synovial sarcoma 5.3.3 
 
Clear cell sarcoma 5.3.4 
 
Blood vessel tumours 5.3.5 
 
Nerve sheath tumours 5.3.6 
 
Alveolar soft part sarcoma 5.3.7 
 
Other specified 5.3.8 
 
Unspecified soft tissue sarcoma 5.4 
   
Melanoma Melanoma 7.1 
   
Thyroid Thyroid Carcinoma 8.1 
   
Head and Neck Nasopharyngeal carcinoma 8.2.1 
 
Other sites in lip, oral cavity and pharynx 8.2.2 
 
Nasal cavity, middle ear, sinuses, larynx and other and ill-defined head and neck 8.2.3 
   
Lung Trachea, bronchus and lung 8.3 
   
Breast Carcinoma of breast (women only) 8.4 
   
Bladder Carcinoma of bladder 8.5.2 
 
Unspecified malignant neoplasms, NEC (in bladder site) 10 
 
Unspecified benign and borderline neoplasms, NEC (in bladder site) Not in AYA 
 
Benign and borderline neoplasms of bladder (ICDO3 code 8010-8589, 8982) Not in AYA 
   
GU Tract (other) Carcinoma of kidney 8.5.1 
 
Carcinoma of other and ill-defined sites in GU tract 8.5.5 
 
Wilms tumour 9.1.1 
   
Ovary Carcinoma of ovary 8.5.3 
 
Germ cell and trophoblastic neoplasms of gonads (women only) 6.1 
 
Other specified gonadal tumours (women only) 9.2.2 
   
Cervix Carcinoma of cervix 8.5.4 
   
Gastrointestinal Tract Carcinoma of colon and rectum 8.6.1 
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Carcinoma of stomach 8.6.2 
 
Carcinoma of liver and intrahepatic bile ducts 8.6.3 
 
Carcinoma of pancreas 8.6.4 
 
Carcinoma of other and ill-defined sites in GI tract 8.6.5 
   
Testis Germ cell gonadal (men only) 6.1 
 
Other specified gonadal tumours (men only) 9.2.2 
   
Other Other non-gonadal sites 6.2.2 
 
Non melanoma skin cancer (non-epithelial tumours only) 7.2 
 
Carcinoma of breast (men only) 8.4 
 
Adrenocortical carcinoma 8.7.1 
 
Carcinoma of other and ill-defined sites, NEC 8.7.2 
 
Neuroblastoma 9.1.2 
 
Other paediatric and embryonal, NEC 9.1.3 
 
Paraganglioma and glomus 9.2.1 
 
Other specified neoplasms, NEC 9.2.4 
 
Unspecified malignant neoplasms, NEC 10 
Abbreviations: AYA= adolescents and young adults; NEC=not elsewhere classified; NOS= not otherwise specified; GI= gastrointestinal; 
GU=genitourinary; CNS= central nervous system; PNET= primitive neuroectodermal tumour.  
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Figure 3.1: Flow diagram showing exclusions for the cohort of Teenage and Young Adult Cancer 
Survivor Study linked with HES.  
 
 
 
 
N=200,945 5- year survivors 
aged 15-39 years at 
diagnosis. 
N=189,846  
Survivors who were Welsh residents, 
n=11,099 
N=179,718  
N=179,329  
Survivors who died or were lost to follow-
up before the study start date: 01 April 
1997. n=10,128 
Survivors with a cerebrovascular event 
recorded in HES before 5-year survival. 
n=339 
Survivors with sequelae of cerebrovascular 
disease recorded in HES with no record of 
a previous cerebrovascular event recorded 
in HES. n=367 N=178,962 
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Table 3.2: Test for over-dispersion - Dispersion parameters and associated p-values 
 
Dispersion 
parameter 
p-value Model for final 
analysis 
Among all TYA cancer survivors    
Any cerebrovascular event 0.044 <0.001 Negative binomial 
Cerebral haemorrhage 0.034 0.243 Poisson 
Cerebral infarction 0.047 0.027 Negative binomial 
‘Other cerebrovascular events’ 0 0.500 Poisson 
CNS tumour survivors    
Any cerebrovascular event 0.104 0.014 Negative binomial 
Cerebral haemorrhage 0 0.500 Poisson 
Cerebral infarction 0 0.500 Poisson 
‘Other cerebrovascular events’ 0.075 0.220 Poisson 
Head & Neck tumour survivors    
Any cerebrovascular event 0 0.500 Poisson 
Cerebral infarction 0 0.500 Poisson 
‘Other cerebrovascular events’ 0 0.500 Poisson 
Leukaemia survivors    
Any cerebrovascular event 0 0.500  Poisson 
Abbreviations: TYA= teenage and young adult; CNS=central nervous system 
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Table 3.3: Cohort characteristics 
    Number of 5-year survivors Percentage 
All Survivors All Survivors 178,962 100% 
FPN Diagnosis Breast 30,956 17.3% 
 Testicular 22,709 12.7% 
 
Cervix 21,220 11.9% 
 
Melanoma 20,709 11.6% 
 
CNS tumour 14,430 8.1% 
 Glial Tumours1 3,985 (27.6%) 
 Pituitary Tumour² 3,294 (22.8%) 
 Meningioma 2,023 (14.0%) 
 Embryonal Tumours³ 273 (1.9%) 
 Ependymoma 667 (4.6%) 
 Craniopharyngioma 418 (2.9%) 
 Germ Cell Intracranial 211 (1.5%) 
 Other Specified4 2,654 (18.4%) 
 Other Unspecified5 905 (6.3%) 
 
Hodgkin Lymphoma 15,120 8.5% 
 
NHL 8,402 4.7% 
 
Thyroid 7,343 4.1% 
 
Gastrointestinal 6,342 3.5% 
 
STS 5,570 3.1% 
 
Leukaemia 4,326 2.4% 
 A L Leukaemia 1,076 (24.9%) 
 C M Leukaemia 885 (20.5%) 
 A M Leukaemia 1,570 (36.3%) 
 Other  Leukaemia 795 (18.4%) 
 
GU (other) 4,095 2.3% 
 
Ovary 4,419 2.5% 
 
Bladder 4,070 2.3% 
 
Head & Neck 3,573 2.0% 
 Nasopharyngeal 438 (12.3%) 
 lip/oral cavity/pharynx 2,543 (71.2%) 
 Nasal cavity/middle ear 592 (16.6%) 
 
Other 5,678 3.2% 
Sex Men 68,845 38.5% 
 
Women 110,117 61.5% 
Age at FPN 
Diagnosis 
15-19 10,926 6.1% 
20-24 19,217 10.7% 
 
25-29 32,396 18.1% 
 
30-34 48,802 27.3% 
 
35-39 67,621 37.8% 
Decade of FPN 
Diagnosis 
1971-1979 19,048 10.6% 
1980-1989 43,313 24.2% 
 
1990-1999 62,854 35.1% 
 
2000-2006 53,747 30.0% 
Attained Age 20-39 27,604 15.4% 
 
40-49 65,579 36.6% 
 
50-59 50,703 28.3% 
 
60+ 35,076 19.6% 
Abbreviations: FPN=first primary neoplasms; CNS=central nervous system; NHL=non-hodgkin lymphoma; STS=soft-tissue sarcoma; A L Leukaemia= acute 
lymphocytic leukaemia; C M Leukaemia= chronic myeloid leukaemia; A M Leukaemia= acute myeloid leukaemia; GU=genitourinary.  
1For Glial Tumours, this category consists of pilocytic astrocytoma, other specified astrocytoma, glioblastoma, anaplastic astrocytoma, astrocytoma not otherwise 
specified, oligodendrogliomas, other specified glioma and glioma not otherwise specified.  
²For Pituitary Tumour, this category consists of tumours of the pituitary (primarily pituitary adenomas), excluding craniopharyngioma 
3For Embryonal Tumours, this category consists of medulloblastoma and supratentorial PNET 
4For Other specified, this category consists of pineal tumours, choroid plexus tumours, CNS nerve sheath tumours and other specified CNS tumours 
5For Other unspecified, this category consists of unspecified malignant CNS tumours and unspecified benign CNS tumour
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Table 3.4: Standardised hospitalisation ratios and absolute excess risks of any cerebrovascular event, cerebral haemorrhage (ICD10: I61-I62), cerebral infarction (ICD10: I63, 
I65-66), other cerebrovascular event (ICD10:I64, I67-I68) by TYA cancer diagnosis, sex, age at diagnosis and decade of diagnosis. 
  Any CV Event (ICD10: I60-I68) Cerebral Haemorrhage (ICD10: I61-I62) Cerebral infarction (ICD10: I63, I65-I66) Other CV Event (ICD10: I64, I67-I68)* 
  O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) 
All Survivors 2782 1.4 (1.3,1.4) 4.2 (3.6,4.8) 618 2.0 (1.8,2.1) 1.6 (1.4,1.9) 1296 1.5 (1.4,1.6) 2.4 (2.0,2.7) 1114 1.4 (1.3,1.5) 1.7 (1.3,2.0) 
FPN            
Breast 288 0.8 (0.7,0.9) -2.0 (-3.1,-0.8) 48 1.0 (0.7,1.3) -0.0 (-0.5,0.4) 127 0.9 (0.8,1.1) -0.4 (-1.1,0.4) 117 0.8 (0.7,1.0) -1.0 (-1.8,-0.3) 
Testicular 278 1.0 (0.9,1.1) 0.1 (-1.3,1.4) 61 1.3 (1.0,1.7) 0.6 (-0.1,1.2) 128 1.0 (0.8,1.2) -0.1 (-1.0,0.8) 97 0.9 (0.8,1.2) -0.2 (-1.0,0.6) 
Cervix 317 1.2 (1.1,1.4) 2.4 (0.9,3.8) 47 1.2 (0.9,1.6) 0.4 (-0.2,0.9) 137 1.4 (1.1,1.6) 1.5 (0.5,2.4) 149 1.4 (1.2,1.6) 1.7 (0.7,2.7) 
Melanoma 155 0.8 (0.7,0.9) -2.0 (-3.2,-0.8) 61 2.0 (1.5,2.6) 1.5 (0.7,2.3) 47 0.6 (0.4,0.8) -1.7 (-2.4,-1.0) 47 0.6 (0.4,0.8) -1.5 (-2.1,-0.8) 
CNS tumour 616 4.6 (4.3,5.0) 33.9 (30.5,37.4) 183 8.3 (7.2,9.6) 11.2 (9.3,13.0) 256 4.4 (3.9,5.0) 13.8 (11.6,16.0) 268 5.1 (4.5,5.8) 15.1 (12.8,17.3) 
Hodgkin Lymphoma 228 1.6 (1.4,1.8) 4.8 (3.1,6.6) 43 1.7 (1.3,2.4) 1.1 (0.3,1.9) 135 2.1 (1.8,2.5) 4.2 (2.9,5.6) 76 1.4 (1.1,1.7) 1.2 (0.2,2.2) 
NHL 139 1.6 (1.4,1.9) 6.7 (3.8,9.5) 33 2.4 (1.6,3.3) 2.3 (1.0,3.7) 70 1.8 (1.4,2.3) 3.9 (1.9,6.0) 47 1.4 (1.0,1.9) 1.7 (0.1,3.4) 
Thyroid 65 0.9 (0.7,1.2) -0.6 (-2.7,1.5) 9 0.8 (0.4,1.6) -0.2 (-1.0,0.6) 34 1.2 (0.8,1.7) 0.7 (-0.8,2.3) 27 1.0 (0.6,1.4) -0.1 (-1.5,1.2) 
Gastrointestinal 88 0.9 (0.7,1.2) -1.0 (-3.9,1.9) 19 1.3 (0.8,2.1) 0.7 (-0.6,2.1) 43 1.0 (0.7,1.4) 0.1 (-2.0,2.1) 43 1.1 (0.8,1.5) 0.7 (-1.4,2.7) 
STS 84 1.3 (1.0,1.6) 3.4 (0.4,6.5) 22 2.2 (1.4,3.3) 2.0 (0.5,3.6) 42 1.5 (1.1,2.0) 2.4 (0.2,4.5) 36 1.4 (1.0,2.0) 1.8 (-0.2,3.8) 
Leukaemia 70 2.5 (1.9,3.1) 10.2 (6.2,14.2) 26 5.2 (3.4,7.6) 5.1 (2.7,7.6) 28 2.3 (1.5,3.3) 3.9 (1.3,6.4) 27 2.6 (1.7,3.8) 4.1 (1.6,6.6) 
GU (other) 93 1.6 (1.3,1.9) 8.3 (3.7,12.8) 22 2.5 (1.6,3.8) 3.2 (1.0,5.4) 46 1.8 (1.3,2.4) 4.9 (1.7,8.1) 33 1.3 (0.9,1.9) 2.0 (-0.7,4.7) 
Ovary 52 1.0 (0.7,1.3) -0.3 (-3.1,2.5) 7 0.9 (0.4,1.9) -0.1 (-1.2,0.9) 23 1.1 (0.7,1.6) 0.4 (-1.5,2.3) 20 0.9 (0.5,1.4) -0.5 (-2.2,1.2) 
Bladder 83 1.0 (0.8,1.2) -0.3 (-4.1,3.5) 10 0.8 (0.4,1.4) -0.6 (-1.9,0.7) 47 1.2 (0.9,1.6) 1.5 (-1.4,4.3) 32 0.9 (0.6,1.3) -0.6 (-2.9,1.8) 
Head & Neck 123 2.6 (2.2,3.1) 21.5 (15.4,27.7) 13 1.7 (0.9,3.0) 1.5 (-0.4,3.5) 75 3.5 (2.8,4.4) 15.0 (10.2,19.8) 51 2.7 (2.0,3.5) 8.9 (5.0,12.8) 
Other 103 1.5 (1.2,1.9) 5.8 (2.6,9.1) 14 1.3 (0.7,2.2) 0.6 (-0.6,1.7) 58 2.0 (1.5,2.5) 4.7 (2.2,7.1) 44 1.6 (1.2,2.2) 2.8 (0.6,4.9) 
Pheterogeneity  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
Sex            
Men 1322 1.5 (1.5,1.6) 6.6 (5.6,7.6) 322 2.2 (2.0,2.5) 2.5 (2.0,3.0) 659 1.6 (1.5,1.7) 3.5 (2.8,4.2) 505 1.6 (1.4,1.7) 2.5 (1.9,3.2) 
Women 1460 1.3 (1.2,1.3) 2.7 (2.1,3.4) 296 1.8 (1.6,2.0) 1.1 (0.8,1.4) 637 1.4 (1.3,1.5) 1.6 (1.2,2.1) 609 1.3 (1.2,1.4) 1.1 (0.7,1.6) 
Pheterogeneity  <0.001 <0.001  0.004 <0.001  0.016 <0.001  0.001 0.006 
Age at FPN Diagnosis(years)            
15-19 148 3.6 (3.0,4.2) 8.9 (6.9,10.9) 44 5.3 (3.8,7.1) 3.0 (1.9,4.1) 67 4.3 (3.3,5.4) 4.3 (2.9,5.6) 56 4.1 (3.1,5.4) 3.5 (2.3,4.8) 
20-24 219 2.0 (1.8,2.3) 5.2 (3.9,6.6) 53 2.7 (2.0,3.5) 1.6 (0.9,2.2) 101 2.3 (1.9,2.8) 2.7 (1.8,3.7) 81 2.2 (1.7,2.7) 2.1 (1.2,2.9) 
25-29 407 1.6 (1.4,1.7) 4.2 (3.1,5.4) 91 2.1 (1.7,2.5) 1.3 (0.8,1.9) 192 1.8 (1.5,2.1) 2.4 (1.7,3.2) 164 1.7 (1.5,2.0) 2.0 (1.2,2.7) 
30-34 722 1.3 (1.2,1.4) 3.6 (2.5,4.6) 176 2.1 (1.8,2.4) 1.8 (1.3,2.3) 318 1.4 (1.2,1.5) 1.7 (1.0,2.4) 255 1.2 (1.1,1.4) 0.8 (0.2,1.5) 
35-39 1286 1.2 (1.2,1.3) 3.5 (2.4,4.6) 254 1.6 (1.4,1.8) 1.5 (1.0,2.0) 618 1.3 (1.2,1.4) 2.3 (1.6,3.1) 558 1.3 (1.2,1.4) 1.7 (1.0,2.4) 
Ptrend  <0.001 <0.001  <0.001 0.079  <0.001 0.007  <0.001 0.002 
Decade of FPN Diagnosis            
1971-1979 809 1.1 (1.1,1.2) 3.9 (1.8,6.0) 118 1.2 (1.0,1.4) 0.8 (-0.0,1.6) 404 1.2 (1.1,1.4) 3.0 (1.5,4.5) 376 1.2 (1.1,1.3) 2.3 (0.8,3.7) 
1980-1989 1097 1.5 (1.4,1.6) 5.6 (4.6,6.7) 235 2.0 (1.7,2.3) 1.9 (1.4,2.3) 519 1.6 (1.5,1.8) 3.2 (2.5,4.0) 448 1.5 (1.4,1.7) 2.5 (1.8,3.2) 
1990-1999 700 1.6 (1.4,1.7) 3.4 (2.7,4.2) 195 2.5 (2.1,2.8) 1.6 (1.2,2.0) 309 1.8 (1.6,2.0) 1.8 (1.4,2.3) 239 1.5 (1.3,1.7) 1.1 (0.7,1.5) 
2000-2006 176 1.7 (1.4,1.9) 3.1 (1.9,4.2) 70 3.7 (2.9,4.7) 2.2 (1.5,3.0) 64 1.5 (1.1,1.9) 0.9 (0.2,1.6) 51 1.4 (1.0,1.8) 0.6 (0.0,1.2) 
Ptrend  <0.001 <0.001  <0.001 0.089  <0.001 <0.001  0.007 <0.001 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; CNS=central nervous system; 
NHL=non-hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. 
*Constituting ICD10: I64-Stroke not specified as haemorrhage or infarction (n=454); I67.0 – Dissection of cerebral arteries, non-ruptured (n=10); I67.1 – Cerebral aneurysm, non-ruptured (n=98); I67.2 – Cerebral atherosclerosis (n=38); I67.4- 
Hypertensive encephalopathy (n=12); I67.5-I67.8 – Other specified cerebrovascular disease (n=399); I67.9- Cerebrovascular disease, unspecified (n=244); I68 – Cerebrovascular disorders in diseases elsewhere classified (n=3).
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Table 3.5: Standardised hospitalisation ratio, relative risk, absolute excess risk and excess 
hospitalisation ratio of any and specific cerebrovascular events according to attained age. 
Cerebrovascular 
Event 
Attained 
Age (years) 
O SHR (95% CI) RR (95% CI)* AER (95% CI) EHR (95% CI)* 
Any CV Event 
(ICD10: I60-I68) 
20-44 549 2.0 (1.9,2.2) 1.0 Ref 3.7 (3.1,4.3) 1.0 Ref 
45-49 433 1.5 (1.3,1.6) 0.9 (0.7,1.0) 3.7 (2.6,4.7) 1.6 (1.2,2.2) 
50-54 512 1.5 (1.4,1.7) 0.9 (0.8,1.1) 6.1 (4.5,7.6) 2.1 (1.4,2.9) 
54-59 455 1.3 (1.2,1.4) 0.9 (0.7,1.0) 5.4 (3.3,7.4) 2.4 (1.5,3.6) 
 60+ 833 1.1 (1.0,1.2) 0.8 (0.7,1.0) 3.5 (0.9,6.2) 2.4 (1.5,4.1) 
 Ptrend  <0.001 0.086 0.122 <0.001 
Cerebral 
Haemorrhage 
(ICD10: I61-I62) 
20-44 193 3.6 (3.1,4.2) 1.0 Ref 1.8 (1.5,2.2) 1.0 Ref 
45-49 110 2.2 (1.8,2.6) 0.7 (0.6,0.9) 1.6 (1.0,2.1) 1.1 (0.7,1.6) 
50-54 106 1.9 (1.6,2.3) 0.7 (0.5,1.0) 1.7 (1.0,2.4) 1.2 (0.7,2.0) 
54-59 92 1.7 (1.4,2.1) 0.7 (0.5,1.0) 1.9 (1.0,2.8) 1.1 (0.6,2.2) 
 60+ 117 1.2 (1.0,1.4) 0.6 (0.4,0.8) 0.7 (-0.2,1.7) 1.0 (0.4,2.3) 
 Ptrend  <0.001 0.016 0.137 0.610 
Cerebral infarction  
(ICD10: I63, I65-
66) 
20-44 197 2.2 (1.9,2.5) 1.0 Ref 1.4 (1.0,1.8) 1.0 Ref 
45-49 191 1.8 (1.5,2.0) 0.9 (0.7,1.1) 2.2 (1.5,2.9) 2.7 (1.8,4.1) 
50-54 242 1.8 (1.6,2.0) 0.9 (0.7,1.2) 3.7 (2.7,4.8) 3.7 (2.3,6.0) 
54-59 238 1.6 (1.4,1.8) 0.8 (0.6,1.1) 4.2 (2.7,5.7) 5.1 (2.9,8.8) 
 60+ 428 1.1 (1.0,1.3) 0.7 (0.5,0.9) 2.5 (0.6,4.4) 5.6 (2.9,10.8) 
 Ptrend  <0.001 0.018 <0.001 <0.001 
Other CV event 
(ICD10: I64, I67-
I68) 
20-44 161 1.8 (1.6,2.1) 1.0 Ref 1.0 (0.6,1.3) 1.0 Ref 
45-49 160 1.6 (1.3,1.8) 1.0 (0.8,1.3) 1.5 (0.8,2.2) 3.0 (1.9,4.9) 
50-54 207 1.6 (1.4,1.9) 1.1 (0.9,1.4) 2.8 (1.8,3.8) 4.4 (2.6,7.4) 
54-59 184 1.3 (1.2,1.6) 1.0 (0.7,1.3) 2.3 (1.0,3.6) 4.6 (2.5,8.7) 
60+ 402 1.1 (1.0,1.3) 0.9 (0.7,1.3) 2.3 (0.5,4.2) 6.4 (3.1,12.9) 
 
Ptrend  <0.001 0.605 <0.001 <0.001 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised 
hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; RR=relative risk; EHR=excess hospitalisation ratio; 
ref= reference level 
*Multivariable models and p-values are adjusted for cancer diagnosis, sex, age at cancer diagnosis, decade of cancer 
diagnosis and attained age 
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Figure 3.2: Cumulative incidence for all and specific types of cerebrovascular events, by attained age.  
Abbreviations: H&N=head and neck, CNS= central nervous system. Other = all TYA cancers excluding CNS, H&N and leukaemia
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Table 3.6: Standardised hospitalisation ratios and absolute excess risks of any cerebrovascular event, cerebral haemorrhage (ICD10: I61-I62), cerebral infarction (ICD10:I63, 
I65-66) or other cerebrovascular event (ICD10:I64, I67-I68) among CNS tumours survivors by tumour diagnosis, sex, age at diagnosis, decade of diagnosis and attained age 
  Any CV Event (ICD10: I60-I68) Cerebral Haemorrhage (ICD10: I61-I62) Cerebral infarction (ICD10: I63, I66-67) Other CV Event (ICD10: I64, I67-I68) 
  O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) O SHR (95% CI) AER (95% CI) 
All CNS tumours 616 4.6 (4.3,5.0) 33.9 (30.5,37.4) 183 8.3 (7.2,9.6) 11.2 (9.3,13.0) 256 4.4 (3.9,5.0) 13.8 (11.6,16.0) 268 5.1 (4.5,5.8) 15.1 (12.8,17.3) 
CNS tumour type             
Glial Tumour 254 10.8 (9.5,12.3) 72.3 (62.5,82.1) 108 26.2 (21.5,31.6) 32.1 (25.8,38.3) 94 9.3 (7.5,11.4) 25.9 (20.1,31.8) 89 10.1 (8.1,12.4) 24.8 (19.1,30.5) 
Embryonal Tumour 21 12.9 (8.0,19.7) 78.0 (41.9,114.2) * * * 13 18.8 (10.0,32.1) 49.1 (20.9,77.3) 12 20.2 (10.4,35.3) 45.6 (18.5,72.7) 
Craniopharyngioma 24 6.0 (3.8,8.9) 43.9 (22.8,65.0) 5 7.3 (2.4,17.0) 9.3 (-0.2,18.7) 12 6.8 (3.5,11.9) 22.1 (7.5,36.8) 10 6.5 (3.1,12.0) 18.5 (5.0,32.0) 
Other Pituitary Tumours 115 3.4 (2.8,4.0) 21.7 (16.1,27.4) 12 2.1 (1.1,3.7) 1.7 (-0.1,3.5) 55 3.8 (2.8,4.9) 10.8 (6.9,14.7) 61 4.6 (3.5,5.9) 12.8 (8.7,16.9) 
Meningioma 52 2.1 (1.5,2.7) 12.9 (6.1,19.6) 13 3.4 (1.8,5.7) 4.3 (1.0,7.7) 24 2.2 (1.4,3.3) 6.2 (1.7,10.8) 20 1.9 (1.2,3.0) 4.6 (0.4,8.7) 
Ependymoma 30 4.9 (3.3,7.0) 35.5 (19.5,51.5) 6 5.7 (2.1,12.4) 7.3 (0.2,14.3) 17 6.1 (3.6,9.8) 21.0 (9.1,32.9) 13 5.5 (3.0,9.5) 15.7 (5.3,26.2) 
Germ Cell Intracranial 9 8.1 (3.7,15.3) 40.5 (10.3,70.8) * * * 5 10.5 (3.4,24.6) 23.1 (0.7,45.5) 5 12.6 (4.1,29.5) 23.4 (1.1,45.7) 
Other specified 56 2.0 (1.5,2.6) 10.3 (4.8,15.7) 22 4.8 (3.0,7.3) 6.5 (3.1,9.9) 19 1.5 (0.9,2.4) 2.4 (-0.8,5.6) 26 2.3 (1.5,3.4) 5.5 (1.8,9.2) 
Other Unspecified 55 5.9 (4.4,7.7) 47.2 (32.2,62.2) 14 9.0 (4.9,15.0) 12.6 (5.2,20.1) 17 4.1 (2.4,6.5) 13.0 (4.8,21.2) 32 8.7 (5.9,12.2) 28.9 (17.6,40.3) 
Pheterogeneity  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
Sex            
Men 339 4.8 (4.3,5.3) 40.8 (35.3,46.3) 105 8.5 (6.9,10.2) 13.9 (10.9,16.9) 140 4.2 (3.5,4.9) 16.0 (12.5,19.5) 153 5.8 (4.9,6.8) 19.1 (15.4,22.7) 
Women 277 4.4 (3.9,4.9) 28.0 (23.8,32.3) 78 8.1 (6.4,10.2) 8.9 (6.6,11.1) 116 4.8 (3.9,5.7) 11.9 (9.2,14.7) 115 4.4 (3.7,5.3) 11.6 (8.9,14.3) 
Pheterogeneity  0.272 <0.001  0.805 0.006  0.280 0.066  0.028 0.001 
Age at FPN Diagnosis (years)            
15-19 79 12.7 (10.1,15.9) 37.7 (28.7,46.8) 28 21.8 (14.5,31.5) 13.7 (8.4,19.0) 32 13.6 (9.3,19.2) 15.2 (9.5,20.9) 30 14.8 (10.0,21.1) 14.4 (8.9,19.9) 
20-24 67 6.3 (4.9,8.0) 25.5 (18.3,32.8) 17 8.5 (5.0,13.7) 6.7 (3.1,10.4) 28 6.7 (4.4,9.6) 10.7 (6.1,15.4) 28 7.5 (5.0,10.9) 10.9 (6.3,15.6) 
25-29 113 5.7 (4.7,6.8) 33.1 (25.7,40.5) 34 9.7 (6.7,13.6) 10.7 (6.7,14.8) 48 5.8 (4.3,7.7) 14.0 (9.2,18.8) 49 6.7 (5.0,8.9) 14.7 (9.9,19.5) 
30-34 146 4.1 (3.4,4.8) 32.5 (25.5,39.5) 53 9.1 (6.8,11.9) 13.8 (9.6,17.9) 52 3.3 (2.5,4.4) 10.7 (6.5,14.8) 56 4.0 (3.1,5.2) 12.3 (8.1,16.6) 
35-39 211 3.5 (3.0,4.0) 38.7 (31.3,46.0) 51 5.4 (4.0,7.1) 10.5 (7.0,14.1) 96 3.5 (2.8,4.2) 17.4 (12.5,22.3) 105 4.1 (3.4,5.0) 20.3 (15.2,25.4) 
Ptrend  <0.001 0.393  <0.001 0.791  <0.001 0.555  <0.001 0.111 
Decade of FPN Diagnosis            
1971-1979 142 3.3 (2.8,3.9) 53.4 (40.9,66.0) 26 4.2 (2.7,6.1) 10.4 (5.1,15.6) 59 3.0 (2.3,3.8) 20.6 (12.6,28.5) 83 4.5 (3.6,5.5) 34.2 (24.7,43.7) 
1980-1989 234 4.6 (4.1,5.3) 38.5 (32.2,44.8) 49 5.8 (4.3,7.7) 8.4 (5.6,11.2) 107 4.9 (4.0,5.9) 17.7 (13.5,21.9) 115 5.9 (4.9,7.1) 19.8 (15.5,24.2) 
1990-1999 179 5.4 (4.6,6.2) 24.8 (20.3,29.2) 72 11.9 (9.3,15.0) 11.1 (8.3,13.9) 71 5.4 (4.2,6.8) 9.8 (7.0,12.6) 57 4.9 (3.7,6.3) 7.7 (5.2,10.2) 
2000-2006 61 8.5 (6.5,10.9) 31.5 (22.5,40.5) 36 26.5 (18.6,36.7) 20.3 (13.4,27.1) 19 6.3 (3.8,9.9) 9.3 (4.4,14.3) 13 5.4 (2.9,9.2) 6.2 (2.1,10.3) 
Ptrend  <0.001 <0.001  <0.001 0.005  <0.001 <0.001  0.451 <0.001 
Attained Age (years)             
20-44 200 8.4 (7.3,9.7) 24.6 (20.7,28.5) 87 17.9 (14.4,22.1) 11.4 (8.9,14.0) 65 8.2 (6.3,10.4) 7.9 (5.7,10.1) 50 6.6 (4.9,8.7) 5.9 (4.0,7.8) 
44-49 118 5.5 (4.6,6.6) 36.0 (28.1,43.9) 40 10.5 (7.5,14.4) 13.4 (8.8,17.9) 52 6.4 (4.8,8.5) 16.2 (11.0,21.5) 54 7.2 (5.4,9.5) 17.2 (11.9,22.5) 
50-54 104 4.4 (3.6,5.4) 41.8 (31.4,52.1) 24 6.1 (3.9,9.1) 10.2 (5.3,15.1) 40 4.1 (2.9,5.5) 15.5 (9.1,21.8) 58 6.6 (5.0,8.5) 25.2 (17.6,32.9) 
54-59 88 3.9 (3.1,4.8) 51.3 (36.8,65.7) 15 4.2 (2.4,7.0) 8.8 (3.0,14.6) 46 4.4 (3.2,5.9) 27.5 (17.2,37.8) 44 4.9 (3.6,6.6) 27.1 (17.1,37.2) 
60+ 106 2.5 (2.1,3.0) 54.6 (37.3,71.9) 17 2.9 (1.7,4.6) 9.1 (2.5,15.8) 53 2.4 (1.8,3.2) 26.0 (14.1,37.9) 62 3.2 (2.4,4.1) 35.7 (22.7,48.6) 
Ptrend  <0.001 <0.001  <0.001 0.441  <0.001 <0.001  <0.001 <0.001 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; CNS=central nervous system; 
NHL=non-Hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. *Omitted from table due to few events (less than 5 observed).
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Figure 3.3: Absolute Excess Risk (95% CI) for any and specific types of cerebrovascular event (CV) according to attained age among survivors of CNS 
tumours. 
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Table 3.7: Standardised hospitalisation ratios and absolute excess risks of any cerebrovascular event, cerebral infarction (ICD10: I63, I65-66) or other 
cerebrovascular event (ICD10: I67-I68) among survivors of head and neck tumours by sex, age at diagnosis, decade of diagnosis and attained age 
 Any CV Event (ICD10: I60-I68) Cerebral infarction (ICD10: I63, I65-66) Other CV Event (ICD10: I64, I67-I68) 
  O SHR (95%CI) AER (95%CI) O SHR (95%CI) AER (95%CI) O SHR (95%CI) AER (95%CI) 
All HN tumours 123 2.6 (2.2,3.1) 21.5 (15.4,27.7) 75 3.5 (2.8,4.4) 15.0 (10.2,19.8) 51 2.7 (2.0,3.5) 8.9 (5.0,12.8) 
Sex          
Men 91 2.9 (2.3,3.6) 30.4 (20.9,39.9) 58 3.8 (2.9,4.9) 21.5 (14.0,29.0) 36 2.9 (2.0,4.0) 11.7 (5.8,17.5) 
Women 32 2.1 (1.4,2.9) 10.5 (3.5,17.6) 17 2.8 (1.6,4.4) 6.9 (1.8,12.0) 15 2.3 (1.3,3.8) 5.4 (0.6,10.2) 
Pheterogeneity  0.098 0.002  0.258 0.001  0.494 0.027 
Age at FPN Diagnosis (years)          
15-24 12 4.6 (2.4,8.0) 16.0 (4.4,27.6) 8 7.8 (3.3,15.3) 11.9 (2.4,21.3) * * * 
25-29 14 2.6 (1.4,4.3) 13.5 (1.9,25.2) 8 3.3 (1.4,6.5) 8.8 (0.1,17.5) 8 3.9 (1.7,7.6) 9.4 (0.6,18.1) 
30-34 31 2.5 (1.7,3.6) 20.4 (8.6,32.3) 18 3.2 (1.9,5.1) 13.5 (4.5,22.4) 13 2.7 (1.4,4.5) 8.7 (1.1,16.3) 
35-39 66 2.5 (1.9,3.2) 28.1 (16.8,39.4) 41 3.3 (2.4,4.5) 20.1 (11.3,28.9) 27 2.4 (1.6,3.5) 11.0 (3.9,18.1) 
Ptrend  0.152 0.053  0.116 0.106  0.288 0.096 
Decade of FPN Diagnosis          
1971-1979 35 1.8 (1.3,2.5) 25.5 (6.8,44.2) 19 2.0 (1.2,3.2) 15.2 (1.7,28.8) 19 2.2 (1.3,3.4) 16.1 (2.7,29.6) 
1980-1989 40 2.5 (1.8,3.4) 21.0 (10.1,31.9) 25 3.4 (2.2,5.1) 15.5 (6.9,24.0) 18 2.8 (1.7,4.5) 10.1 (2.9,17.3) 
1990-2006 48 4.2 (3.1,5.6) 20.5 (12.9,28.1) 31 6.5 (4.4,9.2) 14.6 (8.5,20.7) 14 3.5 (1.9,5.9) 5.6 (1.5,9.7) 
Ptrend  <0.001 0.799  <0.001 0.991  0.158 0.119 
Attained Age (years)          
20-44 23 4.6 (2.9,6.8) 13.2 (6.3,20.1) 15 8.6 (4.8,14.2) 9.7 (4.2,15.3) 6 3.7 (1.4,8.1) 3.2 (-0.3,6.7) 
44-49 22 3.8 (2.4,5.7) 22.6 (9.7,35.4) 14 6.2 (3.4,10.4) 16.3 (6.1,26.5) 7 3.4 (1.4,7.1) 6.9 (-0.3,14.0) 
50-54 23 3.2 (2.1,4.9) 28.6 (11.7,45.5) 16 5.4 (3.1,8.7) 23.3 (9.3,37.3) 8 3.0 (1.3,6.0) 9.5 (-0.3,19.4) 
54-59 18 2.3 (1.3,3.6) 24.5 (4.3,44.7) 10 2.7 (1.3,5.0) 15.3 (0.4,30.2) 7 2.3 (0.9,4.7) 9.3 (-3.0,21.7) 
60+ 37 1.8 (1.3,2.5) 32.7 (8.8,56.5) 20 1.8 (1.1,2.9) 17.9 (0.8,35.0) 23 2.4 (1.5,3.6) 25.7 (7.5,43.9) 
Ptrend  <0.001 0.029  <0.001 0.159  0.215 0.002 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; 
FPN=first primary neoplasms; CNS=central nervous system; NHL=non-Hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary. 
*Omitted from table due to few events (less than 5 observed). 
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Figure 3.4: Absolute Excess Risk (95% CI) for any and specific types of cerebrovascular (CV) event according to attained age among survivors of head & 
neck tumours. 
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Table 3.8: Relative risks and excess hospitalisation ratios of any cerebrovascular event, cerebral infarction (ICD10: I63, I65-66) or ‘other cerebrovascular 
event’ (ICD10: I64, I67-I68) among survivors of head and neck tumours by sex, age at diagnosis and decade of diagnosis. 
 Any CV Event 
 (ICD10: I60-I68) 
Cerebral infarction 
 (ICD10: I63, I65-66) 
Other Cerebrovascular Event 
 (ICD10: I64, I67-I68)   RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) RR (95%CI) EHR (95%CI) 
Sex       
Men 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
Women 0.7 (0.4,1.0) 0.3 (0.1,0.7) 0.7 (0.4,1.1) 0.3 (0.1,0.7) 0.8 (0.4,1.4) 0.5 (0.2,1.4) 
Pheterogeneity 0.035 0.001 0.110 0.005 0.377 0.238 
Age at FPN Diagnosis       
15-24 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
25-29 0.6 (0.3,1.4) 0.5 (0.1,1.9) 0.6 (0.2,1.6) 0.5 (0.1,1.9) 1.1 (0.3,4.5) 1.4 (0.2,11.0) 
30-34 0.6 (0.3,1.3) 0.8 (0.3,2.3) 0.7 (0.3,1.7) 0.8 (0.3,2.5) 0.7 (0.2,2.9) 1.0 (0.1,7.9) 
35-39 0.6 (0.3,1.3) 0.8 (0.3,2.4) 0.8 (0.3,2.0) 0.9 (0.3,2.9) 0.6 (0.1,2.5) 0.7 (0.1,7.7) 
Ptrend 0.378 0.995 0.867 0.785 0.242 0.612 
Decade of FPN Diagnosis       
1971-1979 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
1980-1989 1.2 (0.7,2.1) 1.2 (0.4,3.6) 1.2 (0.6,2.4) 1.1 (0.3,3.7) 1.5 (0.7,3.1) 1.3 (0.4,5.0) 
1990-2006 1.8 (0.9,3.7) 1.8 (0.5,6.7) 1.3 (0.5,3.3) 1.5 (0.4,5.8) 2.0 (0.6,6.3) 2.0 (0.3,13.7) 
Ptrend 0.089 0.229 0.520 0.456 0.221 0.504 
Attained Age       
20-44 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
44-49 0.9 (0.5,1.7) 1.7 (0.7,4.1) 0.7 (0.3,1.5) 1.5 (0.6,4.1) 1.1 (0.4,3.5) 3.0 (0.4,20.1) 
50-54 0.9 (0.5,1.7) 2.6 (0.9,7.3) 0.6 (0.3,1.4) 2.5 (0.8,7.3) 1.1 (0.3,3.7) 5.0 (0.6,44.9) 
54-59 0.7 (0.3,1.6) 2.2 (0.6,8.3) 0.3 (0.1,1.0) 1.7 (0.4,7.2) 0.9 (0.2,3.7) 5.9 (0.5,71.8) 
60+ 0.7 (0.3,1.6) 3.4 (0.7,15.3) 0.2 (0.1,0.8) 2.0 (0.4,10.7) 1.3 (0.3,5.5) 17.6 (1.2,250.6) 
Ptrend 0.313 0.071 0.015 0.267 0.716 0.032 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O/E= observed over expected; SHR=standardised hospitalisation ratio; AER=absolute excess risk; 
CI=confidence interval; RR=relative risk; EHR=excess hospitalisation ratio; ref= reference level; FPN=first primary neoplasms 
*Multivariable models and p-values are adjusted for sex, age at cancer diagnosis, decade of cancer diagnosis and attained age
 
 
107 
 
Table 3.9: Standardised hospitalisation ratios and absolute excess risks, relative risks and excess 
hospitalisation ratios of any cerebrovascular event among survivors of leukaemia by, type of 
leukaemia, sex, age at diagnosis, decade of diagnosis and attained age 
  O SHR (95%CI) RR (95%CI)* AER (95%CI) EHR (95%CI)* 
All Leukaemia 70 2.5 (1.9,3.1) 
 
10.2 (6.2,14.2) 
 
Type of Leukaemia 
     
Acute Lymphoblastic 18 3.7 (2.2,5.9) 1.0 Ref 12.4 (4.6,20.3) 1.0 Ref 
Acute Myeloid 16 1.7 (1.0,2.8) 0.6 (0.3,1.1) 4.5 (-0.8,9.7) 0.3 (0.1,1.7) 
Chronic Myeloid 13 2.9 (1.6,5.0) 0.9 (0.4,2.0) 12.3 (2.1,22.5) 1.1 (0.3,3.8) 
Other 23 2.3 (1.5,3.5) 0.9 (0.4,1.9) 15.9 (4.5,27.3) 1.0 (0.3,3.5) 
Pheterogeneity  
0.13 0.297 0.15 0.322 
Sex 
     
Men 47 2.7 (2.0,3.6) 1.0 Ref 13.0 (7.1,18.9) 1.0 Ref 
Women 23 2.1 (1.3,3.1) 0.8 (0.5,1.4) 6.6 (1.4,11.9) 0.5 (0.2,1.3) 
Pheterogeneity  
0.29 0.409 0.262 0.258 
Age at FPN Diagnosis (years) 
     
15-19 14 5.1 (2.8,8.6) 1.0 Ref 12.0 (4.2,19.9) 1.0 Ref 
20-24 6 2.2 (0.8,4.7) 0.4 (0.2,1.1) 4.7 (-2.3,11.8) 0.4 (0.1,1.8) 
25-29 10 2.4 (1.2,4.4) 0.4 (0.2,1.0) 8.1 (-0.5,16.8) 0.4 (0.1,1.8) 
30-34 22 3.0 (1.9,4.5) 0.5 (0.2,1.2) 17.4 (6.4,28.4) 0.6 (0.1,2.7) 
35-39 18 1.6 (0.9,2.5) 0.2 (0.1,0.7) 7.3 (-2.0,16.6) 0.2 (0.0,1.3) 
Ptrend  
0.007 0.017 0.696 0.15 
Decade of FPN Diagnosis 
     
1971-1979 13 2.3 (1.2,3.9) 1.0 Ref 21.7 (0.5,42.9) 1.0 Ref 
1980-1989 23 2.3 (1.4,3.4) 1.2 (0.5,2.9) 11.0 (3.0,19.0) 1.0 (0.2,4.5) 
1990-2006 34 2.7 (1.9,3.7) 1.7 (0.6,4.7) 8.3 (3.9,12.8) 1.1 (0.2,5.9) 
Ptrend  
0.527 0.162 0.116 0.775 
Attained Age (years) 
     
20-44 22 2.7 (1.7,4.2) 1.0 Ref 5.5 (1.9,9.1) 1.0 Ref 
44-49 19 3.1 (1.9,4.9) 1.6 (0.8,3.3) 17.5 (5.9,29.1) 5.0 (1.3,18.9) 
50-54 14 2.6 (1.4,4.4) 1.6 (0.7,3.5) 20.4 (3.1,37.8) 6.0 (1.2,30.8) 
55+ 15 1.6 (0.9,2.7) 1.3 (0.5,3.6) 16.3 (-4.7,37.4) 7.9 (1.1,55.7) 
Ptrend  
0.142 0.429 0.014 0.01 
 
Abbreviations: O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; 
RR=relative risk; EHR=excess hospitalisation ratio 
* Multivariable models and p-values are adjusted for sex, age at cancer diagnosis, decade of cancer diagnosis and attained 
age
 
 
108 
 
Table 3.10: Relative risks and excess hospitalisation ratios any cerebrovascular event*, cerebral haemorrhage (ICD10: I61-I62), cerebral infarction (ICD10: I63) or ‘other 
cerebrovascular event’ (ICD10: I65-I68) by TYA cancer diagnosis, sex, age at diagnosis and decade of diagnosis. 
  Any CV Event 
 (ICD10: I60-I68) 
Cerebral Haemorrhage 
 (ICD10: I61-I62) 
Cerebral infarction 
 (ICD10: I63, I65-I66) 
Other Cerebrovascular Event 
 (ICD10: I64, I67-I68)     RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) 
FPN Diagnosis Breast 0.6 (0.4,0.7) 0.0 (0.0,.) 0.5 (0.3,0.7) 0.1 (0.0,1.7) 0.5 (0.4,0.8) 0.1 (0.0,1.7) 0.7 (0.5,0.9) 0.0 (0.0,.) 
 
Testicular 0.6 (0.5,0.8) 0.1 (0.0,1.1) 0.5 (0.4,0.8) 0.1 (0.0,1.8) 0.5 (0.4,0.7) 0.0 (0.0,17.3) 0.6 (0.5,0.9) 0.0 (0.0,6127.0) 
 
Cervix 0.8 (0.6,1.0) 0.4 (0.2,1.2) 0.6 (0.4,0.9) 0.2 (0.0,1.3) 0.7 (0.5,1.0) 0.5 (0.2,1.4) 1.1 (0.8,1.6) 1.4 (0.4,5.1) 
 
Melanoma 0.5 (0.4,0.6) 0.0 (0.0,.) 0.8 (0.6,1.3) 0.8 (0.4,1.8) 0.3 (0.2,0.5) 0.0 (0.0,.) 0.5 (0.3,0.7) 0.0 (0.0,.) 
 
CNS tumour 2.9 (2.4,3.6) 6.9 (4.0,11.8) 3.5 (2.4,5.0) 5.8 (3.1,11.1) 2.4 (1.8,3.1) 4.9 (2.5,9.5) 3.6 (2.6,4.9) 12.2 (3.8,38.9) 
 
Hodgkin Lymphoma 0.9 (0.7,1.1) 0.7 (0.3,1.4) 0.7 (0.5,1.1) 0.3 (0.1,1.2) 1.0 (0.8,1.4) 1.3 (0.6,2.7) 0.9 (0.6,1.3) 0.5 (0.1,3.0) 
 
NHL 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
 
Thyroid 0.6 (0.4,0.8) 0.0 (0.0,.) 0.4 (0.2,0.8) 0.0 (0.0,.) 0.6 (0.4,1.0) 0.2 (0.0,3.9) 0.7 (0.4,1.2) 0.0 (0.0,.) 
 
Gastrointestinal 0.6 (0.5,0.8) 0.1 (0.0,37.2) 0.7 (0.4,1.1) 0.3 (0.0,1.9) 0.6 (0.4,0.9) 0.1 (0.0,345.9) 0.9 (0.6,1.3) 0.1 (0.0,2957.0) 
 
STS 0.8 (0.6,1.1) 0.9 (0.4,2.0) 1.0 (0.6,1.7) 0.9 (0.3,2.6) 0.8 (0.6,1.2) 0.9 (0.4,2.5) 1.0 (0.7,1.6) 1.8 (0.4,7.1) 
 
Leukaemia 1.3 (1.0,1.8) 2.1 (1.1,4.1) 1.9 (1.1,3.1) 2.4 (1.1,5.3) 1.1 (0.7,1.7) 1.7 (0.7,4.0) 1.6 (1.0,2.6) 4.0 (1.1,14.6) 
 
GU (other) 1.1 (0.8,1.4) 1.7 (0.8,3.5) 1.2 (0.7,2.1) 1.8 (0.8,4.4) 1.1 (0.7,1.6) 1.7 (0.7,4.0) 1.1 (0.7,1.7) 1.6 (0.3,8.0) 
 
Ovary 0.6 (0.5,0.9) 0.1 (0.0,3073.6) 0.4 (0.2,1.0) 0.0 (0.0,.) 0.6 (0.4,1.0) 0.1 (0.0,29.9) 0.7 (0.4,1.2) 0.2 (0.0,702.7) 
 
Bladder 0.7 (0.5,0.9) 0.2 (0.0,3.0) 0.4 (0.2,0.8) 0.1 (0.0,64.0) 0.7 (0.5,1.0) 0.3 (0.0,3.0) 0.7 (0.4,1.1) 0.0 (0.0,.) 
 
Head & Neck 1.7 (1.3,2.3) 3.8 (2.1,6.8) 0.8 (0.4,1.6) 0.8 (0.2,2.9) 2.1 (1.5,2.9) 4.6 (2.2,9.5) 2.0 (1.3,3.0) 5.6 (1.6,19.3) 
 
Other 0.9 (0.7,1.2) 1.0 (0.4,2.1) 0.6 (0.3,1.1) 0.5 (0.1,1.9) 1.1 (0.7,1.5) 1.3 (0.6,3.1) 1.2 (0.8,1.7) 1.9 (0.5,7.5) 
 
Pheterogeneity <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Sex Men 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
 
Women 0.9 (0.9,1.1) 0.6 (0.5,0.8) 1.0 (0.8,1.2) 0.6 (0.5,0.8) 1.1 (0.9,1.2) 0.6 (0.5,0.8) 0.9 (0.8,1.0) 0.6 (0.5,0.8) 
 
Pheterogeneity 0.316 <0.001 0.960 <0.001 0.551 <0.001 0.155 <0.001 
Age at FPN 
Diagnosis 
15-19 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
20-24 0.7 (0.6,0.9) 0.7 (0.5,1.0) 0.7 (0.4,1.0) 0.6 (0.3,1.0) 0.7 (0.5,0.9) 0.7 (0.5,1.1) 0.6 (0.4,0.9) 0.6 (0.4,1.0) 
 
25-29 0.6 (0.5,0.7) 0.8 (0.6,1.1) 0.6 (0.4,0.9) 0.9 (0.6,1.5) 0.6 (0.4,0.8) 0.6 (0.4,1.0) 0.5 (0.4,0.7) 0.7 (0.4,1.1) 
 
30-34 0.6 (0.4,0.7) 0.8 (0.5,1.1) 0.7 (0.5,1.0) 1.1 (0.7,1.8) 0.5 (0.4,0.7) 0.5 (0.3,0.8) 0.4 (0.3,0.5) 0.4 (0.2,0.8) 
 
35-39 0.5 (0.4,0.7) 0.7 (0.5,1.1) 0.6 (0.4,0.9) 0.9 (0.5,1.6) 0.5 (0.4,0.7) 0.5 (0.3,0.8) 0.4 (0.3,0.6) 0.5 (0.3,0.9) 
 
Ptrend <0.001 0.349 0.074 0.507 0.002 0.079 <0.001 0.124 
Decade of FPN 
Diagnosis 
1971-1979 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
1980-1989 1.2 (1.1,1.4) 0.9 (0.7,1.2) 1.4 (1.1,1.8) 1.1 (0.6,1.9) 1.2 (1.0,1.4) 1.2 (0.8,1.8) 1.2 (1.0,1.4) 0.9 (0.6,1.3) 
 
1990-1999 1.2 (1.0,1.5) 0.8 (0.6,1.2) 1.4 (1.0,2.0) 1.3 (0.7,2.4) 1.2 (0.9,1.5) 1.3 (0.8,2.0) 1.2 (0.9,1.5) 0.7 (0.4,1.1) 
 
2000-2006 1.3 (1.0,1.6) 0.8 (0.5,1.3) 2.0 (1.3,3.0) 1.7 (0.8,3.5) 1.0 (0.7,1.4) 0.9 (0.4,1.8) 1.2 (0.8,1.7) 0.5 (0.2,1.2) 
 
Ptrend 0.013 0.239 0.005 0.070 0.479 0.831 0.161 0.026 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O/E= observed over expected; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; RR=relative risk; 
EHR=excess hospitalisation ratio; ref= reference level; FPN=first primary neoplasms; CNS=central nervous system; NHL=non-hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary.  
*Multivariable models and p-values are adjusted for cancer diagnosis, sex, age at cancer diagnosis, decade of cancer diagnosis and attained age
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Table 3.11: Relative risks and excess hospitalisation ratios of any cerebrovascular event*, cerebral haemorrhage (ICD10: I61-I62), cerebral infarction (ICD10: I63, I65-66) or 
‘other cerebrovascular event ‘(ICD10: I64, I67-I68) among survivors of CNS tumours by CNS tumour diagnosis, sex, age at diagnosis and decade of diagnosis.  
 
 
Any CV Event 
 (ICD10: I60-I68) 
Cerebral Haemorrhage 
 (ICD10: I61-I62) 
Cerebral infarction 
 (ICD10: I63, I65-66) 
Other Cerebrovascular Event 
 (ICD10: I64, I67-I68) 
    RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) RR (95% CI) EHR (95% CI) 
CNS tumour 
type 
Glial Tumour 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
Embryonal Tumour 1.1 (0.7,1.8) 1.1 (0.7,1.9) 0.1 (0.0,0.9) 0.0 (0.0,.) 1.9 (1.0,3.4) 2.0 (1.1,3.7) 1.9 (1.0,3.4) 1.9 (1.0,3.7) 
Craniopharyngioma 0.6 (0.4,0.9) 0.5 (0.3,0.9) 0.3 (0.1,0.8) 0.3 (0.1,0.9) 0.8 (0.4,1.4) 0.7 (0.4,1.5) 0.7 (0.3,1.3) 0.6 (0.3,1.3) 
 Other Pituitary Tumours 0.3 (0.3,0.4) 0.3 (0.2,0.4) 0.1 (0.1,0.2) 0.0 (0.0,0.1) 0.4 (0.3,0.6) 0.3 (0.2,0.5) 0.5 (0.4,0.7) 0.4 (0.3,0.6) 
 Meningioma 0.2 (0.2,0.3) 0.1 (0.1,0.3) 0.2 (0.1,0.3) 0.1 (0.0,0.3) 0.3 (0.2,0.4) 0.2 (0.1,0.4) 0.2 (0.1,0.4) 0.1 (0.1,0.3) 
 Ependymoma 0.5 (0.3,0.7) 0.4 (0.3,0.7) 0.2 (0.1,0.6) 0.2 (0.1,0.6) 0.7 (0.4,1.2) 0.7 (0.4,1.3) 0.6 (0.3,1.0) 0.5 (0.3,1.1) 
 Germ Cell Intracranial 0.7 (0.3,1.3) 0.6 (0.3,1.3) 0.3 (0.1,1.3) 0.3 (0.1,1.4) 1.1 (0.4,2.6) 1.0 (0.4,2.6) 1.2 (0.5,3.0) 1.1 (0.4,3.0) 
 Other specified 0.2 (0.2,0.3) 0.1 (0.1,0.2) 0.2 (0.1,0.3) 0.2 (0.1,0.3) 0.2 (0.1,0.3) 0.1 (0.0,0.3) 0.3 (0.2,0.4) 0.2 (0.1,0.4) 
 Other Unspecified 0.6 (0.4,0.8) 0.6 (0.4,0.8) 0.4 (0.2,0.7) 0.4 (0.2,0.7) 0.5 (0.3,0.8) 0.4 (0.2,0.8) 0.9 (0.6,1.4) 1.0 (0.6,1.5) 
 Pheterogeneity <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Sex Men 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
 Women 1.0 (0.9,1.2) 0.8 (0.6,1.0) 1.3 (0.9,1.7) 0.8 (0.6,1.2) 1.3 (1.0,1.7) 0.9 (0.6,1.2) 0.9 (0.7,1.1) 0.7 (0.5,0.9) 
 Pheterogeneity 0.627 0.059 0.133 0.325 0.034 0.390 0.307 0.003 
Age at FPN 
Diagnosis 
15-19 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
20-24 0.6 (0.4,0.9) 0.8 (0.5,1.2) 0.5 (0.3,1.0) 0.6 (0.3,1.2) 0.6 (0.4,1.0) 0.7 (0.4,1.2) 0.6 (0.4,1.0) 0.7 (0.4,1.3) 
 25-29 0.6 (0.5,0.9) 0.9 (0.6,1.3) 0.7 (0.4,1.1) 0.9 (0.5,1.7) 0.6 (0.4,1.0) 0.7 (0.4,1.2) 0.6 (0.4,1.0) 0.8 (0.5,1.4) 
 30-34 0.5 (0.4,0.8) 1.0 (0.6,1.4) 0.7 (0.4,1.2) 1.3 (0.8,2.3) 0.4 (0.2,0.7) 0.5 (0.3,1.0) 0.5 (0.3,0.8) 0.7 (0.4,1.3) 
 35-39 0.6 (0.4,0.8) 1.0 (0.7,1.6) 0.5 (0.3,0.9) 1.0 (0.5,1.9) 0.5 (0.3,0.9) 0.7 (0.3,1.3) 0.6 (0.3,1.0) 1.0 (0.5,1.9) 
 Ptrend 0.007 0.600 0.083 0.371 0.022 0.335 0.116 0.631 
Decade of 
FPN 
Diagnosis 
1971-1979 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
1980-1989 1.2 (0.9,1.5) 0.9 (0.7,1.3) 1.3 (0.7,2.1) 1.0 (0.5,2.1) 1.5 (1.0,2.1) 1.4 (0.9,2.3) 1.1 (0.8,1.5) 0.8 (0.6,1.3) 
1990-1999 1.2 (0.8,1.7) 0.7 (0.5,1.2) 2.0 (1.1,3.8) 1.4 (0.6,3.1) 1.4 (0.8,2.3) 1.2 (0.7,2.3) 0.8 (0.5,1.3) 0.5 (0.2,0.8) 
 2000-2006 1.6 (1.1,2.6) 1.0 (0.6,1.7) 3.8 (1.8,8.0) 2.5 (1.0,5.9) 1.5 (0.7,3.0) 1.6 (0.7,3.5) 0.9 (0.4,1.8) 0.5 (0.2,1.2) 
 Ptrend 0.067 0.712 <0.001 0.005 0.176 0.421 0.534 0.015 
Attained Age 20-44 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 
44-49 0.9 (0.6,1.1) 1.7 (1.2,2.4) 0.9 (0.6,1.4) 1.7 (1.1,2.7) 1.0 (0.7,1.5) 2.9 (1.7,4.8) 1.3 (0.8,1.9) 3.1 (1.9,5.2) 
 50-54 0.8 (0.6,1.1) 2.2 (1.5,3.2) 0.7 (0.4,1.3) 1.7 (0.9,3.1) 0.7 (0.5,1.2) 3.1 (1.7,5.7) 1.2 (0.7,1.8) 4.3 (2.4,7.6) 
 54-59 0.8 (0.5,1.1) 2.4 (1.5,3.9) 0.6 (0.3,1.3) 1.1 (0.4,3.0) 0.9 (0.5,1.5) 6.1 (3.1,11.9) 0.9 (0.5,1.5) 4.2 (2.1,8.4) 
 60+ 0.6 (0.4,0.9) 2.8 (1.6,4.9) 0.5 (0.2,1.2) 1.5 (0.5,4.3) 0.6 (0.3,1.2) 7.0 (3.1,15.5) 0.6 (0.3,1.1) 5.3 (2.4,11.7) 
 Ptrend 0.033 <0.001 0.144 0.131 0.203 <0.001 0.125 <0.001 
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O/E= observed over expected; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; RR=relative risk; 
EHR=excess hospitalisation ratio; ref= reference level; FPN=first primary neoplasms 
*Multivariable models and p-values are adjusted for CNS tumour type, sex, age at cancer diagnosis, decade of cancer diagnosis and attained age  
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Chapter 4 
Cause-specific mortality in 17,280 5-year survivors of teenage and young 
adult central nervous system tumours 
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4.1 ABSTRACT 
Background: Survival from central nervous system (CNS) tumours diagnosed in teenagers 
and young adults (TYA) has improved over recent years. This population of long-term cancer 
survivors are at increased risk of premature mortality. However, few studies have 
comprehensively investigated the risk of cause-specific mortality among long-term TYA CNS 
tumour survivors 
Methods: The Teenage and Young Adult Cancer Survivor Study is a large population-based 
cohort of 200,945 5-year survivors of cancer diagnosed aged 15-39 years between 1971-2006 
in England & Wales. The risk of cause-specific mortality was investigated using standardised 
mortality ratios (SMRs) and absolute excess risks (AERs) stratified by CNS tumour subtype, 
diagnosis era and years from diagnosis for the 17,280 5-year survivors diagnosed with a CNS 
tumour. 
Results:  Overall 4,099 deaths were observed which was 7-fold expected, and corresponded to 
150 excess deaths per 10,000 person-years (SMR=6.6, 95% confidence interval [CI] =6.4-6.8; 
AER=150.4; CI=145.0-155.8). Neoplasms were the leading cause of death in early follow-up 
within survivors of all CNS tumour types. Beyond 25 years from diagnosis the majority of 
excess deaths were attributable to non-neoplastic causes for survivors of gliomas, 
craniopharyngioma, other pituitary tumours and ependymoma. Among glial tumour survivors, 
the AER for non-neoplastic mortality was 73 subsequent to 25 years from diagnosis, 
contributing 59% of the total AER—strokes contributed 30% of the total AER. Among 
pituitary tumour survivors, the AER for non-neoplastic deaths was 59 subsequent to 25 years 
from diagnosis, contributing 89% of the total AER—strokes and cardiac disease contributed 
25% and 21% of the total AER, respectively. Reassuringly, the AER due to strokes 
significantly decreased in the most recent diagnosis era of survivors of glial and pituitary 
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tumours (Glial tumour: AER=19 in 1971-1979, AER=3 in 1990-2006; Pituitary tumour: 
AER=14 in 1971-1979; AER<1 in 1990-2006). 
Conclusion: This largest ever study of TYA cancer survivors has identified an excess 
mortality due to both neoplastic and non-neoplastic causes within survivors of CNS tumours. 
Of major concern is the increased mortality due to strokes in long-term survivors of glial and 
pituitary tumours; in addition to the increased mortality due to cardiac diseases in long-term 
survivors of pituitary tumours. These non-neoplastic deaths are more likely preventable than 
neoplastic deaths with appropriate clinical follow-up and focus should be on preventing these 
deaths. 
 
4.2 INTRODUCTION 
Survival after central nervous system (CNS) tumours diagnosed in teenagers and young adults 
(TYA) has improved over recent years11— currently, individuals diagnosed with a CNS 
tumour (excluding pilocytic astrocytoma) aged 15-39 years have a 5-year relative survival of 
57%11. This population of cancer survivors are potentially at increased risk of premature 
mortality. However, few studies have comprehensively investigated the risk of cause-specific 
mortality among long-term TYA CNS tumour survivors23-26. The paucity of published 
research has prevented the development of evidence-based clinical guidelines for the long-
term follow-up of TYA CNS tumour survivors1-3. 
 
An increased risk of premature mortality relating to both neoplastic and non-neoplastic causes 
has been well established in survivors of childhood CNS tumours92, 93, 128, 135, 182-184. However, 
very little comparable information is available relating to survivors of TYA CNS tumours. A 
few studies have found an increased risk of premature mortality in TYA CNS tumour 
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survivors23-26, but these were based on small cohorts, few non-neoplastic deaths and did not 
include survivors relating to the entire age range of TYA CNS tumours—aged 15 to 39 years 
at diagnosis. Only one study has investigated both neoplastic and non-neoplastic mortality 
within survivors of TYA CNS tumours diagnosed across a reasonably wide age range (1,135 
5-year survivors, aged 20-34 years at diagnosis)23. The current study includes 15-fold the 
number of 5-year survivors and 8-fold the number of deaths than included in this previous 
study 23.  To our knowledge, the risk of cause-specific mortality has not previously been 
investigated in relation to CNS tumour type, years from diagnosis or diagnosis era within 
TYA CNS tumour survivors. 
 
The aims of this large population-based study are to: 1) determine the risks of specific causes 
of death occurring among 5-year survivors of TYA CNS tumours diagnosed aged 15-39 
years; 2) investigate the extent to which these risks vary according to CNS tumour type, years 
from diagnosis and diagnosis era. 
 
4.3 METHODS 
4.3.1 The Teenage and Young Adult Cancer Survivor Study 
The Teenage and Young Adult Cancer Survivor Study (TYACSS) is to our knowledge the 
largest population-based cohort study to investigate the risks of adverse health outcomes in 
cancer survivors diagnosed age 15-39 years. The cohort consists of 200,945 5-year survivors 
of cancer diagnosed in England and Wales between 1971 and 2006. Of these survivors, 
17,280 were 5-year survivors of a CNS tumour (including malignant, benign and unspecified 
tumours). The cohort was ascertained through the Office for National Statistics and the Welsh 
Cancer Registry. Ethical approval was provided by the National Research Ethics Service (ref: 
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16/LO/0895) and permission to process information without individual consent by the 
National Information Governance Board (NIGB) for Health and Social Care (ref: 3-
03(c)2010). 
 
4.3.2 Ascertainment of deaths 
Record linkage was undertaken with the national population-based death register which is 
maintained by the National Health Service Digital (NHS-Digital). Linkage to NHS-Digital 
provided automatic notification of vital status, date of death, cause of death or date of 
emigration. The underlying cause of death was provided coded using the appropriate revision 
of the International Classification of Diseases (ICD) applicable to the year in which the death 
occurred 185-187.   
 
4.3.3 CNS tumour classification 
Grouping of CNS tumours was based on the internationally acknowledged classification 
scheme for tumours diagnosed in adolescence and young adulthood6, 13, with some 
modifications to produce finer groups. Groupings used were: glial tumours, embryonal 
tumours, craniopharyngioma, other pituitary tumours, meningioma, ependymoma, other 
specified tumours and other unspecified tumours (see Table 4.1).  Glial tumours were 
categorised according to grade (grade I, grade II, high grade [grade III & IV], and non-
specific grade) based on the 2007 World Health Organisation (WHO) classification of 
tumours of the central nervous system (Table 4.2)188.  
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4.3.4 Statistical analysis 
Follow-up of individuals started at date of 5-year survival and ended at the date of the earliest 
of the following events: death, loss to follow-up or study end date, 28th February 2014. 
Standardised mortality ratios (SMRs) were calculated as the ratio of the observed number of 
deaths over the expected number of deaths. The expected number of deaths was derived by 
multiplying age (5-year band), sex and calendar-year (1-year band) specific mortality rates for 
the English and Welsh general population with the corresponding person-years accumulated 
in the cohort. Absolute excess risks (AERs) were used to provide a measure of the absolute 
excess number of deaths observed compared to that expected from general population. AERs 
were calculated as the observed minus the expected number of deaths divided by the person-
years at risk and multiplied by 10,000. In what follows we often do not specify the person-
years at risk, however this is always per 10,000 person-years. For each cause of death with at 
least 75 observed deaths SMRs and AERs were stratified by CNS tumour type. For each 
specific CNS tumour type, SMRs and AERs were further stratified by era of diagnosis and 
years from diagnosis for each cause of death with at least 30 deaths. The simultaneous 
influences of these factors were analysed using multivariable Poisson regression to derive 
relative risks (RR) and excess mortality ratios (EMRs)154. The RR can be interpreted as the 
ratio of the SMRs adjusting for other potential explanatory factors included in the model and 
the EMR can be interpreted as the ratio of the AERs adjusting for other potential explanatory 
factors included within the model. Tests of linear trend in risk across levels of a factor (e.g. 
era of diagnosis: 1971-1979, 1980-1989, ≥1990) were conducted using likelihood ratio tests 
comparing the deviance of a model containing the factor of interest (coded with the median 
value of variable at each level) with the deviance of a model not including the factor of 
interest. 
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Cumulative mortality by years from 5-year survival was calculated for the following causes of 
death: all causes, neoplastic causes, all non-neoplastic causes, respiratory disease, strokes and 
cardiac disease. Deaths due to causes other than the cause of interest were treated as 
competing risks. The expected cumulative mortality was derived from mortality rates from the 
general population, for each specified cause of death, using the Ederer II method 189. All 
statistical analyses were conducted in Stata statistical software, version 13.1. A 2-sided p-
value <0.05 was considered statistically significant for all analyses. 
 
4.4 RESULTS 
4.4.1 Cohort characteristics 
Overall 17,280 5-year survivors of a CNS tumour diagnosed aged 15-39 years were included 
in the analysis, contributing 231,420 person-years of follow-up. The mean length of follow-up 
from 5-year survival was 13.4 years (range: 0-38 years) with 2,450 individuals followed for 
25 years or more. Glial tumours (n=5,113; 30%) and other pituitary tumours (n=3,907; 23%) 
accounted for the majority of CNS tumour types within the cohort (Table 4.1). In total, 4,099 
deaths were observed—the most common causes of death were: neoplastic (n=3194), stroke 
(n=153), cardiac disease (n=144), respiratory disease (n=141), external causes (n=97) and 
nervous system disease (n=95) (Table 4.3). The specific coding of nervous system diseases 
and respiratory diseases as underlying causes of death are provided in Table 4.4 & 4.5. 
 
4.4.2 Cause-specific mortality among CNS tumour survivors 
CNS tumour survivors experienced 7-fold the number of deaths expected from the general 
population (SMR=6.6, 95% confidence interval [CI] =6.4-6.8); corresponding to 150 excess 
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deaths (AER=150.4; CI=145.0-155.8) (Table 4.3). The risk of death was greatest in relation to 
neoplastic causes (which includes recurrence, metastases and subsequent primary neoplasms) 
with an SMR of 13; corresponding to an AER of 127 excess deaths (SMR=13.0, CI=12.5-
13.4; AER=127.4, CI=122.6-132.2). With regards to specific non-neoplastic causes of death, 
survivors were at a substantially increased risk (SMR≥3) of death due to congenital disorder 
(SMR=11.2, CI=8.2-15.0), stroke (SMR=5.5, CI=4.7-6.5), ‘other circulatory disease’ 
(SMR=5.2, CI=4.0-6.6) nervous system disease (SMR=4.7, CI=3.8-5.8), genitourinary 
disease (SMR=4.0, CI=2.4-6.3), endocrine disease (SMR=3.8, CI=2.7-5.3) and respiratory 
diseases (SMR=3.4, CI=2.8-4.0) (Table 4.3). 
 
4.4.3 Cause-specific mortality among glial tumour survivors 
Survivors of glial tumours experienced a 21-fold risk of death compared to the general 
population; corresponding to an AER of 440 excess deaths (SMR=21.3, CI=20.4-22.1; 
AER=440.2, CI=421.8-458.6) (Table 4.6). Glial tumours survivors experienced the greatest 
multiplicative excess risk of death due to neoplasms, stroke, nervous system disease and 
respiratory disease with SMRs of 53.3, 11.3, 8.1 and 7.1, respectively. The number of excess 
deaths due to neoplastic causes increased significantly from 1971 to 2006 (Ptrend<0.001), with 
AERs (% of total AER) of 207 (84%), 339 (90%) and 565 (96%) for survivors of a glial 
tumour diagnosed in 1971-1979, 1980-1989 and 1990-2006, respectively (Table 4.7). 
Whereas the excess number of deaths due to strokes decreased (borderline significance 
Ptrend=0.053) with from 1971 to 2006, with AERs (% of total AER) of 19 (8%), 12 (3%) and 3 
(0.4%) for survivors diagnosed 1971-1979, 1980-1989 and 1990-2006, respectively. The AER 
(% of total AER) for neoplastic deaths declined significantly (Ptrend<0.001) by a factor of 10 
from 574 (96%) at 5-14 years from diagnosis to 52 (41%) subsequent to 25 years from 
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diagnosis (Table 4.8). The AER for non-neoplastic deaths increased significantly 
(Ptrend<0.001) with increasing years from diagnosis. The AER (% of total AER) for non-
neoplastic deaths increased from 24 (4%) to 73 (59%) from 5 to 14 years from diagnosis to 
beyond 25 years from diagnosis, respectively; the corresponding values for stroke were 4 
(1%) to 37 (30%).  The cumulative mortality due to all and neoplastic causes was 61% and 
52% at 35 years from diagnosis, whereas 9% and 4% was expected (Figure 4.1).  The 
cumulative mortality due to stroke was 2.6% at 35 years from diagnosis, 6.5-fold that 
expected. 
 
Both the multiplicative and absolute excess risk of all causes of death and neoplastic causes of 
death increased (all Ptrend <0.001) with glial tumour grade (Table 4.9). The AER for neoplastic 
deaths among survivors of both Grade II and Grade III & IV gliomas increased (all Ptrend 
<0.001) from 1971 to 2006; neoplastic deaths accounted for at least 84% of the total AER 
across all grades and eras of diagnosis (Table 4.10). The AER for neoplastic deaths among 
survivors of Grade II and Grade III & IV gliomas declined with increased years from 
diagnosis (both Ptrend <0.001). The AER for non-neoplastic deaths among survivors of Grade 
II and Grade III & IV gliomas increased with increased years from diagnosis (Ptrend=0.012 and 
0.036 respectively).  
 
4.4.4 Cause-specific mortality among craniopharyngioma survivors 
Craniopharyngioma survivors had 6-fold risk of death compared to that expected (SMR=5.5, 
CI=4.5-6.7); corresponding to an AER of 109 excess deaths (AER=109.2, CI=83.6-134.8) 
(Table 4.6). In contrast to survivors of glial tumours, survivors of craniopharyngioma had a 
greater number of excess deaths due to non-neoplastic causes (AER=61.1, CI=41.8-80.4) than 
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neoplastic causes (AER=48.1, CI=31.3-65.0). 19% of the total excess number of deaths was 
contributed by respiratory and nervous system diseases with AERs (% of total AER) of 10.0 
(9%) and 10.7 (10%), respectively. The AER for neoplastic deaths declined (Ptrend=0.025) 
with increasing years from diagnosis: the AER (% of total AER) was 62 (62%) at 5-14 years 
from diagnosis and 23 (18%) beyond 25 years from diagnosis (Table 4.8).  The AER for non-
neoplastic deaths increased (Ptrend=0.005) with increasing years from diagnosis: the AER (% 
of total AER) was 37 (38%) at 5-14 years from diagnosis and 106 (82%) beyond 25 years 
from diagnosis (Table 4.8). The cumulative mortality due to non-neoplastic causes was 23% 
at 35 years from diagnosis—higher than any other tumour type—whereas only 5% was 
expected (Figure 4.1).  
 
4.4.5 Cause-specific mortality among other pituitary tumour survivors 
Survivors of other pituitary tumours had the lowest excess risk, both in multiplicative and 
absolute terms, for all-cause mortality across the different groups of CNS tumour survivors 
presented in Table 4.6 with a 2-fold risk of death compared to the general population; 
corresponding to 23 excess deaths (SMR=1.9, CI=1.7-2.1; AER=22.8, CI=17.3-28.4) (Table 
4.6). As for craniopharyngioma survivors, among other pituitary tumour survivors the AER 
for non-neoplastic deaths (AER=15.1, CI=10.8-19.5) was greater than the AER for neoplastic 
deaths (AER=7.7, CI=4.3-11.1). Among other pituitary tumour survivors the AER for all 
causes of deaths, all non-neoplastic causes of death combined and stroke deaths declined 
significantly from 1971 to 2006 (each Ptrend<0.001) (Table 4.7). The AER (% of total AER) 
due to all non-neoplastic causes combined declined from 47 (76%) to 1 (17%) for survivors 
diagnosed in 1971-1979 and 1990-2006 respectively. The AER (% of total AER) due to 
strokes declined from 14 (22%) to 0.4 (5%) for survivors diagnosed in 1971-1979 and 1990-
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2006 respectively. The AER for non-neoplastic causes increased (Ptrend<0.001) 13-fold from 4 
prior to 15 years from diagnosis to 59 subsequent to 25 years from diagnosis (Table 4.8). 
Non-neoplastic causes accounted for 89% of all excess deaths subsequent to 25 years from 
diagnosis. The AER for cardiac disease appeared to increase from 2 prior to 15 years from 
diagnosis to 14 subsequent to 25 years from diagnosis, but the model did not converge and so 
an adjusted p-value is not available). The AER for stroke increased (Ptrend<0.001) from 0.5 
prior to 15 years from diagnosis to 17 subsequent to 25 years from diagnosis. Cardiac disease 
and stroke accounted for 21% and 25% of the total AER subsequent to 25 years from 
diagnosis, respectively. The cumulative mortality due to non-neoplastic causes was 14% at 35 
years from diagnosis of a pituitary tumour whereas 6% was expected (Figure 4.1). Cumulative 
mortality due to cardiac disease and stroke was 3.6% and 2.9% at 35 years from diagnosis, 2- 
and 6-fold that expected. 
 
4.4.6 Cause-specific mortality among meningioma survivors 
Survivors of meningioma experienced three-fold the number of deaths expected (SMR=3.0, 
CI=2.7-3.4) which corresponded to an AER of 69 (AER=68.5, CI=57.6-79.4) (Table 4.6). 
This was the second lowest excess (in multiplicative and absolute terms) when compared to 
survivors of other types of CNS tumours (Table 4.6). Similar to glial tumour survivors most 
(82%) of the AER was contributed by neoplastic deaths. The AER due to all and neoplastic 
causes of death declined significantly (Ptrend=0.044 and Ptrend=0.006, respectively) from 1971 
to 2006 (Table 4.7). Meningioma survivors experienced the greatest percentage of excess 
deaths due to neoplastic causes long-term—beyond 25 years from diagnosis 79% of all excess 
deaths were due to neoplasms (Table 4.8). The cumulative incidence due to neoplasms and 
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non-neoplastic causes was 21% and 11% at 35 years from diagnosis, whereas 7% and 8% 
were expected (Figure 4.1). 
 
4.4.7 Cause-specific mortality among embryonal tumour survivors 
Embryonal tumour survivors had the second highest excess mortality (both in multiplicative 
and absolute terms) for all causes and neoplastic deaths after glial tumour survivors 
(SMR=13.7, CI=11.2-16.6; AER=245.0, CI=194.5-295.6) (Table 4.6). The AER (% of total 
AER) for neoplastic deaths was 220 (90%). The AER for neoplastic deaths declined with 
years from diagnosis (Ptrend<0.001): the AER (% of total AER) was 312 (97%) at 5-14 years 
from diagnosis and 131 (56%) beyond 25 years from diagnosis (Table 4.8). The cumulative 
mortality due to all and neoplastic causes was substantial at 53% and 40% at 35 years from 
diagnosis, whereas 8% and 3% were expected (Figure 4.1). 
 
4.4.8 Cause-specific mortality among ependymoma survivors 
Ependymoma survivors experienced 5-fold the number of deaths expected, corresponding to 
an AER of 120 excess deaths overall (SMR=5.4, CI=4.6-6.4; AER=120.1, CI=97.0-143.1) 
(Table 4.6). The AER for neoplastic deaths declined (Ptrend=0.031) with increased years from 
diagnosis (Table 4.8). The AER (% of total AER) was 105 (87%) at 5 to 14 years from 
diagnosis and 53 (42%) beyond 25 years from diagnosis. The AER for non-neoplastic deaths 
increased (Ptrend=0.021) with increased years from diagnosis. The AER (% of total AER) was 
16 (13%) at 5 to 14 years from diagnosis and 73 (58%) beyond 25 years from diagnosis. 
Ependymoma survivors, comparable to craniopharyngioma survivors experienced the greatest 
cumulative mortality due to non-neoplastic causes, reaching 22% at 35 years from diagnosis, 
whereas 7.2% was expected (Figure 4.1). 
  
122 
 
 
4.5 DISCUSSION 
4.5.1 Main findings 
In this largest ever study of TYA CNS tumour survivors, we found that neoplasms are the 
leading cause of death in early follow-up within survivors of all CNS tumour types. The 
excess number of neoplastic deaths declined with years from diagnosis after gliomas, 
craniopharyngioma, embryonal tumours and ependymoma and remained constant for other 
pituitary tumours and meningioma. In contrast the excess number of non-neoplastic deaths 
increased with years from diagnosis for gliomas, craniopharyngioma, other pituitary tumours 
and ependymoma and remained constant for meningioma and embryonal tumours. Therefore 
beyond 25 years from diagnosis the majority of the excess deaths are attributable to non-
neoplastic causes for survivors of gliomas (59%), craniopharyngioma (82%), other pituitary 
tumours (89%) and ependymoma (58%). Whereas beyond 25 years from diagnosis the 
majority of the excess deaths are attributable to neoplastic causes for survivors of meningioma 
(79%) and embryonal tumours (56%). For the majority of CNS tumours, radiotherapy will be 
a large contributor to the number of non-neoplastic deaths in the long-term. Meningiomas are 
benign tumours that are often treated with surgery alone; therefore this will reduce the risk of 
non-neoplastic causes of death. If the meningioma is not fully resected during surgery, the 
chance of recurrence is high189. Embryonal tumours have a high recurrence rate and may recur 
many years after diagnosis190, 191. These are potential reasons why neoplasms are still the 
greatest cause of excess deaths in meningioma and embryonal tumour patients who have 
survived beyond 25 years since diagnosis. 
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Of major concern is the number of excess deaths due to cardiac disease and stroke subsequent 
to 15 years from diagnosis of a pituitary tumour, in addition to the number of excess deaths 
due to stroke subsequent to 25 years from diagnosis of a glial tumour. Reassuringly, glial 
tumour and pituitary tumour survivors treated in 1990-2006 have a significantly decreased 
number of excess deaths due to strokes than survivors treated in previous decades (1971-
1989); however the number of excess deaths due to cardiac disease among pituitary tumour 
survivors did not decrease. This reduction in stroke mortality is likely a result of reducing 
treatment exposures, introduction of endocrine therapy (pituitary tumours192) and advances in 
imaging and diagnostic accuracy. 
 
4.5.2 Previous studies 
The majority of previous studies have focused on individuals diagnosed with a CNS tumour 
before 25 years of age or have only included a small subset of the TYA age range at diagnosis 
24, 25, 92, 93, 128, 135, 182-184. The only previous cohort study investigating both neoplastic and non-
neoplastic causes of mortality among a wide range of TYA CNS tumour survivors—a Finnish 
study of 1,135 5-year survivors of a TYA (diagnosed aged 20 to 34 years) CNS tumour—
reported a significant 12.3-fold risk of all-cause mortality, 40.9-fold risk of neoplastic 
mortality, 2.7-fold risk of circulatory mortality and a 5.5-fold risk of respiratory mortality23. 
Our study of 17,280 5-year survivors of TYA (diagnosed aged 15 to 39 years) CNS tumours 
found an increased risk of all-cause (6.6-fold), neoplastic (13-fold) and non-neoplastic (2.4-
fold) mortality; these risks estimates were consistently lower than observed in the Finnish 
cohort. The Finnish cohort used the International Classification of Childhood Cancer 
(ICCC)79 to define CNS tumours among individuals aged 20-34 years; therefore we 
conducted additional analyses restricting our cohort to the 7,038 5-year survivors diagnosed 
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with a CNS tumour according to the ICCC aged 20-34 years. SMRs were comparable to the 
Finnish cohort for all-cause mortality (10.7-fold), circulatory mortality (2.7-fold) and 
respiratory mortality (5.2-fold); however neoplastic mortality remained considerably lower at 
23.5-fold that expected. 
 
To our knowledge, our study is the first to estimate the risk of cause-specific mortality 
stratified by CNS tumour types among TYA cancer survivors; therefore no previous study is 
directly comparable. In addition, we have provided the risk of cause-specific mortality 
stratified by diagnosis era and years from diagnosis for the first time. 
 
4.5.3 Long-term mortality due to cardiovascular diseases 
This study found that the risk of death due to stroke was increased in survivors of all CNS 
tumour types, particularly long-term survivors of glial tumours and pituitary tumours with 
30% and 25% of all excess deaths due to stroke subsequent to 25 years from diagnosis, 
respectively. Cranial irradiation is associated with an increased risk of stroke among 
childhood CNS tumour survivors 72-74, 168, 193 and a linear dose-response relationship between 
cranial irradiation and the risk of cerebrovascular death has been reported 73, 74. In addition, a 
study of pituitary tumour survivors diagnosed as adults has reported debulking surgery and 
hypothalamic disorders (i.e. hypopituitarism, Cushing’s disease and acromegaly) as risk 
factors for stroke mortality194.  Survivors of pituitary tumour and glial tumour treated in 1990-
2006 had a reduced risk of stroke than survivors treated in 1971-1979; this may relate to 
initiatives to reduce the size of the radiation field and improved surgical techniques. Smaller 
and more focused radiation fields result in less collateral damage to normal tissues and the 
surrounding vasculature.  
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This study observed an increased risk of cardiac mortality among pituitary tumour survivors. 
Non-hormone secreting tumours such as pituitary adenomas are associated with 
hypopituitarism195. Hypopituitarism is associated with obesity and altered low and high 
density lipoproteins which are considered risk factors for cardiovascular disease 195. The 
hormones secreted by functioning pituitary tumours cause conditions such as acromegaly and 
Cushing’s disease196. Individuals with these conditions are at a higher risk of type II diabetes 
mellitus, hypertension and impaired glucose tolerance, all of which are associated with 
cardiovascular disease196.  
 
To our knowledge there are no guidelines or recommendations for stroke or cardiac disease 
prevention specifically for TYA CNS tumour survivors. Unlike death due to recurrent 
tumour/metastatic spread of TYA cancer, these non-neoplastic deaths are more than likely 
preventable with surveillance and regular clinical follow-up, thus in particular glial tumour 
and other pituitary tumour survivors treated in earlier decades (1971-1989) should be 
considered for surveillance of risk factors for cardiovascular disease.  
 
4.5.4 Long-term mortality due to neoplastic causes 
This study observed an increase in the number of excess neoplastic deaths from 1971-1979 to 
1990-2006 within glial tumour survivors. Possible explanations for this increase include: 1) 
death due to the original tumour has been postponed a few years by improvements in initial 
survival from newer treatment regimens5; 2) CNS tumour classifications have been refined 
and modified over time 188; and 3) diagnostic accuracy and imaging have improved 
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dramatically since the earliest cohort, therefore it is possible a larger proportion of gliomas are 
being diagnosed than in the 1970s and 1980s197. 
 
4.5.5 Limitations of the study 
The lack of detailed treatment information may be a potential limitation of the study. 
However by stratifying by CNS tumour type and diagnosis era we have attempted to identify 
individuals who are a particularly increased risk of mortality. To overcome a lack of treatment 
information in the current study nested case-control studies with detailed treatment 
information to address dose-response relationships are needed. Another limitation is the lack 
of potential explanatory factors such as smoking, alcohol intake and co-morbidities which 
may be associated with an increased risk of mortality. 
 
4.6 CONCLUSIONS 
In conclusion, this largest ever study of TYA cancer survivors has identified an excess 
mortality due to both neoplastic and non-neoplastic causes within survivors of CNS tumours. 
Of major concern is the increased mortality due to strokes in long-term survivors of glial and 
pituitary tumours; in addition to the increased mortality due to cardiac diseases in long-term 
survivors of pituitary tumours. These non-neoplastic deaths are likely to be preventable with 
appropriate clinical follow-up and focus should be on preventing these deaths. The risk 
estimates provided begin to address the gap in knowledge regarding adverse health outcomes 
among TYA tumour survivors, an area made a priority by the Department of Health, the 
National Institute for Health and Clinical Excellence and the National Cancer Research 
Institute 145-147. 
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Table 4.1: Distribution of CNS tumour type according to age at diagnosis 
  All ages 15-24 years 25-39 years 
  N % N % N % 
Glial Tumours1 5,113 29.6 1,515 33.0 3,598 28.4 
Grade I 425 9.3 267 17.6 158 4.4 
Grade II 3,216 62.9 873 57.6 2,343 65.1 
Grade III & IV 556 10.9 107 7.1 449 12.5 
Uncertain Grade 916 17.9 268 17.7 648 18.0 
Other Pituitary Tumour² 3,907 22.6 898 19.6 3,009 23.7 
Meningioma 2,264 13.1 253 5.5 2,011 15.9 
Embryonal Tumours³ 326 1.9 157 3.4 169 1.3 
Ependymoma 757 4.4 239 5.2 518 4.1 
Craniopharyngioma 483 2.8 213 3.4 270 2.1 
Other Specified4 3,139 18.2 886 19.3 2,253 17.8 
Other Unspecified5 1,291 7.5 428 9.3 863 6.8 
TOTAL 17,280 100 4,589 100 12,691 100 
1For Glial Tumours, this category consists of pilocytic astrocytoma, other specified astrocytoma, glioblastoma, anaplastic astrocytoma, astrocytoma not otherwise specified, oligodendrogliomas, 
other specified glioma and glioma not otherwise specified. Glial tumours have been further categorised based on the WHO classification of tumours of the central nervous system, percentages 
for glial grade are percentages of total glial tumours. 
²For Pituitary Tumour, this category consists of tumours of the pituitary (primarily pituitary adenomas), excluding craniopharyngioma 
3For Embryonal Tumours, this category consists of medulloblastoma and supratentorial PNET 
4For Other specified, this category consists of pineal tumours, choroid plexus tumours, CNS nerve sheath tumours. germ cell intracranial tumours and other specified CNS tumours 
5For Other unspecified, this category consists of unspecified malignant CNS tumours and unspecified benign CNS tumours.
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Table 4.2: Glial tumours according to the 2007 WHO classification of tumours of the central nervous 
system188  
 
WHO Grade Tumour Description 
Number of 5-year 
survivors (%) 
Grade I Subependyoma 33 
 
Subependymal giant cell astrocytoma 24 
 
Dysembryoplastic neuroepithelial tumour 4 
 
Pilocytic astrocytoma 364 
 
Total 425 
  
 
Grade II Mixed Glioma 192 
 
Astrocytoma, NOS (Diffuse Glioma) 2,016 
 
Protoplasmic astrocytoma 31 
 
Gemistocytic astrocytoma 74 
 
Fibrillary astrocytoma 143 
 
 
Pleomorphic xanthoastrocytoma 9 
 Choroid glioma 4 
 
Oligodendroglioma, NOS 747 
 
Total 3,216 
  
 
Grade III & IV Anaplastic astrocytoma 205 
 
Glioblastoma, NOS 244 
 
Giant cell glioblastoma 8 
 
Gliosarcoma 4 
 
Anaplastic oligodendroglioma 95 
 
Total 556 
  
 
Non-specific  Glioma, NOS 833 
 
Oligodendroblastoma 18 
 
Astroblastoma 65 
  Total 916 
Abbreviations: NOS – not otherwise specified 
†One individual had morphology code 9421/3-decision coded to grade I 
‡Polar spongioblastoma does not appear in WHO classification – decision coded to grade II & IV 
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Table 4.3: Cause-specific excess risks of death, standardised mortality ratios (SMRs) and absolute 
excess risks (AERs), among survivors of all CNS tumours combined 
 
Cause of Death O/E SMR (95%CI) AER (95% CI) 
All Causes 4099/618.2 6.6 (6.4,6.8) 150.4 (145.0,155.8) 
Neoplastic Causes 3194/246.2 13.0 (12.5,13.4) 127.4 (122.6,132.2) 
Non-Neoplastic Causes 905/372.0 2.4 (2.3,2.6) 23.0 (20.5,25.6) 
Stroke 153/27.8 5.5 (4.7,6.5) 5.4 (4.4,6.5) 
Cardiac Disease 144/110.3 1.3 (1.1,1.5) 1.5 (0.4,2.5) 
Respiratory Disease 141/42.0 3.4 (2.8,4.0) 4.3 (3.3,5.3) 
External Causes 97/64.4 1.5 (1.2,1.8) 1.4 (0.6,2.2) 
Nervous System Disease 95/20.2 4.7 (3.8,5.8) 3.2 (2.4,4.1) 
Other Circulatory Disease 67/12.9 5.2 (4.0,6.6) 2.3 (1.6,3.0) 
Digestive Disease 57/48.5 1.2 (0.9,1.5) 0.4 (-0.3,1.0) 
Congenital Disorder 45/4.0 11.2 (8.2,15.0) 1.8 (1.2,2.3) 
Endocrine Disease 37/9.6 3.8 (2.7,5.3) 1.2 (0.7,1.7) 
Infection 21/8.2 2.6 (1.6,3.9) 0.6 (0.2,0.9) 
Genitourinary Disease 19/4.7 4.0 (2.4,6.3) 0.6 (0.2,1.0) 
Muscoskeletal Disease 12/4.4 2.7 (1.4,4.8) 0.3 (0.0,0.6) 
Other 8/4.7 1.7 (0.7,3.4) 0.1 (-0.1,0.4) 
Mental Disorder 6/8.7 0.7 (0.3,1.5) -0.1 (-0.3,0.1) 
Blood Disease 3/1.7 1.8 (0.4,5.2) 0.1 (-0.1,0.2) 
Abbreviations: O=observed, E=expected, SMR=standardised mortality ratio, AER=absolute excess risk, CI= 
confidence intervals
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Table 4.4: Deaths due to respiratory disease by CNS tumour type 
CNS Subtype Pneumonia COPD Pneumonitis Fibrosis Other Total 
Glial Tumours 26 (53.1%) 5 (10.2%) 7 (14.3%) 2 (4.1%) 9 (18.4%) 49 
Embryonal Tumours 3 (100%) 0 0 0 0 3 
Craniopharyngioma 4 (44.4%) 2 (22.2%) 1 (11.1%) 0 2 (22.2%) 9 
Other Pituitary Tumours 14 (60.9%) 4 (17.4%) 2 (8.7%) 0 3 (13.0%) 23 
Meningioma 7 (35.0%) 4 (20.0%) 3 (15%) 1 (5.0%) 5 (25.0%) 20 
Ependymoma 4 (44.4%) 1 (11.1%) 0 0 4 (44.4%) 9 
Other Specified 8 (47.1%) 3 (17.6%) 2 (11.8%) 0 4 (23.5%) 17 
Other Unspecified 4 (36.4%) 2 (18.2%) 5 (45.5%) 0 0 11 
Total 80 (49.7%) 21 (14.9%) 20 (14.2%) 3 (2.1%) 27 (19.2%) 141 
 
 
 
Table 4.5: Deaths due to nervous system disease by CNS tumour type 
CNS Subtype Meningitis Hydrocephalus 
Degenerative 
Disease 
Motor 
Neuron 
Disease 
Multiple 
Sclerosis 
Paralytic 
Syndromes 
Epilepsy Other Total 
Glial Tumours 1 (3.2%) 0 1 (3.2%) 3 (9.7%) 3 (9.7%) 1 (3.2%) 18 (58.1%) 4 (12.9%) 31 
Embryonal Tumours 0 0 0 0 0 0 0 0 0 
Craniopharyngioma 0 1 (11.1%) 2 (22.2%) 0 0 0 5 (55.6%) 1 (11.1%) 9 
Other Pituitary 
Tumours 
0 1 (10.0%) 2 (20.0%) 0 2 (20.0%) 0 3 (30.0%) 2 (20.0%) 10 
Meningioma 0 0 0 0 2 (18.2%) 2 (18.2%) 6 (54.6%) 1 (9.1%) 11 
Ependymoma 1 (14.3%) 1 (14.3%) 0 0 1 (14.3%) 2 (28.6%) 0 2 (28.6%) 7 
Other Specified 1 (8.3%) 0 1 (8.3%) 4 (33.3%) 1 (8.3%) 0 1 (8.3%) 4 (33.3%) 12 
Other Unspecified 0 2 (13.3%) 1 (6.7%) 0 2 (13.3%) 0 10 (66.7%) 0 15 
Total 3 (3.2%) 5 (5.3%) 7 (7.4%) 7 (7.4%) 11 (11.6%) 5 (5.3%) 43 (45.3%) 14 (14.7%) 95 
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Table 4.6: Risk of specific causes of death by CNS tumour type 
Primary Diagnosis Cause of Death O/E SMR (95%CI) AER (95%CI) %of Total AER 
Glial Tumour All Causes 2423/113.9 21.3 (20.4,22.1) 440.2 (421.8,458.6) 100% 
 Neoplasm 2184/41.0 53.3 (51.0,55.5) 408.5 (391.1,426.0) 93% 
 Non-Neoplastic 239/72.9 3.3 (2.9,3.7) 31.7 (25.9,37.4) 7% 
 Respiratory 
Disease 
49/6.9 7.1 (5.2,9.3) 8.0 (5.4,10.6) 2% 
 Stroke 54/4.8 11.3 (8.5,14.7) 9.4 (6.6,12.1) 2% 
 Cardiac Disease 20/20.5 1.0 (0.6,1.5) -0.1 (-1.8,1.6) 0% 
 Nervous System 
Disease 
31/3.8 8.1 (5.5,11.5) 5.2 (3.1,7.3) 1% 
 External Causes 30/16.0 1.9 (1.3,2.7) 2.7 (0.6,4.7) 1% 
      Craniopharyngioma All Causes 104/18.9 5.5 (4.5,6.7) 109.2 (83.6,134.8) 100% 
 Neoplasm 45/7.5 6.0 (4.4,8.0) 48.1 (31.3,65.0) 44% 
 Non-Neoplastic 59/11.4 5.2 (3.9,6.7) 61.1 (41.8,80.4) 56% 
 Respiratory 
Disease 
9/1.2 7.3 (3.3,13.9) 10.0 (2.4,17.5) 9% 
 Stroke 5/0.8 6.1 (2.0,14.2) 5.4 (-0.3,11.0) 5% 
 Cardiac Disease 8/3.3 2.5 (1.1,4.8) 6.1 (-1.0,13.2) 6% 
 Nervous System 
Disease 
9/0.6 14.4 (6.6,27.3) 10.7 (3.2,18.3) 10% 
 External Causes 7/2.2 3.2 (1.3,6.6) 6.2 (-0.5,12.8) 6% 
      Other Pituitary  
Tumours 
All Causes 291/153.9 1.9 (1.7,2.1) 22.8 (17.3,28.4) 100% 
Neoplasm 110/63.8 1.7 (1.4,2.1) 7.7 (4.3,11.1) 34% 
 
Non-Neoplastic 181/90.1 2.0 (1.7,2.3) 15.1 (10.8,19.5) 66% 
 Respiratory 
Disease 
23/10.2 2.2 (1.4,3.4) 2.1 (0.6,3.7) 9% 
 
Stroke 30/6.9 4.4 (2.9,6.2) 3.9 (2.1,5.6) 17% 
 Cardiac Disease 49/26.1 1.9 (1.4,2.5) 3.8 (1.5,6.1) 17% 
 
Nervous System 
Disease 
10/5.1 2.0 (0.9,3.6) 0.8 (-0.2,1.8) 4% 
 External Causes 13/14.6 0.9 (0.5,1.5) -0.3 (-1.5,0.9) -1% 
      Meningioma All Causes 339/112.0 3.0 (2.7,3.4) 68.5 (57.6,79.4) 100% 
 
Neoplasm 236/49.4 4.8 (4.2,5.4) 56.3 (47.2,65.4) 82% 
 Non-Neoplastic 103/62.6 1.6 (1.3,2.0) 12.2 (6.2,18.2) 18% 
 
Respiratory 
Disease 
20/8.4 2.4 (1.4,3.7) 3.5 (0.8,6.1) 5% 
 Stroke 14/5.5 2.6 (1.4,4.3) 2.6 (0.4,4.8) 4% 
 
Cardiac Disease 20/19.1 1.0 (0.6,1.6) 0.3 (-2.4,2.9) 0% 
 Nervous System 
Disease 
11/3.6 3.1 (1.5,5.5) 2.2 (0.3,4.2) 3% 
 
External Causes 9/7.9 1.1 (0.5,2.1) 0.3 (-1.5,2.1) 0% 
      Embryonal Tumour All Causes 105/7.7 13.7 (11.2,16.6) 245.0 (194.5,295.6) 100% 
 Neoplasm 90/2.6 35.0 (28.2,43.1) 220.1 (173.3,266.9) 90% 
 Non-Neoplastic 15/5.1 2.9 (1.6,4.9) 24.9 (5.8,44.0) 10% 
 Respiratory 
Disease 
3/0.4 6.8 (1.4,19.9) 6.4 (-2.1,15.0) 3% 
 Stroke 4/0.3 12.9 (3.5,33.0) 9.3 (-0.6,19.2) 4% 
 Cardiac Disease 1/1.3 0.7 (0.0,4.1) -0.9 (-5.8,4.1) 0% 
 Nervous System 
Disease 
0/0.3 0.0 (.,14.0) -0.7 (-0.7,-0.7) 0% 
 External Causes 2/1.3 1.6 (0.2,5.7) 1.9 (-5.1,8.8) 1% 
      Ependymoma All Causes 156/28.7 5.4 (4.6,6.4) 120.1 (97.0,143.1) 100% 
 Neoplasm 108/10.5 10.3 (8.5,12.5) 92.0 (72.8,111.2) 77% 
 Non-Neoplastic 48/18.3 2.6 (1.9,3.5) 28.1 (15.2,40.9) 23% 
 Respiratory 
Disease 
9/1.9 4.8 (2.2,9.1) 6.7 (1.2,12.3) 6% 
 Stroke 6/1.2 4.9 (1.8,10.6) 4.5 (-0.0,9.0) 4% 
 Cardiac Disease 9/5.8 1.6 (0.7,3.0) 3.0 (-2.5,8.6) 3% 
 Nervous System 
Disease 
7/0.9 7.8 (3.1,16.1) 5.8 (0.9,10.6) 5% 
 External Causes 3/3.4 0.9 (0.2,2.6) -0.4 (-3.6,2.8) 0% 
      Other All Causes 681/183.1 3.7 (3.4,4.0) 78.5 (70.4,86.5) 100% 
 Neoplasm 421/71.4 5.9 (5.3,6.5) 55.1 (48.8,61.4) 70% 
 Non-Neoplastic 260/111.7 2.3 (2.1,2.6) 23.4 (18.4,28.4) 30% 
 Respiratory 
Disease 
28/12.8 2.2 (1.5,3.2) 2.4 (0.8,4.0) 3% 
 Stroke 40/8.3 4.8 (3.5,6.6) 5.0 (3.0,7.0) 6% 
 Cardiac Disease 37/34.3 1.1 (0.8,1.5) 0.4 (-1.4,2.3) 1% 
 Nervous System 
Disease 
27/5.9 4.6 (3.0,6.7) 3.3 (1.7,4.9) 4% 
  External Causes 33/18.9 1.7 (1.2,2.5) 2.2 (0.4,4.0) 3% 
Abbreviations: O=observed, E=expected, SMR=standardised mortality ratio, AER=absolute excess risk, CI= confidence 
intervals 
†Other consists of other specified and other unspecified tumour types
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Table 4.7: Absolute excess risk of specific causes of death by CNS tumour type and era of diagnosis 
  
CNS Tumour Type 
Cause of Death 
 
1971-1979 1980-1989 1990-2006  
O/E AER 
%of Total 
AER 
O/E AER 
%of Total 
AER 
O/E AER 
%of Total 
AER 
Ptrend* 
Glial Tumours           
All Causes 312/39.8 247.4 (216.0,278.9) 100% 753/42.5 376.2 (347.7,404.6) 100% 1358/31.6 587.7 (555.7,619.7) 100% <0.001 
Neoplasm 244/16.1 207.1 (179.3,235.0) 84% 656/15.6 339.0 (312.5,365.6) 90% 1284/9.2 564.9 (533.7,596.0) 96% <0.001 
Non-Neoplastic 68/23.7 40.3 (25.6,55.0) 16% 97/26.9 37.1 (26.9,47.4) 10% 74/22.4 22.9 (15.4,30.3) 4% 0.348 
Respiratory Disease 14/3.0 10.0 (3.4,16.7) 4% 17/2.6 7.6 (3.4,11.9) 2% 18/1.4 7.3 (3.7,11.0) 1% 0.620 
Stroke 23/1.9 19.2 (10.7,27.7) 8% 24/1.8 11.8 (6.7,16.9) 3% 7/1.1 2.6 (0.3,4.9) 0% 0.053 
Nervous System Disease 8/1.2 6.2 (1.2,11.3) 3% 13/1.4 6.1 (2.4,9.9) 2% 10/1.2 3.9 (1.1,6.6) 1% 0.697 
External Causes 7/3.3 3.3 (-1.4,8.0) 1% 8/5.8 1.2 (-1.8,4.1) 0% 15/6.8 3.6 (0.3,7.0) 1% 0.093 
Craniopharyngioma           
All Causes 34/8.2 111.3 (61.9,160.7) 100% 46/7.1 125.9 (82.9,168.9) 100% 24/3.5 85.6 (45.4,125.7) 100% 0.240 
Neoplasm 15/3.5 49.6 (16.8,82.4) 45% 20/2.8 55.7 (27.3,84.0) 44% 10/1.2 36.9 (11.0,62.8) 43% 0.099 
Non-Neoplastic 19/4.7 61.7 (24.8,98.7) 55% 26/4.3 70.2 (37.9,102.6) 56% 14/2.4 48.6 (18.0,79.3) 57% 0.900 
Other Pituitary Tumours           
All Causes 95/39.8 62.2 (40.7,83.8) 100% 128/69.9 24.7 (15.3,34.1) 100% 68/44.2 8.6 (2.8,14.5) 100% <0.001 
Neoplasm 31/17.6 15.1 (2.8,27.4) 24% 43/30.0 5.5 (0.1,11.0) 22% 36/16.2 7.2 (2.9,11.4) 83% 0.068 
Non-Neoplastic 64/22.2 47.1 (29.5,64.8) 76% 85/39.8 19.2 (11.5,26.9) 78% 32/28.1 1.4 (-2.6,5.4) 17% <0.001 
Cardiac Disease 16/7.9 9.1 (0.3,17.9) 15% 24/12.1 5.1 (1.0,9.1) 20% 9/6.1 1.1 (-1.1,3.2) 12% 0.123 
Stroke 14/2.0 13.5 (5.2,21.8) 22% 13/3.1 4.2 (1.2,7.2) 17% 3/1.8 0.4 (-0.8,1.7) 5% <0.001 
Meningioma           
All Causes 116/48.1 80.4 (55.4,105.4) 100% 134/40.9 78.6 (59.4,97.7) 100% 89/23.1 51.4 (37.0,65.8) 100% 0.044 
Neoplasm 80/21.5 69.2 (48.5,90.0) 86% 95/18.8 64.3 (48.2,80.4) 82% 61/9.1 40.4 (28.5,52.4) 79% 0.006 
Non-Neoplastic 36/26.6 11.2 (-2.7,25.1) 14% 39/22.1 14.3 (3.9,24.6) 18% 28/14.0 10.9 (2.9,19.0) 21% 0.227 
Embryonal Tumours           
All Causes 21/2.9 197.1 (99.1,295.2) 100% 37/2.6 248.6 (162.5,334.6) 100% 47/2.2 268.3 (187.9,348.7) 100% 0.709 
Neoplasm 15/1.1 151.3 (68.4,234.1) 77% 31/0.8 217.7 (138.9,296.5) 88% 44/0.6 259.8 (182.0,337.6) 97% 0.908 
Non-Neoplastic 6/1.8 45.9 (-6.5,98.3) 23% 6/1.7 30.9 (-3.7,65.6) 12% 3/1.6 8.5 (-11.8,28.8) 3% 0.521 
Ependymoma           
All Causes 54/11.9 168.4 (110.8,225.9) 100% 47/10.1 100.8 (64.2,137.5) 100% 55/6.8 108.7 (75.9,141.5) 100% 0.104 
Neoplasm 31/4.7 105.0 (61.4,148.6) 62% 36/3.7 88.1 (56.0,120.2) 87% 41/2.0 87.9 (59.6,116.2) 81% 0.123 
Non-Neoplastic 23/7.1 63.4 (25.8,101.0) 38% 11/6.3 12.8 (-5.0,30.5) 13% 14/4.8 20.8 (4.2,37.3) 19% 0.735 
Other†           
All Causes 192/76.1 76.0 (58.2,93.8) 100% 243/62.2 85.8 (71.3,100.3) 100% 246/44.8 74.2 (62.8,85.5) 100% 0.019 
Neoplasm 102/31.7 46.1 (33.1,59.1) 61% 155/25.4 61.5 (49.9,73.1) 72% 164/14.3 55.2 (45.9,64.4) 74% 0.047 
Non-Neoplastic 90/44.4 29.9 (17.7,42.1) 39% 88/36.8 24.3 (15.6,33.0) 28% 82/30.4 19.0 (12.5,25.5) 26% 0.199 
Abbreviations: O=observed, E=expected, AER=absolute excess risk, CI= confidence intervals.  
*Adjusting for attained age, age at diagnosis and sex.  
†Other consists of other specified and other unspecified tumour types 
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Table 4.8: Absolute excess risk of specific causes of death by CNS tumour type and years from diagnosis 
  
CNS Tumour Type 
Cause of Death 
 
5-14 years from diagnosis 15-24 years from diagnosis 25+ years from diagnosis  
O/E AER 
%of Total 
AER 
O/E AER 
%of Total 
AER 
O/E AER 
%of Total 
AER 
Ptrend* 
Glial Tumours           
All Causes 2021/44.0 597.6 (571.0,624.3) 100% 295/35.0 191.4 (166.6,216.2) 100% 107/34.9 124.4 (89.4,159.4) 100% <0.001 
Neoplasm 1910/12.7 573.5 (547.6,599.4) 96% 229/13.1 158.9 (137.1,180.8) 83% 45/15.1 51.5 (28.9,74.2) 41% <0.001 
Non-Neoplastic 111/31.3 24.1 (17.9,30.3) 4% 66/21.9 32.5 (20.8,44.2) 17% 62/19.8 72.8 (46.2,99.5) 59% <0.001 
Respiratory Disease 25/1.9 7.0 (4.0,9.9) 1% 16/2.0 10.3 (4.5,16.1) 5% 8/3.0 8.6 (-1.0,18.2) 7% 0.395 
Stroke 16/1.7 4.3 (1.9,6.7) 1% 15/1.5 9.9 (4.3,15.5) 5% 23/1.5 37.0 (20.8,53.2) 30% <0.001 
Nervous System Disease 18/1.7 4.9 (2.4,7.5) 1% 3/1.1 1.4 (-1.1,3.9) 1% 10/1.1 15.4 (4.7,26.1) 12% 0.160 
External Causes 16/10.3 1.7 (-0.6,4.1) 0% 9/4.1 3.6 (-0.7,8.0) 2% 5/1.7 5.7 (-1.8,13.3) 5% 0.001 
Craniopharyngioma 
         
 
All Causes 46/5.3 98.9 (66.6,131.2) 100% 35/6.5 116.4 (69.0,163.8) 100% 23/7.1 129.4 (52.8,205.9) 100% 0.510 
Neoplasm 27/1.7 61.5 (36.8,86.2) 62% 12/2.6 38.2 (10.5,66.0) 33% 6/3.2 23.0 (-16.1,62.1) 18% 0.025 
Non-Neoplastic 19/3.6 37.4 (16.7,58.2) 38% 23/3.9 78.2 (39.7,116.6) 67% 17/3.9 106.4 (40.6,172.2) 82% 0.005 
Other Pituitary Tumours 
         
 
All Causes 99/49.0 14.6 (8.9,20.2) 100% 103/59.4 22.7 (12.4,33.1) 100% 89/45.4 66.8 (38.5,95.2) 100% 0.005 
Neoplasm 52/17.2 10.1 (6.0,14.3) 70% 32/25.6 3.4 (-2.4,9.1) 15% 26/21.0 7.6 (-7.7,22.9) 11% 0.210 
Non-Neoplastic 47/31.8 4.4 (0.5,8.3) 30% 71/33.8 19.4 (10.8,28.0) 85% 63/24.4 59.2 (35.3,83.1) 89% <0.001 
Cardiac Disease 14/7.5 1.9 (-0.2,4.0) 13% 18/10.6 3.9 (-0.5,8.2) 17% 17/8.1 13.7 (1.3,26.1) 21% -¥ 
Stroke 4/2.2 0.5 (-0.6,1.7) 4% 13/2.6 5.4 (1.7,9.1) 24% 13/2.1 16.8 (5.9,27.6) 25% <0.001 
Meningioma 
         
 
All Causes 156/31.8 66.6 (53.5,79.7) 100% 101/39.1 62.1 (42.3,81.8) 100% 82/41.2 90.9 (51.4,130.4) 100% 0.889 
Neoplasm 122/12.6 58.7 (47.0,70.3) 88% 63/18.0 45.1 (29.5,60.7) 73% 51/18.9 71.5 (40.4,102.7) 79% 0.298 
Non-Neoplastic 34/19.2 7.9 (1.8,14.1) 12% 38/21.1 16.9 (4.8,29.0) 27% 31/22.3 19.4 (-4.9,43.7) 21% 0.412 
Embryonal Tumours 
         
 
All Causes 79/2.8 320.2 (247.0,393.3) 100% 13/2.5 92.4 (30.1,154.8) 100% 13/2.4 232.1 (78.0,386.1) 100% 0.011 
Neoplasm 75/0.7 312.1 (240.8,383.4) 97% 8/0.9 62.8 (13.9,111.7) 68% 7/1.0 131.1 (18.1,244.1) 56% <0.001 
Non-Neoplastic 4/2.1 8.1 (-8.4,24.5) 3% 5/1.6 29.6 (-9.1,68.2) 32% 6/1.4 101.0 (-3.7,205.6) 44% 0.076 
Ependymoma 
         
 
All Causes 83/9.0 120.1 (91.1,149.1) 100% 47/10.0 117.3 (74.8,159.9) 100% 26/9.8 126.4 (48.6,204.1) 100% 0.681 
Neoplasm 67/2.6 104.6 (78.6,130.7) 87% 30/3.7 83.2 (49.2,117.2) 71% 11/4.2 53.1 (2.5,103.7) 42% 0.031 
Non-Neoplastic 16/6.5 15.5 (2.8,28.2) 13% 17/6.2 34.1 (8.5,59.7) 29% 15/5.6 73.3 (14.2,132.4) 58% 0.021 
Other† 
         
 
All Causes 385/54.6 90.7 (80.1,101.2) 100% 186/60.6 67.1 (52.8,81.4) 100% 110/67.9 50.6 (25.9,75.3) 100% <0.001 
Neoplasm 275/17.1 70.8 (61.8,79.7) 78% 94/24.5 37.2 (27.0,47.4) 55% 52/29.8 26.7 (9.7,43.7) 53% <0.001 
Non-Neoplastic 110/37.5 19.9 (14.3,25.5) 22% 92/36.1 29.9 (19.8,40.0) 45% 58/38.1 23.9 (6.0,41.9) 47% 0.569 
Abbreviations: O=observed, E=expected, AER=absolute excess risk, CI= confidence intervals.  
†Other consists of other specified and other unspecified,  
* adjusted for age at diagnosis, diagnosis era and sex.  
¥Could not converge
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Figure 4.1: Cause-specific cumulative mortality, according to CNS tumour type, with years from diagnosis as the time scale 
*Restricted to CNS tumour types with over 25 events 
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Table 4.9:  Risk of all cause, neoplastic and non-neoplastic mortality by grade among glial tumour 
survivors 
 
Cause of Death Glial Grade O/E SMR (95%CI) AER (95%CI) 
All Causes Grade I 38/5.7 6.7 (4.7,9.1) 73.0 (45.7,100.3) 
 
Grade II 1619/68.2 23.7 (22.6,24.9) 477.0 (452.7,501.2) 
 
Grade III & IV 307/8.4 36.7 (32.7,41.0) 756.7 (669.7,843.8) 
 
Ptrend*  
<0.001 <0.001 
Neoplasm Grade I 27/1.7 15.9 (10.5,23.1) 57.2 (34.2,80.2) 
 
Grade II 1480/24.3 60.9 (57.8,64.0) 447.7 (424.5,470.9) 
 
Grade III & IV 286/3.0 96.4 (85.6,108.3) 717.2 (633.2,801.2) 
 
Ptrend*  
<0.001 <0.001 
Non-Neoplastic Grade I 11/4.0 2.7 (1.4,4.9) 15.8 (1.1,30.5) 
 
Grade II 139/43.9 3.2 (2.7,3.7) 29.2 (22.1,36.4) 
 
Grade III & IV 21/5.4 3.9 (2.4,5.9) 39.5 (16.7,62.3) 
  Ptrend*  
0.171 0.195 
Abbreviations: O-observed, E-expected, SMR- standardised mortality ratio, AER= absolute excess risk, CI-confidence interval 
*Adjusted for attained age, age at diagnosis, diagnosis era and sex 
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Table 4.10: Risk of all cause, neoplastic and non-neoplastic mortality by grade and era of diagnosis among glial tumour survivors 
  
1971-1979 1980-1989 1990-2006  
Glial Grade 
Cause of 
Death O/E AER (95%CI) 
%of Total 
AER O/E AER (95%CI) 
%of Total 
AER O/E AER (95%CI) 
%of Total 
AER Ptrend* 
  
         
 
Grade I All Causes 1/0.4 - - 13/2.4 79.5 (26.7,132.3) 100% 24/3.0 70.9 (38.5,103.2) 100% - 
 
Neoplasm 1/0.2 - - 10/0.8 68.6 (22.3,114.9) 86% 16/0.7 51.5 (25.1,77.9) 73% - 
 
Non-Neoplastic 0/0.2 - - 3/1.5 10.9 (-14.4,36.3) 14% 8/2.2 19.4 (0.7,38.1) 27% - 
    
 
  
 
  
  
Grade II All Causes 168/20.3 245.2 (203.1,287.4) 100% 509/27.7 385.5 (350.1,421.0) 100% 942/20.3 658.1 (615.1,701.0) 100% <0.001 
 
Neoplasm 134/8.2 208.8 (171.1,246.5) 85% 447/10.1 350.0 (316.8,383.2) 91% 899/6.0 637.6 (595.6,679.5) 97% <0.001 
 
Non-Neoplastic 34/12.0 36.5 (17.5,55.4) 15% 62/17.6 35.6 (23.2,47.9) 9% 43/14.3 20.5 (11.3,29.7) 3% 0.407 
    
 
  
 
  
  
Grade III & 
IV 
All Causes 29/3.3 267.7 (157.9,377.4) 100% 44/1.7 629.2 (435.9,822.4) 100% 234/3.5 997.4 (867.6,1127.1) 100% <0.001 
 
Neoplasm 23/1.3 225.2 (127.4,322.9) 84% 40/0.6 585.1 (400.9,769.4) 93% 223/1.0 960.4 (833.8,1087.0) 96% <0.001 
 
Non-Neoplastic 6/1.9 42.5 (-7.4,92.4) 16% 4/1.0 44.0 (-14.2,102.3) 7% 11/2.5 36.9 (8.8,65.1) 4% 0.100 
Abbreviations: O=observed, E=expected, AER=absolute excess risk, EMR= excess mortality ratio, CI= confidence intervals 
* Adjusting for attained age, age at diagnosis and sex 
-  Insufficient numbers to reliably estimate. 
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Table 4.11: Risk of all cause, neoplastic and non-neoplastic mortality by grade and years from diagnosis among glial tumour survivors 
  
5-14 years from diagnosis 15-24 years from diagnosis 25+ years from diagnosis  
Glial Grade Cause of Death 
O/E AER (95%CI) 
%of 
Total 
AER O/E AER (95%CI) 
%of 
Total 
AER O/E AER (95%CI) 
%of 
Total 
AER Ptrend* 
           
 
Grade I All Causes 28/3.0 78.2 (45.8,110.6) 100% 9/1.8 71.2 (13.0,129.4) 100% 1/0.9 - - - 
 
Neoplasm 20/0.7 60.3 (32.9,87.7) 77% 7/0.6 63.4 (12.0,114.7) 89% 0/0.4 - - - 
 
Non-Neoplastic 8/2.3 17.9 (0.5,35.2) 23% 2/1.2 7.9 (-19.6,35.3) 11% 1/0.5 - - - 
  
          
Grade II All Causes 1361/27.6 648.6 (613.4,683.7) 100% 192/21.2 201.6 (169.5,233.7) 100% 66/19.4 133.8 (88.1,179.5) 100% <0.001 
 
Neoplasm 1292/8.0 624.5 (590.2,658.8) 96% 157/7.9 176.0 (147.0,205.0) 87% 31/8.4 65.0 (33.6,96.3) 49% <0.001 
 
Non-Neoplastic 69/19.6 24.0 (16.1,32.0) 4% 35/13.3 25.6 (11.9,39.3) 13% 35/11.0 68.8 (35.6,102.1) 51% 0.012 
  
          
Grade III & IV All Causes 281/4.1 961.1 (847.0,1075.1) 100% 19/1.9 250.0 (125.2,374.7) 100% 7/2.4 120.1 (-16.5,256.8) 100% <0.001 
 
Neoplasm 270/1.1 933.0 (821.2,1044.8) 97% 13/0.7 179.1 (76.0,282.3) 72% 3/1.1 50.3 (-39.2,139.7) 42% <0.001 
 
Non-Neoplastic 11/2.9 28.1 (5.5,50.6) 3% 6/1.1 70.8 (0.8,140.9) 28% 4/1.3 69.8 (-33.5,173.1) 58% 0.036 
Abbreviations: O=observed, E=expected, AER=absolute excess risk, EMR= excess mortality ratio, CI= confidence intervals 
* Adjusting for diagnosis era, age at diagnosis and sex 
- Insufficient numbers to reliably estimate.  
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Chapter 5 
Risk of soft-tissue sarcoma among 69,460 5-year survivors of childhood 
cancer in Europe
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5.1 ABSTRACT 
Background: Childhood cancer survivors are at increased risk of developing a subsequent 
primary soft-tissue sarcoma (STS), but the risks of specific STS histological subtypes is 
unknown. We quantified the risk of STS histological subtypes after specific types of 
childhood cancer.  
Methods: The PanCare Childhood and Adolescent Survivor Care and Follow-up Studies 
consortium combined data from 13 European cohorts providing a cohort of 69,460 5-year 
survivors of childhood cancer. Standardised incidence ratios (SIR) and absolute excess risks 
(AER) were calculated to quantify the excess risk of STS. 
Results: Overall, 301 STS developed compared to 19 expected (SIR=16, 95% Confidence 
Interval [CI]=14–18). Highest SIRs were observed for malignant peripheral nerve sheath 
tumours (MPNST) (SIR=41, CI=14–18), leiomyosarcoma (SIR=30, CI=24–37), and 
fibromatous neoplasms (SIR=12, CI=9–16). SIRs and AERs of STS did not vary significantly 
across different treatment decades after adjusting for other explanatory factors (Ptrend=0.699 & 
0.842). AERs for all STS subtypes were generally low at any attained age or years from 
diagnosis (AER<1 per 10,000 survivors per year), except for a leiomyosarcoma among 
retinoblastoma survivors—the AER increased with attained age and years from diagnosis 
reaching 53 per 10,000 survivors per year beyond 45 years from diagnosis.  
Conclusion: Childhood cancer survivors are at increased risk of developing STS, particularly 
leiomyosarcoma, MPNSTs and fibromatous neoplasms. Whilst the observed risks relative to 
the general population were substantial, the absolute risk of developing any STS subtype was 
low, except for leiomyosarcoma after retinoblastoma. These long-term risks provide an 
evidence base for developing clinical follow-up guidelines. 
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5.2 INTRODUCTION 
Within Europe, 79% of children diagnosed with cancer now survive at least 5 years 198. This 
high survival has resulted in a large population of long-term survivors of childhood cancer. 
Childhood cancer survivors are at an increased risk of long-term adverse-health outcomes 
with one of the most serious being the development of a subsequent primary neoplasm 
(SPN)—overall risks 3 to 6-fold that expected from the general population 96, 98, 100, 104, 106, 199. 
STS SPNs are highly fatal, with 5-year survival at only 19–41% after radiation-induced 
sarcomas 200-202.  
 
Previous studies have shown that the risk of developing any subsequent primary soft-tissue 
sarcoma (STS) is substantially elevated following childhood cancer, particularly in survivors 
of heritable retinoblastoma and Wilms tumour 112-115, 203-205. However, because development 
of a STS is rare, previous reports were based on small observed numbers and, to our 
knowledge, no previous study has reported risk estimates for specific histological subtypes of 
STS after all specific types of childhood cancer, except heritable retinoblastoma. 
 
Due to the increased awareness of adverse health outcomes among childhood cancer 
survivors, recent treatments for childhood cancers with a favourable prognosis have moved 
towards lowering therapeutic exposures. So far, the potential impact of such lower therapeutic 
exposure on the risk of STS SPNs has not been investigated. 
 
We investigated the risks of STS within a large-scale pan-European cohort of 69,460 5-year 
survivors of childhood cancer. The current study provides over 3-fold the number of STS 
provided by the largest study on STS SPN published to date which is not included in the 
  
141 
 
present study 112. The aim of this study was to provide risk estimates for all and specific 
histological subtypes of STS after all and specific types of childhood cancer. 
 
5.3 METHODS 
5.3.1 The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up 
Studies (PanCareSurFup) 
PanCareSurFup combines data from across Europe to form the largest collaborative study to 
date to investigate adverse health outcomes in long-term survivors of childhood and 
adolescent cancer (referred to as childhood cancer henceforth). The study comprises data from 
13 European cohorts, within 12 countries, of childhood cancer survivors, with contributions 
from both population-based cancer registries and major treatment centres (Table 5.1). Ethical 
approval was obtained separately for each cohort from the appropriate bodies within each 
specific country. 
 
5.3.2 Cohort ascertainment 
Childhood cancers obtained were coded according to the first, second or third revisions of the 
International Classification of Disease for Oncology (ICD-O). To enable childhood cancers to 
be grouped according to the International Classification of Childhood Cancers (ICCC)79, 
morphology and topography codes were converted into ICD-O-3 using the IARC/IACR 
Cancer Registry Tools software 152. Childhood cancers were excluded if the associated ICD-O 
code was not in ICCC or was not of a malignant behaviour (except for intracranial tumours, 
for which “benign” and “uncertain whether benign or malignant” were included). Childhood 
cancers provided by the Slovenian cancer registry prior to 1983 were coded according to the 
International Classification of Disease (ICD) 7th edition and could not be classified according 
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to ICCC; however these individuals were not excluded and were grouped as “not 
classifiable”. To ensure consistency between cohorts, individuals with Langerhans cell 
histiocytosis, myelodysplastic syndromes, chronic myeloproliferative and lymphoproliferative 
disorders or immunoproliferative diseases were excluded as these conditions were not 
ascertained satisfactorily by all countries (Figure 5.1). In total, the cohort consists of 69,460 
5-year survivors of cancer diagnosed before the age of 20 years between 1940 and 2008 
(Tables 5.1 and 5.2). 
 
5.3.3 Subsequent primary neoplasm ascertainment 
SPNs were ascertained through several different methods and the primary method of 
validation was obtaining pathology reports or in their absence other means of clinical 
diagnosis (see Table 5.1). To be included as a SPN, tumours had to have a different 
histological classification to that of the childhood cancer and have a malignant behaviour 
code—except for intracranial tumours where any behaviour code was included (Figure 5.2). 
The majority (70%) of affected individuals in the cohort were aged 15-39 years at diagnosis 
of a STS, therefore STS SPNs were classified using the adolescents and young adult (AYA) 
cancer classification scheme 13. 
 
5.3.4 General population soft-tissue sarcoma rates for the derivation of expected 
numbers 
To compare the observed number of STS SPNs with the expected numbers from the general 
population, general population STS incidence rates formatted according to the AYA 
classification (by ICD-O morphology) were required. Incidence rates by ICD-O morphology 
were available for the UK (years 1971-2006: England and Wales, only) 206 and Finland (years 
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1953-2011) 207. For other countries we used either the UK or Finnish rates (UK for: France, 
Hungary, Italy, Netherlands, Slovenia and Switzerland; Finnish for: Denmark, Norway, 
Sweden and Iceland). When the range of calendar-years for the general population cancer 
rates did not extend to the ascertainment period of STS, rates from the closest available year 
were used.  
 
5.3.5 Statistical analysis 
Follow-up began at 5-year survival from childhood cancer and ended at the first occurrence of 
death, loss to follow up, or cohort exit date. Analyses involving observed and expected 
numbers allowed multiple STS per individual. Standardised incidence ratios (SIRs) were 
calculated as the observed divided by the expected number of STS. The expected number of 
STS was calculated by accumulating person-years in the cohort by sex, single calendar-year 
and 5-year age-strata and multiplying by the corresponding general population STS incidence 
rates. Absolute excess risks (AERs) were calculated as the observed minus the expected 
number of STS, divided by person-years at risk and multiplied by 10,000. The AER can be 
interpreted as the number of excess STS observed beyond that expected per 10,000 per year. 
The denominator is often not provided in the Results and Discussion as it is always 10,000 
person-years. SIRs and AERs were stratified by sex, country, childhood cancer diagnosis, age 
at and decade of childhood cancer diagnosis, attained age, and years from childhood cancer 
diagnosis for STS subtypes where numbers were sufficient (n>40). The simultaneous effect of 
these potential explanatory factors was analysed using multivariable Poisson regression with a 
user-defined link function to calculate relative risks (RR) and relative excess risks (RER) 154. 
RRs can be interpreted as the ratio of SIRs adjusted for other explanatory factors. RERs can 
be interpreted as the ratio of AERs adjusted for other explanatory factors. 
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Cumulative incidence of the first occurrence of a STS, treating death as a competing risk, was 
calculated by years since 5-year survival. Expected cumulative incidence was calculated using 
the Ederer II method 189. All statistical analyses were conducted in Stata statistical software, 
version 14.1. A 2-sided p-value <0.05 was considered statistically significant. 
 
5.4 RESULTS 
5.4.1 Cohort characteristics  
Overall, individuals contributed 1,126,424 person-years and a median follow-up of 14.5 years 
from 5-year survival (range: 0-62). A total of 301 STS were observed among 299 of the 
69,460 5-year survivors of childhood cancer (Table 5.3). The most commonly observed STS 
were, leiomyosarcoma (n=80, [27%]), fibromatous neoplasms (n=55, [18%]), and malignant 
peripheral nerve sheath tumours (MPNST) (n=45, [15%]). 
 
5.4.2 Overall risk of soft-tissue sarcoma  
Overall, survivors had a 16-fold (95% confidence interval [CI]=14.0–17.6) risk of developing 
a STS compared to that expected from the general population, corresponding to an AER of 
2.5 (Table 5.4). Survivors of each specific type of childhood cancer were at a significantly 
increased multiplicative (SIR) and absolute (AER) excess risk of developing a STS, 
particularly retinoblastoma survivors (SIR=72.8, CI=56.1–93.0; AER=11). The multivariable 
analysis revealed that there was no statistically significant relationship between age at 
diagnosis or decade of diagnosis (1940-2008) with the excess risk of STS in either 
multiplicative or absolute terms. The RR declined significantly with attained age and years 
from diagnosis (Ptrend=0.002 and Ptrend=0.001). The RER increased significantly with 
increasing years from diagnosis and attained age (both Ptrend<0.001). Beyond 45 years from 
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diagnosis the AER was 9. The cumulative incidence of developing a STS was 1.4% (CI=1.1–
1.6) at 45 years from diagnosis, whereas 0.1% was expected (Figure 5.3a).  
 
5.4.3 Risk of leiomyosarcoma  
The SIR of developing a leiomyosarcoma was 30-fold (CI=23.7–37.2) increased among 
survivors of childhood cancer than in the general population; corresponding to an AER of 0.7 
(Table 5.5). The SIR was highest among retinoblastoma survivors (SIR=342.9, CI=245.0–
466.9) and Wilms tumour survivors (SIR=74.2, CI=37.1–132.8). 77% of leiomyosarcomas 
observed after retinoblastoma developed outside of irradiated tissue and 87% of these 
retinoblastomas were known to be heritable (Table 5.6). 91% of leiomyosarcomas observed 
after Wilms tumour developed within irradiated tissue. SIRs were particularly high among 
survivors diagnosed at a young age, with almost a 100-fold increased risk of developing a 
leiomyosarcoma among individuals diagnosed before age 5 years; and the RR declined 
significantly with older age at diagnosis (Ptrend=0.011). This relationship remained after 
excluding survivors of both retinoblastoma and Wilms tumour from the analysis 
(Ptrend=0.016). 65% of survivors diagnosed before age 5 who developed a leiomyosarcoma 
had a genetic predisposition (35 RB1 mutation, 1 neurofibromatosis, 1 Li-Fraumeni 
syndrome). No statistically significant relationship between decade of diagnosis (1940-2008) 
and the excess risk of leiomyosarcoma was observed in either multiplicative or absolute 
terms. The RR did not vary significantly with attained age or years from diagnosis 
(Ptrend=0.765 and Ptrend=0.520). The RER increased substantially with attained age and years 
from diagnosis (both Ptrend<0.001); beyond 45 years from diagnosis the AER was 9. The 
cumulative incidence of developing a leiomyosarcoma was 0.6% (CI=0.4–0.8) at 45 years 
from diagnosis, whereas 0.02% was expected (Figure 5.3b). 
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5.4.4 Risk of fibromatous neoplasms  
Survivors had a 12-fold (CI=9.3–16.0), increased risk of developing a fibromatous SPN than 
that expected, corresponding to an AER of 0.4 (Table 5.7). Survivors were most at risk of 
fibrosarcoma (SIR=25.1, CI=16.5–36.5) and malignant fibrous histiocytoma (SIR=28.3, 
CI=18.3–41.7) (Table 5.3). Bone sarcoma, retinoblastoma and Hodgkin lymphoma survivors 
had the highest risk of developing a fibromatous SPN with SIRs of 34.5, 31.0 and 24.2, 
respectively (Table 5.7). 83%, 57% and 57% of fibrosarcoma after retinoblastoma, bone 
sarcoma and Hodgkin lymphoma occurred in irradiated tissue, respectively (Table 5.6). No 
statistically significant relationship between age at diagnosis or decade of diagnosis (1940-
2008) and the excess risk of fibromatous SPNs was observed in either multiplicative or 
absolute terms. RRs decreased significantly with attained age and years from diagnosis (both 
Ptrend<0.001), whereas the RERs did not vary significantly with attained age or years from 
diagnosis (Ptrend=0.169, Ptrend=0.110, respectively).  The cumulative incidence of developing a 
fibromatous neoplasm increased to 0.12% (CI=0.08–0.15) at 30 years from diagnosis 
compared to 0.01% expected (Figure 5.3c). 
 
5.4.5 Risk of malignant peripheral nerve sheath tumours (MPNST) 
MPNSTs, also known as malignant schwannoma or neurofibrosarcoma, are a rare type of STS 
arising from the cells that surround the nerves. The highest SIR for any STS subtype was 
observed for MPNST SPNs, with a 41-fold (CI=29.6–54.3) increased risk than that expected 
(Table 5.8); the corresponding AER was 0.4. 47% of all MPNST were associated with 
Neurofibromatosis. 63% and 64% of MPNST occurred within irradiated tissue among 
childhood cancer survivors with or without Neurofibromatosis, respectively (Table 5.9).  SIRs 
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were highest among survivors of CNS tumours (SIR=80.5, CI=48.4–125.7), Hodgkin 
lymphoma (SIR=81.3, CI=35.1–160.1), and Wilms tumour (SIR=76.0, CI=27.9–165.4). No 
statistically significant trends in excess risks were observed in relation to years from 
diagnosis, attained age, age at diagnosis or decade of diagnosis (1940-2008), in multiplicative 
or absolute terms. The cumulative incidence of developing a nerve sheath tumour reached 
0.01% (CI=0.07–0.14) at 30 years from diagnosis, whereas 0.002% was expected (Figure 
5.3d). 
 
5.4.6 Risk of soft-tissue sarcoma among retinoblastoma survivors  
As survivors of retinoblastoma experienced the highest risk of developing a STS (SIR=72.8, 
CI=56.1–93.0), particularly leiomyosarcoma (SIR=342.9, CI=245.0–466.9), we investigated 
the risks by the potential explanatory factors in more detail (Table 5.10 & 5.11). The AER for 
STS among survivors of retinoblastoma increased substantially with increasing years from 
diagnosis and attained-age (Ptrend<0.001), reaching 58 beyond 45 years from diagnosis (Table 
5.10). Beyond 45 years from diagnosis, leiomyosarcomas accounted for 91% of all excess 
STS among retinoblastoma survivors, with an AER of 53 (Table 5.11). The cumulative 
incidence of developing a STS among retinoblastoma survivors was 5.4% (CI=3.7–6.9) at 45 
years from diagnosis whereas 0.07% was expected (Figure 5.3a). The cumulative incidence of 
developing a leiomyosarcoma was 3.7% (CI=2.4–5.3) at 45 years from diagnosis, whereas 
0.01% was expected (Figure 5.3b). 
 
5.5 DISCUSSION 
The PanCareSurFup cohort provides unprecedented insight into the absolute and excess risks 
of STS SPN after childhood cancer, particularly in the long-term. The only previous large-
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scale study addressing this topic which did not contribute data to PanCareSurFup is the North 
American Childhood Cancer Survivor Study (CCSS) 112, which included 108 subsequent 
primary sarcomas (both bone and soft-tissue combined) compared to our 301 STS alone. 
More importantly the CCSS study reported just six observed subsequent primary sarcomas 
beyond 30 years from diagnosis 112, whilst in PanCareSurFup this was 80.  
 
 Our study provides, for the first time, separate risk estimates for specific histological types of 
STS, and shows that childhood cancer survivors are at increased risk of developing a STS 
SPN, particularly leiomyosarcoma, MPNST and fibromatous SPNs. The differences in SIRs 
for each STS subtype are more than likely due to differences in the background rate for each 
of these subtypes in the general population— the incidence of MPNST is lower than 
fibromatous neoplasm or leiomyosarcoma in the general population, which results in a higher 
SIR due to MPNST208. Among childhood cancer survivors as years from diagnosis and 
attained age increases the SIR for fibromatous SPNs decreased; in contrast the SIR for 
leiomyosarcoma and MPNST remained consistently high across all years from diagnosis and 
at all attained ages. With regards to the AER, the number of excess fibromatous SPNs and 
MPNST remained low across all years from diagnosis and at all attained ages at less than 1. In 
contrast the number of excess leiomyosarcomas increased with increasing years from 
diagnosis and attained age; especially among retinoblastoma survivors. Leiomyosarcoma are 
associated with the genetic predisposition found in heritable retinoblastoma survivors (RB1 
deletion)209, therefore explains why there is a large excess of this STS subtype among 
retinoblastoma survivors.  
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This study observed a 16-fold risk of STS SPNs compared to the general population, which is 
broadly consistent with the largest studies published so far 96, 100, 104, 112-114, but previous 
studies were based on far fewer STS events.  
 
To our knowledge our study is the first to identify a substantially increased risk of 
leiomyosarcoma in Wilms tumour survivors. This increase in risk is likely related to 
radiotherapy because 10/11 (91%) of leiomyosarcomas observed after Wilms tumour 
developed within tissue directly irradiated (Table 5.6). The high risk of leiomyosarcoma 
among retinoblastoma survivors is consistent with previous literature 204, 210, 211 and is most 
likely caused by a genetic predisposition (heritable retinoblastoma/ RB1 mutation) 205, 211—
77% of such leiomyosarcomas developed outside of tissue directly irradiated to treat the 
retinoblastoma and 87% of these retinoblastomas were known to be heritable (Table 5.6). The 
strong relationship observed between age at childhood cancer and the excess risk of 
leiomyosarcoma is likely due to a genetic predisposition—65% of survivors diagnosed before 
age 5 who developed a leiomyosarcoma had a genetic predisposition. 
 
Some of the excess risk of fibromatous SPNs after bone sarcoma and Hodgkin lymphoma can 
be attributed to radiotherapy as 57% of the fibromatous SPNs observed after bone sarcoma 
and Hodgkin lymphoma developed within tissue directly irradiated (Table 5.6). Kleinerman et 
al identified an increased risk of both fibrosarcoma (398-fold) and malignant fibrous 
histiocytoma (100-fold) among survivors of heritable retinoblastoma 205. The current study 
included few retinoblastoma survivors (n=6) who developed a fibromatous neoplasm (4 
fibrosarcoma, 2 malignant fibrous histiocytoma, 1 dermatofibroma); therefore detailed 
comparison is not possible.   
  
150 
 
 
Neurofibromatosis is a genetic condition associated with the development of cancer, 
particularly MPNST and CNS tumours (gliomas) 212. In our cohort, 21/45 (47%) of MPNST 
were associated with neurofibromatosis, which is consistent with previous reports 213, 214. 
 
Previous literature suggests that MPNSTs may also arise in individuals previously treated 
with radiotherapy who do not have neurofibromatosis 214. It is apparent from Table 5.9 that 
about two-thirds of MPNST developed in tissue directly irradiated to treat the original 
childhood cancer irrespective of whether neurofibromatosis was known to be present or not.  
 
Over the last few decades (1970s, 1980s, 1990s), cumulative therapeutic exposures have 
decreased for cancers with a favourable prognosis, however; within PanCareSurFup the 
excess risk of developing any type of STS did not vary significantly across decades of 
diagnosis (≤1970, 1970-1979, 1980-1989, 1990-2008). Consequently, there is no evidence so 
far that interventions to reduce the toxicity of cancer treatments are having measurable impact 
on the long-term risk of STS SPNs. 
 
The AER for leiomyosarcoma increased substantially with attained age and years from 
diagnosis after retinoblastoma reaching 53 and 37 excess leiomyosarcomas beyond 45 years 
from diagnosis and 40 years of age, respectively. This study provides evidence that clinical 
follow-up guidelines should recommend long-term surveillance for leiomyosarcoma among 
retinoblastoma survivors. In contrast, the AER for both fibromatous SPNs and MPNSTs 
remained below 1 across all years from diagnosis and attained ages, i.e. the absolute risk was 
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low. Thus far there is no evidence to suggest long-term surveillance of fibromatous SPNs or 
MPNST among childhood cancer survivors is warranted.  
 
5.5.1 Limitations 
A potential limitation of our study is the observed significant heterogeneity between the 
contributing cohorts (Table 5.4). However, when the French cohort was excluded, the p-value 
for heterogeneity in SIRs between cohorts was no longer significant (Pheterogeneity=0.083). The 
French cohort was ascertained through five treatment centres, but a large proportion of 
survivors attended the two main centres (Institut Gustave Roussy and Insititut Curie) which 
are international referral centres for difficult cases, particularly with relapsed and recurrent 
disease. Therefore it was anticipated that cumulative doses of radiotherapy administered to 
patients at these centres would be higher than in a population-based setting. Sensitivity 
analyses revealed that SIRs, AERs, RRs and RERs were remarkably similar to those 
presented here when the French cohort was excluded, therefore we did not exclude French 
cohort in our analyses (Table 5.12). 
 
A limitation is the absence of detailed information on cumulative radiotherapy and 
chemotherapy exposure during treatment for the childhood cancer. However a nested case-
control study is in progress which will relate the risk of STS SPN to cumulative doses of 
radiation from radiotherapy and cumulative doses of individual cytotoxic drugs. 
 
5.6 CONCLUSIONS 
Childhood cancer survivors are at increased risk of developing STS, particularly 
leiomyosarcoma, MPNSTs and fibromatous neoplasms. The risk of STS did not vary across 
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different decades of diagnosis. Whilst the observed risks relative to the general population 
were substantial, the absolute risk of developing any STS subtype was low, except for 
leiomyosarcoma after retinoblastoma. These long-term risks provide an evidence base for 
developing clinical follow-up guidelines.
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Figure 5.1: Flow diagram showing exclusion criteria for childhood cancer
N=105,015  Myelodysplastic Syndromes (ICDO3 codes 9980 to 
9989), n=95 
 Langerhans Cell Histiocytosis (ICDO3 codes 9751 to 
9753), n=246 
 Chronic myeloproliferative and lymphoproliferative 
disorders (ICDO3 codes 9950 to 9975) , n=188 
 Immunoproliferative diseases (ICDO3 codes 9760 to 
9769), n=2 
 
N=102,548 
Age at childhood cancer diagnosis not between 0–19 inclusive, 
n=6 
N=102,542 
N=69,460 
N=104,484 
Non 5-year survivor, n=33,082 
 
 Behaviour code of 6 or 9. Cannot be certain if primary 
cancer, n=278 
 Non-malignant behaviour code (excess cranial), n=873 
 Not included within ICCC classification, n=785 
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Table 5.1: Characteristics of 5-year cancer survivor cohorts contributing to the European PanCareSurFup cohort 
Cohort No. of 5-year 
survivors 
Study Design Period of 
Childhood Cancer 
diagnosis 
Age at Childhood 
Cancer Diagnosis 
End of 
Follow-up 
Childhood Cancer Inclusion 
Criteria 
Method of SPN 
Ascertainment 
SPN Inclusion Criteria 
France 3,138 Treatment 
centre 
1946–1986 <19 Sep-14 malignant or intracranial, 
excludes leukaemia 
Multiple methods1 malignant or intracranial 
Hungary 4,885 Population 
based 
1971–2008 <20 Dec-14 malignant or intracranial Multiple methods2 malignant or intracranial 
Italy PB 7,436 Population 
based 
1965–2005 <20 May-10 malignant or intracranial Multiple methods3 malignant or intracranial 
Italy HB 1,490 Treatment 
centre 
1960–2007 <20 Dec-12 malignant or intracranial Multiple methods3 malignant or intracranial 
Netherlands 6,044 Population 
based 
1963–2001 <18 Dec-12 malignant or intracranial Multiple methods4 malignant or intracranial 
Denmark 4,840 Population 
based 
1943–1998 <20 Dec-03 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Sweden 7,709 Population 
based 
1958–1998 <20 Dec-03 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Norway 3,783 Population 
based 
1953–1997 <20 Dec-02 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Finland 6,229 Population 
based 
1953–2006 <20 Dec-11 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Iceland 275 Population 
based 
1955–1998 <20 Dec-03 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Slovenia 1,252 Population 
based 
1960–2002 <17 Jul-14 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Switzerland 4,379 Population 
based 
1964–2005 <20 Dec-13 malignant or intracranial Multiple methods5 malignant or intracranial 
UK 17,960 Population 
based 
1940–1991 <15 Dec-06 malignant or intracranial Population based malignant, intracranial or of 
bladder 
Abbreviations: SPN-Subsequent primary neoplasm, PB-population based, HB-hospital based, UK- United Kingdom 
1Multiple methods include: long-term follow-up clinics, questionnaires to survivors, national mortality records and health insurance registries. 
2Multiple methods include: long-term follow-up clinics, questionnaires to survivors and medical records/hospital data. 
3Multiple methods include: medical records/ hospital data, national mortality records. 
4Multiple methods include: population-based cancer registries, long-term follow-up clinics and medical records/hospital data. 
5Multiple methods include: population-based cancer registries, long-term follow-up clinics, and national mortality records
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Table 5.2: Characteristics of the survivor cohorts included in the PanCareSurFup cohort 
 
  All Countries France Hungary Italy PB Italy HB Netherlands Denmark 
  N % N % N % N % N % N % N % 
Overall 69,460 100.0 3,138 100.0 4,885 100.0 7,476 100.0 1,490 100.0 6,044 100.0 4,840 100.0 
Sex   
            
Male 37,738 54.3 1,731 55.2 2,729 55.9 4,087 54.7 808 54.2 3,362 55.6 2,684 55.5 
Female 31,722 45.7 1,407 44.8 2,156 44.1 3,389 45.3 682 45.8 2,682 44.4 2,156 44.6 
Age at Diagnosis   
            
<5 years 26,969 38.8 1629 51.9 2106 43.1 2,311 30.9 654 43.9 2,733 45.2 1,421 29.4 
5–9 years 15,587 22.4 748 23.8 1283 26.3 1,455 19.5 438 29.4 1,627 26.9 859 17.8 
10–14 years 15,423 22.2 657 20.9 1135 23.2 1,606 21.5 319 21.4 1,291 21.4 936 19.3 
15–19 years 11,482 16.5 104 3.3 361 7.4 2,104 28.1 79 5.3 393 6.5 1,624 33.6 
Decade of Diagnosis   
            
<1970 8,993 13.0 674 21.5 0 0.0 183 2.5 32 2.2 117 1.9 1,214 25.1 
1970–1979 13,479 19.4 1,375 43.8 368 7.5 470 6.3 188 12.6 954 15.8 893 18.5 
1980–1989 20,900 30.1 1,089 34.7 1,280 26.2 1,404 18.8 338 22.7 1,899 31.4 1,270 26.2 
1990–1999 19,260 27.7 0 0.0 1,686 34.5 3,545 47.4 684 45.9 2,487 41.2 1,463 30.2 
≥2000 6,828 9.8 0 0.0 1,551 31.8 1,874 25.1 248 16.6 587 9.7 0 0.0 
Attained Age   
            
0–19 years 16,397 23.6 290 9.2 2,190 44.8 2,603 34.8 362 24.3 1,294 21.4 1,081 22.3 
20-–29 years 22,329 32.2 445 14.2 1,717 35.2 2,868 38.4 567 38.1 2,078 34.4 1,458 30.1 
30–39 years 17,522 25.2 1,050 33.5 798 16.3 1,551 20.8 375 25.2 1,771 29.3 1,099 22.7 
≥40 years 13,212 19.0 1,353 43.1 180 3.7 454 6.1 186 12.5 901 14.9 1,202 24.8 
Years from Diagnosis   
            
5–14 years 23,833 34.3 334 10.6 2,752 56.3 4,703 62.9 465 31.2 1,555 25.7 2,018 41.7 
15–24 years 22,282 32.1 423 13.5 1,443 29.5 1,871 25.0 576 38.7 2,316 38.3 1,242 25.7 
25–34 years 14,087 20.3 1193 38.0 604 12.4 674 9.0 305 20.5 1,583 26.2 748 15.5 
35–44 years 6,796 9.8 871 27.8 86 1.8 223 3.0 131 8.8 545 9.0 436 9.0 
45+ years 2,462 3.5 317 10.1 0 0.0 5 0.1 13 0.9 45 0.7 396 8.2 
FPN Diagnosis   
            
Leukaemia 16,595 23.9 0 0.0 1,509 30.9 1,805 24.1 671 45.0 2,058 34.1 793 16.4 
Hodgkin Lymphoma 6,000 8.6 218 7.0 447 9.2 965 12.9 146 9.8 404 6.7 408 8.4 
Non-Hodgkin Lymphoma 3,350 4.8 113 3.6 252 5.2 397 5.3 69 4.6 367 6.1 194 4.0 
Central Nervous System 14,096 20.3 442 14.1 964 19.7 1,307 17.5 153 10.3 842 13.9 1,223 25.3 
Neuroblastoma 3,169 4.6 419 13.4 361 7.4 314 4.2 102 6.9 319 5.3 123 2.5 
Retinoblastoma 2,578 3.7 147 4.7 122 2.5 149 2.0 12 0.8 33 0.6 204 4.2 
Wilms Tumour 4,756 6.9 633 20.2 328 6.7 289 3.9 94 6.3 591 9.8 210 4.3 
Bone Sarcoma 3,147 4.5 228 7.3 251 5.1 338 4.5 68 4.6 369 6.1 191 4.0 
STS 4,502 6.5 362 11.5 246 5.0 417 5.6 76 5.1 451 7.5 339 7.0 
Other* 10,905 15.7 576 18.4 405 8.3 1,495 20.0 99 6.6 610 10.1 1,155 23.9 
Not classifiable 363 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
  
156 
 
Table 5.2 continued: 
  Sweden Norway Finland Iceland Slovenia Switzerland UK 
  N % N % N % N % N % N % N % 
Overall 7,709 100.0 3,783 100.0 6,229 100.0 275 100.0 1,252 100.0 4,379 100.0 17,960 100.0 
Sex 
              
Male 4,021 52.2 1,990 52.6 3,180 51.1 152 55.3 692 55.3 2,425 55.4 9,877 55.0 
Female 3,688 47.8 1,793 47.4 3,049 49.0 123 44.7 560 44.7 1,954 44.6 8,083 45.0 
Age at Diagnosis               
<5 years 2,548 33.1 1,198 31.7 1,982 31.8 77 28.0 451 36.0 1,590 36.3 8,268 46.0 
5–9 years 1,407 18.3 622 16.4 1,066 17.1 53 19.3 278 22.2 967 22.1 4,784 26.6 
10–14 years 1,433 18.6 650 17.2 1,217 19.5 53 19.3 322 25.7 934 21.3 4,870 27.1 
15–19 years 2,321 30.1 1,313 34.7 1,964 31.5 92 33.5 201 16.1 888 20.3 38 0.2 
Decade of Diagnosis               
<1970 1,337 17.3 620 16.4 918 14.7 35 12.7 116 9.3 2 0.1 3,745 20.9 
1970–1979 1,588 20.6 773 20.4 859 13.8 46 16.7 212 16.9 382 8.7 5,371 29.9 
1980–1989 2,263 29.4 1,256 33.2 1,342 21.5 83 30.2 364 29.1 1,170 26.7 7,142 39.8 
1990–1999 2,521 32.7 1,134 30.0 1,797 28.9 111 40.4 417 33.3 1,713 39.1 1,702 9.5 
≥2000 0 0.0 0 0.0 1,313 21.1 0 0.0 143 11.4 1,112 25.4 0 0.0 
Attained Age 
              
0–19 years 1,955 25.4 917 24.2 1,319 21.2 72 26.2 183 14.6 1,430 32.7 2,701 15.0 
20-–29 years 2,311 30.0 1,177 31.1 1,865 29.9 104 37.8 356 28.4 1,906 43.5 5,477 30.5 
30–39 years 1,769 23.0 974 25.8 1,426 22.9 48 17.5 364 29.1 758 17.3 5,540 30.9 
≥40 years 1,674 21.7 715 18.9 1,619 26.0 51 18.6 349 27.9 285 6.5 4,242 23.6 
Years from Diagnosis 
              
5–14 years 3,188 41.4 1,647 43.5 2,328 37.4 135 49.1 264 21.1 2,384 54.4 2,060 11.5 
15–24 years 2,126 27.6 1,130 29.9 1,739 27.9 79 28.7 417 33.3 1,479 33.8 7,441 41.4 
25–34 years 1,371 17.8 617 16.3 1,109 17.8 40 14.6 318 25.4 462 10.6 5,063 28.2 
35–44 years 954 12.4 311 8.2 609 9.8 19 6.9 185 14.8 54 1.2 2,372 13.2 
45+ years 70 0.9 78 2.1 444 7.1 2 0.7 68 5.4 0 0.0 1,024 5.7 
FPN Diagnosis               
Leukaemia 1,343 17.4 722 19.1 1,297 20.8 49 17.8 222 17.7 1,275 29.1 4,851 27.0 
Hodgkin Lymphoma 660 8.6 297 7.9 616 9.9 30 10.9 99 7.9 384 8.8 1,326 7.4 
Non-Hodgkin Lymphoma 235 3.1 127 3.4 401 6.4 6 2.2 61 4.9 248 5.7 880 4.9 
Central Nervous System 1,991 25.8 786 20.8 1,333 21.4 57 20.7 168 13.4 721 16.5 4,109 22.9 
Neuroblastoma 165 2.1 143 3.8 211 3.4 8 2.9 31 2.5 207 4.7 766 4.3 
Retinoblastoma 255 3.3 133 3.5 176 2.8 6 2.2 20 1.6 121 2.8 1,200 6.7 
Wilms Tumour 394 5.1 160 4.2 296 4.8 10 3.6 53 4.2 220 5.0 1,478 8.2 
Bone Sarcoma 336 4.4 178 4.7 265 4.3 16 5.8 30 2.4 213 4.9 664 3.7 
STS 452 5.9 248 6.6 383 6.2 20 7.3 63 5.0 271 6.2 1,173 6.5 
Other* 1,878 24.4 989 26.1 1,251 20.1 73 26.6 142 11.3 719 16.4 1,513 8.4 
Not classifiable 0 0.0 0 0.0 0 0.0 0 0.0 363 29.0 0 0.0 0 0.0 
Abbreviations: FPN- first primary neoplasm; NHL- Non-Hodgkin lymphoma; CNS- Central nervous system; STS- soft tissue sarcoma; PB- 
population based; HB-hospital based 
*Most common ‘Other’ neoplasms: malignant gonadal germ cell tumours (n=2,285, 21%), malignant melanoma (n=1,439, 13%), thyroid 
carcinoma (n=1,283, 12%) and Burkitt lymphoma (n-703, 6%).
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Figure 5.2: Flow diagram showing exclusion criteria for subsequent primary neoplasms  
N=4,633  Myelodysplastic Syndromes (ICDO3 codes 9980 
to 9989), n=13 
 Langerhans Cell Histiocytosis (ICDO3 codes 
9751 to 9753), n=0 
 Chronic myeloproliferative and 
lymphoproliferative disorders (ICDO3 codes 
9950 to 9975) , n=3 
 Immunoproliferative diseases (ICDO3 codes 
9760 to 9769), n=0 
N=4,468 
SPN excluded due to childhood cancer exclusion, n=88 
N=4,380 
N=4,048 
N=4,617 
 Behaviour code of 6 or 9. Cannot be certain if 
primary cancer, n=20 
 Non-malignant behaviour code (extracranial), 
n=129 
 
SPN occurred before 5-year survival, n=332 
SPN occurred after exit date, n=16 
SPN has no exit date, n=2 
  
N=4,032 
301 STS 
SPNs 
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Table 5.3: Standardised incidence ratios (SIRs) and absolute excess risks (AERs) of developing a 
subsequent primary STS in 69,460 5-year survivors of childhood cancer in the European 
PanCareSurFup cohort, by histological type. 
STS Diagnosis O/E SIR (95%CI) AER (95%CI) 
All STS 301/19.2 15.7 (14.0 to 17.6) 2.5 (2.2 to 2.8) 
Malignant Peripheral Nerve Sheath Tumour 45/1.1 40.6 (29.6 to 54.3) 0.4 (0.3 to 0.5) 
Leiomyosarcoma 80/2.7 29.9 (23.7 to 37.2) 0.7 (0.5 to 0.8) 
Fibromatous Neoplasms 55/4.5 12.3 (9.3 to 16.0) 0.4 (0.3 to 0.6) 
Malignant Fibrous Histiocytoma 25/0.9 28.3 (18.3 to 41.7) 0.2 (0.1 to 0.3) 
Fibrosarcoma 27/1.1 25.1 (16.5 to 36.5) 0.2 (0.1 to 0.3) 
Dermatofibroma 3/2.5 1.2 (0.2 to 3.5) 0.0 (-0.0 to 0.0) 
Rhabdomyosarcoma 22/1.6 13.4 (8.4 to 20.4) 0.2 (0.1 to 0.3) 
Liposarcoma 19/1.8 10.5 (6.3 to 16.4) 0.2 (0.1 to 0.2) 
Synovial Sarcoma 9/1.3 6.8 (3.1 to 12.9) 0.1 (0.0 to 0.1) 
Other Specified Sarcoma 4/0.6 6.3 (1.7 to 16.2) 0.0 (-0.0 to 0.1) 
Blood Vessel Tumour 12/2.5 4.8 (2.5 to 8.3) 0.1 (0.0 to 0.1) 
Clear Cell Sarcoma 0/0.1 - - 
Alveolar Soft Part Sarcoma 0/0.1 - - 
Unspecified Sarcoma 55/2.6 20.9 (15.8 to 27.3) 0.5 (0.3 to 0.6) 
Abbreviations: O– observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER- absolute excess risk, 
95%CI- 95% confidence interval. 
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Table 5.4: Risk of developing a subsequent primary STS among 69,460 5-year survivors of childhood cancer by 
potential explanatory factors. 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI)* 
Overall All combined 301/19.2 15.7 (14.0 to 17.6)  2.5 (2.2 to 2.8)  
Sex Male 161/10.5 15.4 (13.1 to 17.9) Ref 2.5 (2.1 to 2.9) Ref 
Female 140/8.7 16.1 (13.6 to 19.0) 1.2 (0.9–1.5) 2.5 (2.1 to 2.9) 1.0 (0.8–1.3) 
Pheterogeneity  0.648 0.235 0.992 0.922 
Country France  48/1.5 32.2 (23.8 to 42.7) Ref 5.6 (4.0 to 7.2) Ref 
Hungary 6/0.6 9.6 (3.5 to 20.9) 0.3 (0.1 to 0.8) 1.1 (0.1 to 2.0) 0.3 (0.1 to 0.8) 
Italy (PB) 12/1.0 11.8 (6.1 to 20.5) 0.4 (0.2 to 0.8) 1.6 (0.6 to 2.5) 0.4 (0.2 to 0.8) 
Italy (HB) 1/0.3 3.0 (0.1 to 16.6) 0.1 (0.0 to 0.9) 0.3 (-0.6 to 1.1) 0.1 (0.0 to 1.1) 
Netherlands 32/1.5 20.8 (14.2 to 29.4) 0.8 (0.5 to 1.3) 2.9 (1.9 to 4.0) 0.8 (0.5 to 1.3) 
Denmark 18/1.7 10.3 (6.1 to 16.3) 0.4 (0.2 to 0.7) 2.1 (1.0 to 3.1) 0.4 (0.2 to 0.7) 
Sweden 25/2.2 11.4 (7.4 to 16.8) 0.4 (0.3 to 0.7) 2.0 (1.1 to 2.8) 0.4 (0.3 to 0.8) 
Norway 9/1.0 9.0 (4.1 to 17.2) 0.3 (0.2 to 0.7) 1.5 (0.4 to 2.6) 0.4 (0.2 to 0.8) 
Finland 27/2.3 12.0 (7.9 to 17.4) 0.5 (0.3 to 0.8) 2.4 (1.4 to 3.3) 0.5 (0.3 to 0.8) 
Iceland 2/0.1 30.6 (3.7 to 110.7) 1.2 (0.3 to 5.1) 5.6 (-2.4 to 13.6) 1.3 (0.3 to 5.9) 
Slovenia 5/0.5 10.9 (3.6 to 25.5) 0.7 (0.2 to 2.0) 1.8 (0.1 to 3.6) 0.7 (0.2 to 2.2) 
Switzerland 9/0.6 14.5 (6.6 to 27.5) 0.5 (0.2 to 1.1) 1.8 (0.5 to 3.1) 0.5 (0.2 to 1.1) 
UK 107/5.8 18.4 (15.1 to 22.3) 0.5 (0.4 to 0.8) 2.7 (2.2 to 3.3) 0.5 (0.4 to 0.8) 
Pheterogeneity  <0.001 <0.001 <0.001 0.003 
Age at 
Diagnosis 
0–4 years 142/5.9 24.2 (20.3 to 28.5) Ref 2.9 (2.4 to 3.4) Ref 
5–9 years 50/4.0 12.4 (9.2 to 16.3) 0.9 (0.6 to 1.3) 1.8 (1.3 to 2.3) 0.9 (0.6 to 1.3) 
10–14 years 73/5.2 14.1 (11.0 to 17.7) 1.1 (0.7 to 1.6) 2.7 (2.0 to 3.4) 1.1 (0.7 to 1.7) 
15–19years 36/4.1 8.9 (6.2 to 12.3) 0.9 (0.5 to 1.5) 2.1 (1.3 to 2.8) 0.8 (0.5 to 1.5) 
Ptrend  <0.001 0.951 0.150 0.937 
Type of first 
Childhood 
Cancer 
Leukaemia 19/2.8 6.8 (4.1 to 10.6) Ref 0.7 (0.3 to 1.1) Ref 
Hodgkin Lymphoma 33/1.7 19.0 (13.1 to 26.7) 3.2 (1.8 to 5.8) 3.6 (2.3 to 4.9) 3.5 (1.8 to 6.8) 
Non-Hodgkin Lymphoma 8/1.0 8.1 (3.5 to 16.0) 1.3 (0.6 to 3.0) 1.3 (0.3 to 2.3) 1.3 (0.5 to 3.4) 
Central Nervous System 42/4.0 10.4 (7.5 to 14.0) 1.7 (1.0 to 3.0) 1.7 (1.1 to 2.2) 1.8 (1.0 to 3.4) 
Neuroblastoma 17/0.7 24.5 (14.3 to 39.2) 3.0 (1.5 to 5.8) 3.0 (1.5 to 4.4) 3.2 (1.5 to 6.7) 
Retinoblastoma 64/0.9 72.8 (56.1 to 93.0) 10.9 (6.3 to 19.0) 10.5 (7.9 to 13.1) 12.2 (6.6 to 22.7) 
Wilms Tumour 34/1.3 25.5 (17.6 to 35.6) 3.2 (1.8 to 5.7) 3.4 (2.2 to 4.6) 3.5 (1.8 to 6.7) 
Bone Sarcoma 23/1.1 21.1 (13.4 to 31.6) 3.3 (1.8 to 6.4) 4.2 (2.4 to 6.0) 3.7 (1.8 to 7.5) 
STS 26/1.5 17.1 (11.2 to 25.1) 2.6 (1.4 to 4.8) 3.0 (1.8 to 4.2) 2.9 (1.5 to 5.7) 
Other 34/3.8 9.0 (6.2 to 12.5) 1.6 (0.9 to 2.9) 1.7 (1.0 to 2.3) 1.7 (0.9 to 3.3) 
Not classifiable† 1/0.3 3.7 (0.1 to 20.8) - 0.6 (-1.0 to 2.3) - 
Pheterogeneity  <0.001 <0.001 <0.001 <0.001 
Decade of 
Diagnosis 
<1970 114/6.9 16.6 (13.7 to 19.9) 1.2 (0.9 to 1.6) 3.7 (3.0 to 4.5) 1.1 (0.8 to 1.5) 
1970-1979 84/5.4 15.4 (12.3 to 19.1) Ref 2.5 (1.9 to 3.1) Ref 
1980-1989 67/4.7 14.1 (11.0 to 18.0) 0.9 (0.7 to 1.3) 1.8 (1.4 to 2.3) 1.0 (0.7 to 1.4) 
>=1990 36/2.1 17.2 (12.1 to 23.9) 1.3 (0.8 to 2.0) 1.8 (1.2 to 2.4) 1.4 (0.8 to 2.2) 
Ptrend  0.632 0.699 <0.001 0.842 
Attained Age 0–19 years 69/3.2 21.2 (16.5 to 26.9) Ref 1.6 (1.2 to 2.0) Ref 
20–29 years 95/5.6 16.9 (13.6 to 20.6) 0.8 (0.6 to 1.2) 2.3 (1.8 to 2.8) 1.6 (1.1 to 2.2) 
30–39 years 83/5.3 15.8 (12.6 to 19.6) 0.7 (0.5 to 1.1) 3.6 (2.8 to 4.5) 2.5 (1.7 to 3.6) 
40+ years 54/5.0 10.8 (8.1 to 14.0) 0.5 (0.3 to 0.8) 4.3 (3.0 to 5.5) 2.9 (1.8 to 4.5) 
Ptrend  <0.001 0.002 <0.001 <0.001 
Years from 
Diagnosis 
 
5–14 years 108/5.7 18.8 (15.4 to 22.7) Ref 1.8 (1.4 to 2.2) Ref 
15–24 years 82/5.8 14.2 (11.3 to 17.6) 0.7 (0.5 to 0.9) 2.3 (1.7 to 2.8) 1.2 (0.9 to 1.6) 
25–34 years 58/4.5 13.0 (9.8 to 16.7) 0.5 (0.4 to 0.7) 3.4 (2.4 to 4.3) 1.6 (1.1 to 2.3) 
35–44 years 41/2.3 17.5 (12.6 to 23.8) 0.6 (0.4 to 0.9) 7.1 (4.8 to 9.4) 3.1 (2.0 to 4.8) 
45+ years 12/0.8 15.0 (7.8 to 26.2) 0.5 (0.2 to 0.9) 9.1 (3.6 to 14.6) 3.7 (1.9 to 7.2) 
Ptrend  0.298 0.001 <0.001 <0.001 
Abbreviations: O– observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER- absolute excess risk, 95%CI- 95% 
confidence interval, PB- population based, HB- hospital based, RR- relative risk, RER- relative excess risk, ref- reference category 
†Childhood cancer survivors diagnosed in Slovenia before 1983 – excluded from multivariable analysis 
* Model containing years from diagnosis was adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Model containing attained age was adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Not classifiable tumours were excluded from multivariable analysis.
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Figure 5.3: Cumulative incidence of all and selected histological types of subsequent primary STS in 5-year survivors of childhood cancer, by years from 
diagnosis. 
Abbreviations: HL- Hodgkin lymphoma; CNS- central nervous system; Rb-retinoblastoma; STS- soft tissue sarcoma; MPNST– malignant peripheral nerve sheath tumours
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Table 5.5: Risk of subsequent primary leiomyosarcoma among 69,460 5-year survivors of childhood 
cancer, by potential explanatory factors 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95%CI)* 
Overall All combined 80/2.7 29.9 (23.7 to 37.2)  0.7 (0.5 to 0.8)  
Sex Male 32/0.9 36.6 (25.0 to 51.7) Ref 0.5 (0.3 to 0.7) Ref 
Female 48/1.8 26.6 (19.6 to 35.3) 0.9 (0.6–1.5) 0.9 (0.6 to 1.1) 1.7 (1.1–2.7) 
Pheterogeneity  0.159 0.762 0.021 0.029 
Country France  17/0.2 84.0 (48.9 to 134.5) Ref 2.0 (1.0 to 3.0) Ref 
Hungary 1/0.0 21.7 (0.5 to 120.7) 0.3 (0.0 to 2.4) 0.2 (-0.2 to 0.6) 0.3 (0.0 to 2.2) 
Italy1 1/0.1 8.0 (0.2 to 44.4) 0.1 (0.0 to 1.1) 0.1 (-0.1 to 0.3) 0.1 (0.0 to 1.3) 
Netherlands 4/0.1 27.5 (7.5 to 70.3) 0.5 (0.2 to 1.5) 0.4 (-0.0 to 0.8) 0.5 (0.1 to 1.5) 
Nordic Countries2 13/1.3 10.3 (5.5 to 17.7) 0.2 (0.1 to 0.5) 0.3 (0.1 to 0.5) 0.2 (0.1 to 0.5) 
Slovenia 0/0.1 - - - - 
Switzerland 0/0.1 - - - - 
UK 44/0.8 56.0 (40.7 to 75.1) 0.5 (0.3 to 1.0) 1.2 (0.8 to 1.5) 0.5 (0.3 to 1.0) 
Pheterogeneity  <0.001 0.002 <0.001 0.002 
Age at 
Diagnosis 
0–4 years 57/0.6 98.3 (74.4 to 127.4) Ref 1.2 (0.9 to 1.5) Ref 
5–9 years 10/0.5 20.7 (9.9 to 38.1) 0.6 (0.3 to 1.3) 0.4 (0.1 to 0.6) 0.6 (0.3 to 1.5) 
10–19 years 13/1.6 8.0 (4.3 to 13.8) 0.3 (0.1 to 0.8) 0.3 (0.1 to 0.5) 0.4 (0.1 to 1.0) 
Ptrend  <0.001 0.011 <0.001 0.042 
Type of 
Childhood 
Cancer 
Leukaemia 2/0.2 8.2 (1.0 to 29.5) Ref 0.1 (-0.0 to 0.2) Ref 
Hodgkin Lymphoma 4/0.2 17.2 (4.7 to 44.0) 4.0 (0.7 to 23.3) 0.4 (-0.0 to 0.9) 4.1 (0.6 to 26.2) 
Non-Hodgkin Lymphoma 1/0.1 8.2 (0.2 to 45.7) 1.4 (0.1 to 16.2) 0.2 (-0.2 to 0.5) 1.3 (0.1 to 20.6) 
Central Nervous System 1/0.6 1.7 (0.0 to 9.4) 0.3 (0.0 to 3.7) 0.0 (-0.1 to 0.1) 0.2 (0.0 to 11.7) 
Neuroblastoma 2/0.1 28.8 (3.5 to 103.9) 2.0 (0.3 to 15.0) 0.3 (-0.2 to 0.9) 1.8 (0.2 to 14.7) 
Retinoblastoma 40/0.1 342.9 (245.0 to 466.9) 30.2 (6.8 to 134.9) 6.6 (4.6 to 8.7) 31.2 (6.6 to 146.9) 
Wilms Tumour 11/0.1 74.2 (37.1 to 132.8) 5.3 (1.1 to 25.4) 1.1 (0.5 to 1.8) 5.3 (1.0 to 26.7) 
Bone Sarcoma 5/0.2 28.9 (9.4 to 67.4) 6.6 (1.2 to 36.8) 0.9 (0.1 to 1.8) 6.8 (1.1 to 40.9) 
STS 6/0.2 26.4 (9.7 to 57.4) 4.3 (0.8 to 22.4) 0.7 (0.1 to 1.3) 4.4 (0.8 to 24.1) 
Other 8/0.7 11.3 (4.9 to 22.4) 3.2 (0.6 to 16.3) 0.4 (0.1 to 0.7) 3.3 (0.6 to 17.9) 
Not classifiable† 0/0.0 - - - - 
Pheterogeneity  <0.001 <0.001 <0.001 <0.001 
Decade of 
Diagnosis 
<1970 48/1.4 33.3 (24.6 to 44.2) 1.0 (0.5 to 2.0) 1.6 (1.1 to 2.1) 1.1 (0.6 to 2.1) 
1970–1979 17/0.7 25.0 (14.6 to 40.0) Ref 0.5 (0.3 to 0.8) Ref 
>=1980 15/0.6 26.8 (15.0 to 44.3) 1.8 (0.9 to 3.8) 0.3 (0.1 to 0.4) 1.5 (0.7 to 3.3) 
Ptrend  0.347 0.235 <0.001 0.502 
Attained 
Age 
0–29 years 22/0.6 35.4 (22.2 to 53.7) Ref 0.3 (0.2 to 0.4) Ref 
30–39 years 26/0.7 37.0 (24.2 to 54.3) 1.1 (0.6 to 2.1) 1.2 (0.7 to 1.6) 5.4 (2.9 to 10.1) 
40+ years 32/1.4 23.6 (16.1 to 33.3) 0.9 (0.4 to 1.9) 2.7 (1.7 to 3.7) 12.5 (6.3 to 25.0) 
Ptrend  0.128 0.765 <0.001 <0.001 
Years from 
Diagnosis 
5–24 years 18/1.0 17.5 (10.4 to 27.6) Ref 0.2 (0.1 to 0.3) Ref 
25–34 years 28/0.8 33.7 (22.4 to 48.6) 1.9 (0.9 to 3.7) 1.7 (1.1 to 2.4) 8.0 (4.0 to 16.1) 
35–44 years 23/0.6 38.3 (24.3 to 57.5) 1.7 (0.7 to 3.8) 4.1 (2.4 to 5.8) 17.0 (7.5 to 38.6) 
45+ years 11/0.2 50.7 (25.3 to 90.7) 1.3 (0.5 to 3.3) 8.7 (3.5 to 14.0) 28.2 (11.0 to 72.1) 
Ptrend  0.001 0.520 <0.001 <0.001 
Abbreviations: O– observed number of leiomyosarcoma, E – expected number of leiomyosarcoma, SIR- standardised 
incidence ratio, AER- absolute excess risk, 95%CI- 95% confidence interval, PB- population based, HB- hospital based, RR- 
relative risk, RER- relative excess risk, ref- reference category 
1Due to small numbers all Italian cohorts were grouped 
2Due to small numbers all Nordic cohorts were grouped 
†Childhood cancer survivors diagnosed in Slovenia before 1983– excluded from multivariable analysis 
* Model containing years from diagnosis was adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and 
decade of childhood cancer diagnosis. Model containing attained age was adjusted for gender, country, age at diagnosis, 
childhood cancer diagnosis and decade of childhood cancer diagnosis. Not classifiable tumours were excluded from 
multivariable analysis.
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Table 5.6: Location of STS with regards to radiotherapy field (inside/outside) for original childhood 
cancer. 
LEIOMYOSARCOMA 
Childhood Cancer Inside RT Field Outside RT Field$ Unknown 
Leukaemia 1 (50%) 1 (50%) 0 
Hodgkin Lymphoma 2 (100%) 0 2 
Non-Hodgkin Lymphoma 0 0 1 
Central Nervous System 0 1 (100%) 0 
Neuroblastoma 2 (100%) 0 0 
Retinoblastoma 9 (23%)* 30 (77%)# 1 
Wilms tumour 10 (91%) 1 (9%) 0 
Bone tumour 1 (20%) 4 (80%) 0 
Soft-tissue sarcoma 3 (50%) 3 (50%) 0 
Other 5 (71%) 2 (29%) 1 
Total 33 (44%) 42 (56%) 5 
FIBROMATOUS NEOPLASMS 
Childhood Cancer Inside RT Field Outside RT Field Unknown 
Leukaemia 2 (67%) 1 (33%) 0 
Hodgkin Lymphoma 4 (57%) 3 (43%) 3 
Non-Hodgkin Lymphoma 0 1 (100%) 0 
Central Nervous System 3 (38%) 5 (63%) 0 
Neuroblastoma 1 (100%) 0 0 
Retinoblastoma 5 (83%) 1 (17%) 0 
Wilms tumour 4 (100%) 0 0 
Bone tumour 4 (57%) 3 (43%) 2 
Soft-tissue sarcoma 4 (67%) 2 (33%) 2 
Other 1 (50%) 1 (50%) 3 
Total 28 (62%) 17 (38%) 10 
MALIGNANT PERIPHERAL NERVE SHEATH TUMOURS 
Childhood Cancer Inside RT Field Outside RT Field Unknown 
Leukaemia 1 (33%) 2 (67%) 0 
Hodgkin Lymphoma 6 (86%) 1 (14%) 1 
Non-Hodgkin Lymphoma 1 (50%) 1 (50%) 0 
Central Nervous System 6 (38%) 10 (63%) 3 
Neuroblastoma 2 (100%) 0 0 
Retinoblastoma 0 0 0 
Wilms tumour 5 (83%) 1 (17%) 0 
Bone tumour 0 0 0 
Soft-tissue sarcoma 3 (100%) 0 0 
Other 2 (100%) 0 0 
Total 26 (63%) 15 (37%) 4 
Percentages calculated for those that have information on whether STS is located within the field or not. 
$ Includes those not receiving radiotherapy for the original childhood cancer 
* 8 (89%) of these 9 retinoblastomas were heritable 
# 26 (87%) of these 30 retinoblastomas were heritable.
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Table 5.7: Risk of subsequent primary fibromatous neoplasms among 69,460 5-year survivors of 
childhood cancer survivors, by potential explanatory factors 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI)* 
Overall All combined 55/4.5 12.3 (9.3 to 16.0)  0.4 (0.3 to 0.6)  
Sex Male 36/2.3 15.7 (11.0 to 21.8) Ref 0.6 (0.4 to 0.8) Ref 
Female 19/2.2 8.7 (5.2 to 13.6) 0.6 (0.3–1.0) 0.3 (0.2 to 0.5) 0.6 (0.3–1.2) 
Pheterogeneity  
0.034 0.056 0.079 0.138 
Country France  12/0.3 43.0 (22.2 to 75.2) Ref 1.4 (0.6 to 2.2) Ref 
Hungary 2/0.1 16.7 (2.0 to 60.5) 0.3 (0.1 to 1.4) 0.4 (-0.2 to 0.9) 0.3 (0.1 to 1.5) 
Italy1  3/0.3 11.2 (2.3 to 32.9) 0.2 (0.1 to 0.8) 0.3 (-0.1 to 0.7) 0.2 (0.0 to 0.9) 
Netherlands 5/0.3 16.9 (5.5 to 39.4) 0.4 (0.1 to 1.1) 0.5 (0.0 to 0.9) 0.4 (0.1 to 1.2) 
Nordic Countries2 19/2.2 8.6 (5.2 to 13.5) 0.2 (0.1 to 0.4) 0.5 (0.2 to 0.7) 0.3 (0.1 to 0.7) 
Slovenia 1/0.1 11.5 (0.3 to 64.0) 0.5 (0.1 to 4.3) 0.4 (-0.4 to 1.2) 0.4 (0.0 to 6.8) 
Switzerland 1/0.1 8.5 (0.2 to 47.3) 0.2 (0.0 to 1.3) 0.2 (-0.2 to 0.6) 0.1 (0.0 to 1.7) 
UK  12/1.1 10.8 (5.6 to 18.9) 0.2 (0.1 to 0.5) 0.3 (0.1 to 0.5) 0.2 (0.1 to 0.5) 
Pheterogeneity  
0.001 0.016 0.047 0.065 
Age at 
Diagnosis 
0–4 years 16/1.2 12.9 (7.3 to 20.9) Ref 0.3 (0.1 to 0.5) Ref 
5–9 years 13/0.9 14.6 (7.8 to 25.0) 1.6 (0.7 to 3.8) 0.5 (0.2 to 0.8) 2.0 (0.8 to 5.1) 
10–14 years 15/1.2 12.6 (7.0 to 20.7) 1.8 (0.7 to 4.5) 0.5 (0.2 to 0.9) 2.3 (0.8 to 6.6) 
15–19years 11/1.1 9.6 (4.8 to 17.1) 2.4 (0.8 to 7.1) 0.6 (0.2 to 1.1) 3.1 (0.9 to 11.3) 
Ptrend  
0.437 0.199 0.067 0.09 
Type of 
Childhood 
Cancer 
Leukaemia 3/0.6 5.0 (1.0 to 14.5) Ref 0.1 (-0.0 to 0.3) Ref 
Hodgkin Lymphoma 10/0.4 24.2 (11.6 to 44.4) 5.1 (1.3 to 20.0) 1.1 (0.4 to 1.8) 7.0 (1.1 to 43.3) 
Non-Hodgkin Lymphoma 1/0.2 4.5 (0.1 to 25.2) 0.9 (0.1 to 8.7) 0.1 (-0.2 to 0.5) 1.2 (0.1 to 17.9) 
Central Nervous System 8/1.0 8.2 (3.5 to 16.2) 1.9 (0.5 to 7.3) 0.3 (0.1 to 0.6) 2.3 (0.3 to 14.7) 
Neuroblastoma 1/0.1 7.1 (0.2 to 39.3) 1.1 (0.1 to 11.1) 0.2 (-0.2 to 0.5) 1.5 (0.1 to 21.7) 
Retinoblastoma 6/0.2 31.0 (11.4 to 67.5) 8.0 (1.8 to 35.3) 1.0 (0.2 to 1.8) 11.5 (1.6 to 83.9) 
Wilms Tumour 4/0.3 14.2 (3.9 to 36.4) 2.3 (0.5 to 10.9) 0.4 (-0.0 to 0.8) 3.2 (0.4 to 24.2) 
Bone Sarcoma 9/0.3 34.5 (15.8 to 65.5) 6.9 (1.7 to 27.6) 1.7 (0.6 to 2.8) 9.6 (1.5 to 61.0) 
STS 8/0.4 22.6 (9.8 to 44.5) 4.5 (1.2 to 17.9) 0.9 (0.3 to 1.6) 6.4 (1.0 to 41.1) 
Other 5/1.0 5.1 (1.7 to 11.9) 1.3 (0.3 to 5.6) 0.2 (-0.0 to 0.5) 1.4 (0.2 to 11.1) 
Not classifiable† 0/0.0 - - - - 
Pheterogeneity  
<0.001 0.001 <0.001 0.001 
Decade of 
Diagnosis 
<1970 19/1.7 11.3 (6.8 to 17.7) 1.4 (0.7 to 2.8) 0.6 (0.3 to 0.9) 1.2 (0.6 to 2.5) 
1970–1979 16/1.3 12.5 (7.2 to 20.4) Ref 0.5 (0.2 to 0.7) Ref 
1980–1989 11/1.1 10.2 (5.1 to 18.3) 0.7 (0.3 to 1.6) 0.3 (0.1 to 0.5) 0.6 (0.3 to 1.5) 
>=1990 9/0.4 20.3 (9.3 to 38.5) 1.3 (0.5 to 3.4) 0.5 (0.1 to 0.8) 1.1 (0.4 to 3.2) 
Ptrend  
0.397 0.314 0.184 0.387 
Attained Age 0–19 years 18/0.5 33.5 (19.9 to 53.0) Ref 0.4 (0.2 to 0.6) Ref 
20–29 years 18/1.5 11.8 (7.0 to 18.6) 0.2 (0.1 to 0.5) 0.4 (0.2 to 0.6) 0.6 (0.3 to 1.4) 
30+ years 19/2.4 7.9 (4.8 to 12.3) 0.1 (0.1 to 0.3) 0.5 (0.2 to 0.8) 0.5 (0.2 to 1.3) 
Ptrend  
<0.001 <0.001 0.655 0.169 
Years from 
Diagnosis 
  
5–14 years 26/1.3 19.7 (12.9 to 28.9) Ref 0.4 (0.3 to 0.6) Ref 
15–24 years 19/1.5 12.8 (7.7 to 19.9) 0.5 (0.3 to 1.0) 0.5 (0.3 to 0.8) 1.1 (0.5 to 2.1) 
25+ years 10/1.7 6.0 (2.9 to 11.0) 0.2 (0.1 to 0.4) 0.4 (0.1 to 0.6) 0.5 (0.2 to 1.4) 
Ptrend  
0.001 <0.001 0.879 0.11 
Abbreviations: O– observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER- absolute excess risk, 
95%CI- 95% confidence interval, RR – relative risk, RER – relative excess risk, ref – reference category 
1Due to small numbers all Italian cohorts were grouped 
2Due to small numbers all Nordic cohorts were grouped 
3Due to small numbers bone sarcomas and STS were grouped 
†Childhood cancer survivors diagnosed in Slovenia before 1983 – excluded from multivariable analysis 
* Model containing follow-up is adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Model containing attained age is adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of 
childhood cancer diagnosis. Not classifiable tumours were excluded from multivariable analysis. 
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Table 5.8: Risk of subsequent primary malignant peripheral nerve sheath tumours among 69,460 5-
year survivors of childhood cancer survivors, by potential explanatory factors 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI)* 
Overall All combined 45/1.1 40.6 (29.6 to 54.3)  0.4 (0.3 to 0.5)  
Sex Male 26/0.6 42.1 (27.5 to 61.8) Ref 0.4 (0.3 to 0.6) Ref 
Female 19/0.5 38.6 (23.2 to 60.3) 1.0 (0.5–1.8) 0.4 (0.2 to 0.5) 0.9 (0.5–1.6) 
Pheterogeneity  
0.77 0.995 0.56 0.686 
Country France  6/0.1 93.1 (34.2 to 202.7) Ref 0.7 (0.1 to 1.3) Ref 
Hungary 2/0.0 50.2 (6.1 to 181.5) 0.5 (0.1 to 2.7) 0.4 (-0.2 to 0.9) 0.5 (0.1 to 3.0) 
Italy1  3/0.1 37.6 (7.8 to 109.8) 0.4 (0.1 to 1.9) 0.3 (-0.1 to 0.7) 0.5 (0.1 to 2.1) 
Netherlands 3/0.1 35.1 (7.2 to 102.7) 0.4 (0.1 to 1.8) 0.3 (-0.0 to 0.6) 0.5 (0.1 to 2.0) 
Nordic Countries2 14/0.5 29.3 (16.0 to 49.2) 0.3 (0.1 to 0.9) 0.4 (0.2 to 0.6) 0.5 (0.2 to 1.6) 
Slovenia 0/0.0 - - - - 
Switzerland 3/0.0 78.9 (16.3 to 230.7) 0.9 (0.2 to 4.0) 0.6 (-0.1 to 1.4) 1.0 (0.2 to 4.6) 
UK  14/0.3 46.3 (25.3 to 77.7) 0.5 (0.2 to 1.3) 0.4 (0.2 to 0.6) 0.5 (0.2 to 1.5) 
Pheterogeneity  
0.328 0.526 0.796 0.828 
Age at 
Diagnosis 
0–4 years 19/0.4 51.1 (30.7 to 79.8) Ref 0.4 (0.2 to 0.6) Ref 
5–9 years 4/0.2 16.2 (4.4 to 41.4) 0.2 (0.1 to 0.7) 0.1 (-0.0 to 0.3) 0.2 (0.1 to 0.8) 
10–14 years 15/0.3 54.1 (30.3 to 89.2) 0.8 (0.3 to 1.8) 0.6 (0.3 to 0.9) 0.8 (0.3 to 1.9) 
15–19years 7/0.2 33.0 (13.3 to 67.9) 0.7 (0.2 to 2.3) 0.4 (0.1 to 0.8) 0.7 (0.2 to 2.3) 
Ptrend  
0.657 0.724 0.411 0.853 
Childhood 
Cancer 
Leukaemia 3/0.2 15.4 (3.2 to 45.0) Ref 0.1 (-0.0 to 0.3) Ref 
Hodgkin Lymphoma 8/0.1 81.3 (35.1 to 160.1) 6.1 (1.5 to 25.1) 0.9 (0.3 to 1.5) 6.6 (1.4 to 29.9) 
Non-Hodgkin Lymphoma 2/0.1 35.7 (4.3 to 128.8) 2.7 (0.4 to 16.6) 0.4 (-0.2 to 0.9) 2.9 (0.4 to 19.7) 
Central Nervous System 19/0.2 80.5 (48.4 to 125.7) 6.4 (1.8 to 22.6) 0.8 (0.4 to 1.2) 6.9 (1.7 to 27.3) 
Neuroblastoma 2/0.0 48.2 (5.8 to 174.3) 2.1 (0.3 to 13.1) 0.4 (-0.1 to 0.9) 2.1 (0.3 to 14.6) 
Retinoblastoma 0/0.1 - - - - 
Wilms Tumour 6/0.1 76.0 (27.9 to 165.4) 3.8 (0.9 to 16.1) 0.6 (0.1 to 1.1) 4.0 (0.9 to 18.9) 
Bone Sarcoma 
3/0.13 21.6 (4.5 to 63.1) 1.5 (0.3 to 7.7)3 0.2 (-0.0 to 0.5) 1.6 (0.3 to 9.0)3 
STS 
Other 2/0.2 9.8 (1.2 to 35.5) 0.7 (0.1 to 4.6) 0.1 (-0.1 to 0.3) 0.7 (0.1 to 5.3) 
Not classifiable† 0/0.0 - - - - 
Pheterogeneity  
0.001 <0.001 <0.001 <0.001 
Decade of 
Diagnosis 
<1970 11/0.3 35.9 (17.9 to 64.3) 0.9 (0.4 to 2.2) 0.4 (0.1 to 0.6) 0.9 (0.4 to 2.1) 
1970–1979 12/0.3 39.4 (20.4 to 68.9) Ref 0.4 (0.2 to 0.6) Ref 
1980–1989 16/0.3 48.9 (27.9 to 79.4) 1.4 (0.6 to 3.0) 0.5 (0.2 to 0.7) 1.4 (0.7 to 3.2) 
>=1990 6/0.2 35.1 (12.9 to 76.4) 1.0 (0.3 to 3.1) 0.3 (0.1 to 0.6) 1.1 (0.4 to 3.5) 
Ptrend  
0.761 0.624 0.966 0.381 
Attained Age 0–19 years 11/0.2 44.6 (22.3 to 79.9) Ref 0.3 (0.1 to 0.4) Ref 
20–29 years 18/0.5 37.6 (22.3 to 59.4) 0.8 (0.4 to 1.8) 0.5 (0.2 to 0.7) 1.7 (0.7 to 3.9) 
30+ years 16/0.4 41.7 (23.9 to 67.8) 1.0 (0.4 to 2.6) 0.5 (0.2 to 0.7) 1.9 (0.7 to 5.0) 
Ptrend  
0.956 0.877 0.141 0.187 
Years from 
Diagnosis 
  
5–14 years 17/0.5 36.8 (21.4 to 58.8) Ref 0.3 (0.1 to 0.4) Ref 
15–24 years 21/0.4 56.7 (35.1 to 86.7) 1.5 (0.7 to 3.0) 0.6 (0.3 to 0.9) 2.2 (1.1 to 4.3) 
25+ years 7/0.3 25.3 (10.2 to 52.2) 0.6 (0.2 to 1.8) 0.3 (0.1 to 0.5) 1.1 (0.4 to 3.0) 
Ptrend  
0.597 0.563 0.564 0.491 
Abbreviations: O– observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER- absolute excess risk, 
95%CI- 95% confidence interval, RR – relative risk, RER – relative excess risk, ref – reference category 
1Due to small numbers all Italian cohorts were grouped 
2Due to small numbers all Nordic cohorts were grouped 
3Due to small numbers bone sarcomas and STS were grouped 
†Childhood cancer survivors diagnosed in Slovenia before 1983– excluded from multivariable analysis 
* Model containing follow-up is adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Model containing attained age is adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of 
childhood cancer diagnosis. Not classifiable tumours were excluded from multivariable analysis. 
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Table 5.9: Location of malignant peripheral nerve sheath tumours with regards to radiotherapy field 
(inside/outside) for original childhood cancer stratified by Neurofibromatosis status. 
NEUROFIBROMATOSIS PRESENT 
Childhood Cancer Inside RT Field Outside RT Field$ Unknown 
Leukaemia 0 0 0 
Hodgkin Lymphoma 2 (100%) 0 0 
Non-Hodgkin Lymphoma 0 0 0 
Central Nervous System 5 (45%) 6 (55%) 2 
Neuroblastoma 0 0 0 
Retinoblastoma 0 0 0 
Wilms tumour 2 (67%) 1 (33%) 0 
Bone tumour 0 0 0 
Soft-tissue sarcoma 2 (100%) 0 0 
Other 1 (100%) 0 0 
Total 12 (63%) 7 (37%) 2 
NEUROFIBROMATOSIS ABSENT 
Childhood Cancer Inside RT Field Outside RT Field Unknown 
Leukaemia 1 (33%) 2 (67%) 0 
Hodgkin Lymphoma 4* (80%) 1 (20%) 1# 
Non-Hodgkin Lymphoma 1 (50%) 1 (50%) 0 
Central Nervous System 1 (20%) 4 (80%) 1 
Neuroblastoma 2 (100%) 0 0 
Retinoblastoma 0 0 0 
Wilms tumour 3 (100%) 0 0 
Bone tumour 0 0 0 
Soft-tissue sarcoma 1 (100%) 0 0 
Other 1 (100%) 0 0 
Total 14 (64%) 8 (36%) 2 
* 1 has other genetic condition 
$ Includes those not receiving radiotherapy for the original childhood cancer. 
#Unknown whether neurofibromatosis present
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Table 5.10: Risk of all subsequent primary STS among 2,578 5-year survivors of retinoblastoma, by 
potential explanatory factors 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI) 
Overall All combined 64/0.9 72.8 (56.1 to 93.0)  10.5 (7.9 to 13.1)  
Sex Male 31/0.5 64.1 (43.5 to 90.9) Ref 9.7 (6.2 to 13.2) Ref 
Female 33/0.4 83.5 (57.5 to 117.3) 1.3 (0.8 to 2.2) 11.3 (7.4 to 15.2) 1.2 (0.7 to 2.0) 
Pheterogeneity  
0.288 0.255 0.555 0.496 
Country France  7/0.1 133.3 (53.6 to 274.7) Ref 18.9 (4.8 to 33.0) Ref 
Hungary 2/0.0 137.7 (16.7 to 497.2) 1.4 (0.3 to 6.8) 13.1 (-5.2 to 31.3) 1.3 (0.3 to 6.4) 
Italy1  0/0.0 - - - - 
Netherlands 3/0.0 391.9 (80.8 to 1145.2) 3.4 (0.9 to 13.4) 46.4 (-6.2 to 99.0) 3.5 (0.9 to 13.7) 
Nordic Countries2 11/0.3 42.0 (21.0 to 75.2) 0.3 (0.1 to 0.7) 6.4 (2.5 to 10.3) 0.3 (0.1 to 0.7) 
Slovenia 0/0.0 - - - - 
Switzerland 0/0.0 - - - - 
UK 41/0.5 82.4 (59.1 to 111.8) 0.5 (0.2 to 1.2) 12.1 (8.3 to 15.8) 0.5 (0.2 to 1.1) 
Pheterogeneity  
0.003 0.005 0.009 0.007 
Decade of 
Diagnosis 
<1970 45/0.5 82.2 (59.9 to 110.0) Ref 14.7 (10.4 to 19.1) Ref 
 ≥1970 19/0.3 57.3 (34.5 to 89.5) 0.8 (0.4 to 1.5) 6.2 (3.4 to 9.1) 0.8 (0.4 to 1.6) 
 Ptrend  
0.186 0.446 0.001 0.558 
Attained 
Age 
0–29 years 21/0.4 49.2 (30.4 to 75.2) Ref 4.5 (2.6 to 6.5) Ref 
30–39 years 21/0.2 90.3 (55.9 to 138.1) 1.7 (0.9 to 3.3) 21.7 (12.3 to 31.1) 4.7 (2.4 to 9.0) 
40+ years 22/0.2 100.2 (62.8 to 151.8) 1.8 (0.9 to 3.8) 40.8 (23.6 to 58.0) 8.7 (4.3 to 17.7) 
Ptrend  
0.011 0.074 <0.001 <0.001 
Years from 
Diagnosis 
  
5–24 years 18/0.4 50.1 (29.7 to 79.1) Ref 4.3 (2.3 to 6.3) Ref 
25–34 years 18/0.2 75.2 (44.6 to 118.8) 1.4 (0.7 to 2.7) 15.5 (8.2 to 22.7) 3.5 (1.8 to 6.9) 
35–44 years 17/0.2 93.1 (54.2 to 149.0) 1.6 (0.8 to 3.6) 30.1 (15.6 to 44.5) 6.8 (3.2 to 14.8) 
45+ years 11/0.1 113.1 (56.5 to 202.5) 1.9 (0.8 to 4.5) 57.7 (23.3 to 92.1) 12.7 (5.3 to 30.0) 
Ptrend   0.016 0.119 <0.001 <0.001 
Abbreviations: O – observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER – absolute excess risk, 
RR- relative risk, RER- relative excess risk, 95%CI- 95% confidence interval, ref- reference category 
¹Due to small numbers all Italian cohorts were grouped 
2Due to small numbers all Nordic cohorts were grouped 
* Model containing follow-up is adjusted for gender, country, childhood cancer and Decade of childhood cancer diagnosis. Model containing 
attained age is adjusted for gender, country, childhood cancer diagnosis and Decade of childhood cancer diagnosis. Not classifiable tumours 
were excluded from multivariable analysis.  
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Table 5.11: Risk of all subsequent primary leiomyosarcoma among 2,578 5-year survivors of 
retinoblastoma, by potential explanatory factors 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI) 
Overall All combined 40/0.1 342.9 (245.0 to 466.9)  6.6 (4.6 to 8.7)  
Sex Male 17/0.0 429.4 (250.1 to 687.4) Ref 5.4 (2.8 to 8.0) Ref 
 Female 23/0.1 298.5 (189.2 to 447.9) 0.8 (0.4 to 1.5) 7.9 (4.7 to 11.2) 1.5 (0.8 to 2.8) 
 Pheterogeneity  
0.253 0.424 0.232 0.208 
Country France  5/0.0 1027.6 (333.7 to 2398.0) Ref 13.6 (1.7 to 25.5) Ref 
 Hungary 1/0.0 1233.0 (31.2 to 6869.8) 1.4 (0.2 to 12.9) 6.6 (-6.3 to 19.5) 1.2 (0.1 to 11.1) 
 Italy1  0/0.0 - - - - 
 Netherlands 0/0.0 - - - - 
 Nordic Countries2 5/0.0 143.2 (46.5 to 334.1) 0.1 (0.0 to 0.5) 3.0 (0.3 to 5.6) 0.2 (0.0 to 0.6) 
 Slovenia 0/0.0 - - - - 
 Switzerland 0/0.0 - - - - 
 UK 29/0.1 401.8 (269.1 to 577.1) 0.4 (0.1 to 1.1) 8.6 (5.5 to 11.8) 0.4 (0.2 to 1.2) 
 Pheterogeneity  
0.041 0.08 0.044 0.095 
Decade of 
Diagnosis 
<1970 31/0.1 334.8 (227.5 to 475.2) Ref 10.2 (6.6 to 13.8) Ref 
 ≥1970 9/0.0 374.2 (171.1 to 710.3) 1.1 (0.4 to 3.1) 3.0 (1.0 to 5.0) 1.0 (0.4 to 2.7) 
 Ptrend  
0.769 0.84 <0.001 0.948 
Attained Age 0–29 years 7/0.0 267.8 (107.7 to 551.7) Ref 1.5 (0.4 to 2.7) Ref 
 30–39 years 13/0.0 401.4 (213.7 to 686.5) 1.6 (0.6 to 4.5) 13.6 (6.2 to 21.0) 8.8 (3.3 to 23.5) 
 40+ years 20/0.1 344.1 (210.2 to 531.4) 1.5 (0.5 to 4.6) 37.3 (20.9 to 53.7) 25.5 (9.1 to 71.2) 
 Ptrend  
0.599 0.465 <0.001 <0.001 
Years from 
Diagnosis 
  
5–24 years 6/0.0 298.7 (109.6 to 650.2) Ref 1.4 (0.3 to 2.6) Ref 
 25–34 years 11/0.0 380.9 (190.1 to 681.5) 1.3 (0.4 to 3.7) 9.5 (3.9 to 15.2) 6.3 (2.3 to 17.5) 
 35–44 years 13/0.0 332.1 (176.8 to 567.9) 1.2 (0.4 to 3.9) 23.2 (10.5 to 35.8) 15.9 (5.2 to 48.3) 
 45+ years 10/0.0 350.3 (168.0 to 644.3) 1.2 (0.4 to 4.1) 52.7 (20.0 to 85.5) 34.9 (10.8 to 112.8) 
 Ptrend  
0.858 0.827 <0.001 <0.001 
Abbreviations: O – observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER – absolute excess risk, 
RR- relative risk, RER- relative excess risk, 95%CI- 95% confidence interval, ref- reference category 
¹Due to small numbers all Italian cohorts were grouped 
2Due to small numbers all Nordic cohorts were grouped 
* Model containing follow-up is adjusted for gender, country, childhood cancer and Decade of childhood cancer diagnosis. Model containing 
attained age is adjusted for gender, country, childhood cancer diagnosis and Decade of childhood cancer diagnosis. Not classifiable tumours 
were excluded from multivariable analysis.
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Table 5.12: Risk of developing a subsequent primary STS among 69,460 5-year survivors of childhood cancer 
by potential explanatory factors (Excluding France). 
Factor Level O/E SIR (95% CI) RR (95% CI)* AER (95% CI) RER (95% CI)* 
Overall All combined 253/17.7 14.3 (12.6,16.2) 
 
2.3 (2.0,2.6) 
 
Sex Male 135/9.6 14.0 (11.8,16.6) 1.0 (1.0,1.0) 2.3 (1.8,2.7) 1.0 (1.0,1.0) 
Female 118/8.1 14.7 (12.1,17.5) 1.1 (0.9,1.5) 2.3 (1.8,2.7) 1.0 (0.8,1.3) 
Pheterogeneity  
0.7 0.358 0.965 0.984 
Country France  
 
- - - - 
Hungary 6/0.6 9.6 (3.5,20.9) 1.0 (1.0,1.0) 1.1 (0.1,2.0) 1.0 (1.0,1.0) 
Italy (PB) 12/1.0 11.8 (6.1,20.5) 1.3 (0.5,3.4) 1.6 (0.6,2.5) 1.3 (0.4,3.6) 
Italy (HB) 1/0.3 3.0 (0.1,16.6) 0.4 (0.0,3.1) 0.3 (-0.6,1.1) 0.3 (0.0,4.1) 
Netherlands 32/1.5 20.8 (14.2,29.4) 2.5 (1.0,6.1) 2.9 (1.9,4.0) 2.6 (1.0,6.7) 
Denmark 18/1.7 10.3 (6.1,16.3) 1.2 (0.5,3.1) 2.1 (1.0,3.1) 1.3 (0.5,3.6) 
Sweden 25/2.2 11.4 (7.4,16.8) 1.4 (0.5,3.5) 2.0 (1.1,2.8) 1.4 (0.5,3.9) 
Norway 9/1.0 9.0 (4.1,17.2) 1.1 (0.4,3.1) 1.5 (0.4,2.6) 1.1 (0.4,3.6) 
Finland 27/2.3 12.0 (7.9,17.4) 1.4 (0.6,3.6) 2.4 (1.4,3.3) 1.5 (0.6,4.1) 
Iceland 2/0.1 30.6 (3.7,110.7) 3.9 (0.8,19.9) 5.6 (-2.4,13.6) 4.4 (0.8,23.8) 
Slovenia 5/0.5 10.9 (3.6,25.5) 2.2 (0.6,8.0) 1.8 (0.1,3.6) 2.3 (0.6,8.9) 
Switzerland 9/0.6 14.5 (6.6,27.5) 1.7 (0.6,4.7) 1.8 (0.5,3.1) 1.5 (0.5,4.8) 
UK  107/5.8 18.4 (15.1,22.3) 1.7 (0.7,4.0) 2.7 (2.2,3.3) 1.7 (0.7,4.1) 
Pheterogeneity  
0.015 0.083 0.047 0.151 
Age at 
Diagnosis 
0-4 yrs 116/5.2 22.3 (18.5,26.8) 1.0 (1.0,1.0) 2.6 (2.1,3.1) 1.0 (1.0,1.0) 
5-9 yrs 40/3.7 10.9 (7.8,14.8) 0.9 (0.6,1.3) 1.5 (1.0,2.1) 0.9 (0.6,1.4) 
10-14 yrs 62/4.8 12.9 (9.9,16.5) 1.1 (0.7,1.7) 2.4 (1.8,3.1) 1.1 (0.7,1.8) 
15-19yrs 35/4.0 8.8 (6.1,12.2) 0.9 (0.5,1.6) 2.0 (1.3,2.8) 0.9 (0.5,1.6) 
Ptrend  
<0.001 0.971 0.318 0.953 
Type of 
Childhood 
Cancer 
Leukaemia 19/2.8 6.8 (4.1,10.6) 1.0 (1.0,1.0) 0.7 (0.3,1.1) 1.0 (1.0,1.0) 
Hodgkin Lymphoma 29/1.6 17.8 (11.9,25.6) 3.1 (1.6,5.6) 3.3 (2.0,4.6) 3.3 (1.7,6.6) 
Non-Hodgkin Lymphoma 6/0.9 6.5 (2.4,14.1) 1.0 (0.4,2.7) 1.0 (0.1,1.9) 1.0 (0.3,3.0) 
Central Nervous System 39/3.9 10.1 (7.2,13.8) 1.7 (1.0,3.0) 1.6 (1.0,2.2) 1.8 (0.9,3.4) 
Neuroblastoma 11/0.5 20.8 (10.4,37.3) 3.0 (1.4,6.4) 2.4 (0.9,3.9) 3.2 (1.4,7.4) 
Retinoblastoma 57/0.8 69.0 (52.2,89.4) 10.8 (6.1,19.1) 9.9 (7.3,12.6) 12.1 (6.4,23.0) 
Wilms Tumour 27/1.0 26.5 (17.4,38.5) 3.9 (2.1,7.1) 3.4 (2.1,4.7) 4.3 (2.2,8.4) 
Bone Sarcoma 18/1.0 18.7 (11.1,29.5) 3.1 (1.6,6.1) 3.7 (1.9,5.5) 3.4 (1.6,7.2) 
Soft-Tissue Sarcoma 18/1.3 13.5 (8.0,21.3) 2.2 (1.2,4.3) 2.3 (1.1,3.4) 2.4 (1.2,5.0) 
Other 28/3.5 8.0 (5.3,11.6) 1.5 (0.8,2.7) 1.5 (0.9,2.1) 1.5 (0.8,3.1) 
Not classifiable† 1/0.3 3.7 (0.1,20.8) 
 
0.6 (-1.0,2.3) 
 
Pheterogeneity  
<0.001 <0.001 <0.001 <0.001 
Decade of 
Diagnosis 
<1970 100/6.4 15.6 (12.7,19.0) 1.2 (0.8,1.7) 3.6 (2.8,4.3) 1.1 (0.8,1.6) 
1970-1979 63/4.8 13.1 (10.1,16.8) 1.0 (1.0,1.0) 2.1 (1.5,2.7) 1.0 (1.0,1.0) 
1980-1989 54/4.4 12.3 (9.3,16.1) 1.0 (0.7,1.4) 1.6 (1.1,2.0) 1.0 (0.7,1.5) 
>=1990 36/2.1 17.2 (12.1,23.9) 1.4 (0.9,2.2) 1.8 (1.2,2.4) 1.5 (0.9,2.4) 
Ptrend  
0.641 0.887 <0.001 0.756 
Attained Age 0-19 rs 58/3.1 19.0 (14.4,24.6) 1.0 (1.0,1.0) 1.4 (1.0,1.8) 1.0 (1.0,1.0) 
20-29 yrs 79/5.3 15.0 (11.9,18.7) 0.9 (0.6,1.2) 2.0 (1.6,2.5) 1.6 (1.1,2.4) 
30-39 yrs 69/4.8 14.5 (11.3,18.3) 0.8 (0.5,1.2) 3.3 (2.5,4.1) 2.7 (1.7,4.1) 
40+ yrs 47/4.6 10.2 (7.5,13.6) 0.6 (0.3,0.9) 4.1 (2.8,5.4) 3.3 (2.0,5.5) 
Ptrend  
0.003 0.026 <0.001 <0.001 
Years from 
Diagnosis 
  
5-14 yrs 96/5.5 17.4 (14.1,21.3) 1.0 (1.0,1.0) 1.7 (1.3,2.0) 1.0 (1.0,1.0) 
15-24 yrs 67/5.4 12.4 (9.6,15.8) 0.7 (0.5,0.9) 2.0 (1.5,2.5) 1.1 (0.8,1.6) 
25-34 yrs 43/4.0 10.8 (7.8,14.5) 0.5 (0.3,0.8) 2.8 (1.9,3.7) 1.5 (1.0,2.3) 
35-44 yrs 36/2.1 17.3 (12.1,24.0) 0.7 (0.4,1.1) 7.1 (4.7,9.6) 3.5 (2.1,5.7) 
45+yrs 11/0.7 15.5 (7.8,27.8) 0.5 (0.3,1.1) 9.6 (3.6,15.7) 4.3 (2.1,8.8) 
Ptrend  
0.447 0.013 <0.001 <0.001 
Abbreviations: O– observed number of STS, E – expected number of STS, SIR- standardised incidence ratio, AER- absolute excess risk, 95%CI- 95% 
confidence interval, PB- population based, HB- hospital based, RR- relative risk, RER- relative excess risk, ref- reference category 
†Childhood cancer survivors diagnosed in Slovenia before 1983– excluded from multivariable analysis 
* Model containing years from diagnosis was adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Model containing attained age was adjusted for gender, country, age at diagnosis, childhood cancer diagnosis and decade of childhood cancer 
diagnosis. Not classifiable tumours were excluded from multivariable analysis.
  
169 
 
Chapter 6 
Risk of malignant breast cancer among 31,722 female survivors of 
childhood cancer in Europe
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6.1 ABSTRACT 
Background: Female survivors of childhood cancer exposed to chest irradiation are at an 
increased risk of subsequent primary breast neoplasms (breast SPNs). Risk-based surveillance 
is recommended for young women after chest irradiation, until at least age 50. For women 
aged over 40 years, however, little empiric information on the magnitude of breast cancer risk 
is available. 
Methods: We calculated standardised incidence ratios (SIRs) and absolute excess risks 
(AERs) to quantify the risk of malignant breast cancer in a large, pan-European childhood 
cancer survivor population of 31,722 female survivors where 20% were aged over 40 years. 
Results: Overall, 411 breast SPNs were observed compared to 146 expected (SIR=2.8, 
CI=2.5-3.1). Highest SIRs were observed after Hodgkins lymphoma  (SIR=11.3, CI=9.4-
13.5), Wilms tumour (SIR=4.5, CI=3.2-6.2) and bone sarcoma (SIR=4.6, CI=3.3-6.1). 
Beyond age 50 years, the SIR remained significantly elevated (SIR=1.5; CI=1.1-1.9). The 
AER increased with increasing attained age until age 40 years and remained significantly 
elevated thereafter (AER=14, CI=9-20 at age 40-49 years and AER=13, CI=3-23 at 50+ 
years). Among survivors of Hodgkin lymphoma and Wilms tumour the AERs increased with 
increasing attained age, and showed no sign of a decline with 99 (CI=66-132) and 26 (CI=1-
50) excess breast cancers per 10,000 survivors per year beyond age 40 years, respectively. 
Among sarcoma survivors, the AER increased significantly with attained age until age 40 
years (Ptrend<0.001) and remained significantly elevated thereafter (AER=25, CI=16-35 at age 
30-39 years and AER=14, CI=2-26 at age 40+ years). The SIR and AER did not vary across 
diagnosis decades (≤1970, 1970-1979, 1980-1989, 1990-2008) (Ptrend=0.152 and Ptrend=0.119).   
Conclusion: Wilms tumour, Hodgkin lymphoma and sarcoma survivors have an increased 
number of excess breast SPNs beyond age 40 years. We provide new empiric evidence on the 
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long-term risks of breast cancer that should aid in revising the current international breast 
cancer surveillance guidelines for survivors of cancer diagnosed during childhood or 
adolescence. 
 
6.2 INTRODUCTION 
Over the last few decades, advances in the treatment of childhood cancer have resulted in a 
substantial increase in survival from childhood cancer over time. In Europe, 80% of childhood 
cancer patients can now expect to survive at least five years198. However, the growing 
survivor population is at risk of long-term adverse health outcomes50, 92-95. Subsequent 
primary neoplasms (SPNs) are one of the most severe adverse health outcomes and account 
for 50% of the total excess mortality beyond 45 years from diagnosis of childhood cancer92.  
 
Besides basal cell carcinoma of the skin, breast cancer is the most commonly diagnosed SPN 
among female childhood cancer survivors97-99, 102, 104. Treatment for childhood cancer with 
high-dose chest radiotherapy is an established risk factor for the development of breast 
SPNs31, 55, 57, 122-126. Current long-term follow-up guidelines recommend yearly breast cancer 
surveillance for female childhood cancer survivors aged 25-50 years with a history of high-
dose chest radiotherapy 58. It is unclear, though, if continuation of this intense surveillance 
schedule is warranted as women age. In addition, recommendations for screening of 
individuals aged 40-50 years are based on studies with small number of person-years and 
breast events after age 40 years57, 98, 99, 123, particularly after specific childhood cancers (e.g. 
Wilms tumour) 31, 125, 215. If the excess risk were to decrease with increasing attained age, it 
may be appropriate to stop the high-risk screening program at a certain age19, and rather, refer 
women to regular, population-based screening programs for post-menopausal women in effect 
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in many western countries216.  However, few studies have investigated whether the number of 
breast SPNs remains increased among ageing survivors98, 99, 123. Breast cancer is most 
common after age 50 in the general population, therefore if any increased risk of breast SPNs 
sustains into older age among childhood cancer survivors this could result in a large number 
of survivors developing a breast SPN.  
 
Increased awareness of late effects among childhood cancer survivors has resulted in smaller 
fields and lower doses of radiotherapy applied in more recent diagnosis eras217; therefore it is 
not inconceivable that survivors treated more recently are at lower risk of developing a breast 
SPN than survivors treated in earlier decades31.  
 
We investigated the risk of developing a breast SPN among the largest cohort of childhood 
and adolescent cancer survivors. This study provides over 57,000 person-years beyond age 40 
years to determine if the increased risk of developing a breast SPN persists when the 
background risk in the general population starts to increase. The specific aims were three-
fold: 1) quantify risk of breast SPNs among survivors of all and specific childhood cancers; 2) 
quantify risk of breast SPNs among an ageing survivor population; and 3) ascertain if the risk 
of breast SPNs is lower among childhood cancer survivors treated in recent diagnosis eras. 
 
6.3 METHODS 
6.3.1 The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up 
Studies (PanCareSurFup) 
PanCareSurFup combines data from 13 European cohorts of childhood and adolescent cancer 
survivors to form a pan-European cohort study to investigate the long-term risk of adverse 
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health outcomes among this population. Ethical approval for the study was obtained from the 
appropriate bodies within each participating country. Data were obtained from both 
population-based cohorts and individual treatment centres to provide a pan-European cohort 
consisting of 69,460 5-year survivors of cancer diagnosed before age 20 years between 1940 
and 2011. Ascertainment of the cohort has been described in-depth previously (see Chapter 
5). In short, individuals were eligible to be included in the cohort if the first primary neoplasm 
(FPN): (1) could be grouped according to the International Classification of Childhood 
Cancers (ICCC)79, (2) was of a malignant behaviour (with the exception of intracranial 
tumours, for which any behaviour was allowed), (3) and was not a Langerhans cell 
histiocytosis, myelodisplastic syndrome, chronic myeloproliferative and lymphoproliferative 
disorder or an immune proliferative disease, as these were not ascertained by all 13 individual 
cohorts. For the current analyses, males were excluded, resulting in 31,722 female childhood 
cancer survivors eligible for analyses.  
 
6.3.2 Subsequent primary breast cancer ascertainment 
SPNs were ascertained through several different methods including: linkage with population-
based cancer registries (Denmark, Finland, Iceland, Italy, Netherlands, Norway, Slovenia, 
Sweden, Switzerland, and UK), long-term follow-up clinics (France, Hungary, Netherlands, 
Slovenia and Switzerland), questionnaires to survivors (France and Hungary), medical 
records/hospital data (France, Hungary, Italy, Netherlands and Slovenia), national mortality 
records (France,  Italy and Switzerland) and the health insurance reimbursement database 
(France). The primary method of validation was through pathology reports or in their absence 
other means of clinical diagnosis. A breast SPN was defined as any tumour of malignant 
behaviour that was not a metastases or recurrence of the childhood cancer (defined as a 
  
174 
 
different histological classification) that was located within the breast. Breast site was defined 
using the International Classification of Diseases (ICD) — C50 (ICD-10), 174 (ICD-8/9) and 
170 (ICD-7)185-187. 
 
6.3.3 General population cancer incidence rates 
Cancer incidence rates for the general population were ascertained from the Cancer Incidence 
in Five Continents CI5PLUS dataset218. Rates were available per 5-year age strata and 1-year 
calendar period strata for France (1975-2007), Italy (1978-2007), the Netherlands (1989-
2007), Denmark (1953-2007), Sweden (1958-2007), Norway (1953-2007), Finland (1953-
2007), Iceland (1958-2007), Slovenia (1963-2007), Switzerland (1970-2007) and the UK 
(1975-2007). Rates were unavailable for Hungary; but because of the close geographical 
proximity surrogate Italian rates were used. When the year of cancer diagnosis was outside of 
the available range of the general population cancer rates, the rate for the closest available 
year was used. 
 
6.3.4 Statistical analysis 
Childhood cancer survivors were at risk of a breast SPN from the date of 5-year survival after 
childhood cancer until the first occurrence of death, emigration, or the study end date for the 
respective cohort. Contralateral breast SPNs per individual were allowed for all analyses with 
the exception of cumulative incidence where the first event only was included. The expected 
number of SPNs was calculated by multiplying the total person-years stratified by age (5-year 
bands) and calendar year (1-year bands) by the corresponding general population breast 
cancer incidence rates. Standardised incidence ratios (SIRs) were derived as the observed 
number of breast SPNs divided by the expected number of breast SPNs. Absolute excess risks 
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(AERs) were calculated as the observed number of breast SPNs minus the expected number 
of breast SPNs divided by the accumulated person-years, and then multiplied by 10,000153. 
SIRs and AERs were stratified by childhood cancer, country and attained age. Poisson 
regression models incorporating the expected number of breast SPNs were used to calculate 
the SIR and AER by continuous attained age (1-year categories fitted as a restricted cubic 
spline) and results were shown graphically.  
 
The effect of diagnosis era (<1970/1970-79/1980-89/1990-99/≥2000) on the development of 
breast SPNs was investigated using multivariable Poisson regression incorporating the 
expected number of breast SPNs to calculate the relative risk (RR) and relative excess risk 
(RER) adjusting for childhood cancer type (among all survivors only), age at diagnosis, 
country, and attained age (1-year categories fitted as a restricted cubic spline)154. The RR can 
be interpreted as the ratio of SIRs adjusting for potential explanatory factors. The RER can be 
interpreted as the ratio of AERs adjusting for potential explanatory factors.  The cumulative 
incidence at age 60 years for all childhood cancer survivors and age 50 years for subgroups of 
childhood cancer survivors was calculated treating death as a competing risk189. 
 
All analyses were also conducted separately for survivors of Hodgkin lymphoma, Wilms 
tumour, sarcoma (bone & soft-tissue), leukaemia, and all other childhood cancers. These 
groups were selected based on the high risk of breast cancer associated with chest 
radiotherapy (Hodgkin lymphoma31, 55, 57, 122, 123, 126 and Wilms tumour57, 123, 126) and 
chemotherapy (sarcoma and leukaemia)126, 219, 220 reported in previous studies. 
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To confirm the robustness of all of the multivariable Poisson regression models with attained 
age fitted as a restricted cubic spline, Cox regression models with attained age as the time 
metric were also fitted. In addition stratified Cox regression models with country as strata 
were also fitted. Similar results were obtained for all three model types (not shown); 
therefore, only the Poisson regression models are reported. Tests for trend and heterogeneity 
were calculated using likelihood-ratio tests comparing the deviance of a multivariable model 
including the factor of interest (with median values at each level of the relevant factor— fitted 
as linear for trend and categorical for heterogeneity) to the deviance of a multivariable model 
without the factor of interest. All p-values<0.05 were taken as statistically significant. All 
analyses were conducted in Stata 14.1 
 
6.4 RESULTS 
6.4.1 Cohort characteristics 
In total, 411 breast SPNs (excluding in situ-tumours) were diagnosed in 385 of the 31,722 
female childhood cancer survivors in the cohort (Table 6.1). Total follow-up from 5-year 
survival was 524,884 person-years. The median age at last follow-up was 29 years (range: 5-
79) and the median age at diagnosis of a breast SPN was 39 years (range: 15-71). Of the 
survivors, 13% had an attained age at exit of 40-49 years and 7% had an attained age of 50 
years or older; beyond age 40 years almost 57,000 person-years of follow-up were available. 
With respect to childhood cancer diagnosis era, 14% were diagnosed before 1970, 20% 
between 1971-1979, 30% between 1980-1989, 27% between 1990-1999 and 10% in 1990 or 
after. The most common type of breast cancer was infiltrating duct carcinoma (72%) followed 
by lobular carcinoma (8%) (Table 6.2).  
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6.4.2 Risk compared to the general population 
Childhood cancer survivors had a 3-fold risk of developing a breast SPN compared to that 
expected from the general population (SIR=2.8, 95% confidence interval [CI]=2.5-3.1), 
corresponding to an AER of 5 per 10,000 person-years (CI=4.3-5.8). This implies that, for 
each additional year of follow-up, on average, a new excess breast SPN developed in 5 of 
10,000 female 5-year childhood cancer survivors (Table 6.3). Survivors of each type of 
childhood cancer (where observed≥10) had a significantly increased risk of developing a 
breast SPN than the general population, except CNS tumour survivors (SIR=1.0, CI=0.7-1.4). 
Survivors of Hodgkin lymphoma, bone sarcoma and Wilms tumour had the greatest risk of 
developing a breast SPN than in the general population with SIRs of 11.3 (CI=9.4-13.5), 4.6 
(CI=3.3-6.1) and 4.5 (CI=3.2-6.2), respectively. With regards to country specific risks, SIRs 
were highest for Italy-HB (SIR=14.0, CI=7.4-23.9), Hungary (SIR=6.7, CI=2.7-13.8) and the 
Netherlands (SIR=5.8, CI=4.2-7.9) (Figure 6.1, Table 6.4). There was significant 
heterogeneity in the RR between countries (Pheterogeneity<0.001); when the UK was taken as 
baseline the RR was significantly higher for survivors in France (RR=1.6, CI=1.2-2.3), Italy-
HB (RR=2.5, CI=1.4-4.6), the Netherlands (RR=1.6, CI=1.0-2.3) and Finland (RR=1.8, 
CI=1.2-2.5) (Table 6.4). However, when these countries were excluded there was no 
significant heterogeneity in breast cancer risk between countries (Pheterogeneity=0.232).  In the 
entire cohort, cumulative incidence at age 50 years was 3.7% and at age 60 years was 6.0%, 
whereas 1.9% and 4.4% were expected, respectively (Table 6.3). Cumulative incidence at age 
50 years was highest for survivors of Hodgkin lymphoma (12.5%), bone sarcoma (6.1%), 
retinoblastoma (4.5%), leukaemia (4.4%) and Wilms tumour (4.2%) (Table 6.3, Figure 6.2). 
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6.4.3 Breast cancer risk by attained age 
Among all childhood cancer survivors, the SIR for breast SPNs decreased significantly with 
increasing attained age (Ptrend<0.001) (Figure 6.3A).  The SIR decreased from 7.8 (CI=5.8-
10.2) at age 20-24 years to 1.5 (CI=1.1-1.9) beyond age 50 years. Statistically significant 
decreasing trends in SIRs with increasing attained age were observed among Hodgkin 
lymphoma, Wilms tumour and sarcoma survivors (Table 6.5). SIRs decreased from 27 to 7 
among Hodgkin lymphoma survivors aged 5-29 and ≥40 years (Ptrend<0.001). Within the same 
attained age groups, SIRs decreased from 9.3 to 2.5 among Wilms tumour survivors 
(Ptrend=0.020) and from 12.2 to 1.7 among sarcoma survivors (Ptrend<0.001). 
 
Among all childhood cancer survivors, the AER increased significantly with increasing 
attained age until age 40 (Ptrend<0.001), and remained significantly elevated thereafter (see 
Figure 6.3B). For each additional year of follow-up, a new excess breast SPN developed in 3 
(CI=2-3), 14 (CI=11-16), 14 (CI=9-20) and 13 (CI=3-23) of 10,000 childhood cancer 
survivors aged 20-29, 30-39, 40-49 and aged 50 or older, respectively. Significant increasing 
trends in the AER of breast cancer with increasing attained age were observed among 
Hodgkin lymphoma and Wilms tumour survivors (both Ptrend<0.001) (Table 6.5). For each 
additional year of follow-up, a new excess breast SPN developed in 99 (CI=66-132) and 25 
(CI=1-50) of 10,000 Hodgkin lymphoma and Wilms tumour survivors aged 40 or older, 
respectively. Among sarcoma survivors, the AER increased significantly with attained age 
until age 40 (Ptrend<0.001) and remained significantly elevated thereafter. For each additional 
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year of follow-up a new excess breast SPN developed in 25 (CI=16-35) and 14 (CI=2-26) of 
10,000 sarcoma survivors aged 30-39 and aged 40 or older, respectively.  
 
6.4.4 Breast cancer risk by diagnosis era (1940-1969/1970-1979/1980-1989/1990-2008) 
The multivariable Poisson regression revealed that RRs and RERs did not differ significantly 
across the diagnosis eras for survivors of all childhood cancer or survivors of specific FPNs 
including Hodgkin lymphoma, Wilms tumour, sarcoma or leukaemia (all Ptrend>0.05) (Table 
6.6).  
 
6.5 DISCUSSION 
6.5.1 Main findings 
This is the largest cohort study to assess the long-term risk of malignant breast SPNs among 
female childhood cancer survivors, with 31,722 5-year survivors, 524,884 person-years at risk 
and 411 observed breast SPNs. Beyond age 40 years more than 57,000 person-years accrued 
enabling robust estimates of excess risks to be reported—a research priority identified by the 
International Guideline Harmonisation Group (IGHG), a consortium of experts aiming to 
harmonise breast cancer surveillance guidelines for childhood, adolescent and young adult 
cancer survivors58. 
 
Here we show that among childhood cancer survivors the excess risk of breast cancer remains 
increased beyond age 50 years—the number of excess breast SPNs increases until age 40 
years and remains significantly elevated thereafter. After each of Hodgkin lymphoma and 
Wilms tumour the excess number of breast SPNs increases with increasing attained age. 
Among sarcoma survivors, the AER increases significantly with attained age until age 40 and 
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remains significantly elevated thereafter. Beyond age 40 years, 99, 26 and 14 excess breast 
SPNs per 10,000 survivors per year were observed among survivors of Hodgkin lymphoma, 
Wilms tumour and sarcoma, respectively. Multivariable regression also revealed that breast 
SPN risk does not differ across the diagnosis eras (1940-1969, 1970-1979, 1980-1989, 1990-
2008), regardless of childhood cancer type; so, despite substantial adaptations to radiotherapy 
practices, women treated for childhood cancer in recent decades did not have a significantly 
lower risk of developing a breast SPN than individuals treated in earlier diagnosis eras.  
 
6.5.2 Previous studies 
The British Childhood Cancer Survivor Study (BCCSS)98—which contributes data to the 
current study—did not observe a significantly increased risk of breast SPNs among childhood 
cancer survivors aged over 50 years (SIR=1.0, CI=0.6-1.8). A Nordic study100—again which 
contributes data to the current study— reported an increased risk of breast cancer among 
lymphoma survivors aged over 40 years (SIR=5.9, CI=3.9-8.5), but not among any other 
childhood cancer survivor. By combining 13 European cohorts of cancer survivors, the 
PanCareSurFup Cohort Study provides a large number of breast SPNs and person-years of 
follow-up beyond age 40 years; we were able to detect a 2-fold (CI=1.7-2.4) and 1.5-fold 
(CI=1.1-1.9) excess risk of breast SPNs among survivors aged 40-49 years and at least 50 
years, respectively. This is lower than observed in the North American Childhood Cancer 
Survivor Study (CCSS)99, where 5.5-fold (CI=4.5-6.7) risk beyond age 40 years was reported. 
Due to differing diagnosis periods (PanCareSurFup=1940-2008; CCSS=1970-1986) thus 
shorter follow-up among the CCSS, the childhood cancer survivors reaching age 40 in the 
CCSS cohort mainly represent cancers diagnosed in older children such as Hodgkin 
lymphoma and sarcoma, which are known to have a high risk of breast SPNs, which may in 
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part explain the higher risk observed among the CCSS than in this study. In addition the 
CCSS does not include survivors of retinoblastoma or ‘other’ childhood cancers. Due to the 
difference in follow-up, childhood cancer types and diagnostic period between the CCSS and 
PanCareSurFup, the results are not directly comparable. Therefore we conducted a sensitivity 
analysis, restricting to survivors who were diagnosed with childhood cancer (excluding 
retinoblastoma and ‘other’ childhood cancers) between 1970 and 1986 (results not shown). 
The SIR beyond age 40 years was 3.7 (CI=2.8-4.8), which is closer to the SIR reported by the 
CCSS99.  
 
In more recent decades, treatment of childhood cancer has turned to lower doses of 
radiotherapy and smaller radiation fields in order to optimize survival and reduce the risk of 
adverse health outcomes such as breast SPNs217, 221. However, among this cohort, the risk of 
breast SPNs did not decrease with more recent diagnosis (1940-2008), regardless of 
childhood cancer type. A Dutch study of survivors of Hodgkin lymphoma diagnosed aged 15-
50 years also reported that the risk of breast cancer did not decrease with more recent 
diagnosis decade (1965-2000)36. Several studies have reported that reducing the volume of 
breast tissue that is irradiated in supradiagphragmatic fields results in a lower risk of breast 
SPNs36, 123. This reduction in volume of irradiated breast tissue may not have been used 
widely enough for a lower risk in more recent diagnosis decades to be observed in our cohort. 
Another potential explanation could be an increase in breast SPNs detected by clinical 
surveillance (e.g. Hodgkin lymphoma survivors recalled for breast screening) in recent 
diagnosis periods—the Dutch Hodgkin lymphoma study reported that the proportion of breast 
SPNs detected by screening increased from 30% before 2001, to 61% after 200136. Prior to 
the published guidelines on breast screening, some late effect clinics have been advising 
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childhood cancer survivors to attend breast screening prior to the start of regular post-
menopausal screening in the general population since the early 2000s222, 223. Therefore these 
screening-detected breast SPNs may be “picked up” earlier than they would have been in 
previous decades.  
 
Exposure to chest irradiation is an established risk factor for breast SPNs in childhood cancer 
survivors 31, 55, 57, 122-126; and largely explains the increased risk of breast SPNs among 
survivors of Hodgkin lymphoma and Wilms tumour who are often treated with mantel field 
radiotherapy and whole lung irradiation for lung metastases, respectively 31, 38, 55, 57, 123, 224, 225. 
The effects of chemotherapy on the risk of breast SPNs are more uncertain. Previous studies 
have reported that treatment with alkylating agents for Hodgkin lymphoma can cause ovarian 
damage and consequently reduced hormonal stimulation and reduced risk of breast SPNs55, 56. 
Studies among all childhood cancer survivors did not find any significant associations 
between specific chemotherapeutic agents and breast cancer risk57, although two recent 
studies have reported a dose-response relationship between alkylators and anthracyclines and 
the risk of breast SPNs among survivors of sarcoma and leukaemia 219, 220. In addition, a 
genetic predisposition to cancer may increase the risk of breast cancer among some childhood 
cancer survivors. Sarcoma, leukaemia and breast cancer are known to be associated with Li 
Fraumeni Syndrome, a genetic syndrome where a germline mutation in the TP53 gene is 
present226. Therefore the increased risk of breast SPNs among the sarcoma and leukaemia 
survivors in the PanCareSurFup cohort may be partly explained by genetic predisposition. 
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6.5.3 Clinical Implications 
The IGHG consortium recommend yearly breast screening to female childhood cancer 
survivors treated with chest radiotherapy (≥20Gy) who have reached age 50 years, however 
more evidence is required to justify recommending this intense yearly screening in this 
population rather than recommending attending regular population-based screening 
programs58. In addition, previous studies reporting risks after age 40 years for specific 
childhood cancers groups have been based on small number of events and person-years of 
follow-up 31, 57, 98, 99, 123, 125, 215. This study provides evidence that Hodgkin lymphoma, Wilms 
tumour and sarcoma survivors have substantially increased excess numbers of breast SPNs 
beyond age 40 years. Our study provides evidence that should aid in revising and updating the 
current guidelines. However, studies including detailed information on cumulative doses of 
chest irradiation, in addition to cumulative chemotherapy exposures, among this ageing 
cancer survivor population are needed to provide more conclusive evidence.  
 
6.5.4 Limitations 
A limitation of this study is the lack of detailed treatment information; which prevents 
investigations into dose-response relationships between cumulative radiotherapy and 
chemotherapy doses and the associated risk of breast SPNs. However we provide risk 
estimates beyond age 50 years, and highlight the childhood cancer groups who are still at an 
increased risk of breast SPNs later in life, thus provide a basis for future studies. 
 
A potential limitation is the observed heterogeneity between contributing cohorts included in 
PanCareSurFup. When France, Italy-PB, Netherlands and Finland were excluded, there was 
no significant heterogeneity in RR of breast SPNs between countries (Pheterogeneity=0.232). 
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However, the risk estimates produced from the stratified Cox regression models with country 
as strata, were very similar to the Poisson models that did not stratify by country (country 
included as categorical variable), suggesting that any heterogeneity between countries did not 
have a large effect on the overall risks of breast SPNs in the PanCareSurFup cohort. A large 
proportion of the French cohort attended two main treatment centres which are international 
referral centres for metastatic or otherwise difficult cancers, thus likely received high 
cumulative doses of radiotherapy. Clinical follow-up centres in the Netherlands and Italy-HB 
have invited survivors treated with high-dose chest radiotherapy to be screened for breast 
cancer since the early 2000s, therefore may diagnose breast SPNs earlier than if screening had 
not taken place222.  
 
6.6 CONCLUSIONS 
This large pan-European study provides evidence that the excess number of breast SPNs 
remains substantially increased among Hodgkin lymphoma, Wilms tumour and sarcoma 
survivors beyond 40 years of age. We provide new empiric evidence on the long-term risks of 
breast cancer that should aid in revising the current international breast cancer surveillance 
guidelines for survivors of cancer diagnosed during childhood or adolescence.
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Table 6.1: Cohort characteristics of whole cohort and number of breast cancers 
  Total number of individuals Number of Breast Cancers 
  n % n % 
Overall 31,722 100.0 411 100.0 
Country 
    France 1,407 4.4 59 14.4
Hungary 2,156 6.8 9 2.2 
Italy PB 3,389 10.7 17 4.1 
Italy HB 682 2.2 14 3.4 
Netherlands 2,682 8.5 47 11.4 
Denmark 10,809 6.8 34 8.3 
Sweden 3,688 11.6 36 8.8 
Norway 1,793 5.7 12 2.9 
Finland 3,049 9.6 7 18.5 
Iceland 123 0.4 0 0.0 
Slovenia 560 1.8 6 1.5 
Switzerland 1,954 6.2 6 1.5 
UK 8,083 25.5 95 23.1 
Childhood Cancer Diagnosis 
    Leukemia 7,631 24.1 24 5.8
Hodgkins Disease  2,397 7.6 122 29.7 
Non-Hodgkin Lymphoma 1,041 3.3 16 3.9 
Central Nervous System Tumour 6,516 20.5 33 8.0 
Neuroblastoma  1,551 4.9 7 1.7 
Retinoblastoma 1,233 3.9 18 4.4 
Wilms Tumour 2,363 7.5 37 9.0 
Bone Tumour 1,417 4.5 45 11.0 
Soft-Tissue Sarcoma 1,976 6.2 33 8.0 
Other 5,432 17.1 71 17.3 
Not in ICCC* 165 0.5 5 1.2 
Decade of Childhood Cancer Diagnosis 
    <1970 4,302 13.6 165 40.2
1970-1979 6,199 19.5 136 33.1 
1980-1989 9,447 29.8 83 20.2 
1990-1999 8,693 27.4 25 6.1 
>=2000 3,081 9.7 2 0.5 
Age at Childhood Cancer Diagnosis 
    0-4 years 12,344 38.9 68 16.6
5-9 years 6,684 21.1 45 11.0 
10-14 years 7,221 22.8 173 42.1 
15-19 years 5,473 17.3 125 30.4 
Attained Age at Exit 
    0-29 years 17,306 54.6 55 13.4
30-39 years 8,044 25.4 175 42.6 
40-49 years 4,043 12.8 116 28.2 
50+ years 2,329 7.3 65 15.8 
Abbreviations: PB- population based, HB- hospital based, ICCC- international classification of childhood cancer. 
*Not in ICCC- Survivors diagnosed before 1983 in Slovenia were classified in ICD7 and thus could not be converted to 
ICCC.
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Table 6.2 Morphology of subsequent primary breast neoplasms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: NOS- not otherwise specified 
 
Morphology Description N % 
85003 Infiltrating duct carcinoma, NOS 293 71.3 
85203 Lobular carcinoma, NOS 35 8.5 
81403 Adenocarcinoma, NOS 21 5.1 
80103 Carcinoma, NOS 20 4.9 
85223 Infiltrating duct and lobular carcinoma 8 2.0 
85233 Infiltrating duct mixed with other types of carcinoma 5 1.2 
84803 Mucinous adenocarcinoma 3 0.7 
85013 Comedocarcinoma, NOS 3 0.7 
85103 Medullary carcinoma, NOS 3 0.7 
85213 Infiltrating ductular carcinoma 3 0.7 
90203 Phyllodes tumour, malignant 3 0.7 
80003 Neoplasm, malignant 2 0.5 
80333 Pseudosarcomatous carcinoma 1 0.2 
80823 Lymphoepithelial carcinoma 1 0.2 
80953 Metatypical carcinoma  1 0.2 
81413 Scirrhous adenocarcinoma 1 0.2 
81903 Trabecular adenocarcinoma 1 0.2 
85123 Medullary carcinoma with lymphoid stroma 1 0.2 
85133 Atypical medullary carcinoma 1 0.2 
85403 Paget's disease, mammary 1 0.2 
85413 Paget's disease and infiltrating duct carcinoma of breast 1 0.2 
85433 Paget's disease and intraductal carcinoma of breast 1 0.2 
88013 Spindle cell sarcoma 1 0.2 
Unknown Unknown 1 0.2 
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Table 6.3 – Standardised incidence ratios, absolute excess risks and cumulative incidence stratified by childhood cancer diagnosis 
Childhood Cancer Median 
Attained Age 
O/E SIR (95% CI) AER (95% CI) Cumulative Incidence at 
age 50 years (95%CI) 
All Childhood Cancer 28.8 411/146.0 2.8 (2.5,3.1) 5.0 (4.3,5.8) 
50 years: 3.7 (3.2,4.1) 
60 years: 6.0 (5.3,7.0) 
Leukaemia 24.6 24/9.4 2.6 (1.6,3.8) 1.4 (0.5,2.3) 4.4 (1.5,10.0) 
Hodgkin Lymphoma 31.7 122/10.8 11.3 (9.4,13.5) 34.6 (27.9,41.4) 12.5 (9.8,15.5) 
Non Hodgkin Lymphoma 30.3 16/5.4 3.0 (1.7,4.8) 6.3 (1.6,10.9) 4.2 (1.9,7.7) 
Central Nervous System Tumour 28.4 33/32.0 1.0 (0.7,1.4) 0.1 (-1.0,1.1) 1.0 (0.6,1.5) 
Neuroblastoma 23.5 7/3.7 1.9 (0.8,3.9) 1.2 (-0.7,3.1) - 
Retinoblastoma 30.2 18/6.4 2.8 (1.7,4.4) 4.0 (1.1,6.9) 4.5 (2.5,8.1) 
Wilms Tumour 27.8 37/8.2 4.5 (3.2,6.2) 6.1 (3.6,8.7) 4.2 (2.6,6.4) 
Bone Sarcoma 31.8 45/9.8 4.6 (3.3,6.1) 15.0 (9.4,20.6) 6.1 (4.1,8.5) 
Soft Tissue Sarcoma 30.7 33/12.8 2.6 (1.8,3.6) 5.6 (2.5,8.7) 3.1 (1.9,4.6) 
Other 33.6 71/45.2 1.6 (1.2,2.0) 2.7 (1.0,4.5) 2.6 (1.9,3.4) 
Not in ICCC* 45.7 5/2.4 2.1 (0.7,4.8) 4.7 (-3.3,12.8) - 
Abbreviations: SIR- standardized incidence ratio, AER-absolute excess risk, 95%CI- 95% confidence interval, ICCC-International Classification of Diseases. 
*Not in ICCC- Survivors diagnosed before 1983 in Slovenia were classified in ICD7 and thus could not be converted to ICCC
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Figure 6.1: Risk of breast SPNs among childhood cancer survivors* stratified by country of diagnosis: 
a) Standardised Incidence ratios and b) Absolute excess risks 
Abbreviations: SIR- standardized incidence ratio, AER- absolute excess risk, 95% CI- 95% confidence interval, PB-
population based, HB- hospital based. 
AERs are per 10,000 person-years 
* Leukaemia survivors were not included in the French cohort; therefore leukaemia survivors were excluded when providing 
comparisons between countries. The observed number of breast SPNs among leukaemia survivors were 0 for Denmark, 
Norway, Iceland and Slovenia; 1 for Italy-HB and Italy-PB, 2 for Hungary, Sweden and Switzerland, 3 for Finland, 6 for UK 
and 7 for Netherlands
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Figure 6.2: Cumulative incidence of breast SPNs stratified by childhood cancer type with attained age 
as time scale.
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Table 6.4: Standardised incidence ratios, absolute excess risks, relative risks and relative excess risks stratified by country of diagnosis* 
Country of Diagnosis O SIR (95% CI) RR (95%CI)† AER (95% CI) RER (95% CI) † 
France 59 3.9 (3.0,5.1) 1.6 (1.2,2.3) 11.6 (7.6,15.5) 2.2 (1.4,3.4) 
Hungary 7 6.7 (2.7,13.8) 1.2 (0.6,2.7) 3.9 (0.5,7.3) 1.2 (0.5,3.2) 
Italy-PB 16 4.0 (2.3,6.6) 0.9 (0.5,1.6) 5.0 (1.7,8.3) 0.9 (0.5,1.9) 
Italy-HB 13 14.0 (7.4,23.9) 2.5 (1.4,4.6) 22.6 (9.4,35.9) 2.8 (1.5,5.5) 
Netherlands 40 5.8 (4.2,7.9) 1.6 (1.0,2.3) 10.6 (6.6,14.5) 1.8 (1.1,3.0) 
Denmark 34 2.0 (1.4,2.8) 1.3 (0.9,2.0) 5.4 (1.8,9.0) 1.0 (0.5,2.0) 
Sweden 34 1.9 (1.3,2.6) 1.0 (0.7,1.6) 3.1 (0.9,5.4) 0.7 (0.4,1.4) 
Norway 12 1.8 (0.9,3.1) 0.9 (0.5,1.6) 2.4 (-0.7,5.5) 0.6 (0.2,1.4) 
Finland 73 3.2 (2.5,4.0) 1.8 (1.2,2.5) 11.5 (7.6,15.3) 1.4 (0.8,2.3) 
Iceland 0 - - - - 
Slovenia 6 2.1 (0.8,4.6) 0.4 (0.1,3.1) 3.3 (-1.7,8.3) 0.4 (0.0-3.1) 
Switzerland 4 2.1 (0.6,5.3) 0.4 (0.2,1.2) 1.4 (-1.2,4.0) 0.4 (0.1,1.2) 
UK 89 2.3 (1.8,2.8) Reference 3.8 (2.4,5.3) Reference 
Pheterogeneity
   <0.001  <0.001 
Abbreviations: SIR- standardized incidence ratio, AER- absolute excess risk, RR- relative risk, RER- relative excess risk, 95% CI- 95% confidence interval, PB-population based, HB- hospital 
based. 
* Leukaemia survivors were not included in the French cohort; therefore leukaemia survivors were excluded when providing comparisons between countries. The observed number of breast 
SPNs among leukaemia survivors were 0 for Denmark, Norway, Iceland and Slovenia; 1 for Italy-HB and Italy-PB, 2 for Hungary, Sweden and Switzerland, 3 for Finland, 6 for UK and 7 for 
Netherland 
†multivariable models were adjusted for age at diagnosis, decade of diagnosis, childhood cancer diagnosis and attained age (1-year age categories fitted as a restricted cubic spline).
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Figure 6.3: Risk of breast SPNs among survivors of all childhood cancer expressed as a) standardized 
incidence ratios and b) absolute excess risks.  
 
Abbreviations: SIR- Standardised Incidence Ratio, AER- absolute excess risk.  
Smoothed estimate was calculated using a restricted cubic spline. Point estimates are for attained age groups: 20-29, 30-39, 
40-49, 50+ and plotted at the median attained age value for each category. 
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Table 6.5: Standardised incidence ratios and absolute excess risks stratified by childhood cancer type and attained age.  
 Median 
Attained 
Age 
0-29 years 30-39 years 40+ years Trend 
Childhood 
Cancer 
O SIR (95% CI) AER (95% CI) O SIR (95% CI) AER (95% CI) O SIR (95% CI) AER (95% CI) 
SIR 
Ptrend
† 
AER 
Ptrend
† 
Hodgkin 
Lymphoma 
31.7 16 27.1 (15.5,44.0) 8.0 (3.9,12.1) 59 18.1 (13.8,23.4) 63.0 (46.0,80.1) 47 6.8 (5.0,9.0) 98.6 (65.5,131.7) <0.001 <0.001 
PYs* 19198.2 8842.2 4060.9   
Wilms 
tumour 
27.8 5 9.3 (3.0,21.6) 1.2 (0.0,2.4) 20 7.1 (4.4,11.0) 24.9 (12.2,37.6) 12 2.5 (1.3,4.3) 25.9 (1.3,50.4) 0.020 <0.001 
PYs 37198.9 6912.4 2766.0   
Sarcoma 31.2 10 12.2 (5.8,22.4) 2.5 (0.8,4.1) 39 7.6 (5.4,10.5) 25.4 (16.2,34.5) 29 1.7 (1.2,2.5) 13.8 (2.0,25.5) <0.001 <0.001 
 PYs 37291.6 13363.4 8954.1   
Leukaemia 24.6 7 5.3 (2.1,11.0) 0.6 (0.1,1.2) 11 2.2 (1.1,4.0) 4.6 (-0.4,9.5) 6 1.9 (0.7,4.2) 14.3 (-9.5,38.1) 0.088 0.490 
 PYs 90872.0 13211.9 2017.4   
Other 30.3 17 4.8 (2.8,7.7) 0.7 (0.3,1.2) 46 2.1 (1.6,2.8) 4.1 (1.9,6.4) 87 1.2 (1.0,1.5) 4.4 (-0.3,9.0) <0.001 0.004 
 PYs 181951.9 59067.2 39175.8   
Abbreviations: SIR-standardised incidence ratio, AER-absolute excess risk, 95% CI- 95% confidence interval, PYs- person-years at risk 
†models for trend were adjusted for decade of treatment, age at diagnosis and attained age. 
* Person-years at risk shown in grey for each attained age strata.
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Table 6.6: Relative risks and relative excess risks by decade of childhood cancer diagnosis  
  O RR (95%CI)* RER (95%CI)* 
All 
Childhood 
Cancer 
<1970 165 0.9 (0.7,1.2) 0.7 (0.5,1.0) 
1970-1979 136 Reference Reference 
1980-1989 83 1.0 (0.8,1.4) 0.9 (0.7,1.4) 
≥1990 27 1.3 (0.8,2.0) 1.1 (0.6,1.9) 
Ptrend  0.152 0.119 
Hodgkin 
lymphoma 
<1970 27 0.7 (0.4,1.2) 0.7 (0.4,1.2) 
1970-1979 52 Reference Reference 
1980-1989 29 0.7 (0.4,1.2) 0.7 (0.4,1.2) 
≥1990 14 1.0 (0.5,2.1) 0.9 (0.4,2.0) 
Ptrend  0.837 0.759 
Wilms 
tumour 
<1970 19 1.1 (0.5,2.7) 1.2 (0.4,3.9) 
1970-1979 10 Reference Reference 
1980-1989 7 2.4 (0.8,6.8) 4.0 (1.2,13.4) 
≥1990 1 7.8 (0.7,82.0) 14.4 (1.0,199.5) 
Ptrend  0.268 0.113 
Sarcoma <1970 26 0.7 (0.4,1.3) 0.5 (0.2,1.3) 
1970-1979 25 Reference Reference 
1980-1989 22 1.3 (0.7, 2.4) 1.3 (0.7,2.8) 
≥1990 5 1.4 (0.4, 4.2) 1.5 (0.5,5.1) 
Ptrend  0.109 0.059 
Leukaemia <1970 2 0.6 (0.1,4.1) . 
1970-1979 12 Reference Reference 
1980-1989 6 0.8 (0.3,2.5) 0.9 (0.1,6.3) 
≥1990 4 2.8 (0.5,14.4) 4.0 (0.4,40.0) 
Ptrend  0.324 0.194 
Abbreviations: RR- relative risk, RER-relative excess risk, 95%CI-95% confidence interval 
* Adjusting for country, age at diagnosis, childhood cancer type (overall only) and attained age (1-year age categories fitted 
as a restricted cubic spline).
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Chapter 7 
Discussion and Summary of Thesis
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7.1 PRINCIPAL FINDINGS 
The cohort study presented in Chapter 2 of this thesis quantified the risk of specific SPNs 
after each of 17 types of TYA cancer. Overall, 12,321 SPNs were diagnosed in 11,565 
survivors; most frequently among survivors of breast cancer, cervical cancer, testicular 
cancer, and Hodgkin lymphoma. Among these survivors, the excess number of SPNs 
observed increased with increasing years from diagnosis for all SPNs combined and for SPNs 
at each specific anatomical site which would have been directly irradiated if radiotherapy had 
been used to treat the TYA cancer. Beyond 30 years from diagnosis the percentage of excess 
numbers of SPNs was at greatest risk at such directly irradiated sites or at sites of likely 
smoking-related cancers (lung cancer). Beyond 30 years from diagnosis, lung cancer 
accounted for 45% of the excess number of SPNs after breast cancer in women; lung, 
colorectal, and bladder cancers accounted for 82% of the excess number of SPNs after 
cervical cancer; prostate, bladder, colorectal and lung cancer accounted for 61% of the excess 
number of SPNs after testicular cancer; breast and lung cancer accounted for 58% of the 
excess number of SPNs after Hodgkin lymphoma in women; lung cancer accounted for 41% 
of the excess number of SPNs after Hodgkin lymphoma in men. Age at diagnosis/treatment 
was not an important risk factor for the development of SPNs, except for breast cancer after 
Hodgkin lymphoma in women. Chapter 2 provides risk estimates that are a considerable 
advance on previous knowledge and provide an initial basis for developing evidence-based 
long-term clinical follow-up guidelines for TYA cancer survivors in relation to SPNs. No 
such guidelines currently exist. 
 
Chapter 3 reported on the risks of hospitalisation for specific cerebrovascular events among 
TYA cancer survivors by linking the TYACSS cohort to the HES database (England only). 
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Overall, 2,782 cancer survivors were hospitalised for a cerebrovascular event, which was 40% 
higher than expected (SHR=1.4, CI=1.3-1.4). With regards to types of cerebrovascular event, 
TYA cancer survivors were at 2-fold, 1.5-fold and 1.4-fold increased risk of a cerebral 
haemorrhage, cerebral infarction and `other cerebrovascular event`, respectively. Survivors of 
CNS tumours (SHR=4.6, CI=4.3-5.0), head & neck tumours (SHR=2.6, CI=2.2-3.1) and 
leukaemia (SHR=2.5, CI=1.9-3.1) were at greatest risk. By age 60 years, 9%, 6%, and 5% of 
CNS tumour, head & neck tumour, and leukaemia survivors, respectively, had been 
hospitalised for a cerebrovascular event. Of particular concern was the number of excess 
cerebral infarctions among CNS tumour survivors beyond age 60 years and head & neck 
tumour survivors at any age. Beyond age 60, every year 0.4% of CNS tumour survivors were 
hospitalised for a cerebral infarction (versus 0.1% expected). Whereas at any age, every year 
0.2% of head & neck tumour survivors were hospitalised for a cerebral infarction (versus 
0.06% expected). The findings from Chapter 3 suggest that survivors of CNS tumours, head 
& neck tumours, and leukaemia, should be considered for surveillance and counselling in 
relation to cerebrovascular risk factors, and further studies are needed to investigate the 
potential impact of pharmacological interventions for cerebral infarction prevention. 
 
Chapter 4 reported the risk of premature mortality among survivors of TYA CNS tumours by 
linking the TYACSS cohort to the national death registers. Overall 4,099 deaths were 
observed which was 7-fold that expected (SMR=6.6, CI=6.4-6.8). Beyond 25 years from 
diagnosis the majority of the excess deaths were attributable to non-neoplastic causes for 
survivors of gliomas (59%), craniopharyngioma (82%), other pituitary tumours (89%) and 
ependymoma (58%). Whereas beyond 25 years from diagnosis the majority of the excess 
deaths were attributable to neoplastic causes for survivors of meningioma (79%) and 
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embryonal tumours (56%). Of particular concern was the increased mortality due to strokes in 
long-term survivors of glial and pituitary tumours; as well as the increased mortality due to 
cardiac diseases in long-term survivors of other pituitary tumours. Among glial tumour 
survivors, strokes contributed 30% of the total AER beyond 25 years from diagnosis. Among 
other pituitary tumour survivors, strokes and cardiac disease contributed 25% and 21%, 
respectively, of the total AER beyond 25 years from diagnosis. In contrast to deaths due to 
neoplastic causes the excess of non-neoplastic deaths might be preventable with appropriate 
clinical surveillance and interventions. The general conclusion is that focus should be on 
prevention of long-term deaths from non-neoplastic causes among CNS tumour survivors, 
especially stroke and cardiac deaths among glial and other pituitary tumour survivors. 
 
Chapter 5 reports the first of two investigations in this thesis to utilise the PanCareSurFup 
cohort. The risk of subsequent soft-tissue sarcoma among childhood cancer survivors was 
investigated. Overall, 301 soft-tissue sarcoma were observed, which was 16-fold that 
expected (CI=14–18). With regards to specific types of soft-tissue sarcoma, highest SIRs were 
observed for malignant peripheral nerve sheath tumours (SIR=41, CI=14–18), 
leiomyosarcoma (SIR=30, CI=24–37), and fibromatous neoplasms (SIR=12, CI=9–16). In 
recent decades (1980s onwards), treatment for good prognosis childhood cancer has involved 
smaller radiation fields and reduced cumulative doses than in earlier decades, however among 
survivors in the PanCareSurFup cohort the excess risk of soft-tissue sarcoma overall and for 
specific soft-tissue sarcoma subtypes did not decrease from <1970 to 1990-2008. With 
regards to the AER, the number of excess fibromatous neoplasms and malignant peripheral 
nerve sheath tumours remained constantly low across all years from diagnosis and at all 
attained ages at less than 1 per 10,000 survivors per year. In contrast the number of excess 
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leiomyosarcomas increased with increasing years from diagnosis and attained age; especially 
among retinoblastoma survivors, for whom beyond 45 years from diagnosis there were 53 
excess leiomyosarcomas observed per 10,000 survivors per year. This study provides 
evidence that clinical follow-up guidelines should recommend long-term surveillance for 
leiomyosarcoma among retinoblastoma survivors. In contrast, there is no evidence to suggest 
long-term surveillance for fibromatous neoplasms or malignant peripheral nerve sheath 
tumours among childhood cancer survivors is warranted.  
 
Chapter 6 reports the second of two investigations in this thesis to utilise the PanCareSurFup 
cohort. The risk of breast SPNs experienced by survivors of childhood and adolescent cancer 
was investigated, particularly among long-term survivors (>40 years of age). The 
International Guideline Harmonisation Group (IGHG) consortium strongly recommends 
breast surveillance in the form of annual mammography between the ages of 15-50 years for 
female childhood cancer survivors treated with high-dose chest radiotherapy (≥20 Gy). 
However, there is a lack of empirical evidence to establish if this high level of surveillance 
should also be recommended for survivors after age 50 years58. In addition, current IGHG 
recommendations for breast cancer surveillance of individuals aged 40-50 years are based on 
evidence provided from studies with small number of person-years and few breast cancers 
observed after age 40 years, particularly for specific childhood cancers. Chapter 6 within this 
thesis provides evidence that childhood cancer survivors remain at increased risk of breast 
SPNs beyond age 50 years. Furthermore, Hodgkin lymphoma, Wilms tumour and sarcoma 
survivors had substantially increased excess numbers of breast SPNs beyond age 40 years 
with 99, 26 and 14 excess breast SPNs per 10,000 survivors per year, respectively. Our study 
provides evidence that should aid revising and updating of the current breast cancer 
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surveillance guidelines for female survivors of childhood cancer. However, observational 
studies, such as case-control studies including detailed information on the regimen and 
fractionation of radiotherapy to the chest and cumulative chemotherapy exposures (doses of 
each chemotherapeutic drug) among this ageing cancer survivor population are needed to 
provide more robust evidence. Such studies currently exist, however the number of ageing 
survivors diagnosed as children included in most, if not all, such studies is small55, 57. 
 
7.2 STRENGTHS AND LIMITATIONS OF RESEARCH 
Chapters 2-4 in this thesis are based on the largest ever population-based cohort study 
(TYACSS) of long-term adverse health outcomes among TYA cancer survivors worldwide. A 
major strength of the TYACSS is its population-based design and large size with over 
200,000 5-year survivors of TYA cancer, this enables unprecedentedly reliable estimates of 
excess risks of adverse health outcomes to be quantified. A principal advantage of population-
based studies over hospital or treatment centre (non-population based studies) studies is that 
they are less likely to be subject to selection bias 227. Selection bias can occur when the study 
population is not representative of the eligible population228 (e.g. all TYA cancer survivors). 
For example in treatment centre based cohorts, the study population is often ascertained from 
the hospital in which the cancer survivor received treatment, therefore the study population is 
likely to be younger than the eligible population because the long-term clinical follow-up of 
patients tends to decrease with age as older patients are more likely to be “lost to follow-up”; 
in addition the study population may not include all diagnostic types of cancer. This may 
result in any risk estimates produced not being generalisable to the full eligible population228. 
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Another strength of the TYACSS is the ability to undertake electronic record linkage of the 
cohort to the national death register, national cancer register and the HES database. This 
enables a complete spectrum of fatal and non-fatal adverse health outcomes to be investigated 
in all survivors of TYA cancer in England and Wales in a relatively easy and inexpensive 
manner. Such linkage opportunities with electronic health databases currently only exist in 
very few countries. Furthermore, unlike studies which rely on (self-reported) questionnaire 
data, this methodology is not susceptible to recall or non-responder bias 227.   
 
Nonetheless, the TYACSS is also subject to some limitations. Pathological reports to provide 
confirmation of SPNs were not available for the study in Chapter 2, which estimated the 
excess risk of SPNs in the TYACSS cohort. Pathology reports are a way to confirm whether 
the information provided on cancer registrations is accurate and distinguish 
recurrence/relapse/metastatic spread of the original primary tumour from subsequent primary 
tumours. To ensure that the excess risk of SPNs was not an overestimate, a conservative 
method (IACR/IARC rules and exclusion of same site tumours) was implemented to 
distinguish between a SPN and a recurrence/relapse/metastatic spread of the original TYA 
cancer. Therefore the risk estimates provided in Chapter 2 were likely to underestimate the 
true risk of developing a SPN within TYA survivors.  
 
Chapter 5 and 6 of this thesis are based on the largest cohort in the world ever assembled to 
investigate the risk of SPNs among childhood cancer survivors. Previous cohort studies of 
childhood and adolescent cancer survivors within individual countries had insufficient 
numbers of survivors aged over 40 years to satisfactorily address the risks of developing a 
SPN among older survivors96, 98, 100, 102, 104, 106. The major strength of PanCareSurFup is that 
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the pooled cohort of childhood and adolescent cancer survivors from 13 European countries 
provides a large number of survivors with very long follow-up and thus enables reliable 
estimates of long-term risks of SPNs to be quantified. Another advantage of the large size of 
the cohort and long follow-up was that reliable risk estimates stratified by numerous potential 
explanatory factors could be quantified (e.g. specific morphological types of soft-tissue 
sarcoma), which was previously not possible.  
 
Another strength of the PanCareSurFup study is that several contributing countries have a 
long history of population-based cancer registrations dating as far back as the 1940s, therefore 
for the first time, risk estimates based on large number of SPNs and person-years beyond age 
40 years were produced. Many of the cohorts in PanCareSurFup (see Table 5.1) ascertained 
SPNs through linkage with population-based cancer registries. This has several advantages 
over the North American Childhood Cancer Survivor Study (CCSS), a non-population-based 
cohort study of 34,033 survivors of childhood cancer that may be susceptible to selection bias 
as described above 99.  
 
 A potential limitation of the PanCareSurFup cohort is the significant heterogeneity in excess 
risk between contributing cohorts particularly between population-based and hospital-based 
cohorts (treatment centres). This is more than likely due to differences in treatment 
prescribing in the treatment centre based cohorts, which are often international referral centres 
for relapsed/recurrent cancers and therefore disproportionately include higher levels of 
treatment exposures. When sensitivity analyses were conducted excluding treatment centre 
based cohorts for both studies in Chapters 5 and 6, the overall estimates of excess risk did not 
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change appreciably across remaining cohorts, indicating that the heterogeneity in excess risk 
is partially attributable to the treatment centre based cohorts.  
 
A limitation of both the TYACSS and PanCareSurFup study is the lack of available 
information on: cumulative exposures, types and doses of specific chemotherapy drugs; 
cumulative exposures and fractionation of radiotherapy; and details of any genetic condition 
that may affect the excess risk of adverse health outcomes. To obtain this information, 
medical records for each of the 200,945 TYA cancer survivors and 69,460 childhood cancer 
survivors would need to be obtained. As a large proportion of the PanCareSurFup cohort and 
the entire TYACSS cohort are obtained from population-based cancer registries, this 
information is not readily available and it would not be practically feasible to collect this 
information for the large numbers of survivors included in both cohorts. To overcome this 
limitation, nested case-controls studies could be conducted. This would involve selecting 
cases (survivors with the outcome of interest- e.g. soft-tissue sarcoma SPN) and matched 
controls (survivors without the outcome of interest) from the underlying cohorts. Although it 
would still be a research intensive and labour-some process to obtain medical records for 
nested case-control studies; this would be a much more manageable task than obtaining this 
information for the full PanCareSurFup and TYACSS cohorts. As part of the PanCareSurFup 
study, nested case-control studies are currently being conducted to investigate the dose-
response relationship between cumulative dose of radiation from radiotherapy, cumulative 
dose of specific chemotherapy drugs, existing genetic conditions, and the risk of the following 
adverse health outcomes: subsequent soft-tissue sarcoma, subsequent bone sarcoma, 
subsequent genitourinary neoplasms, subsequent digestive neoplasms and cardiac disease. 
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Therefore, limitations of the studies included in this thesis are already starting to be addressed 
with further studies.  
 
Another limitation of all the studies presented in this thesis was that information on 
modifiable lifestyle factors such as diet, smoking, alcohol, exercise and obesity, or 
comorbidities such as diabetes and hypertension that may also contribute to the excess risk of 
adverse health outcomes were not available. At present, outside of case-control studies it is 
difficult to overcome this limitation. There are plans for linkage with GP prescriptions and 
also with supermarket consumption, but this is not yet fully available.  
 
7.3 RECOMMENDATIONS FOR FUTURE RESEARCH 
It is not possible or necessary for every cancer survivor to be on regular long-term clinical 
follow-up of adverse health outcomes, therefore it is important to risk-stratify cancer 
survivors so that appropriate recommendations on clinical follow-up can be advised. Risk 
stratification is a process whereby cancer survivors are grouped based on their previous 
treatment exposures and after other risk factors including genetic predisposition (e.g. RB1, 
BRCA1/2, and NF1/2), and then stratified in relation to anticipated risk. Studies such as those 
presented in this thesis can be used to provide a basis for risk stratifying cancer survivors; 
however evidence-based guidelines always require further studies to provide the most 
appropriate recommendation possible. Thus there is a need to build in regular updates into 
guidelines as evidence accumulates. 
 
Currently individuals in the general population who at high risk of having a stroke (e.g. 
individuals with hypertension or high blood pressure) are recommended to receive 
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pharmacological interventions to reduce the risk of cerebral infarction 180, 181. Currently there 
are no pharmacological interventions offered to TYA cancer survivors at high risk of cerebral 
infarction thus future studies should investigate the potential impact of pharmacological 
interventions for cerebral infarction prevention among survivors of CNS tumour, head & neck 
tumours and leukaemia. 
 
Future studies should take advantage of the existing national population-based electronic 
health databases, such as HES, the Patient Episode Database for Wales (PEDW)229, and the 
National Institute for Cardiovascular Outcomes Research (NICOR) databases230. PEDW 
database contains information on hospitalisations to hospitals in Wales, and is similar to the 
HES database 229. The NICOR collects information from hospitals on individuals who have 
cardiovascular diseases. These electronic databases provide an easy and efficient method of 
analysing adverse health outcomes.  
 
In Chapters 2 through 4, information on exposures to cancer treatment (chemotherapy drugs 
and doses, radiotherapy regimens and fractions) was not available; therefore studies are 
needed in which cumulative exposures of treatment are investigated. As stated above, this 
could be achieved through nested case-control studies. A problem often encountered with 
retrospective cohorts is that information on treatments obtained from medical notes has been 
destroyed or are very difficult to obtain (time-consuming and expensive). In recent years, 
several national standards have been produced which requires the collection and recording of 
treatment exposures among cancer patients in England. In 2012, the collection of all systemic 
anti-cancer therapy including chemotherapy in English NHS hospitals was launched and 
recording of this data became mandatory for all NHS trusts in 2014, the data collected  forms 
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the Systemic Anti-Cancer Therapy (SACT) dataset 231. Since 2009, all NHS providers of 
radiotherapy services are required to record information on all radiotherapy given and this is 
recorded in the National Radiotherapy Dataset (RTDS) 232. In the future these datasets could 
be used to make available, for research purposes, treatment exposures from cancer survivors 
treated in more recent diagnostic periods. For example, a prospective cohort study of cancer 
survivors could be conducted where all treatment information for the cancer is obtained from 
the SACT and RTDS datasets. This will enable treatment risk factors for adverse health 
outcomes to be quantified without the problems of retrospective treatment data collection.  
 
In chapter 5, the risks of STS SPNs among the PanCareSurFup cohort were reported, however 
as mentioned in the previous section, information to investigate the association of treatment 
exposures and excess risk of STS SPNs was not available. To overcome this limitation, a 
nested case-control study is required. As previously mentioned as part of the PanCareSurFup 
objectives, a nested case-control study is currently on-going as part of one of the 
PanCareSuFup objectives. Information on the cumulative exposure to chemotherapy and 
radiotherapy, and underlying genetic conditions of childhood cancer survivors in the study 
has currently been collected. The next stage is to perform radiation dosimetry so that the exact 
radiation dose to the site where the tumour developed can be determined. This enables the 
relationship of the excess risk of STS and dose of radiotherapy to be investigated. 
 
In chapter 6, the risks of breast SPNs among the PanCareSurFup were reported with a 
particular focus on survivors over age 40 years. A major risk factor for breast SPNs is 
previous exposure to chest irradiation (including any high-dose radiotherapy that has the chest 
in the field). IGHG requires additional evidence to support a guideline for the continued 
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surveillance of childhood cancer survivors beyond age 50 years who were treated with chest 
radiotherapy, thus more observational studies including detailed information on cumulative 
doses of irradiation to the chest and cumulative chemotherapy exposures among this ageing 
cancer survivor population are needed to provide more conclusive evidence.  
 
7.4 OVERALL CONCLUSION 
This thesis aimed to investigate the risk of adverse health outcomes among two populations of 
long-term survivors of childhood, teenage and young adult cancers. The thesis provides 
evidence to help risk stratify childhood, teenage and young adult cancer survivors according 
to their risk of specific adverse health outcomes, and thus identifies survivors who would 
benefit from long-term clinical surveillance. In particular the studies presented in this thesis 
provide an evidence base for updating existing and producing new guidelines and 
recommendations for the long-term surveillance of adverse health outcomes in childhood, 
teenage and young adult cancer survivors.
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